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Abstract 
 
Members of the Kelch-like family display various functions at the cellular level, such as 
being involved in signalling pathways, as mediators of cytoskeletal changes and most 
prominently by targeting specific substrates for proteasomal degradation.  
Previous studies suggested a role for Kelch-like 31 (Klhl31) during myogenesis, as its 
expression is dependent on signals responsible for the induction of myogenesis in the 
somites and is slightly delayed compared to the expression of early myogenic regulatory 
factors.  
With this study we wanted to analyse the function of Klhl31 during myogenesis in more 
detail. Using C2C12 mouse myotubes as our model cell line to study myogenic 
differentiation and myofibrillogenesis, we found that Klhl31 is closely associated with 
Actin fibres in differentiated, multi-nucleated myotubes and that observed co-
localisation can be linked to C2C12 differentiation. Furthermore, we used a Yeast-2-
Hybrid screen approach and GST-pull downs to find interaction partners for Klhl31. 
Putative interacting proteins for Klhl31 were analysed and found to be structural 
components of the sarcomere with many of them also being involved in 
myofibrillogenesis, such as Nebulin, Actin, CapZ and tropomyosin. 
We also analysed a possible role of Klhl31 in proteasomal degradation, as Klhl31 was 
shown to negatively regulate canonical Wnt-signalling. We gathered evidence that 
Klhl31 might interact with components of E3-Ubiquitin ligase complexes and might 
target specific substrates including itself for degradation by the 26S proteasome. 
Furthermore, we analysed the expression of Klhl31 during heart development in chick 
embryos, where it was restricted to the myocardium.  
We concluded that Klhl31 might be important during myofibrillogenesis in striated 
muscles. A role for Klhl31 in mature muscle might involve providing structural 
stabilisation in sarcomeres and during muscle contraction.  
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1. Introduction 
 
1.1 Somitogenesis 
 
All vertebrates share the same body plan defined by a segmented body axis. 
Segmentation takes place during early development and can first be observed as the 
formation of somites (see figure 1.1), which are paired epithelial segments on either side 
of the neural tube (Christ and Ordahl, 1995; Dequeant and Pourquie, 2008). The somites 
originate from the posterior paraxial mesoderm, whilst the anterior paraxial mesoderm, 
also called the head or cephalic mesoderm, gives rise to the bones and the muscles of 
the head (Noden, 1991; Pourquie, 2003). Tissues generated from the presomitic 
mesoderm (the posterior part of the paraxial mesoderm) include skeletal muscles, 
smooth muscles, cartilage, bones, including the vertebrae, connective tissues and parts 
of the skin (Dequeant and Pourquie, 2008; Yusuf and Brand-Saberi, 2012).  
Each bilateral pair of somites is segregated from the anterior tip of the PSM in regular 
temporal intervals until for each species a defined number of somites have formed (for a 
schematic overview of somitogenesis see figure 1.1; (Dequeant and Pourquie, 2008; 
Maroto and others, 2012; Richardson and others, 1998). Furthermore the timing of each 
interval of somite formation is also characteristic for each species (Dequeant and 
Pourquie, 2008; Maroto and others, 2012). A pair of somites in chick embryos is formed 
every 90 minutes, while a cycle in mice somitogenesis lasts 120 minutes and for human 
embryos it takes between 4 and 5 hours to form a somite pair (Dequeant and Pourquie, 
2008).  
17 
 
 
Figure 1.1: Somitogenesis 
Somites are formed from the paraxial mesoderm in an anterior -posterior pattern.  Once 
somite segregat ion has taken place,  cells in the somite different iate to  give r ise to the 
dermomyotome and the sclerotome.  
Figure taken from (Yusuf and Brand-Saberi,  2012)  
As soon as the new epithelial somite has separated from the pre-somitic mesoderm, it 
starts to differentiate and mature (Maroto and others, 2012; Yusuf and Brand-Saberi, 
2012). The differentiation processes are initiated by signalling molecules from the 
surrounding tissues, such as the notochord, the neural tube and the surface ectoderm 
(Aoyama and Asamoto, 1988; Christ and others, 1992; Munsterberg and Lassar, 1995). 
Specification of dermal and myogenic progenitor cells is induced in the dorsal part of 
the somites, whilst the cells in the ventral part of the somite will undergo epithelial–
mesenchymal transition (EMT) and eventually give rise to the sclerotome (Christ and 
others, 2007; Maroto and others, 2012; Yusuf and Brand-Saberi, 2012).  
Tissues generated from the sclerotome comprise the bones of the skeleton, the vertebrae 
and the syndetome, which contain the progenitor cells for axial tendons (Brent and 
others, 2003; Christ and others, 2004; Christ and others, 2000; Dubrulle and Pourquie, 
2003; Monsoro-Burq, 2005). Sclerotome differentiation in the ventral somite is 
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activated by Sonic Hedgehog (Shh) and Noggin / gremlin 1 signals from the notochord 
(Borycki and others, 1998; Brand-Saberi and others, 1993; Brunet and others, 1998; 
Christ and others, 2004; Christ and others, 2000; Marcelle and others, 1999; Stafford 
and others, 2011; Streit and Stern, 1999) resulting in the expression of paired box 1 
(Pax1) and Nkx3.1 (Monsoro-Burq, 2005). In fact Pax1 expression is activated by 
Noggin and Shh. It was shown that in Noggin mutants Pax1 expression is delayed 
(McMahon and others, 1998), whilst overexpression of Shh in cultured, unsegmented 
paraxial mesoderm enhanced Pax1 expression (Fan and others, 1995; Fan and Tessier-
Lavigne, 1994; Johnson and others, 1994; Munsterberg and others, 1995).  
Myogenesis is induced by dorsalizing signals secreted from the dorsal neural tube and 
the surface ectoderm (Buckingham, 2001).  
 
1.2 Myogenesis 
 
Induction of the dermomyotome is first observed by the expression of myogenic 
determination genes, such as Pax3, Myf 5 and MyoD (Tajbakhsh and others, 1998; 
Tajbakhsh and Buckingham, 2000). Myogenesis is activated by Wnt-ligands Wnt-1, -3a 
and -4 derived from the dorsal neural tube and surface ectoderm, as well as Shh 
signalling from the notochord and floor plate (Tajbakhsh and Buckingham, 2000).  
It was shown that ectopic expression of Wnt ligands can induce dorsal markers like 
Pax3 and MyoD in chick somites (Munsterberg and others, 1995; Wagner and others, 
2000) and further studies revealed that myogenic induction is mediated by β-catenin/ 
TCF signalling (Schmidt and others, 2000); for an overview of canonical Wnt-
signalling see figure 1.2).  
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Figure 1.2: Schematic overview of canonical Wnt-signalling 
(A)  In the absence of Wnt - ligands,  cytoplasmic β-catenin is bound to a destruct ion 
complex containing Axin, APC, GSK3β and CK1 leading to  the phosphorylat ion 
of β-catenin by CK1 and subsequent ly by GSK3β. Following phosphorylat ion ,  β-
catenin is recognised by β-Trcp, an E3-ubiquit in ligase ,  target ing β-catenin for 
proteasomal degradat ion.  
(B) In the presence of Wnt  ligands,  the Wnt receptor Frizzled (Fz) forms a complex 
with its co-receptors LRP5/6. Furthermore, Dishevelled (Dvl) is then recruited to 
Fz leading to  the phosphorylat ion of LRP5/6 and subsequent  binding o f Axin to 
the co-receptors.  Subsequent ly the destruct ion complex dissociates and 
phosphorylat ion and proteasomal degradation of β -catenin is inhibited leading to 
β-catenin accumulat ion in the nucleus,  where it  act ivates Wnt -responsive genes 
together with TCF.   
Figure taken from (MacDonald and others, 2009)  
Wnt signalling in the ventral part of the somites, the future sclerotome is inhibited by 
secreted forms of Wnt-receptors, such as Frzb and secreted Frizzled-related proteins 
(Sfrps) (Bovolenta and others, 2008; Leyns and others, 1997). Frzb is a homologue of 
Frizzled, which is lacking the transmembrane domain and therefore has been described 
to function as a soluble antagonist of Wnt-signalling by binding and sequestering of 
Wnt-ligands (Leyns and others, 1997). Sfrp2, as an example for Sfrps inhibits 
specifically Wnt-1 and Wnt-4 signalling in the myotome, where its expression is 
regulated by Shh derived from the floor plate and the notochord (Lee and others, 2000).  
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As mentioned previously, Shh signalling is needed for myogenic induction in the 
somites (Buckingham, 2001; Buckingham and others, 2003). It was reported that Shh 
signalling in the dorsal somite is regulated by Wnt-signalling (Borycki and others, 
2000). These authors reported that Wnt-1 and Wnt-4 by signalling via β-catenin 
together with signals from the surface ectoderm can restrict Gli2 and Gli3 expression, 
but not Gli1 expression, to the myotome in the developing somite. The Gli proteins are 
transcriptional effectors of the Shh transduction cascade (for a summary of Shh/ Gli 
signalling see (Hui and Angers, 2011). As ectopic expression of Shh in somites of chick 
embryos was shown to increase the sclerotome and to inhibit dermomyotome formation, 
it was thought that the function of Shh-signalling in the induction of either the myotome 
or the sclerotome depend on the dose of Shh (Dietrich and others, 1997; Johnson and 
others, 1994). Furthermore, a dose dependency was also highlighted for dorsalizing 
signals and it was shown that the myotome was only induced when the levels of 
Wnt/Shh were present in appropriate levels in a specific region of the somite (Dietrich 
and others, 1997). Interestingly though studies using a Shh null mouse still revealed the 
presence of the myotome, although compromised in the epaxial somite leading to the 
suggestion that Shh might not be directly involved in myogenic induction (Borycki and 
others, 1999; Kruger and others, 2001). 
Muscle progenitor cells reside in the dermomyotome, where they respond to dorsalizing 
signals that induce myogenic differentiation (Buckingham, 2001). Myogenic precursor 
cells have been shown to migrate out of the dermomyotome to form the myotome (see 
figure 1.3). However, how the cells migrate is not fully understood yet.  
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Figure 1.3: The formation of the myotome 
The scheme represents the migrat ion of muscle progenitor cells from the edges of the 
dermomyotome to form the myotome. 
Figure taken from (Buckingham, 2001) 
 
Electroporation of a GFP reporter into early somites of chick embryos followed by real-
time cell lineage analysis showed that myotome formation is established in two distinct 
phases and requires migration of myocytes from all four borders of the dermomyotome 
(Gros and others, 2004). The first phase was described to mediate myotome growth, as 
myocytes exclusively derived from the medial border of the dermomyotome migrate 
into the myotome. In the following second phase myocytes from all four borders (the 
medial, caudal, cranial or rostral and ventrolateral dermomyotome border) contribute to 
the myotome.  
Cells of the myotome differentiate to form myofibres. Differentiation of myoblasts 
involves de-novo myofibrillogenesis, the establishment of the sarcomeric structures and 
requires the withdrawal of the myocytes from the cell cycle, followed by expression of 
muscle-specific genes and fusion of myocytes to generate multi-nucleated myotubes 
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(Andres and Walsh, 1996; Kontrogianni-Konstantopoulos and others, 2006; Pownall 
and others, 2002).  
Skeletal muscle development is regulated by basic helix-loop-helix (bHLH) domain 
containing myogenic regulatory factors (MRFs); Myf 5 and MyoD as myogenic 
determination marker genes and MRF4 and myogenin as differentiation marker genes 
(Pownall and others, 2002). 
Myf 5 and MyoD have been shown to be expressed in proliferating myoblasts 
(Emerson, 1990). It was further reported that both genes auto regulate their expression 
to establish a constant Myf 5/ MyoD signal leading to the suggestion that both genes are 
involved in maintaining the myocyte population (Emerson, 1990; Thayer and others, 
1989). Expression of myogenin and MRF4 is induced during myoblast differentiation 
and might mediate the expression of sarcomeric proteins (i.e. proteins of the contractile 
apparatus) by function together with Myf 5 and MyoD (Edmondson and Olson, 1989; 
Lassar and others, 1991; Miner and Wold, 1990; Rhodes and Konieczny, 1989; Wright 
and others, 1989) 
 
1.3 Myofibrillogenesis  
 
Myofibrillogenesis describes the assembly of sarcomeric proteins and their maturation 
(Sanger and others, 2002). 
The first evidence for primitive myofibrils was already reported in 1913 when non-
striated fibres were observed close to the cell membrane during trout muscle 
development (Heidenhain, 1913) as cited by (Sanger and others, 2010). Similar non-
striated filamentous structures have also been seen in newly formed chick musculature 
(Fischman, 1967; Hibbs, 1956). Furthermore it was observed that the thick filament 
elongated daily during muscle development in drosophila melanogaster leading to the 
suggestion that muscle structures are assembled over a distinct period of time (Auber, 
1969) as cited by (Sanger and others, 2010). Advanced techniques in microscopy and 
the generation of muscle cell cultures made it possible to study myofibrillogenesis in 
more detail. Gene expression studies revealed that during myofibrillogenesis Desmin is 
the first of the sarcomeric proteins to be expressed, followed by titin, muscle-specific 
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Actin, myosin heavy chains and Nebulin (Furst and others, 1989). Furst et al (1989) 
reported that during mouse development around gestation day 11-12, before fusion of 
myoblast to form multinucleated myotubes at gestation day 13-14, first immature 
myofibrils were established displaying periodic striation for myosin and Nebulin, whilst 
titin was seen localised to the Z-disc. It was therefore suggested that the structures of 
the Z-disc and the thick filament, i.e. the myosin, form separately from each other and 
only align during later part of muscle development (Furst and others, 1989).  
As myofibrillogenesis was studied in more detail in cultured muscle cells and during 
embryonic muscle development, it became clear that myofibril assembly followed 
similar patterns. It was described that myosin was one of the earliest proteins seen to 
display a striated pattern during muscle differentiation (Dlugosz and others, 1984; 
Kulikowski and Manasek, 1979; Moncman and Wang, 1996). Furthermore it was found 
that a non-muscular isoform of myosin is present in early premyofibrils (the precursor 
for myofibrils as described by (Rhee and others, 1994), which is replaced by muscle 
specific myosin during muscle differentiation and maturation (see figure 1.3; (Dabiri 
and others, 1997; Dlugosz and others, 1984; Fallon and Nachmias, 1980; Mittal and 
others, 1987; Rhee and others, 1994; Sanger and others, 2002).  
A further structure seen to be formed during myofibrillogenesis and also already present 
in premyofibrils are primitive Z-discs (Rhee and others, 1994). α-Actinin associated to 
early thin filament was shown to display puncta, also described as beaded Z-bands in 
cultured myocytes, which eventually aligned laterally and fused into linear structures 
during muscle maturation (Dabiri and others, 1997; Rhee and others, 1994; Sanger and 
others, 1986; Sanger and others, 1984a; Sanger and others, 1984b). Furthermore it was 
shown in cell culture and early chick hearts that non-muscular myosin aligned with the 
Z-bodies in an alternating fashion (Du and others, 2008; Rhee and others, 1994). These 
structures were termed minisarcomeres. As the minisarcomeres mature, the Z-bands 
connect laterally and the Actin and non-muscle myosin start to co-localise and 
eventually display an organised overlapping pattern (Mittal and others, 1987). Cells, 
which revealed overlapping Actin/ non-muscular myosin structures were termed nascent 
myofibrils (see figure 1.4; (Sanger and others, 2010). Furthermore, nascent myofibrils 
already express muscle-specific myosin II, although at this point it does not align to the 
present striated filaments (Rhee and others, 1994; Wang and others, 2005a).  
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Mature myofibrils have established sarcomeric structures containing partially 
overlapping, defined thick and thin filaments (see figure 1.4 and chapter 1.4;(Sanger 
and others, 2010; Wang and others, 2005a)). Non-muscle myosin has now completely 
been removed and replaced by muscle-specific myosin II (Dabiri and others, 1997; 
Rhee and others, 1994).  
 
 
Figure 1.4: De-novo myofibrillogenesis 
Schematic out line of myofibr illogenesis: Premyofibr ils are formed when Z -bodies begin 
to form at  the edges of muscle cells,  comprising α -Act inin st ructures linked with Act in,  
Act in binding proteins and non-muscular myosin II.  During further maturat ion muscular     
myosin and t it in are added to the minisarcomeres and Z -bodies align in register to create 
nascent  myofibr ils.  Mature myofibr ils are defined by linear Z -discs.  In mature myofibr ils  
non-muscular myosin is absent  and myosin-binding proteins are incorporated into the 
thick filament .  
Figure taken from (Sanger and others, 2010) 
 
However, there are still processes during myofibrillogenesis, which are controversially 
discussed. Based on their observation, Dlugosz et al. (1984) described that non-
muscular myosin II fibres would act as scaffolds for myofibrils assembly, whilst Rhee 
et al. (1994) suggested that structures comprising α-Actinin, non-muscle myosin and 
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Actin would be the initiation point of myofibrillogenesis. A further hypothesis for 
myofibrillogenesis was proposed reporting that the Z-band proteins and the myosin 
thick filament (termed I-Z-I brush) would assemble separately from each other (Holtzer 
and others, 1997; Schultheiss and others, 1990). A similar observation was made for 
cardiac myofibrillogenesis (Ehler and others, 1999; Rudy and others, 2001). 
Furthermore it was reported that both structures, the thick and the thin filament, would 
eventually associate with each other mediated by interactions with the titin filament and 
Nebulin (Holtzer and others, 1997). However, Sanger et al. (2010) contradict the I-Z-I 
brush hypothesis based on the described evidence for premyofibrils, which contains Z-
disc proteins associated with myosin in minisarcomeres (Rhee and others, 1994; Sanger 
and others, 2010). However, it was shown that titin might play a key part during 
myofibrillogenesis as it was suggested that titin might mediate thick filament assembly 
and its alignment to the Z-disc, thereby stabilising the sarcomeric protein organisation 
(Turnacioglu and others, 1997a; Turnacioglu and others, 1997b). Also, the involvement 
of non-muscular myosin for thick filament alignment during myofibrillogenesis was 
confirmed by using phosphorylation inhibition studies (Du and others, 2003).  
On the other hand the presence of premyofibrils is also open for discussion, as 
premyofibrils could not be confirmed in heart muscles in some publications (Ehler and 
others, 1999; Rudy and others, 2001; Tullio and others, 1997). Recent studies however 
showed that cardiac myofibrillogenesis also requires premyofibrils (Du and others, 
2003; Du and others, 2008), leading to the suggestion that myofibrillogenesis both in 
heart and skeletal muscles follow similar temporal patterns (Sanger and others, 2010). 
Mature myofibrils display a defined complex of proteins, which will eventually mediate 
muscle contraction: the sarcomere.  
 
1.4 The sarcomere 
 
The basic unit of the contractile apparatus is called a sarcomere. Sarcomeres are linked 
in an end-to-end fashion forming long tubes called myofibrils. One muscle fibre is made 
up of a variable number of parallel aligned myofibrils, which also align parallel to each 
other to generate one striated muscle (see figure 1.5; (Craig and Padron, 2004). 
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Figure 1.5: The striated muscle 
The sarcomere (d) is the basic unit  of st riated muscles.  Hundreds of sarcomeres make up 
myofibr ils (c) and parallel aligned myofibr ils are the subunits of one muscle  fibre (b). 
The st riated muscle also consist s of a bundle of hundreds to  thousands of muscle fibres 
(a). 
Figure taken from SPORTS’N SCIENCE (http://sportsnscience.utah.edu/95 -miles-per-
hour-performance-physio logy-of-pitchers/).   
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Skeletal and cardiac muscles are both striated muscles. These muscles have been termed 
striated after the striped pattern observed in images of skeletal and heart muscle fibres 
originating from alternating striations of the Actin and myosin filaments in the 
sarcomere. The Actin filament is also known as the thin filament, whilst the myosin 
filament was termed the thick filament (see figure 1.6).   
 
 
Figure 1.6: An electron microscopy image of a sarcomere 
The striat ions of the Act in filament  (light  grey within the I -band) and the myosin 
filament  (dark within in the A-band) can be observed in thin sect ions of a muscle fibre.  
Figure modified from (Agarkova and Perriard,  2005) 
Based on optical and electron microscope images of muscle fibres (see figure 1.6), parts 
of the sarcomeres have been identified and analyzed. One sarcomere stretches from one 
Z-disc to another Z-disc, whilst the area of the dark myosin filament is termed the A-
band (anisotropic in polarised light). In the middle of the sarcomere a further dark area 
has been termed the M-band, derived from the German word Mittelscheibe, which 
means the disc in the middle, or central disc. At the M-band myosin is associated to 
other sarcomeric proteins, for example the elastic titin filament (Houmeida and others, 
1995). The area, which contains only the Actin thin filament, is called the I-band 
(isotrophic in polarised light). 
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When sarcomeres were analysed, it was reported that Actin and myosin were the most 
abundant proteins in the sarcomere, making up around 70% of the myofibril (Hanson 
and Huxley, 1957; Huxley and Hanson, 1957).  
The thin filament consists not only of Actin; it also interacts with Nebulin, tropomyosin 
and troponin, whilst the thick filament consists of myosin and other associated proteins, 
such as MyBP-C and MyBP-H (Craig and Padron, 2004; Offer and others, 1973; 
Squire, 1997; Starr and Offer, 1983). Titin has been reported to associate with both, the 
thin and the thick filament (Sanger and Sanger, 2001).  
A sarcomere in the myocardium displays similar structure as a sarcomere in skeletal 
muscle fibres (see figure 1.7). 
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Figure 1.7: Sarcomeric structure in cardiac and skeletal muscle  
Both, cardiac muscle and skeletal muscle sarcomeres, display a similar sarcomeric structure. The Actin 
thin filament is linked to the Z-disc via α-Actinin and overlaps partially with the thick filament. Also in 
both sarcomeres, Nebulin is associated with the whole length of the Actin filament. Cardiac muscle 
exclusively expresses Nebulette, which binds to Actin, but only close to the Z-disc. 
Figure taken from (Pappas and others, 2011) 
 
However, assembly of sarcomeres in the heart has been described to be much quicker 
compared to skeletal muscle myofibrillogenesis (Ehler and others, 1999). During heart 
development in chick embryos the first proteins described to associate were titin and α-
Actinin during the formation of early Z-discs, followed by myosin and later Actin 
(Tokuyasu and Maher, 1987a; Tokuyasu and Maher, 1987b). It was furthermore 
reported that the cardiomyocytes aligned with other neighbouring cells very early 
during cardiogenesis potentially to establish a scaffold for the assembly of myofibrils 
(Shiraishi and others, 1993; Shiraishi and others, 1995; Tokuyasu, 1989). Further data 
analysing the assembly of chick heart myofibrils was obtained from triple-immuno-
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stained developing hearts. It was reported that myofibrils in chick hearts assembled 
without the intermediate stage of premyofibrils (Ehler and others, 1999); as described 
previously).  However, the presence of premyofibrils during heart development has 
been recently confirmed as well, as non-muscular myosin was detected during 
myofibrillogenesis in precardiac mesoderm explants and during avian heart 
development in situ (Du and others, 2003; Du and others, 2008). 
Each sarcomeric protein has a specific localisation and function as described in the 
following sections. 
 
1.5 The thin filament 
 
1.5.1 Actin 
 
Together with myosin, the Actin filament is the most abundant protein in the sarcomere 
and it is the main component of the thin filament (Pollard, 1990; Pollard and Cooper, 
2009). The thin filament is assembled as globular (G) Actin monomers self-associate to 
form filamentous Actin, or F-Actin (Pollard, 1990). Furthermore, two Actin polymer-
strands twist around each other forming a double helix (O'Brien and Dickens, 1983). 
Within the structure of the Actin monomer lie binding sites for the thick filament. One 
Actin monomer was described to consist of two major domains each comprising 2 
subdomains. The smaller of the two major domains comprises subdomains 1 and 2 and 
is located at the periphery of the thin filament, whilst subunits 3 and 4 built the core of 
the filament. Between both major domains is the central cleft, which contains a tightly 
bound nucleotide, in vivo Mg 
2+
, and either an ATP or an ADP molecule (Cooke, 1997). 
The cation is potentially involved in stabilising the structural organisation of the two 
major domains, whilst hydrolysis of ATP is needed for polymerization of the Actin 
filament (Kabsch and others, 1990; Kabsch and Vandekerckhove, 1992; Pollard, 1990). 
Only subdomain 1 in the Actin monomer was shown to associate with the myosin head 
during muscle contraction (Miller and others, 1995; Sutoh and others, 1991). 
The Actin fibres within the thin filament associate to various other sarcomeric proteins, 
such as Nebulin, tropomyosin, troponin and capping proteins (Craig and Padron, 2004).  
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1.5.2 Proteins of the Z-disc 
 
α-Actinin is the main part and the backbone of the Z-disc. However, various other 
proteins, such as Z-protein, Znin, FATZ, amorphin, myotilin, ZASP and myopalladin, 
as well as overlapping ends of Nebulin, titin and CapZ can be identified in the Z-disc. 
The intermediate filaments can also be associated to the Z-disc (Craig and Padron, 
2004). 
The major protein of the Z-disc as mentioned previously is α-Actinin. Its function is the 
connection and stabilisation of the Actin and the titin filament in adjacent sarcomeres 
(Vigoreaux, 1994). It was suggested that α-Actinin can itself form bridge-like structure 
cross-linking the thin filament of neighbouring sarcomeres, whilst for the binding of the 
titin filament a complex of α-Actinin together with Actin is needed (Luther, 1991; 
Young and others, 1998). 
Further compounds of the Z-disc amongst others are myopalladin, myopodin and 
myozenin. Myopalladin has been reported to connect Nebulin to α-Actinin and thereby 
associating it to the Z-disc (Bang and others, 2001), whilst myopodin is an actin-
bundling protein potentially involved in stabilising the Z-disc (Weins and others, 2001). 
Myozenin or FATZ has been shown to bind to α-Actinin, γ-filamin and telethonin and 
might cross-link these proteins with each other (Takada and others, 2001). It was also 
suggested that myozenin might be involved in mediating dimerization of Z-disc 
proteins.  
Most other proteins of the Z-disc are less well described, but a brief overview of various 
other Z-disc related proteins can be found in Craig and Padron (2004). 
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1.5.3 Nebulin 
 
Nebulin has been described to be a potential ruler for the thin filament (Labeit and 
others, 1991). It was reported that Nebulin interacts with Actin monomers along the 
whole length of the Actin filament and that the size of Nebulin correlates with the 
length of the Actin fibre in different muscle types (Kruger and others, 1991; Labeit and 
others, 1991; Labeit and Kolmerer, 1995a). Furthermore it was shown that Nebulin 
interacts with the thin filament capping proteins consistent with a potential role for 
Nebulin as a length specifier (McElhinny and others, 2001; Pappas and others, 2008). 
Nebulin has also been shown to be involved in muscle contraction (Bang and others, 
2009; Chandra and others, 2009) 
 
1.5.4 Tropomyosin/Troponin 
 
The thin filament is interacting with the troponin/tropomyosin complex as mentioned 
previously. This complex contains tropomyosin associated to one molecule of troponin 
C, troponin I and troponin T (Craig and Padron, 2004; Farah and Reinach, 1995; Squire, 
1997). Only troponin C can bind free Calcium ions, whilst troponin T connects troponin 
C and troponin I with tropomyosin. Troponin I associate with tropomyosin along the 
Actin thin filament in non-active muscle, partially covering myosin binding sites and 
thereby preventing Actin-myosin interactions (Bailey, 1948; Farah and Reinach, 1995; 
Gomes and others, 2002). In active muscle troponin I stays associated to tropomyosin 
along the Actin filament, although its localisation is slightly shifted as compared to in 
non-active muscles (Farah and Reinach, 1995). 
The troponin/tropomyosin complex regulates muscle contraction by responding to 
changes of cellular Ca 
2+
 concentrations  (see chapter 1.9;(Farah and Reinach, 1995). 
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1.5.5 Thin filament capping proteins 
 
A constant, stable Actin filament is necessary for the sarcomere, as muscle contraction 
is dictated by the ratio of overlapping thin filament to thick filament (Huxley, 1957; 
Huxley and Simmons, 1971). Capping proteins are preventing depolymerization and 
also additional polymerization above specific length in the thin filament (Cooper and 
Schafer, 2000; Fowler, 1996; Littlefield and Fowler, 1998). Cap Z, also known as β-
Actinin, interacts with Actin at its barbed end (at the Z-disc) (Casella and others, 1986; 
Fowler, 1996; Maruyama and others, 1990). Therefore, Cap Z prevents disassociation 
and re-association of the Actin filament. Furthermore it was shown that CapZ also 
interacts with the Z-disc protein α-Actinin thereby anchoring the thin filament to the Z-
disc (Papa and others, 1999). This link is established during myofibrillogenesis and also 
involves the specification of the polarity of the Actin filament (Schafer and others, 
1995).  
At the pointed ends the thin filament is capped by tropomodulins (Fowler and others, 
1993; Gregorio and others, 1995; Weber and others, 1994). Capping of the thin filament 
by tropomodulins has been described as being tight in striated muscle to prevent further 
polymerization and elongation of the thin filament (Fowler and others, 1993; Gregorio 
and Fowler, 1995; Mudry and others, 2003). Tropomodulin in association with 
tropomyosin prevents shortening of Actin fibres (Kostyukova and others, 2006; 
Kostyukova and others, 2005; Mudry and others, 2003). It was furthermore suggested 
that Nebulin might place tropomodulin at the end of growing pointed ends of the thin 
filament (McElhinny and others, 2001).  Recently it was shown that both capping 
proteins display a highly dynamic nature in cultured myocytes (Gregorio and others, 
1995; Littlefield and others, 2001). Although the capping proteins still restrict the length 
of the thin filament, a constant de-and repolymerisation of Actin monomers at both ends 
has been observed. 
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1.6 The thick filament 
 
1.6.1 Myosin 
 
Myosins belong to the family of ATP-dependent motor proteins and are usually 
associated with Actin (Sellers, 2000). Myosins in smooth and skeletal muscle have been 
described extensively and have been shown to play a key role in muscle contraction and 
force transmission (Cooke, 1997; Sellers, 2000), but myosins have also been described 
in eukaryotes, mammals and plants (Sellers, 2000). Based on differences and/ or 
similarities mainly in the motor domain, myosins have been organised into 15 classes 
(for a phylogenic tree and description of each class, see (Sellers, 2000). 
All known myosins so far have been described to interact with Actin, hydrolyze ATP 
and produce different types of movement including previously mentioned muscle 
contraction, but also trafficking along fibres and cell migration (Cooke, 1997; Lecuona 
and others, 2009; Rayment and others, 1993; Vicente-Manzanares and others, 2009). 
Myosins typically contain three functional subdomains: the motor domain, which 
comprises Actin-binding properties and a catalytic centre for ATP hydrolysis, a neck 
domain, which is associated with either myosin light chains or Calmodulin and the 
distal tail domain, which is involved in anchoring and positioning the myosin head or 
motor domain in the right orientation for its interaction with Actin (Sellers, 2000). 
Whilst the motor domain across different types of myosin have been reported to be 
relatively conserved, the neck and the tail domain can vary across species and even 
across myosin classes themselves (Sellers, 2000). The neck domain can contain a 
diverse number of Calmodulin/ light chain binding sites, whilst the tail domain can 
contain distinct additional functional domains (Cheney and Mooseker, 1992; Sellers, 
2000). Furthermore, many myosins can dimerize and therefore form two-headed 
molecules (Sellers, 2000). Dimerization takes place along the myosin tail comprising 
specific coiled-coil forming sequences. 
In striated muscles, myosin is a hexamer comprising two identical myosin heavy chains 
and two pairs of myosin light chains (Lowey and others, 1979; Lowey and others, 1969; 
Lowey and others, 1991). The C-terminus of the myosin heavy chains form a dimer 
along the tail region (Lowey and others, 1969), whilst the N-terminus of each heavy 
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chain separately forms a globular head (Rayment and others, 1993). The globular head 
contains the distinct ATP- and Actin-binding sites and structural changes in the myosin 
head mediated by ATP hydrolysis are a requirement for muscle contraction (Cooke, 
1997; Rayment and others, 1993). The role for myosin during muscle contraction is 
described in chapter 1.9. 
 
1.6.2 The proteins of the M-band 
 
Creatine kinase, M-protein and Myomesin make up the M-band. However, parts of the 
myosin filament, as well as the C-terminus of titin and a splicing isoform of myomesin, 
Skelemin can also be found in the M-band (Agarkova and others, 2000; Furst and 
others, 1999; Wallimann and Eppenberger, 1985). 
As proteins of the M-band are not a main focus of this project, I will not describe the M-
band any further. However, further information about Creatine kinase, Myomesin, M-
protein and Skelemin be found in (Agarkova and others, 2000; Furst and others, 1999; 
Grove and others, 1984; Kushmerick, 1998; Morimoto and Harrington, 1972; 
Obermann and others, 1996; Obermann and others, 1995; Price and Gomer, 1993; 
Steiner and others, 1999; Turner and others, 1973; Van Der Ven and others, 1996; 
Wallimann and others, 1977; Woodhead and Lowey, 1983).   
Based on obtained data for the proteins found in the M-band, it was reported that the 
main functions of the M-band involve stabilizing the thick filament between 
neighbouring sarcomeres, as well as restoring and buffering the ATP-levels within the 
myofibril (Agarkova and Perriard, 2005; Elliott and others, 1963; Kushmerick, 1998; 
Obermann and others, 1996; Wallimann and Eppenberger, 1985). 
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1.7 The intermediate filament 
 
The intermediate filaments can be observed in the periphery of the sarcomere and its 
main function is the establishment and maintenance of the structure of muscle fibres by 
transverse cross-linking of neighbouring myofibrils (Craig and Padron, 2004; Goldman 
and others, 2012). Intermediate filaments also connect myofibrils to the sarcolemma and 
surrounding nuclei (Herrmann and Aebi, 2000; Stromer, 1990; Wang and Ramirez-
Mitchell, 1983).  
Intermediate filaments have been reported to surround the myofibril around the Z-disc 
and also along the M-band by forming filamentous rings (Stromer, 1990; Wang and 
Ramirez-Mitchell, 1983). These rings have been shown to connect adjacent Z-disc- and 
M-band- rings of neighbouring myofibrils with each other (Stromer, 1990).  
Desmin is the main protein of the intermediate filament in both developing and adult 
muscles (Edstrom and others, 1980; Herrmann and Aebi, 2000; Paulin and Li, 2004). It 
has been shown to be linked to the Z-disc as well as to associate with Nebulin along the 
Actin filament (Bang and others, 2002). Furthermore Desmin forms cross-links between 
a sarcomere and the sarcolemma, mitochondria and nuclei in skeletal muscle fibres 
(Lazarides, 1982). It was therefore suggested that Desmin might play a crucial role in 
sarcomere alignment, sarcomere stabilisation, muscle contraction and force transmission 
(Balogh and others, 2005; Boriek and others, 2001; Paulin and Li, 2004). The 
generation of Desmin KO mice have further highlighted the function of Desmin in 
myofibril stabilisation, maintenance of myofibril integrity and myofibril regeneration 
(Li and others, 1996; Milner and others, 1996).   
Further proteins of the intermediate filaments are Vimentin, Synemin, Nestin and 
Paranemin. These proteins are not described any further in this section, as they are not 
relevant for this project. However, their functions are described in following 
publications: (Bellin and others, 1999; Bilak and others, 1998; Granger and others, 
1982; Hemken and others, 1997; Herrmann and Aebi, 2000; Lendahl and others, 1990; 
Ngai and others, 1985; Sax and others, 1989; Schweitzer and others, 2001).  
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1.8 The titin filament 
 
Titin is a huge muscle-specific protein, which can be between 3-4 MDa large. It is 
associated to the Z-disc, where it interacts with α-Actinin and elongates into the M-
band, where it binds to the M-band protein myomesin (Gautel, 1996; Gautel and others, 
1996; Labeit and Kolmerer, 1995b; Maruyama, 1976; Maruyama and others, 1976; 
Obermann and others, 1996; Obermann and others, 1995; Vinkemeier and others, 1993; 
Wang and others, 1979). After myosin and Actin, titin is the third most abundant protein 
is striated muscle (Fukuda and others, 2008). Analysing the structure and properties of 
titin in more detail, it was shown that titin can act as a molecular spring thereby 
sustaining elasticity in the sarcomere (Labeit and Kolmerer, 1995b; Linke and Granzier, 
1998). However, only the region of titin localised to the I-band is elastic (Labeit and 
Kolmerer, 1995b). This region consists of two segments of tandemly arranged 
immunoglobulin-like (Ig) domains, one close to the Z-disc the second one further distal, 
which are spatially separated by a PEVK amino acid sequence, rich in proline (P), 
glutamate (E), valine (V) and lysine (K) residues and a N2B element  (Labeit and 
Kolmerer, 1995b), see figure 1.8). All of the mentioned domains display spring-like 
functions and allow the protein to extend (Helmes and others, 1999; Labeit and 
Kolmerer, 1995b).  
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 Figure 1.8: The titin spring in the sarcomere 
Tit in funct ions as a spring localised in the I -band of the sarcomere. In heart  muscle three 
splicing isoforms for t it in have been reported. However,  all t it in iso forms share 
conserved st ructural domains in the extensible region, such as Ig segments and the PEVK 
domain.  
Figure taken from (LeWinter and Granzier ,  2010) 
 
Functions of the titin filament have been studied extensively in cardiomyocytes and also 
in skeletal myocytes. For cardiac titin three isoforms have been described, whilst 
skeletal titin exists in at least two isoforms (Fry and others, 1997; Granzier and Labeit, 
2002; LeWinter and Granzier, 2010) During relaxation the muscle is stretched and a 
passive force independent of actomyosin interaction is generated leading to the 
extension of the sarcomere (Fukuda and others, 2008). The titin Ig domain has been 
shown to respond first to the passive force by changing their alignment. If the muscle is 
stretched further, the PEVK domain can extend and furthermore the Ig domain is also 
able to unfold allowing further extension of the titin spring (Fukuda and others, 2005; 
Helmes and others, 1999).  
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Furthermore, the titin filament is also responsible for generating a restoring force 
pushing the Actin fibres away from the Z-disc, increasing the myosin/Actin overlapping 
area and re-establishing the original structure and length of the sarcomere (Helmes and 
others, 1996) 
More recently, a role for titin in myofibrillogenesis was also reported (Gregorio and 
others, 1999; Holtzer and others, 1997; Turnacioglu and others, 1997a; Turnacioglu and 
others, 1997b). 
 
1.9 Muscle contraction 
 
Muscle contraction is needed to generate force to mediate various processes inside the 
organism’s body. For example, muscle contraction in skeletal muscles mediates 
movement, while contraction of cardiac muscle is needed to provide a constant 
circulation of blood.  
Muscle contraction was first described as the sliding of the Actin and myosin filaments 
due to cross-bridges formed between the myosin from the A-band with specific binding 
sites in the actin filaments (Huxley, 1957). Since then the two-filament model has been 
reviewed and refined (Herzog and others, 2012). With the revelation of the structure of 
the myosin head bound to its attachment site in the Actin filament, a more detailed 
model for the formation of cross-bridges was described (Rayment and others, 1993). 
Not only did this model describe how the sliding of the two filaments was regulated, it 
also explained how ATP hydrolysis was involved in generating the energy for muscle 
contraction. 
Actomyosin complex formation and muscle contraction has been described to involve 
as 3-step process, which starts with the formation a collision complex between Actin 
and myosin, followed by a direct interaction of both (attached state), which then in turn 
is coupled to ATP hydrolysis, as myosin bound to ATP is inhibited from binding to 
Actin (Geeves and Conibear, 1995; McKillop and Geeves, 1993).  Following the 
formation of the attached state, muscle contraction takes place and subsequently both 
the Actin and myosin filament dissociate (rotated state) (Geeves, 1991; Geeves and 
Conibear, 1995) 
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Geeves and Conibear (1995) further reported that potentially two myosin heads are 
associated to one Actin binding site. However only one of these myosin heads is 
directly attached to the Actin filament, whilst the other stays detached.  
Based and summarised on published data, muscle contraction can be described as 
follows (Alberts and others, 1994): 
Muscle contraction is initiated by an action potential, which triggers the release of 
Calcium-ions from the sarcoplasmic reticulum. Free Ca 
2+
 is subsequently bound to 
troponin C, which leads to a rearrangement of the tropomyosin/troponin complex along 
the Actin filaments and opens up binding sites for myosin in the Actin filament (Farah 
and Reinach, 1995; Gordon and others, 2000; Perry, 2001; Squire, 1997). The myosin 
head can now bind to Actin and formation of the actomyosin complex leads to the 
activation of the ATPase. ATP is subsequently hydrolyzed within the catalytic site of 
the myosin head and a weak association of the myosin head and the Actin filament is 
initiated. Release of the inorganic phosphate (Pi), which was also reported to interact 
with the Actin polymer, leads to strengthening of the interaction between myosin and 
Actin. Furthermore, the ADP is released changing the conformation of the myosin head 
triggering a pulling action along the Actin fibres, called the power-stroke. The myosin 
head will stay interlocked with the Actin filament until a new ATP molecule is bound. 
Upon binding of ATP, the myosin head undergoes structural changes releasing it from 
its Actin binding site and allowing it to travel along the Actin fibres towards a new 
Actin binding site. Once the myosin head is close to a further Actin binding site, the 
ATP cycle starts again and ATP hydrolysis will eventually trigger a further power 
stroke (see figure 1.9).  
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Figure 1.9: The Actomyosin complex during muscle contraction 
A myosin head binds to  the Act in filament .  Upon release of Pi,  st ructural changes in the 
myosin head occurs leading to the establishment  of a strong Act in/myosin interact ion and 
force generat ion. The obtained force is  used upon ADP release to  mediate a power st roke 
init iat ing muscle contract ion.   
Figure taken from (Alberts and others, 1994) and based on (Rayment  and others, 1993) 
 
42 
 
1.10 Kelch 
 
Kelch was first identified in Drosophila melanogaster and based on its specific kelch-
repeats domain further Kelch-like and Kelch-related proteins have been found (Adams 
and others, 2000; Xue and Cooley, 1993) 
 
1.10.1 Kelch 
 
As mentioned previously, Kelch was first identified in Drosophila melanogaster 
(Schupbach and Wieschaus, 1991; Xue and Cooley, 1993). It was reported that 
drosophila females bearing a mutation in the kelch gene are sterile due to insufficient 
cytoplasm transport throughout oogenesis (Schupbach and Wieschaus, 1991; Xue and 
Cooley, 1993). Cytoplasm transport from nurse cells to the oocyte in drosophila takes 
place along intercellular bridges, also known as ring canals, and transport of cytoplasm 
is important for the oocyte as with the cytoplasm the oocyte receives mRNAs, proteins 
and organelles needed for its development (Mahajan-Miklos and Cooley, 1994). It was 
shown that ring canals in egg chambers of Kelch-mutant drosophila contained all 
necessary cytoskeletal protein except Kelch, but the proteins of specifically the inner 
rim of the ring canal, such as Actin and HTS, were disorganized (Robinson and others, 
1994; Tilney and others, 1996). It was reported that the Actin cytoskeleton was affected 
the most, as Actin-filament bundles were shown to grow into the lumen of the ring 
canal thereby partially blocking the lumen and preventing the influx of cytoplasm into 
the oocyte (Robinson and others, 1994; Tilney and others, 1996).  Kelch was named 
based on the shape of sterile eggs affected by Kelch-mutation as sterile oocytes 
displayed a cup-like egg shell structure (Kelch is a German word for a goblet or cup) 
(Xue and Cooley, 1993). The structure of Kelch was analysed further revealing an N-
terminal BTB-domain and six C-terminal Kelch repeats (Robinson and Cooley, 1997). 
Furthermore it was suggested that Kelch based on its structure and its mutation 
phenotype could organize the Actin filament of the ring canals by cross-linking Actin 
bundles. It was additionally reported that both the BTB domain and the Kelch-repeats 
were involved in binding to the Actin filament and that Kelch might function as a dimer 
being linked via its BTB-domains (Robinson and Cooley, 1997). Recently Robinson 
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and Cooley’s hypotheses were tested and confirmed by (Kelso and others, 2002). 
However, Kelso et al. (2002) also found a temporal correlation between the Arp2/3 
complex function in potentially de novo actin polymerization and Actin cross-linking 
properties by Kelch. But it is not clear yet, how this correlation is mediated.  
More recently a role for Kelch as part of a Cullin3-RING ubiquitin ligase complex was 
reported suggesting that Kelch might target ring canal proteins other than Actin for 
ubiquitinylation and subsequent protein degradation (Hudson and Cooley, 2010). 
 
1.11 The structural domains of Kelch 
 
Drosophila Kelch protein was shown to contain an N-terminal BTB domain and C-
terminal Kelch repeats (Robinson and Cooley, 1997). Since the discovery of Kelch, 41 
Kelch-like proteins have been identified in human beings displaying the same structural 
properties (http://www.genenames.org/genefamilies/KLHL). 
 
1.11.1 Structure and function of the BTB domain 
 
The BTB/POZ domain has first been identified in Drosophila melanogaster and was 
later described to be a conserved motif, which has also been found in bric-à-brac, 
tramtrack and broad complex transcription (BTB) regulators and various pox virus and 
Zinc-finger (POZ) proteins (Bardwell and Treisman, 1994; Robinson and Cooley, 1997; 
Xue and Cooley, 1993; Zollman and others, 1994). 
The core part of the BTB domain was termed the BTB fold and was shown to contain a 
95 amino acid cluster of 5 α-helix structures, which is capped by a short three-stranded 
β-sheet. Both clusters are linked by an additional hairpin-like motif and an extended 
region (Stogios and others, 2005). 
Interestingly though, although the tertiary structure of the BTB fold is very similar 
between all members of the BTB family, the amino acid sequences display little 
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similarity (Stogios and others, 2005). It was reported that the flexibility in the primary 
sequence of the fold allows the BTB domain to exhibit a huge array of functions.  
BTB-domain containing proteins have been shown to be involved in transcriptional 
repression, cytoskeleton regulation, ion channel gating and most prominently in protein 
ubiquitinylation and degradation by binding associated proteins or substrates via the 
BTB-domain (Ahmad and others, 2003; Furukawa and others, 2003; Geyer and others, 
2003; Kang and others, 2004; Kobayashi and others, 2004; Krek, 2003; Minor and 
others, 2000; Pintard and others, 2004; Xu and others, 2003).  
However it was also suggested and proven for some BTB-proteins that, via its BTB-
domain, Kelch and other related proteins can form homodimers (Chen and others, 2002; 
Robinson and Cooley, 1997; Stogios and others, 2005; Zhang and others, 2005).  
 
1.11.2 Structure and function of the Kelch-repeats 
 
Kelch contains six Kelch repeats and it was shown that other proteins containing kelch-
repeats can have between 4 and 7 of these motifs (Bork and Doolittle, 1994; Robinson 
and Cooley, 1997).  
The Kelch motif contains between 44-46 amino acids and the sequence identity between 
individual kelch-repeats is again rather low (Bork and Doolittle, 1994). However, the 
primary structure has some highly conserved features. It was shown that the centre of a 
kelch-repeat domain comprises eight conserved residues; four hydrophobic amino acids 
followed by two glycine residues and two aromatic amino acids. Structural analysis of 
crystals of kelch motifs revealed that seven of described kelch-repeats collectively form 
a β-propeller, wherein each single kelch motif folded as a four-stranded β-sheet makes 
up on blade of the propeller (Ito and others, 1994; Li and others, 2004). The propeller 
structure is assembled around a central axis and is closed by an interaction between the 
first and the last blade of the propeller (Adams and others, 2000) (see figure 1.10). 
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Figure 1.10: The β-propeller of the kelch-repeats 
Β-propellers consist  of 7 kelch-repeats (β1-β7).    
(a) View from the top inside a β -propeller based on the crystal st ructure for the 
galactose oxidase from hypomyces rosellus.  The β -propeller  contains 7 kelch-
repeat blades  
(b)  Side view of the galactose oxidase β-propeller as seen in (a)  
(c) The ring of the galactose oxidase β -propeller is closed by an N-terminal β4 strand 
(orange)                                                                                                                                                       
Figure modified from (Adams and others, 2000) 
 
Many Kelch motif containing proteins have been characterised and their function varies 
just as their sequence similarities vary, including being part of a virus, transcriptional 
repression, for example Leucine-zipper-like transcriptional regulator 1 or muscle 
specific function, e.g. like sarcosin, which is involved in myofibrillogenesis (Adams and 
others, 2000; Goebel and others, 1990; Kurahashi and others, 1995; Paxton and others, 
2011; Taylor and others, 1998). A number of Kelch motif containing proteins have been 
shown to associate with the Actin cytoskeleton (Chen and others, 2002; Kim and others, 
1999; Robinson and Cooley, 1997; Sasagawa and others, 2002; Schmid and others, 
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1994; Soltysik-Espanola and others, 1999; Way and others, 1995), whilst others 
influence the cytoskeleton indirectly without associating to Actin (Adams and others, 
1998; von Bulow and others, 1995). 
 
1.12 The Kelch-like protein family 
 
Kelch-like (Klhl) proteins contain both described structural domains, i.e. the BTB/POZ 
domain and the Kelch-repeats. As more Kelch-like proteins were analysed it was shown 
that Klhl proteins are conserved in nearly all eukaryotes (Adams and others, 2000; 
Robinson and Cooley, 1997).  
 
1.12.1 The structure of Kelch-like proteins 
 
 
Like BTB-containing proteins, Kelch-like proteins have been shown to be involved in 
targeting various substrates for ubiquitinylation and subsequent proteasomal 
degradation as part of an E3 ubiquitin ligase complex (Angers and others, 2006; 
Furukawa and Xiong, 2005; Maerki and others, 2009; Salinas and others, 2006; 
Sambuughin and others, 2012; Zhang and others, 2004). Furthermore, several Klhl 
proteins bind to Actin via their Kelch-repeats (Aromolaran and others, 2012; Chen and 
others, 2002; Hara and others, 2004; Kim and others, 1999; Soltysik-Espanola and 
others, 1999). 
 
Based on structural analysis of both, the Kelch-repeats and BTB domain a model for 
dimerization and formation of a Cullin based E3- ubiquitin ligase complex was 
described (Stogios and others, 2005). Dimerization was reported to occur at the BTB 
domain, whilst the Kelch-repeats are thought to be involved in binding of the ligands, 
such as Cullin-3 (Stogios and others, 2007; Stogios and others, 2005). Between the N-
terminal BTB domain and the Kelchlike repeats at the C-term, a linker domain, the 
BACK-domain, can be found. The model described above suggests a role of the BACK 
domain in positioning bound substrate in the vicinity of the Cul3-ligase complex, but 
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the function of the BACK domain has so far not been proven due to the lack of a crystal 
structure of this domain (Stogios and others, 2005). Recently, Klhl proteins as part of an 
E3 ubiquitin ligase complex have been described in more detail and data obtained from 
functional and structural studies helped describing a better picture of the role of Kelch-
like proteins as part of proteasomal degradation processes (Canning and others, 2013) 
 
 
1.12.2 Ubiquitinylation as a code for protein degradation 
 
Ubiquitinylation is a process used in cells to encode information about the fate of 
proteins. In general, ubiquitinylation is a process involving three types of enzymes; the 
ubiquitin-activating enzymes (E1), the ubiquitin-conjugating enzymes (E2) and the 
ubiquitin ligase enzymes (E3) (Komander and Rape, 2012).  Ubiquitin is first activated 
by the E1 enzyme in an ATP-dependent manner, which involves the transfer of 
ubiquitin to an active site cysteine of an E2 enzyme. The E3 enzyme subsequently 
catalyzes the transfer of the activated ubiquitin from the E2 to a substrate lysine residue 
(Hershko and Ciechanover, 1998; Schulman and Harper, 2009). 
Initially the target protein will be mono-ubiquitinylated. Later lysine-residues in the 
attached ubiquitin-molecule will subsequently by ubiquitinylated as well (Komander 
and Rape, 2012). The generated ubiquitin-chains can vary in length and can be linear or 
branched. Within these ubiquitin chains, it was suggested, lies a code that determines 
the future of the ubiquitinylated protein, for example Lys11- linked ubiquitin-chains 
mediate proteasomal degradation, while Lys63 ubiquitinylation is linked with kinase 
activation and Met1-linked chains are involved in regulating NF-κB signalling (Deng 
and others, 2000; Jin and others, 2008; Rahighi and others, 2009). 
As mentioned before ubiquitin will eventually be ubiquitinylated itself in distinct 
pattern, e.g. in a linear or branched pattern. This is possible as ubiquitin contains 7 
lysine residues along it N-terminus, which all point into a different directions 
(Komander and Rape, 2012). Which type of ubiquitinylation is used on specific 
substrates is coordinated by the co-operation of E2 and E3 enzymes.  
The ubiquitin-code for proteasomal degradation has been studied in yeast and was 
shown to start with the mono-ubiquitinylation of Lys48 (Chau and others, 1989). This 
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was later shown to be the case in other eukaryotes as well (Li and others, 2007; Petroski 
and Deshaies, 2005b). It was later reported that mono-ubiquitinylation at Lys11 residues 
could also trigger a proteasomal response (Jin and others, 2008; Matsumoto and others, 
2010). Some E3 Ubiquitin ligase enzymes not only mediate ubiquitinylation, they also 
bind to the proteasome to link ubiquitinylation and proteasomal degradation of targeted 
proteins (Seeger and others, 2003; Verma and others, 2000).  
Members of the Kelch-like family belong to a group of proteins that are subunits of 
Cullin-really interesting new gene (RING) E3 ubiquitin ligase (CRL) complexes 
(Angers and others, 2006; Canning and others, 2013; Kigoshi and others, 2011; Lee and 
others, 2010; Maerki and others, 2009; Moghe and others, 2011; Nam and others, 2009; 
Ohta and others, 2013; Sumara and others, 2007). CRLs, depending on present subunits 
and their spatial arrangements, can modify various distinct proteins (Canning and 
others, 2013). CRLs furthermore contain a Cullin-subunit (Cul 1-5 or Cul7). Cullins 
have been reported to form a scaffold, which is involved in placing the substrate binding 
site and other catalytic centres in the right orientation for ubiquitinylation of the target 
protein (Petroski and Deshaies, 2005a; Zimmerman and others, 2010). Also the Cullin 
subunit has been reported to be able to bind to both the target protein and the RING 
protein, which itself can then associate with an E2 enzyme (Canning and others, 2013; 
Zimmerman and others, 2010). Furthermore Neddylation (NEDD8 in CRLs) of the 
carboxy terminus of the Cullin subunit is a requirement for ubiquitinylation as it 
mediates structural changes in the CRL complex allowing the E2 enzyme and the 
substrate to locate in close vicinity to each other (Duda and others, 2008; Saha and 
Deshaies, 2008). 
Kelch-like proteins and in general proteins containing a BTB-domain bind to Cullin3 as 
their CRL subunit (Pintard and others, 2004). Cullin3 based E3 ubiquitin ligase 
complex containing BTB-proteins differ distinctively from other known E3 enzymes as 
they can form dimers, which allows them to bind to two Cullin subunits and as they also 
usually contain a second substrate binding domain. Therefore the Klhl/ BTB-domain 
containing protein in the CRL can act both as a substrate recognition element and a 
substrate adaptor for E3 ubiquitin ligase complexes (Canning and others, 2013; Pintard 
and others, 2004). 
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1.12.3 Functions of Kelch-like proteins 
 
As mentioned previously, various functions for Kelch-like proteins have been described 
in vertebrates. A muscle-specific protein of the Kelch related protein family is Kelch-
related protein 1 (Krp1) or Sarcosin. Although not named a member of the Klhl protein 
family, Sarcosin too has the defined protein domains that characterise Kelch-like 
proteins, an N-terminal BTB domain and five C-terminal Kelch-repeats (Spence and 
others, 2000; Taylor and others, 1998). Sarcosin was reported to be expressed in 
skeletal muscle and at much lower levels in the cardiac muscles (Taylor and others, 
1998) and it was suggested that it might play a role in myofibrils as it was shown to 
interact with Nebulin and Nebulin-related anchoring protein (N-RAP) (Lu and others, 
2003; Spence and others, 2006). Expression studies in mouse muscles, which were 
carried out in embryonic and adult muscles revealed that Sarcosin is highly expressed 
between laterally fusing nascent myofibrils (du Puy and others, 2012). Furthermore 
studies in C2C12 cell culture showed that Sarcosin was expressed in low levels in 
myoblasts and was upregulated during later stages of muscle differentiation (du Puy and 
others, 2012). At around day 3 of C2C12 differentiation Sarcosin was shown to align to 
α-Actinin along primitive Z-discs. However although Sarcosin expression seemed to be 
linked to myofibrillogenesis, a silencing approach of Sarcosin during C2C12 
differentiation did not disturb C2C12 fusion and myofibrillogenesis (du Puy and others, 
2012). It was therefore thought that Sarcosin might be involved in mediating the correct 
function of sarcomeres, rather than its assembly. 
Kelch-like ECH associating protein 1 (Keap1) has been shown to control the expression 
of antioxidant genes by targeting the transcriptional factor Nrf2 for ubiquitinylation and 
subsequent degradation (Furukawa and Xiong, 2005). Further E3-Ubiquitin-ligase 
associated Klhl proteins include among others Klhl20, Klhl21 and Klhl9 and Klhl13. It 
has been described that Klhl20 binds to Death-associated protein kinase (DAPk), 
locating it close to a Cul3-E3-Ligation complex, which subsequently leads to the 
proteasome-dependent degradation of the DAPk (Lee and others, 2010). Functions for 
Kelch-like proteins have also been described in the regulation of cell division. 
Klhl21/Klhl22 could be shown to be involved in the completion of cytokinesis by 
mediating ubiquitinylation of Aurora B (Maerki and others, 2009). A similar role was 
described for Klhl9 and Klhl13 in the ubiquitinylation of Aurora A (Sumara and others, 
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2007). It has been observed that the Cul3-Klhl9/Klhl13-E3 and the Cul3-Klhl21/Klhl22-
Ubiquitin ligase complex are involved in aligning the chromosomes to the midline 
during anaphase (Maerki and others, 2009; Sumara and others, 2007). Recently Klhl12 
has been shown to be involved in the regulation of Wnt-β-catenin signalling by 
targeting dishevelled for ubiquitinylation (Angers and others, 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.1: Members of the Kelch-like protein family 
Various Klhl proteins have different  funct ions and few have been described to  associate 
to  the Act in cytoskeleton. The following list  gives an overview o f funct ion and 
localisat ion of published Kelch- like proteins.  
 
Legend: ‘x’ confirms an existing interaction with Actin or a reported function as an E3- Ubiquitin Ligase, 
KR-Kelch-repeats
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Gene 
alternative 
name 
Actin-binding 
Actin binding 
domain 
E3-
Ubiquitin-
Ligase 
function 
Function Literature 
     
 
  
Kelch-like 1 MRP2 x KR not reported 
Klhl1 is an actin-binding protein in neuronal 
tissues. Klhl1 modulates calcium channel 
activity/calcium influx. Klhl1 may also be 
involved in mediating neurite outgrowth of 
oligodendrocytes in a GSK3β-dependent manner. 
(Aromolaran and others, 
2010; Aromolaran and 
others, 2012) 
Kelch-like 2 Mayven x KR x 
Klhl2 is an actin-binding protein involved in 
regulating outgrowth in oligodendrocytes. It also 
has been shown to target neuronal pentraxin for 
ubiquitinylation. 
(Tseng and Bixby, 2011; 
Williams and others, 
2005) 
Kelch-like 3 
 
not reported 
 
x 
Klhl3 in a Cul3-Klhl3 E3 ligase complex has been 
shown to regulate blood pressure by interacting 
with / and ubiquitinylating of WNK isoforms. 
(Louis-Dit-Picard and 
others, 2012; Ohta and 
others, 2013) 
Kelch-like 4 
 
not reported 
 
not reported 
Klhl4 mutation can cause X-linked cleft palate 
(CPX), a rare non-syndromic form of orofacial 
clefting. 
(Braybrook and others, 
2001; Cheroki and others, 
2008) 
Kelch-like 5 
 
x not reported not reported 
Klhl5 might participate in cytoskeletal 
reorganization as a part of platelet activation.  
Klhl5 expression is regulated by miR-495. 
(Nagalla and others, 2011) 
Kelch-like 6 
 
not reported 
 
not reported 
A mutation in Klhl6 causes defects in B-lineage 
cells and might therefore play a role in the 
immune system by mediating BCR signal 
transduction. 
(Kroll and others, 2005) 
Kelch-like 7 
 
not reported 
 
x 
Mutations Klhl7 cause autosomal-dominant 
retinitis pigmentosa. 
(Friedman and others, 
2009; Kigoshi and others, 
2011) 
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Kelch-like 8 
 
not reported 
 
x 
Klhl8 is involved in ubiquitinylation of rapsyn and 
GLR-1 receptors. 
(Nam and others, 2009; 
Schaefer and Rongo, 
2006) 
Kelch-like 9 
 
not reported 
 
x 
Klhl9 mutation leads to slow progressing distal 
myopathies.  Furthermore it was reported that 
Klhl9 is important for completion of cytokinesis 
by regulating Aurora B dynamics. 
(Cirak and others, 2010; 
Sumara and others, 2007) 
Kelch-like 10 
 
not reported 
 
not reported 
Mutations in Klhl10 are linked to male infertility 
(process not completely understood). 
(Kaplan and others, 2010; 
Qiu and others, 2009) 
Kelch-like 11 
 
not reported 
 
not reported 
Klhl11 is downregulated in human colorectal 
cancer. 
(Cekanova and others, 
2008) 
Kelch-like 12 
 
not reported 
 
x 
Klhl12 targets dishevelled for ubiquitinylation 
(thereby negatively regulating Wnt-signalling) and 
has also been shown to interact with/ target the 
dopamine D4 receptor and SEC31 for 
ubiquitinylation. 
(Angers and others, 2006; 
Jin and others, 2012; 
Rondou and others, 2011) 
Kelch-like 13 
 
not reported 
 
x 
Klhl9 and Klhl13 are both part of a Cul3-
Ubiquitin ligase complex which is required 
for the chromosome alignment during metaphase 
and completion of cytokinesis. The Cul3-
Ubiquitin ligase complex removes components of 
the chromosomal passenger complex, such as 
Aurora B from mitotic chromosomes thereby 
allowing their accumulation on the central spindle 
during anaphase. Furthermore Aurora B is bound 
directly by Klhl9/Klhk13. 
(Sumara and others, 2007) 
Kelch-like 14 Printor not reported 
 
not reported Klhl14 interacts with torsinA in the brain. 
(Giles and others, 2009) 
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Kelch-like 15 
 
not reported 
 
x 
Klhl15 targets B’β, a subunit of the Protein 
phosphatase 2A, for ubiquitinylation and 
proteasomal degradation. 
(Oberg and others, 2012) 
Kelch-like 16 Gigaxonin not reported 
 
x 
Mutations in Klhl16 lead to neurodegenerative 
disorders with alterations in the neurofilament 
network. It was furthermore shown that Klhl16 
targets Tubulin Folding Cofactor B for 
ubiquitinylation and degradation. 
(Bomont and others, 2000; 
Ganay and others, 2011 
; Wang and others, 2005b) 
Kelch-like 17 Actinfilin x KR x 
Klhl17 targets GluR6 kainate receptor subunits for 
ubiquitinylation and degradation. It was further 
suggested that Klhl16 regulates the stability of the 
actin cytoskeleton in neurons. 
(Chen and Li, 2005; 
Salinas and others, 2006) 
Kelch-like 18 
 
not reported 
 
x 
Klhl18 is required for the timely entry into mitosis 
by potentially ubiquitylating and activating 
Aurora-A. 
(Moghe and others, 2011) 
Kelch-like 19 
KEAP 1,  
Inhibitor of 
Nrf2 (INrf2) 
not reported 
 
x 
Klhl19 represses Nrf2 activation Nrf2 regulates 
expression of genes of the antioxidant-response 
element (ARE), such as phase II detoxifying and 
oxidative stress enzymes. 
(Tkachev and others, 
2011; Villeneuve and 
others, 2010) 
Kelch-like 20 KLEIP x KR x 
Klhl20 negatively regulates Death-associated 
protein kinase (DAPK). 
(Hara and others, 2004; 
Lee and others, 2010) 
Kelch-like 21 
 
not reported 
 
x 
The Cul3-Klhl21 E3-ubiquitin ligase targets 
aurora B for ubiquitinylation and is required for 
cytokinesis by regulating the localisation of the 
chromosomal passenger complex to the 
microtubular midzone during anaphase. 
(Maerki and others, 2009) 
Kelch-like 22 
 
not reported 
 
x 
The Cul3- Klhl22 E3-ubiquitin ligase targets 
aurora B for ubiquitinylation and is required for 
cytokinesis by regulating the localisation of the 
chromosomal passenger complex to the 
microtubular midzone during anaphase. 
(Maerki and others, 2009) 
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Kelch-like 23 
 
not reported 
 
not reported 
Klhl23 might be involved in autosomal dominant 
cone-rod dystrophy. 
(Manes and others, 2011) 
Kelch-like 24 DRE1, KRIP6 not reported 
 
not reported 
Klhl24 regulates kainate receptors by directly 
binding to its subunit GluR6 and by inhibiting 
modulation of the kainate receptor by PICK1. 
(Laezza and others, 2007; 
Laezza and others, 2008) 
Kelch-like 25 
Ectoderm-
neural cortex 
protein 2 
     
Kelch-like 26 
 
not reported 
 
not reported Klhl26 might be regulated by P53. 
(Simeonova and others, 
2012) 
Kelch-like 27 
IPP, 
intracisternal 
A particle-
promoted 
polypeptide 
x KR not reported 
Klhl27 is activated by calphoglin, a mediator of 
Ca
2+ 
mammalian cell activation. 
(Kim and others, 1999) 
Kelch-like 28 btbd5 
     
Kelch-like 29 
      
Kelch-like 30 
      
Kelch-like 31 
    
Klhl31 might play vital roles during muscle and 
heart development. It might also be an inhibitor of 
canonical Wnt –signalling. 
(Abou-Elhamd; Abou-
Elhamd and others, 2009; 
Yu and others, 2008) 
Kelch-like 32 
      
Kelch-like 33 
      
Kelch-like 34 
      
Kelch-like 35 
 
not reported 
 
not reported 
Klhl35 is methylated in hepatocellular carcinoma 
and in renal cell carcinoma. 
(Morris and others, 2011; 
Shitani and others, 2012) 
Kelch-like 36       
Kelch-like 37 ENC1, Klhl35      
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Kelch-like 38 
      
Kelch-like 39 
influenza 
virus NS1A 
binding 
protein, 
IVNS1ABP, 
NS1-BP 
 
 
  
not reported 
Klhl39 interacts with alpha-enolase/MBP-1 and 
might be involved in c-Myc gene transcriptional 
control. Klhl39 also binds to the NS1 protein of 
the influenza A virus. 
(Perconti and others, 
2007; Wolff and others, 
1998) 
Kelch-like 40 
sarcosynapsin, 
kbtbd5      
Kelch-like 41 
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In summary, recent findings suggested that Kelch-like proteins can be involved in 
mediating cell signalling, as well as various cellular processes and cytoskeletal 
changes. In some of these functions, Kelch-like proteins have been shown to 
regulate associated protein levels, especially by targeting specific substrates for 
ubiquitin-dependent degradation.  
 
1.13 Klhl31 
 
Klhl 31 was first described in zebrafish showing high expression in cardiac and 
skeletal tissues (Wu and Gong, 2004). It was also observed that Klhl31 is also 
expressed in human skeletal muscles and the heart. Further studies on human 
Klhl31 revealed that Klhl31 encodes for a 70 kDa protein containing 634 amino 
acids (Yu and others, 2008). Klhl31 was shown to contain an N-terminal BTB-
domain and six kelch-like repeats at the carboxy-terminus (see figure 1.11). 
 
 
 
Figure 1.11: Schematic representation of the human Klhl31 protein 
Klhl31 contains two conserved structural domains, the BTB domain at the N-terminus and six 
kelch-like repeats at the C-terminus, linked by the BACK domain. 
 
Expression studies showed that Klhl31 was highly expressed in human cardiac 
and skeletal muscle tissues. Localisation studies in Cos-7 cells and mouse 
cardiomyocytes revealed a cytoplasmic and nuclear localisation for Klhl31 (Yu 
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and others, 2008). Furthermore it was reported that Klhl31 could act as 
transcriptional repressors for TRE and SRE-mediated transcriptional activation 
with the BTB-domain being the main domain involved. In addition, Klhl31 was 
also able to decrease MAPK/JNK-signalling (Yu and others, 2008).  
 
Data obtained in our lab further analysed a role for Klhl31 during muscle 
development (Abou-Elhamd and others, 2009). Expression studies in chick 
embryos showed that Klhl31 is first detected at Hamburger-Hamilton (HH) stage 
8 (Hamburger and Hamilton, 1992) in the mesoderm of the anterior intestinal 
portal (figure 6.3;  a). Cardiac progenitors express Klhl31 from HH stage 9 
onwards and the gene is expressed throughout heart development. Klhl31 was also 
shown to be expressed in the myotome and later in development in all skeletal 
muscles tissues, including muscles of limbs (see figure 1.12).  
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Figure 1.12: expression pattern of Klhl31in chick embryos  compared 
to the expression of MyoD 
Whole mount in-situ hybridisation of chick embryos for Klhl31 and MyoD and related 
cryosections revealing the expression pattern of Klhl31 during myogenesis.  
 (C, D; E-H) Klhl31 was observed first in the dorsomedial somite at around HH 11, temporally 
delayed compared to the expression of MyoD.  
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(I-K; M-P) At HH 13 Klhl31 was still seen to be expressed in the somites, still lacking behind 
MyoD expression. 
(Q-U; V-Z) During later stages of Klhl31 expression (HH 19+), Klhl31 expression overlapped 
with MyoD expression. 
Figure taken from (Abou-Elhamd and others, 2009) 
 
Tissue ablation and rescue experiments showed that in the myotome Klhl31 is 
activated by combined signalling of sonic hedgehog together with either Wnt-1 or 
Wnt-6 (Abou-Elhamd and others, 2009). Furthermore, ectopic expression of Myf 
5, but not of myogenin, was able to induce Klhl31 expression in the neural tube 
(Abou-Elhamd). Comparing the temporal expression of Klhl31 with known 
myogenic markers, such as MyoD, it was shown that Klhl31 expression was 
detected 6 hours after MyoD expression (see figure 1.12). This data, together with 
the suggestion that Klhl31 expression might be activated by early MRFs, lead to 
the hypothesis that Klhl31 expression might be important for myogenesis and 
myogenic differentiation in skeletal muscles of the somites.  
Further data obtained in our lab indicated a role of Klhl31 in the negative 
regulation of Wnt signalling. Klhl31 was able to rescue an ectopic axis induced by 
injection of Wnt3a or β-catenin RNA into the ventral side of  a Xenopus laevis 
embryo (Abou-Elhamd and Garcia-Morales). Furthermore, by using a luciferase 
assay, it was shown that Klhl31 can inhibit the expression of a reporter plasmid 
(TOPFLASH) responsive to Wnt3a and β-catenin (see figure 1.13; (Abou-
Elhamd) 
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Figure 1.13: Klhl31 can inhibit β-Catenin induced luciferase activity 
Klhl31 full length protein and Klhl31 lacking the C-terminal kelch-repeats were able to inhibit β-
catenin stimulated luciferase expression by around 20 %, whilst a BTB deletion mutant of Klhl31 
could only inhibit luciferase activity by around 10%.  
Figure kindly provided by Dr. Alaa Abou-Elhamd 
Both, the luciferase assay and the axis-duplication assay highlighted the functions 
of the distinct structural domains of Klhl31 (see figure 1.13; (Abou-Elhamd). 
Only the deletion of the BTB domain reduced the ability of Klhl31 to antagonize 
canonical Wnt-signalling, revealing that interaction between a target substrate and 
Klhl31 is potentially mediated by the BTB domain. However, it is still not clear if 
Klhl31 targets β-catenin directly or a potential substrate downstream of β-catenin 
in the Wnt-signalling pathway.  
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1.14 Aims of this project: Investigating the role of Klhl31 during 
myogenesis 
 
Klhl31 expression during development is highly restricted in heart and skeletal 
muscles. In developing somites it has been shown to be activated by signalling 
factors, including Wnt signals, which also activate early MRFs and regulate 
cardiac fate (Abou-Elhamd and others, 2009; Tzahor, 2007). However, a specific 
function for Klhl31 during muscle development has not been described so far. 
We were interested in analysing the function of Klhl31 during skeletal muscle 
development on a cellular level.  
Firstly, we wanted to analyse Klhl31 expression and localisation during 
differentiation of myogenic cells. We chose C2C12 cells, which have the potential 
to form multi-nucleated myotubes and which are a good tool to study 
myofibrillogenesis. 
A further aim was to investigate potential interaction partners for Klhl31 during 
myogenesis and also in adult musculature. To achieve this, we used a Yeast-2-
Hybrid screen and GST-pull down assays. 
Selected hits from the screens were analysed further with the aim to verify 
interactions with Klhl31. 
As myogenesis and myofibrillogenesis also take place in cardiac muscle, we 
analysed Klhl31 expression in more detail during chick cardiogenesis. 
Overall the work contributes novel insights into the possible role of Klhl31 during 
striated muscle development. 
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2. Material and Methods 
 
2.1 Materials 
 
2.1.1 Chemicals, Biochemicals and Services  
 
Chemicals used in the laboratory were purchased from Sigma-Aldrich (Sigma-
Aldrich Company Ltd, Dorset, UK), Fisher Scientific (Fisher Scientific UK Ltd, 
Loughborough, UK), Roche (Roche Diagnostics Ltd, Burgess Hill, UK), BDH 
(VWR International Ltd., Lutterworth, UK) and Melford (Melford Laboratories 
Ltd., Ipswich, UK).  
Kits for Mini- , Midi-, or Hi-speed purification of DNA were obtained from 
Qiagen (Qiagen Ltd, Crawley, UK).  
Restriction enzymes and buffers were purchased from either Roche (Roche 
Diagnostics Ltd, Burgess Hill, UK) or NEB (New England Biolabs (UK) Ltd, 
Wilbury Way Hitchin, UK). 
Fertilized eggs were ordered from Henry Stewart & Co. Ltd (Louth, Lincolnshire, 
UK). 
Designed primers were obtained from Operon (Eurofins MWG Operon, 
Ebersberg, Germany). 
Sepharose beads for GST-pull down were purchased from GE Healthcare Life 
Sciences Amersham (GE Healthcare Life Sciences Amersham, Place little 
Chalfont, Buckinghamshire, UK). 
Sequencing was carried out by DNA Sequencing & Services (Dundee, Scotland, 
UK) and the Yeast-2-Hybrid Screen was carried out by Hybrigenics (Hybrigenics 
Services, Paris, France). 
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2.1.2 Frequently used Solutions 
 
APS (Ammonium persulfate) 
 10% w/v APS 
BCIP (5-bromo-4-chloro-3'-indolyphosphate p-toluidine salt) 
 50 mg/ ml BCIP in DMF 
Coomassie Blue Staining Solution 
10% v/v glacial acetic acid, 50% v/v Methanol, 0.25% w/v Coomassie 
brilliant Blue R-250 
DAPI (4', 6-diamidino-2-phenylindole) 
 5 mg/ml in PBS 
Destain Solution for SDS-PAGE Gels (Coomassie-Blue staining) 
 7.5% v/v glacial acetic acid, 25 % v/v Methanol 
DIG (Digioxigenin) labelled NTP mixture 
10 mM ATP, 10 mM GTP, 10 mM CTP, 6.5 mM UTP, 3.5 mM DIG-11-
UTP 
DNA Loading Buffer 6x 
50% v/v Glycerol, 0.1% w/v Bromophenol-Blue, 0.1% w/v Xylene Cyanol 
dNTP mix 10 mM in sigma water 
 10 mM ATP, 10 mM TTP, 10 mM GTP, 10 mM CTP 
Fixing solution for SDS-PAGE Gels (prior to Coomassie-Blue staining) 
 10% v/v glacial acetic acid, 50 % v/v Methanol 
Gelatine 
 0.3% w/v Gelatine (autoclaved) 
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Hybridisation Mix 
50% v/v Formamide, 1.3 x SSC, 5mM EDTA pH8, 50μg/ml Yeast RNA, 
0.2% v/v Tween-20, 0.5% w/v CHAPS, 100μg/ml Heparin 
IPTG (Isopropyl β-D-1-thiogalactopyranoside) 
 200 mg/ml  
LB (Luria-Bertani) -Agar 
 1.5% w/v bacto-agar in LB-Medium (autoclaved) 
LB (Luria-Bertani) Medium 
1% w/v bacto-tryptone, 1.5% w/v bacto-yeast extract, 1% w/v NaCl, pH 
7.5 (autoclaved) 
MABT 
100mM maleic acid, 150mM NaCl, 0.1% v/v Tween-20, pH 7.5 
(autoclaved) 
MABT-BBR 
 MABT, 2% w/v Boehringer Blocking Reagent (BBR) 
MgCl2 (Magnesium Chloride) 
 2 M MgCl2 
Mild Lysis Buffer (for GST Pull-down assays) 
50mM Tris pH 7.5, 150mM NaCl, 5mM EDTA pH7.5, 1% v/v NP-40, 
10% v/v Glycerol, 1mM Na3VO4, 1mM PMSF, add 1 Complete Mini, 
EDTA-free Protease inhibitor cocktail tablet (Roche Diagnostics Ltd, 
Burgess Hill, UK) per 10ml of buffer 
Mild stripping buffer pH 2.2    
0.2M Glycine, 0.1% w/v SDS, 1% v/v Tween-20  
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Mild washing buffer (for GST Pull-down assays) 
50mM Tris pH 7.5, 150mM NaCl, 5mM EDTA pH7.5, 0.1% v/v NP-40, 
10% v/v Glycerol, 1mM Na3VO4, 1mM PMSF 
NaF (Sodium Fluoride) 
 100 mM NaF 
NaCl (Sodium Chloride) 
 5M NaCl (autoclaved) 
NaOAc (Sodium Acetate)  
 3M CH3COONa pH 5.2 
Na3VO4 (Sodium Vanadate) 
 100 mM Na3VO4 
NBT (nitro-blue tetrazolium chloride) 
 75 mg/ ml in 70% v/v DMF 
NTMT 
 100mM NaCl, 100mM Tris pH 9.5, 50mM MgCl2, 1% v/v Tween-20 
PBS (Phosphate Buffered Saline)  
0.14M NaCl, 2.5mM KCl, 8mM Na2HPO4, 1.5mM KH2PO4  pH 7.3 
(autoclaved) 
PFA (Paraformaldehyde) 
 4% w/v PFA in PBS 
PMSF (Phenylmethylsulfonyl-fluoride) 
 200 mM in Ethanol 
Ponceau-Red 
 0.1% w/v Ponceau S, 5% v/v acetic acid 
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Proteinase K 
 10 μg/ ml in PTW 
Protein Loading Buffer 5x 
25% v/v Glycerol, 200mM Tris, 5% w/v SDS, 0.1% w/v Bromophenol-
Blue 
Protein Lysis (RIPA) Buffer 
50mM Tris pH 7.5, 150mM NaCl, 25mM EDTA, 1% v/v NP-40, 0.2% 
w/v SDS, 1mM DTT, add 1 Complete Mini EDTA-free Protease inhibitor 
cocktail tablet (Roche Diagnostics Ltd, Burgess Hill, UK) per 10ml of 
buffer 
Protein Lysis Buffer for Klhl31 
50 mM Tris pH 7.5, 150 mM NaCl, 5 mM EDTA pH 8, 1% v/v NP-40, 
0.2% w/v SDS, 1 mM Na3VO4 (sodium vanadate), 1 mM NaF (sodium 
fluoride), add 1 Complete Mini EDTA-free Protease inhibitor cocktail 
tablet (Roche Diagnostics Ltd, Burgess Hill, UK) per 10ml of buffer and 
store at – 20 °C for up to 12 weeks. On the time of usage, defrost buffer, 
remove an aliquot with the volume needed and add PMSF to 1mM final 
concentration. Use Buffer immediately. 
PTW  
PBS, 0.1 % v/v Tween-20 
SOC (Super Optimal Growth with Catabolic repression) Medium 
2% w/v bacto-tryptone, 0.5% w/v bacto-yeast extract, 10mM NaCl, 
2.5mM KCl, 10mM MgCl2, 20mM Glucose (autoclaved) 
SSC-Buffer 20x pH 5.0 
3M NaCl, 0.3M Na Citrate (Na3C6H5O7 x 2H2O), adjust pH to 5.0 with 
citric acid (autoclaved) 
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STE Buffer 
 0.1M NaCl, 10mM Tris pH 8.0, 1mM EDTA pH 8.0 
TAE Buffer 
20 mM Tris pH 8.0, 1mM EDTA, 1 % v/v acetic acid 
TBS (Tris buffered Saline) 10x  
 1.4 M NaCl, 0.2M Tris pH 7.5, 0.02M KCl (autoclaved) 
TBST 
 1x TBS, 0.1% v/v Tween-20 
TG (Tris –Glycine) 10x 
 0.25M Tris, 2M Glycine (autoclaved) 
Wash Buffer (for GST-pull down) 
50 mM Tris pH 7.5, 150 mM NaCl, 5 mM EDTA pH 8, 0.1% v/v NP-40, 
0.2% w/v SDS, 1 mM Na3VO4 (sodium vanadate), 1 mM NaF (sodium 
fluoride), add 1 Complete Mini EDTA-free Protease inhibitor cocktail 
tablet (Roche Diagnostics Ltd, Burgess Hill, UK) per 10ml of buffer and 
store at – 20 °C for up to 12 weeks. On the time of usage, defrost buffer, 
remove an aliquot with the volume needed and add PMSF to 1mM final 
concentration. Use Buffer immediately. 
Washing solution (for in situ hybridisation) 
 50% v/v Formamide, 1x SSC, 0.1% v/v Tween-20 
Western blot colour development solution 1 
0.1M Tris pH 8.8, 2.5mM Luminol, 0.4mM p-Coumaric acid 
Western blot colour development solution 2 
0.1M Tris pH 8.5, 0.02% v/v H2O2 
Western blot lower gel buffer  
 1.5M Tris pH8.8 
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Western blot Running Buffer 
 1x TG, 0.1% w/v SDS  
Western Blot Transfer Buffer 
 1xTG, 20% v/v Methanol 
Western blot upper gel buffer 
 0.6M Tris pH6.8 
X-Gal (5-bromo-4-chloro-indolyl-β-D-galactopyranoside) 
 20 mg/ml in DMF 
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2.2 Methods 
 
2.2.1 Transformation of competent DH5α- cells 
 
100 μl of chemically competent E.coli DH5α cells (Sambrook, 1989) were 
aliquoted into a 1.5 ml eppendorf tube and kept on ice. Up to 0.5μg of plasmid 
DNA were added to the cells and the mixture was incubated on ice for further 30 
minutes. The heat shock treatment was carried out for 5 minutes at 37 °C followed 
by five minutes of further incubation on ice. After addition of 200μl of SOC-
medium, the mixture was shaken at approx. 200 rpm at 37 °C for 40 minutes. 
100μl of the cell suspension were plated out on LB-Agar plates containing the 
selected antibiotic, to which the plasmid confers resistance. For blue-white 
selections, if the plasmid contained a β-galactosidase gene, the cell suspension 
was plated out on LB-agar plates coated with 40 μl Xgal and 4 μl IPTG. Plates 
were incubated overnight at 37 °C and later stored at 4 °C. 
 
2.2.2 Mini- Midi- and Hispeed DNA purification protocols 
 
DNA-preparations using either Mini- , Midi- or Hispeed purification kits were 
carried out as described in the manufacturer’s manual delivered with each kit by 
Qiagen (Qiagen Ltd, Crawley, UK). After purification of the DNA, the DNA was 
diluted in water (Sigma-Aldrich Company Ltd, Dorset, UK) and stored at -20 °C. 
The concentration of the DNA was measured based on the absorption of the 
solution at 260 nm using a Nanodrop spectrophotometer (Thermo Scientific, 
Wilmington, USA). Purity was determined by calculating the 260/280 and the 
260/230 ratios. 
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2.2.3 Restriction digests of DNA  
 
Restriction enzymes were selected based on the restriction sites of the DNA 
plasmid. The reaction was either carried out for 3 hours at 37 °C or overnight at 
room temperature, depending on the efficiency of the restriction enzyme.  
For digest reactions using two different restriction enzymes, the plasmid was cut 
with both restriction enzymes simultaneously when compatibility of both enzymes 
in the same restriction buffer was expected. If the enzymes were not guaranteed to 
work in the same buffer, the enzymes would be used separately in a two-step 
process. After the first enzymatic digest, the DNA was purified using the 
QIAquick PCR purification kit (Qiagen Ltd, Crawley, UK) or by Ethanol 
precipitation (see section 2.2.4). Following the purification the linearised DNA 
was then digested with the second restriction enzyme.  
Digested DNA was analysed on a 1% Agarose gel (as described in section 2.2.7). 
 
2.2.4 Ethanol precipitation 
 
DNA or RNA, which are kept in aqueous solutions, can be purified or 
concentrated by using the process of Ethanol precipitation. Up to 50μl DNA 
solution in an eppendorf tube was mixed with 50μl of sodium acetate solution, pH 
5.2.  RNA was mixed with 50 μl of 5M sodium chloride solution. 500μl of 100 % 
ethanol was added and the liquids were briefly mixed by inverting the eppendorf 
tube. Precipitation was allowed to occur for one hour or overnight at -20 °C. The 
obtained DNA or RNA pellet was recovered by spinning down at 13000 rpm for 
10 – 15 minutes at 4 °C and subsequently washed with 70 % ethanol. The pellet 
was again recovered by centrifugation as described before, the ethanol supernatant 
completely removed and the pellet dried at room temperature until it became 
clear. The DNA or RNA pellet were then re-dissolved in water (Sigma-Aldrich 
Company Ltd, Dorset, UK) and stored at -20 °C. 
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2.2.5 Preparation of an antisense RNA probe for in-situ hybridisation 
 
A probe is a RNA molecule, which is labelled with a fluorophore, a radioactive 
element or an organic group that can be detected with an antibody. An antisense 
probe contains a nucleotide sequence, which is complimentary to the mRNA of a 
specific gene. Therefore an antisense RNA probe can be used to visualize the 
transcripts of a gene in cells or embryonic tissue. For the preparation of a RNA 
probe the plasmid (for a full list of RNA probes, see table 2.1), which contains the 
DNA fragment on which the probe was based, was linearised first by restriction 
digest as described in section 2.2.3. The linearised DNA was subsequently 
purified by using a Phenol/Chloroform extraction (see section 2.2.6). The purified 
and linearised DNA was then used for the synthesis of the RNA probe. The 
antisense probe was made by using an NTP mixture containing digioxigenin 
(DIG) -labelled UTP.  
The reaction mixture for the synthesis of the probe was prepared as described 
below: 
5  μl  sigma water 
2  μl  (DIG-labelled UTP) NTP mix (100 mM) 
4  μl  Transcription buffer (5x) 
2  μl  DTT (100 mM) 
1  μl  RNAse inhibitors 
4  μl  DNA construct/ template 
2  μl  transcription enzyme 
20μl  total volume 
 
The reaction was incubated for two hours at 37 °C. Success of probe synthesis 
was analysed on a 1% Agarose gel (as explained in section 2.2.7). 
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After the synthesis, the RNA probe needed to be cleansed from residual NTPs and 
enzymes. Therefore 30μl of Diethylpyrocarbonate (DEPC) treated H2O was added 
to the RNA probe synthesis sample and the mixture was placed into a freshly 
prepared illustra ProbeQuant G-50 Micro Column (GE Healthcare, Little 
Chalfont, UK). The transcribed RNA probe was recovered and purified by 
centrifugation at 3000 rpm for two minutes at room temperature. The obtained 
50μl of solution were mixed with 50μl of formamide to prevent degradation of the 
RNA probe. The diluted probe was then stored at -20 °C or mixed with 
hybridisation mix (5μl of probe in 1 ml of hybridisation buffer), when used for an 
in-situ hybridisation. 
Table 2.1: List of RNA-probes 
The table gives details about the plasmid backbone, the restriction site and the transcription 
enzyme of various RNA antisense probes 
antisense 
RNA probe 
vector 
Restriction 
enzyme for 
linearization 
Transcriptional 
promoter 
source 
Klhl31 pGEM-T NcoI Sp6 
(Abou-Elhamd 
and others, 
2009) 
Nkx2.5 
Bluescript 
II SK- 
HindIII T3 
(Schultheiss 
and others, 
1995) 
Pitx2 
no 
information 
available 
BamHI T7 
(Campione and 
others, 1999) 
vMHC pGEM 4Z NdE7 T7 
(Bisaha and 
Bader, 1991) 
Islet1 
no 
information 
available 
XbaI T7 
gift from Frank 
Schubert 
cHex1 
no 
information 
available 
EcoRI Sp6 
gift from Frank 
Schubert 
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2.2.6 Phenol/Chloroform Extraction 
 
To purify an aqueous DNA or RNA solution the process of Phenol/Chloroform 
extraction can be used, as it achieves high purity for short nucleotide sequences. A 
specified volume of DNA solution is mixed with the same volume of phenol. Both 
solutions were mixed by vortexing and separated by centrifugation at 13000 rpm 
at 4 °C for 5 minutes. The DNA or RNA should now be in the top layer, the 
aqueous phase, which is removed from the phenol mixture and placed into a fresh 
eppendorf tube. After adding the same volume of Chloroform: Isoamylalcohol 
mixture (24:1) and mixing of both phases, the layers were again separated by 
centrifugation as described before. Again, the top aqueous phase was removed 
and DNA purified from the phase by using the ethanol precipitation as described 
in section 2.2.4. 
 
2.2.7 Agarose gel electrophoresis 
 
To prepare a 0.8 – 1% Agarose gel, 0.4 – 0.5 g of Agarose powder was dissolved 
in 50 ml of TAE-buffer. To achieve complete solubilisation, the mixture was 
heated until boiling using a microwave. The dissolved agarose solution was 
cooled down and Ethidium bromide (Sigma-Aldrich Company Ltd, Dorset, UK) 
was added before pouring the solution into the gel tank. Once the gel was settled, 
100 ml of TAE-buffer were poured on top of the gel into the gel tank. DNA 
samples were prepared by mixing a specified volume of DNA with 1/6 of the total 
volume of DNA loading buffer. 6 μl of the sample were applied to the gel and the 
gel was run at 65 V for approximately 45 minutes. Obtained DNA bands were 
analysed using a trans-illuminator of the ChemiDoc™ XRS+ System (Life 
Science, Bio-Rad Laboratories Ltd., Hemel Hempstead, UK) 
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2.2.8 Culturing and harvesting of chick embryos 
 
Fertilized eggs were stored after arrival at 16 °C.  The eggs were then slowly 
warmed up to room temperature and subsequently incubated at 37 °C using a 
humidified incubator to grow to desired stages as described by Hamburger and 
Hamilton (Hamburger and Hamilton, 1992). Embryos were harvested by opening 
the egg shell with blunt forceps or scissors, cutting the embryo out of the vitelline 
membrane and washing in DEPC treated PBS. Subsequently the embryos were 
fixed in 4 % PFA for five to ten minutes. Following the fixation, the extra-
embryonic membranes were dissected using a fine needle and fine forceps. 
Harvesting and dissecting the embryos was carried out on a Zeiss SV 11 
dissecting microscope (Carl Zeiss Microscopy Ltd, Cambridge, UK). Embryos 
were subsequently dehydrated by passing through a methanol series (25%, 50%, 
75% and 100% methanol in PBS). Harvested embryos were stored at -20 °C in 
100% methanol. 
 
2.2.9 Whole mount In Situ Hybridisation (WISH) 
 
 Rehydration of chick embryos 
Chick embryos which were stored in 100% methanol were rehydrated by using a 
methanol series (100%, 75%, 50% and 25% and 0% methanol in PBS). Embryos 
were then placed into 6-well dishes and washed twice in PTW.  
 Treatment with Proteinase K 
Subsequently the embryos were treated with 10 μg/ ml proteinase K according to 
their HH stages (Hamburger and Hamilton, 1992) as described in table 2.2. 
 
 
 
75 
 
 
Table 2.2: Proteinase K treatment of chick embryos 
Proteinase K treatment is dependent of the age of the chick embryos. 
Chick embryos HH stages Time of treatment 
6-12 10 minutes 
12-20 15 minutes 
21-25 20 minutes 
 
 Post-fixing and pre-treatment for Hybridisation 
Following the proteinase K treatment, the embryos were carefully rinsed with 
PTW and post-fixed with PFA containing additional glutaraldehyde to 0.1% for 
20 minutes at room temperature. The PFA was removed and embryos washed 
twice in PTW, before incubated in 1:1 (v/v) PTW/hybridisation mix for about 10-
15 minutes or until embryos have settled down in the bottom of the well. The 
same process was repeated once more, but now the embryos were incubated in 
hybridisation buffer only. Once the embryos settled down in the bottom of the 
well, the hybridisation mix was replaced with a fresh aliquot of hybridisation 
solution which had previously been preheated to 65 °C. The chick embryos were 
then incubated in hybridisation mix at for a minimum of one hour at 65 °C.  
 Preparation of the RNA probe and Hybridisation 
In the meantime the antisense RNA probe diluted in hybridisation solution was 
also preheated to 65 °C. Once the chick embryos had been incubated in the warm 
hybridisation mixture, the hybridisation buffer was removed and the embryos 
were incubated in the pre-warmed hybridisation / RNA probe solution overnight 
at 65 °C. The following morning the RNA probe in hybridisation buffer was 
recovered from the embryos and stored at -20 °C. The embryos were rinsed twice 
in to 65 °C pre-heated hybridisation mixture and washed with a fresh aliquot of 
pre-warmed hybridisation buffer for 10 minutes, before being washed twice with 
pre-heated washing solution for 30 minutes at 65 °C. Following the described 
washing steps, the chick embryos are incubated for 10 minutes at 65 °C in pre-
heated washing solution/MABT (1:1 v/v).  
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 Blocking and antibody incubation 
All following steps were carried out at room temperature. Firstly, the chick 
embryos were rinsed three times in MABT, followed by two washes at each 30 
minutes in MABT. The embryos were subsequently blocked in MABT-BBR for a 
minimum of one hour, before being incubated with MABT-BBR containing 10% 
heat-treated goat serum for between one or two hours. After removing the 
blocking solution, the chick embryos are incubated overnight at 4 °C with an anti-
DIG antibody (Roche Diagnostics Ltd, Burgess Hill, UK) diluted 1:2000 in 
MABT-BBR-goat serum buffer. The anti-DIG antibody is conjugated to an 
alkaline phosphatase. The next morning the antibody was removed and the 
embryos rinsed three times with MABT at room temperature. After six washes in 
MABT at room temperature, each wash lasting approximately one hour, the 
embryos were incubated overnight in fresh MABT.  
 Colour reaction, post-fixing and storage 
The MABT was removed the following morning and the embryos washed twice 
for 10 minutes in NTMT at room temperature. For the colour reaction the chick 
embryos were incubated in the dark with NTMT containing additional 9 μl NBT 
and 7 μl BCIP per 1 ml of NTMT at room temperature. NBT and BCIP are 
substrates for the alkaline phosphatase and when reacted with are displaying a 
blue precipitate. Therefore, if a gene is transcribed into mRNA and the RNA 
probe can bind to the mRNA, expression can be seen as a dark blue staining in 
specific embryonic tissues. The time of colour development or also known as the 
time of incubation in the substrates is depending on the strength of a specific 
probe and can vary from 10 minutes to several days. If the colour was developed 
to desired strength the colour reaction was stopped by removing the substrates and 
washing in 5X TBST. Should the colour has not been developing to the desired 
extent, the embryos were washed overnight at 4 °C in TBST. The next day the 
colour reaction was then repeated as described before. Once the blue staining was 
strong enough and the colour reaction had been stopped, the embryos were post-
fixed overnight at room temperature in PFA containing 0.1% Glutaraldehyde, 
washed three times with PTW and stored in PTW at 4 °C until processed further. 
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2.2.10 Processing chick embryos for imaging 
 
Chick embryos harvested from eggs or obtained from in-situ hybridisation can 
reveal staining either from contamination with egg yolk or in older embryos from 
blood residues. Blood stains could be removed from the embryos by washing the 
chick embryos at room temperature in PTW containing 0.2 % v/v H2O2. Further 
staining and clearance of the embryos could be achieved by incubating the 
embryos in a gradient of glycerol (25%, 50%, 75% and 100% glycerol in PTW). 
Embryos can be stored in 100% glycerol at 4 °C. Images of whole embryos were 
taken on a Zeiss SV11 dissecting microscope with a micropublisher 3.5 camera 
using the associated acquisition software. Images were exported into Adobe 
Photoshop (Adobe Systems Europe Ltd, Maidenhead, UK) for labelling and 
formatting. 
 
2.2.11 Sectioning of chick embryos 
 
To prepare embryos for cryosectioning the embryos that were stored in glycerol 
after WISH were firstly passed through a gradient of Glycerol (75%, 50%, 25% 
and 0% Glycerol in PTW) until diluted in PTW. To remove all residual Glycerol 
embryos were then washed with fresh PTW three times for 5 minutes at room 
temperature. Subsequently the embryos were mounted in OCT (a frozen section 
embedding medium, Agar Scientific, Stansted, UK) and placed into plastic 
mounting capsules (VWR International Ltd, Lutterworth, UK). The embryos were 
incubated in OCT overnight at 4 °C. The following day, the OCT saturated 
embryos were adjusted in the capsules to lie with their anterior side towards the 
bottom of the capsules. The embryos were immediately frozen in a dry ice/ 
isopropanol mixture to prevent further movement. Frozen specimens were stored 
at -20 °C until further usage. Cryosectioning was carried out using a Leica CM 
1850 Cryostat (Leica Microsystems (UK) Ltd, Milton Keynes, UK). Embryos 
were sectioned at 20 μm and the obtained sections were collected on TESPA or 
Poly-L-Lysine coated slides (prepared in our laboratory). Slides were dried 
overnight at 37 °C and subsequently washed twice in pre-warmed PBS. Pre-
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warmed Hydromount (AGTC Bioproducts t/a National Diagnostics UK, Hessle, 
UK) was gently pipetted on top of the sections and a coverslip was placed unto 
the slide to cover the sections on the slide. Mounted sections can be stored at 
room temperatures. Images of the sections were taken at a widefield upright 
microscope (Carl Zeiss Microscopy Ltd, Cambridge, UK) equipped with a 
monochrome CCD camera using AxioVision software (Carl Zeiss Microscopy 
Ltd, Cambridge, UK). Images were exported into Adobe Photoshop (Adobe 
Systems Europe Ltd, Maidenhead, UK) for labelling and formatting purposes. 
 
2.2.12 Extracting RNA from cell tissue and chick embryos 
 
Mammalian cells were grown to about 80% confluency, washed with PBS and 
then trypsinised. Detached Cells were resuspended in 500 μl PBS and pipetted 
into a 1.5 ml Eppendorf-tube. The cell suspension was kept on ice. Cells were 
spun down at 4°C and 20000 rpm, the supernatant removed and the cell pellet 
further processed for RNA extraction. RNA was either extracted using the 
RNeasy® Mini Kit (Qiagen Ltd, Crawley, UK) or by following the TRIZOL® 
Reagent manufacturer’s instructions (Invitrogen, Life Technologies Ltd, Paisley, 
UK). 
For RNA extraction from chick embryos, the embryos were harvested as 
described in section 2.2.8. Embryos were placed into a 1.5 ml eppendorf tube and 
manually homogenized in RTL-buffer containing 143 mM β- Mercaptoethanol. 
RNA was obtained by using the RNeasy® Mini Kit as described in the 
manufacturer’s instructions (Qiagen Ltd, Crawley, UK). Obtained RNA was 
diluted in sigma water (Sigma-Aldrich Company Ltd, Dorset, UK) and stored at -
20 °C. 
The quality and concentration of the purified RNA was measured by using the 
RNA Nanodrop device (Thermo Scientific, Wilmington, USA).  
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2.2.13 Transcription of RNA into complementary DNA (cDNA) 
 
RNA was transcribed into cDNA using the Moloney Murine Leukaemia Virus 
(MoMuLV) reverse transcriptase and MMLV-RT Buffer (Thermo Fisher 
Scientific UK Ltd, Loughborough, UK). Firstly, extracted RNA was denatured at 
70°C for 15 minutes and the M-MLV-RT Buffer was warmed up to 37 °C to 
dissolve any occurring precipitation. 
For the transcription reaction between 1 – 2 μg of total RNA has been used. 
A standard mixture for one sample contained: 
9.9   μl Sigma H2O 
  6    μl M-MLV-RT Buffer (5x) 
  1    μl dNTP mixture (10 mM) 
1 μl MoMuLV reverse transcriptase 
1    μl DTT (100 mM) 
  1    μl random Hexamer mixture (200 ng/ μl) 
0.1 μl RNAsin 
10    μl RNA extract (1-2 μg) 
30    μl total volume 
 
Transcription into cDNA was carried out at 42 °C for 1 hour. Synthesised cDNA 
was stored at – 20 °C. 
The quality of obtained cDNA was analysed by PCR as described in the following 
section (2.2.14). 
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2.2.14 Polymerase chain reaction (PCR) for controlling the quality of cDNA  
 
To control the quality of cDNA, a PCR against housekeeping genes (see list in 
table 2.3) was performed using the Bioline Bio-Mix Red (Bioline, London, UK). 
The PCR was carried out by using a DNA Engine Dyad Peltier Thermal Cycler 
(Bio-Rad Laboratories Ltd, Hempstead, UK). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.3: List of primers designed for PCR 
Following list contains the sequence information of primers used in PCR processes, either for 
cloning, expression analysis or quality control. 
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Primer Sequence product size 
restriction 
site 
Source 
chick 
GAPDH 
Forward  5’ AGTCATCCCTGAGCTGAATG 3’ 330 bp / 
Munsterberg and Lassar, 
1995 
  Reverse 3’ ACCATCAAGTCCACAACACG 5’   /   
Mouse β-
Actin 
Forward  5’ GAAATCGTGCGTGACATTAAGGAG 3’ 500 bp / Given by Dr. Niels Haan 
  Reverse 3’ ATACTCCTGCTTGCTGATCCACAT 5’   / 
 obtained from MWG 
Biotech AG 
Chick β-
Actin 
Forward  5’ CCAGCTGGGAGGAGCCGGT 3’ 300 bp / 
 Dr. Katarzyna 
Goljanek-Whysall 
  Reverse 3’ CTGGGGAACACAGCCCGCTT 5’   /   
mouse 
Klhl31 FL 
for 
expression 
analysis 
Forward 5' AAGGCAACAGCCCAGAAAT 3' 1177 bp / Constanze Ochmann 
  Reverse 3' ACTTCTTCTCGCCCTCGTTC 5'   / 
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human 
Klhl31 for 
expression 
analysis 
Forward 5' AAAGCAGCAGCCCAGAAAT 3' 1177 bp / Constanze Ochmann  
  Reverse 3' ACTTCTTCTCGCCCTCGTTC 5'   / 
 
human 
Klhl31 FL 
for GST-pull 
down                                                      
(pGEX-5X-
1) 
Forward 5' GAATTCATGGCACCCAAAAAGAAGATT 3' 1900 bp EcoRI Constanze Ochmann  
  Reverse 3' CTCGAGTCAGATACTGACTGGCACAGAAG 5'   XhoI and Dr. Timothy Grocott 
internal for 
sequencing 
Reverse 3' AAATACTCACTGCATGAAGCCAT 5' / /   
chick Klhl31 
for pEGFP-
C1 
constructs                                     
FL / ΔBTB 
Forward 5' TCCGGAATGGCACCTAAGAAGAAGAAC 3' 
1900 bp /            
1400 bp 
BspEI Constanze Ochmann  
  
Reverse 3' 
GAATTCTCAAGCGTAATCTGGAACATCGTATGGGTAAATACTGACTGGTACAGAAG 5' 
  EcoRI 
 
ΔKR 
Reverse 3' 
GAATTCTCAAGCGTAATCTGGAACATCGTATGGGTATCTGAATCCTCCACGAATCC 5' 
900 bp EcoRI 
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chick Klhl31 
for pEGFP-
N1/ DsRed-
N1 
constructs 
FL / ΔBTB 
Forward 5' CTCGAGATGGCACCTAAGAAGAAGAAC 3' 
1900 bp /                          
1400 bp 
XhoI Constanze Ochmann  
  Reverse 3' GAATTCCAATACTGACTGGTACAGAAGA 5'   EcoRI 
 
ΔKR Reverse 3' GAATTCCTCTGAATCCTCCACGAATCCT 5' 900 bp EcoRI   
Nebulin 
Variation 2 
(HA tag) 
Forward 5' ATGCGGCCGCATGGACACAGTCAGTGATGTAAA 3' 500 bp Not1 Constanze Ochmann  
  
Reverse 3' 
ATGAATTCTCAAGCGTAATCTGGAACATCGTATGGGTATTTATAAAGGATATCG 5' 
  EcoRI 
 
Nebulin 
Variation 3 
(HA tag) 
Forward 5' ATGCGGCCGCATGGATGCCCTAGACATTGTCTA 3' 600 bp Not1 Constanze Ochmann  
  
Reverse 3' 
ATGAATTCTCAAGCGTAATCTGGAACATCGTATGGGTATTTATAAAGGATATCG 5' 
  EcoRI 
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The reaction mixture for the PCR was prepared as described below: 
10    μl Bio-Mix Red 2x (Bioline, London, UK) 
  0.5 μl forward primer 
  0.5 μl reverse primer 
  3    μl template DNA (diluted 1:1000) 
  6    μl sigma water 
20    μl total volume 
 
The PCR reaction was carried out using the PCR program “PCR housekeeping gene” with 
following settings: 
1.   5 minutes 94 °C 
2.   1 minute 94 °C  
3.   1 minute 50 °C 
4.   1 minute 72 °C 
5.   5 minutes 72 °C 
Following the Polymerase Chain reaction the samples were run on a 0.8 – 1% Agarose gel to 
analyse the obtained PCR products as described in section 2.2.7. 
 
2.2.15 Polymerase chain reaction (PCR) for analysing the expression of Klhl31  
 
The expression of Klhl31 was detected by PCR. The samples were prepared in Bioline Bio-
Mix Red (Bioline, London, UK) as described in section 2.2.14 and the PCR was carried out 
by using a DNA Engine Dyad Peltier Thermal Cycler (Bio-Rad Laboratories Ltd, Hempstead, 
UK). 
Repeated for 30 circles 
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The settings for the polymerase chain reaction were saved as the program “Kelch PCR” and 
contained following steps:  
1.   60 seconds 95 °C 
2.   30 seconds 95 °C  
3.   30 seconds 61 °C 
4.   40 seconds 72 °C 
5.   5 minutes 72 °C 
The samples were analysed as described before on a 1% Agarose Gel (section 2.2.7).  
 
2.2.16 Polymerase chain reaction (PCR) to amplify DNA for Cloning 
 
Polymerase chain reactions to amplify the sequences for Klhl31- full length, Klhl31-ΔBTB 
and Klhl31-ΔKR were carried out by using a DNA Engine Dyad Peltier Thermal Cycler 
(Bio-Rad Laboratories Ltd, Hempstead, UK). The Klhl31 Full length sequence as well as the 
Klhl31-ΔKR sequence have been amplified from chick complementary DNA (cDNA) HH 
stage 10 (Hamburger and Hamilton, 1992). The Klhl31-ΔBTB sequence was amplified from 
the pCaβ-IRES-GFP-Klhl31- ΔBTB plasmid (created by Oliver Cooper and Alaa Abou-
Elhamd).  
For the cloning of GST-Klhl31 construct, a human Klhl31 clone (IMAGE clone 9021264) 
was obtained from Source BioScience Life Sciences (Source BioScience UK Limited, 
Nottingham, UK). The fragments of Nebulin Variation 2 and Nebulin Variation 3 have been 
amplified from the plasmids sent from Hybrigenics (Hybrigenics Services, Paris, France). 
Sequence and plasmid information for Nebulin Isoform 1 and Isoform 2 can be found in the 
appendix.  
For a complete list of primers see table 2.3 in sub-chapter 2.2.14. 
The PCR was carried out by using the high fidelity polymerase Phusion (New England 
Biolabs, Herts, UK). 
 
 
Repeated for 30 circles 
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The reaction mixture for one sample was prepared as described below: 
 
        5  μl  5x Phusion buffer (New England Biolabs, Herts, UK) 
    0.5 μl   dNTPs (100 mM) 
        1  μl  forward primer (10 nM) 
        1  μl  reverse primer (10 nM) 
    1.3 μl  DNA template (diluted 1:1000) 
   0.75  μl  DMSO  
  14.5 μl  sigma water 
              0.25 μl  Phusion (New England Biolabs, Herts, UK) enzyme 
    0.5 μl  Taq-Polymerase 
     25 μl  total volume 
The polymerase chain reaction was carried out using the PCR program “Gradient Phusion” 
designed with the following settings: 
1. 60 seconds 95 °C 
2. 30 seconds 95 °C  
3. 30 seconds gradient of 50 - 65 °C 
4. 40 seconds 72 °C 
5. 5 minutes  72 °C 
 
To elongate the PCR product with a Poly-Adenine-Tag, 1μl of taq-polymerase was added to 
each sample.  The mixture was then incubated for further 15 minutes at 72 °C. 
PCR products were analysed using a 1% Agarose gel as described in section 2.2.7. 
 
Repeated for 30 circles 
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2.2.17 Purification of DNA fragments out of an agarose gel 
 
DNA bands in the agarose gel were visualised under UV light using a trans-illuminator whilst 
wearing suitable face protection. DNA bands displayed the desired sequence length were 
excised from the gel using a clean razor blade and placed in a 1.5 ml Eppendorf tube. The 
DNA was extracted from the agarose gel as described in the manufacturer instructions for the 
use of the QIAEX
®
 II gel extraction kit (Qiagen Ltd, Crawley, UK) and stored diluted in 
water at -20 °C. 
 
2.2.18 Ligation of the PCR products in pGEM-T easy 
 
The pGEM-T easy Vector contains a single 3’ thymidine-residue at both strands to ligate 
PCR products with overhanging adenines into the pGEM-T vector. Ligation of DNA 
fragments into the pGEM-T vector was carried out using below described ligation mix. 
0.5 μl  pGEM-T vector (25 ng)  (Promega UK Ltd, Southampton, UK) 
5    μl 2 x ligation buffer  (Promega UK Ltd, Southampton, UK) 
1    μl  T4 Ligase   (Promega UK Ltd, Southampton, UK) 
DNA insert was added to the vector in a ratio vector : DNA of 1 : 3, using up to 3.5μl of 
DNA insert, making the total volume of each ligation to 10μl. Sigma water was added to the 
pGEM-T ligation mixture as a negative control for the ligation. 
The ligation sample was incubated at room temperature for 3 hours or at 16° C overnight. 
Immediately after the ligation process, the obtained pGEM-T constructs were transformed 
into DH5α cells as described in section 2.2.1 and plated out on carbenicillin containing LB-
agar plates. The following day several clones were picked from the plate, grown up in 5 ml 
LB medium with additional carbenicillin and the DNA extracted from the cells using a 
Qiagen Mini prep approach as described in section 2.2.2. The presence of the desired insert 
was firstly analysed by restriction digest (as described in section 2.2.3) using the enzyme 
EcoRI, as the multiple cloning site of the pGEM-T easy vector is flanked on both sides with 
the recognition sequence for EcoRI. The digested DNA was run on a 1% Agarose Gel as 
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described in section 2.2.7 and positive clones were sent for sequencing to verify the exact 
sequence of the inserted DNA fragment.  
 
2.2.19 Cloning of DNA inserts from pGEM-T into expression vectors 
 
To subclone DNA inserts into the desired overexpression vector, the DNA insert were cut out 
of the pGEM-T vectors using the restriction enzymes as stated in table 2.4 in this section. 
Digested DNA was analysed on a 1% agarose gel and obtained fragments were purified from 
the agarose gel as described in chapter 2.2.16. Purified DNA was stored at –20 °C until 
further usage. The chosen vectors were linearised as described in chapter 2.2.3 using the 
same restriction sides as used for the DNA insert which is to be cloned into the vector 
backbone. 
A list of all cloned overexpression constructs including information about the plasmid size, 
the protein size and the used restriction enzymes can be found below: 
 
 
 
 
 
 
Table 2.4: List of cloned overexpression constructs  
The following list gives detailed information about the cloned overexpression constructs. It contains data about 
the plasmids used including plasmid sizes inclusive of the DNA fragments, the protein sizes of the cloned 
Fusion proteins and the restriction sides, which were used to cut and paste the DNA from the pGEM-T vector 
into the chosen vector. All protein sizes marked with an asterisk (*) are predicted protein sizes.
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Overexpression construct use 
plasmid 
size 
protein size restriction site 
 
 pGEX-5X-1 Klhl31 FL prey for GST-pull down experiments 6700 bp 95 kDa EcoRI N-term 
 
        XhoI C-term 
 
 pEGFP-C1 Klhl31 FL  
overexpression constructs / GFP Fusion 
proteins 
6800 bp 96 kDa BspEI N-term      
 
 pEGFP-C1 Klhl31 dBTB GFP at N-terminus of Klhl31 6300 bp  ~ 77 kDa * EcoRI C-term 
 
pEGFP-C1 Klhl31 ΔKR   5800 bp ~ 59 kDa * 
for all 
constructs  
 pEGFP-N1/                                                     
DsRed-N1 Klhl31 FL  
overexpression constructs / GFP or DSRED 
Fusion proteins 
6800 bp 96 kDa  XhoI N-term 
 
 pEGFP-N1 /                                                             
DsRed-N1 Klhl31 ΔBTB 
GFP or DSRED at C-terminus of Klhl31 6300 bp  ~ 77 kDa * EcoRI C-term 
 
pEGFP-N1/ DsRed-N1 Klhl31ΔKR   5800 bp ~ 59 kDa * 
for all 
constructs  
pCaβ Nebulin Variation 2 IRES GFP  (HA tag) bait for GST pull down >4900 bp ~ 18 kDa * Not1 N-term 
 
        EcoRI C-term 
 
pCaβ Nebulin Variation 3 IRES GFP (HA tag) bait for GST pull down > 5000 bp ~ 23 kDa * Not1 N-term 
 
        EcoRI C-term 
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To control the linearization of the overexpression vector and the excision of the DNA 
fragment, both samples were analysed using a 1% agarose gel (section 2.2.7). If successful, 
both the DNA insert from the pGEM-T vector, as well as the linearised overexpression vector 
backbone were purified from the agarose gel as explained in 2.2.17.  
The ligation of the insert into the chosen overexpression vector was carried out using T4 
DNA ligase. Variations of vector to insert ratios (from 1:1, up to 10:1 insert : vector) were 
tested to find the most successful ligation settings. These ratios were calculated based on the 
concentration of the vector used. 
A calculation would be set up as follows: 
ng (insert) = ng (vector) x kb (size of insert) x ratio 
     kb (size of vector) 
For example; Using 200 ng vector with a size of 3.5 kb, the DNA fragment size being 0.6 kb. 
The ratio insert : vector would be 3:1. 
y ng = 200 ng x 0.6 kb x 3  
             3.5 kb 
        = 102.9 ng DNA insert 
The calculated ng for insert and vector DNA would then be converted into a volume that can 
be used in a T4 Ligation sample preparation. 
A mixture for one sample is usually made up as described below: 
1 μl of 10x Ligation Buffer (Roche Diagnostics Ltd, Burgess Hill, UK) 
1      μl of T4 DNA Ligase      (Roche Diagnostics Ltd, Burgess Hill, UK) 
x      μl of vector DNA      
y      μl of DNA insert 
z      μl of sigma water      
10    μl of total volume 
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The ligation reaction was incubated overnight at 16 °C and the next morning transformed into 
competent DH5α cells, as described for the ligation into pGEM-T in 2.2.18. 
The clones were checked for presence of the insert by using a colony PCR approach using the 
primers that were designed for the cloning process (for primer information see table 2.3, 
section 2.2.14).  
The colony PCR was set up using the Bioline Mix, picking one bacterial colony from the LB-
agar plate with a pipette tip. A fresh LB-agar plate was scratched with the pipette tip to 
inoculate it with the bacterium and the residues of the bacterial colony were then resuspended 
in the PCR mixture.  
A reaction mixture for one sample was prepared as described below: 
10    μl Bio-Mix Red 2x (Bioline, London, UK) 
  0.5 μl forward primer 
  0.5 μl reverse primer 
  9    μl sigma water 
20    μl total volume 
The program “Colony” was used to run the PCR reaction using the DNA Engine Dyad Peltier 
Thermal Cycler (Bio-Rad Laboratories Ltd, Hempstead, UK).  
The PCR program contained the following settings: 
1. 4 minutes  98 °C 
2. 30 seconds 98 °C  
3. 30 seconds 55 °C 
4. 60 seconds 72 °C 
5. 5 minutes  72 °C 
Once the presence of the right sized insert was verified by the colony PCR, a few clones, 
which contained the DNA insert, were cultured in 5 ml of LB medium. The DNA was then 
extracted as explained in section 2.2.2 and further analysed using a restriction enzyme 
approach (as described in section 2.2.3). Two or three clones, which revealed the expected 
sized insert of the cloned DNA fragment, were sent for sequencing. Only clones with the 
Repeated for 30 circles 
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correct nucleotide sequences were used for further experiments. The DNA was stored at -20 
°C. 
 
2.2.20 Culture of mammalian Cells 
 
Human Embryonic Kidney 293 cells (HEK 293) (Graham and others, 1977) and 3T3 mouse 
fibroblast cells (Todaro and Green, 1963) were cultured in Nunc EasYFlask 75cm
2 
flasks 
(Thermo Scientific, Fisher Scientific UK Ltd, Loughborough, UK) using DMEM (Dulbecco's 
Modified Eagle's Medium) containing low glucose, GlutaMAX™ and pyruvate (Invitrogen 
Life Technologies Ltd, Paisley, UK) in a humidified chamber in a 5% CO2 environment at 37 
°C. The medium contained additional heat inactivated foetal bovine serum (FBS) (10% v/v) 
and a penicillin/ streptomycin antibiotic mixture (1% v/v) (both obtained from Invitrogen 
Life Technologies Ltd, Paisley, UK). Cells were cultured until they reached a confluency of 
about 95%, before they were passaged either in a 1:10 or 1:20 ratio.  
 
2.2.21 Culture and Differentiation of C2C12 (mouse myoblasts) 
 
C2C12 (Yaffe and Saxel, 1977) mouse myoblasts were cultured in growth medium made up 
of DMEM (high glucose, NEAA, no glutamine), 10% heat inactivated FBS and 1% Pen/Strep 
(all obtained from Invitrogen Life Technologies Ltd, Paisley, UK) in Nunc EasYFlask 75cm
2 
flasks (Thermo Scientific, Fisher Scientific UK Ltd, Loughborough, UK). C2C12 were 
grown in a humidified incubator at 37 °C with 5% CO2. As C2C12 myoblasts commence 
differentiation due to cell-cell contact, when becoming very confluent (> 90%), the growing 
C2C12 cells were splitted at a confluency of 60 – 70 % to prevent self-induced myotube 
formation.  
C2C12 destined to differentiate were cultured up to a confluency of 90%, washed with PBS 
and the medium changed to differentiation medium (DMEM high glucose, NEAA, no 
glutamine) with added 2% of horse serum and 1% Pen/Strep (all purchased from Invitrogen 
Life Technologies Ltd, Paisley, UK). Myotube formation begins to occur within 2-3 days of 
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starvation and fully formed myotubes can be observed after 4-5 days in differentiation 
medium.  
However, the C2C12 cells cultured and used in the here described experiments differentiated 
slower compared to fresher and healthier C2C12 cells. We did occasionally observe fully 
differentiated myotubes at day 4, but most cells were still differentiating. Also due to 
technical difficulties and increasing cell detachment, we were not able to culture C2C12 for 
more than 4-5 days in starvation medium.  
During differentiation the medium was changed every day and in later stages twice a day, as 
metabolic products from the cell culture start to acidify the medium                             
(information and protocol according to Katherine Fisher-Aylor and Brian Williams: 
http://genome.ucsc.edu/ENCODE/protocols/cell/mouse/C2C12_Wold_protocol.pdf).  
Occasionally C2C12 cells differentiated poorly, which could be seen in a further temporal 
delay of differentiation or by a very low differentiation index (number of differentiated 
C2C12 divided by number of present cells). Usually we would expect to see elongated 
myotubes by around Day 2 of differentiation and the first multi-nucleated myotubes would be 
observed around day 3. We usually also expected to see a differentiation index above 30 %. 
When we did not observe normal differentiation, e.g. when differentiation was significantly 
delayed or the differentiation index fell below 30%, cultured cells were checked for 
mycoplasma infection.  
 
2.2.22 Screen and treatment of cells for mycoplasma 
 
Mycoplasma are small, self-replicating organisms, which depend on host cells to perform 
major metabolic processes, such as synthesizing nucleic acids and amino acids. In cell 
culture, mycoplasma cannot be seen, neither by the naked eye nor by using a microscope and 
although they do not necessary change properties of the medium (for example, the pH or 
metabolic products), they can have major implication on the behaviour of cultured cell lines 
(McGarrity and others, 1992). 
We used a PCR based approach to detect mycoplasma designed by Dr. Rosemary Bass. 
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Mycoplasma DNA can be detected in culture media. Therefore for this approach at least 1 ml 
of medium, in which cells have been cultured in for a minimum of two days, was removed 
from the cell culture and boiled at 100 °C for 5 minutes. The solution was then spun down for 
one minute at 13000 rpm at room temperature.  
Subsequently the PCR sample was prepared as described below using the high fidelity DNA 
polymerase Phusion: 
           5  μl  5x Phusion buffer (New England Biolabs, Herts, UK) 
    0.5 μl   dNTPs (100 mM) 
      2.5 μl  forward primer (10 nM) 
      2.5 μl  reverse primer (10 nM) 
       3 μl  boiled culture supernatant  
11.25 μl  sigma water 
              0.25 μl  Phusion (New England Biolabs, Herts, UK) enzyme 
     25 μl  total volume 
 
Following the sample preparation, the polymerase chain reaction was carried out in a DNA 
Engine Dyad Peltier Thermal Cycler (Bio-Rad Laboratories Ltd, Hempstead, UK). 
Primers used are described below: 
Myco1  GGGAGCAAACAGGATTAGATACCCT 
Myco2  TGCACCATCTGTCACTCTGTTAACCTC 
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The settings for the PCR were saved under the file name “MycoPCR” and comprised of 
following steps: 
1. 30 seconds 98 °C 
2. 10 seconds 98 °C  
3. 20 seconds 52 °C 
4. 30 seconds 72 °C 
5. 2 minutes  72 °C 
The samples were then analysed on a 1% Agarose Gel as described in 2.2.7. Presence of 
mycoplasma was detected as a band on the gel with a size of around 270 bp. Infected cells 
were treated subsequently with the antibiotic Ciprofloxacin (final concentration in cell culture 
10 μg/ ml) for a time course of up to one week or until the mycoplasma could not be detected 
anymore. The treated cells were incubated in fresh medium for a couple of days afterwards to 
recover from the antibiotic stress and were subsequently used for further experiments. 
 
2.2.23 Passaging of mammalian cells 
 
For the preparation of the cells for splitting, the culture medium was removed from the cells 
and the cells washed twice in PBS. Then the cells were incubated with 0.25% Trypsin-EDTA 
(Invitrogen Life Technologies Ltd, Paisley, UK) until the cells detached from the flask. 
Following trypsination, detached cells were resuspended in fresh medium and splitted in 
desired ratio. 
If a specified number of cells were needed, for example for a transfection experiment, the 
number of cells was counted using a haemocytometer. For this approach 100 μl of 
resuspended cells after detaching from the flask were aliquoted into an eppendorf tube. A 
couple of drops of described cell suspension were added between the coverslip and the 
gridded haemocytometer slide. As the depth and length of the grids are specified, the volume 
of each square is known. Therefore, by counting the number of cells in a minimum of 5 
squares, the number of cells in the original suspension can be calculated based on counted 
Repeated for 40 circles 
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amount and theoretical volume. The specified number of cells was subsequently passaged 
into a fresh flask or a multiple well dish. 
2.2.24 Transfection of mammalian cells 
 
Transfection was performed by using the transfectant Lipofectamine® 2000 (Invitrogen Life 
Technologies Ltd, Paisley, UK) following the manufacturer’s instructions. 
The number of cells required for transfection of different volumes in either wells or flasks 
can be found in the instructions, as well as information about the amount of DNA and 
Lipofectamine® 2000 reagent needed for transfection. 
For example, for one well of a 6-well dish 0.25–1 x 106 cells were plated out in 2 ml of 
growth medium. After 48 hours of further incubation cells were prepared for transfection by 
replacing the growth medium with growth medium without additional FBS (serum-free 
medium). Cells were transfected with 6-15μl of Lipofectamine® 2000 reagent and up to 14 
μg of plasmid DNA. After 4 hours in the Transfection medium, cells were incubated in 
growth medium containing FBS for further 48 hours before being harvested or processed for 
further experiments. 
 
2.2.25 Luciferase Assay  
 
A luciferase assay is a tool to study the involvement of a protein with mediators of signalling 
pathways or transcriptional activators and repressors.  
 Preparation 
For the preparation of a luciferase assay, 30,000 3T3 cells were seeded into each well of a 
Nunc 96-well dish (Thermo Scientific, Fisher Scientific UK Ltd, Loughborough, UK) and 
cultured in DMEM containing low glucose, GlutaMAX™ and pyruvate (Invitrogen Life 
Technologies Ltd, Paisley, UK) for further 24 hours.  
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 Transfection 
Transfection was carried out as described in the manufacturer’s instruction for 
Lipofectamine® 2000 (Invitrogen Life Technologies Ltd, Paisley, UK) as explained in 
section 2.2.24. Each assay was carried out at least three times in triplicates.  
The luciferase reporter vector pGL3 (Promega UK, Southampton, UK) was used as a 
transfection control.  As the reporter vector for the luciferase assay, a Super 8X TOPFLASH 
vector containing 8 active LEF/TCF binding sites fused to a firefly luciferase was used. As a 
negative control, we used a Super 8X FOPFLASH firefly luciferase vector, in which the 
LEF/TCF binding sites were mutated and therefore non-active. Both vectors were gifts from 
Randy Moon. Activation of the reporter assay was achieved by co-transfecting the cells with 
pCaβ-β-Catenin-IRES-GFP. For normalisation purposes 3T3 cells were also transfected with 
the plasmid pRLTK (Promega UK, Southampton, UK) expressing a renilla luciferase. To 
analyse the influence of our cloned constructs on the reporter vector, 3T3 cells were also 
transfected with a plasmid expressing the fusion-protein or with a plasmid containing only 
the vector backbone as a negative control.  
The preparation of a set of experiments with one sample for each condition would look as 
follows: 
 
 
 
 
 
 
 
Table 2.5: Setting up a Luciferase assay 
The following list gives details about the volume of medium, the amount of DNA and the volume of 
Lipofectamine® 2000 used for one sample of each setting in a luciferase reporter assay. 
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  pGL3 
β-
catenin 
8x TOP-
FLASH 
8x FOP-
FLASH 
vector  
over-
expression 
construct 
Renilla 
Lipofect-
amine® 
2000  
volume 
(transfection 
mixture) 
volume in 
well 
trans-
fection 
control 
100ng / / / / / / 0.5μl 2 x 25μl 100μl 
vector 
only 
positive 
/ 100ng 10ng / 10ng / 10ng 0.5μl 2 x 25μl 100μl 
vector 
only 
negative 
/ 100ng / 10ng 10ng / 10ng 0.5μl 2 x 25μl 100μl 
construct 
positive 
/ 100ng 10ng / / 10ng 10ng 0.5μl 2 x 25μl 100μl 
construct 
negative 
/ 100ng / 10ng / 10ng 10ng 0.5μl 2 x 25μl 100μl 
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After the Transfection, the cells were incubated in fresh medium containing 10% FBS 
for further 48 hours. 
 Measurement of Luciferase activity 
The Luciferase activity was measured as described for the dual-luciferase® reporter 
assay (DLR®) (Promega UK, Southampton, UK) according to the manufacturer’s 
instruction. The DLR® system allows the detection of two different luciferase signals. 
Firefly luciferase and renilla luciferase are evolutionary distinct enzymes and require 
different substrates, which makes this dual reporter assay ideal for experimental 
purposes. In the first instance the signal obtained from the metabolic reaction for the 
firefly luciferase is measured indicating the success of activating or inhibiting the 
LEF/TCF transcription factors. The reaction is then stopped and the renilla firefly 
activity is measured by adding a different substrate. The renilla firefly activity is a 
reading for the transfection efficiency for each sample and can be used to normalise the 
samples against each other.  
To prepare the transfected cells for luciferase activity measurement, the medium was 
removed from the cells and the 3T3 cells were rinsed gently once with PBS. 
Subsequently 20μl of 1x passive lysis buffer (Promega UK, Southampton, UK) were 
added to each well and cells were lysed for 20 minutes at room temperature whilst 
rocking slowly. The lysate was then aliquoted into a black Nunc 96-well dish (Thermo 
Scientific, Fisher Scientific UK Ltd, Loughborough, UK). 
The Luciferase activity was measured on an EnVision Multilabel Plate Reader 
(PerkinElmer, Cambridge, UK). 
The first step was to measure the firefly luciferase activity. 100μl of Luciferase Assay 
Reagent II (LARII) (Promega UK, Southampton, UK) were added to each lysate and the 
reading was taken. The second step comprised the immediate stop of firefly luciferase 
activity and the measurement of the renilla luciferase activity. The firefly activity was 
quenched by adding 100μl of Stop&Glo solution (Promega UK, Southampton, UK) to 
each sample and as the Stop&Glo solution also contained the substrate for the renilla 
luciferase, the activity could be measured directly after addition of the second solution. 
Obtained firefly luciferase readings were normalised based on the measured renilla 
activity. The luciferase activity obtained for the sample transfected with the reporter 
genes and the empty vector was set to 100% and all other measured activities were 
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compared to this sample. Statistics were carried out using the non-parametric Mann-
Whitney-U-test using SPSS statistics software (IBM Corporation, New York, USA). 
 
2.2.26 Immuno-Staining of C2C12 cells 
 
 Preparation of C2C12 myoblasts 
Round coverslips with a diameter of 5 mm were sterilised by autoclaving and carefully 
placed into each well of a Nunc 6-well dish (Thermo Scientific, Fisher Scientific UK 
Ltd, Loughborough, UK). The coverslips were coated with gelatine by incubation for 
15-20 minutes in a 0.3% gelatine solution. C2C12 myoblasts were aliquoted onto each 
coated coverslip and cultured in growth medium for further 24 hours before being 
processed for immuno-histochemistry. For immuno-staining of differentiated mouse 
myotubes, C2C12 were seeded unto gelatine covered coverslips, grown to high 
confluency and the medium changed to differentiation medium (as described in section 
2.2.21) until cells reached the desired stage of differentiation. 
 Fixing and Permeabilisation of C2C12 cells 
The medium was removed from the C2C12 and cells were immediately fixed with 3% 
PFA. Undifferentiated C2C12 cells were incubated in PFA for 15 minutes, whilst 
differentiated C2C12 were fixed in PFA for 30 minutes. After fixation, the coverslips 
were moved into a clean Nunc 6-well dish (Thermo Scientific, Fisher Scientific UK Ltd, 
Loughborough, UK) and the cells were washed three times with PBS for 5 minutes each 
at room temperature shaking on a very slow rocker. Cells were then permeabilized by 
using a 0.25% Triton X solution (in PBS); either 20 minutes for C2C12 myoblasts or 30 
minutes for C2C12 myotubes. Again, the cells were washed subsequently three times 
with PBS as described before.  
 Blocking and antibody treatment 
Following the pre-treatment, the cells were blocked with 10% goat serum (in PBS) at 
room temperature for 40 minutes without shaking.  In the meantime the antibodies were 
diluted in 0.1% goat serum. For a list of antibodies used and dilution factors see table 
2.6. Two antibodies could be used at the same time when the species of the animal, in 
which they were raised, was different. 
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Table 2.6:  Primary Antibodies used for Immuno-histochemistry 
Following list contains information of all primary antibodies used for the Immuno-histochemistry of 
C2C12 cells. 
name species detection dilution manufacturer 
ab62181 rabbit Klhl31 "1:1000" abcam®, Cambridge,UK 
YL1/2 rat alpha tubulin "1:1000" 
MorphoSys UK Ltd t/a 
AbD Serotec, Oxford,UK 
NB2 mouse Nebulin "1:200" abcam®, Cambridge,UK 
 
Also, whilst the cells were blocked in 0.1% goat serum, a humidified chamber was 
prepared. The humidified chamber comprised of a large western blot blocking tray, 
which was covered with wet paper tissue. On top of the wet layer squares of parafilm 
(Alcan Packaging, Bristol, UK) were laid out.  
40 – 50 μl of each antibody solution were pipetted onto the parafilm layer and the 
coverslips were carefully placed on top of the drop with the cell-displaying surface 
facing towards the solution. The cells were incubated in the primary antibody solution 
for 2 hours at room temperature or overnight in the cold room at 4 °C. Following the 
incubation with the primary antibody, the coverslips were placed into a new Nunc 6-
well dish (Thermo Scientific, Fisher Scientific UK Ltd, Loughborough, UK) and 
washed 7 times, each step lasting for 5 minutes, with PBS.  
 Treatment with the secondary antibody 
The secondary antibodies were chosen based on the species the primary antibody was 
raised in. For example, when using the Klhl31 antibody, the secondary antibody had to 
be an anti-rabbit secondary antibody to be able to bind to the primary antibody. Dyes 
and secondary antibodies used are conjugated to a fluorophore and can be excited by 
specific wavelengths of light. The emitted light from the fluorophore can then be 
visualised using a detector. For a list of dyes and secondary antibodies see table 2.7 
below. 
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Table 2.7:  Secondary Antibodies and Dyes used for Immuno-histochemistry 
Following list contains information of all secondary antibodies and dyes used for the Immuno-
histochemistry of C2C12 cells. 
name antibody dye species 
emitted 
colour 
De-
tection 
dilution manufacturer 
Alexa 
Fluor® 488 
x   rabbit green / "1:1000" 
Invitrogen 
Life 
Technologies 
Ltd, Paisley, 
UK 
Alexa 
Fluor® 488 
x   rat green / "1:1000" 
Invitrogen 
Life 
Technologies 
Ltd, Paisley, 
UK 
Alexa 
Fluor® 488 
x   mouse green / "1:1000" 
Invitrogen 
Life 
Technologies 
Ltd, Paisley, 
UK 
Alexa 
Fluor® 568 
x   rabbit red / "1:1000" 
Invitrogen 
Life 
Technologies 
Ltd, Paisley, 
UK 
Alexa 
Fluor® 568 
x   mouse red / "1:1000" 
Invitrogen 
Life 
Technologies 
Ltd, Paisley, 
UK 
Texas-
Red® X 
Phalloidin 
  x / red F-Actin "1:400" 
Invitrogen 
Life 
Technologies 
Ltd, Paisley, 
UK 
Phalloidin-
488 
  x / green F-Actin "1:1000" 
Invitrogen 
Life 
Technologies 
Ltd, Paisley, 
UK 
DAPI   x / blue DNA 
"1:10000
" 
Invitrogen 
Life 
Technologies 
Ltd, Paisley, 
UK 
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The secondary antibodies or dyes were diluted in 0.1% goat serum and a humidified 
chamber was prepared as previously described. Again, 40-50 μl of dye or secondary 
antibody solution was pipetted onto the parafilm surface and the coverslip placed on top 
of it with the cells facing the liquid. The cells were incubated with the secondary 
antibody or dye for 35 minutes at room temperature in the dark without shaking. The 
coverslips were subsequently carefully placed into a clean 6-well dish and washed 
gently 7 times in PBS for 5 minutes each without shaking. Following the washing steps 
the cells were incubated in a DAPI solution (1:10000 in PBS) for 5 minutes in the dark 
and then washed immediately 3 times in PBS for 5 minutes each time.  
 Mounting of the coverslip on microscopy slides 
Whilst the cells were incubated with the secondary antibody or dye, the hydromount 
solution (AGTC Bioproducts t/a National Diagnostics UK, Hessle, UK) was warmed up 
to 37 °C. The slides were labelled and a drop of hydromount was pipetted onto the slide. 
The washed coverslips were gently removed from the well, briefly dried on paper and 
placed on the slide with the cells facing the hydromount solution. The slides were left to 
dry overnight at room temperature in the dark. The following day, residual hydromount 
was carefully removed. The coverslips were stored for 2-3 weeks at -20 °C without any 
significant loss in signal strength of the fluorophore. 
Images of the cells were taken at a widefield upright microscope (Carl Zeiss 
Microscopy Ltd, Cambridge, UK) equipped with a monochrome CCD camera using 
AxioVision software (Carl Zeiss Microscopy Ltd, Cambridge, UK). Images were 
exported into Adobe Photoshop (Adobe Systems Europe Ltd, Maidenhead, UK) for 
labelling and formatting purposes. 
 Image processing techniques 
As we had experienced high, mainly red, background fluorescence in C2C12 cells, we 
needed to process images to exclude falsely-observed labelling. Negative samples for 
immuno-staining were prepared by processing fixed cells exactly as described 
previously. However, these cells were only incubated in incubation solution without 
primary antibody for the primary antibody step and later in incubation medium with the 
secondary antibody added. Negative samples for cells labelled with a dye were 
incubated in both incubation steps in incubation solution only.  
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For the image processing, pictures were taken for both the negative and the positive 
samples at the same settings (same wavelength, same (fixed) time of exposure, same 
saving mode .tif). Firstly the background signal was removed from the negative images 
by using the feature ‘levels’ in Adobe Photoshop (Adobe Systems Europe Ltd, 
Maidenhead, UK) and the setting for obtained exposure levels were saved for each 
channel. To remove potential background level from positive images, the determined 
exposure levels were imposed onto the original image. An example is given in the 
figure below: 
 
Figure 2.1: Reducing the background noise from immuno-labelled C2C12 
myotubes 
High autofluorescence in C2C12 myotubes overshadowed real fluorescent signalling. Removing the red 
background signal revealed a clearer labelling. However, the potential real signal was also weakened.  
 
2.2.27 Latrunculin B treatment of C2C12 cells 
 
Latrunculin B is a drug that can be used to reversibly depolymerise the actin 
cytoskeleton of a mammalian cell (Spector and others, 1983).  
For preparation of C2C12 cells, myoblasts were cultured in a Nunc 6-well dish (Thermo 
Scientific, Fisher Scientific UK Ltd, Loughborough, UK) and differentiated into 
myotubes as described in section 2.2.21.  
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Once the C2C12 myoblasts reached a medium confluency of around 75% or C2C12 
myotubes had differentiated to a specific degree, the cells were incubated in fresh 
growth or differentiation medium (see 2.2.21) containing 1 nM latrunculin B. The 
incubation with latrunculin B was carried for 15 minutes in the humidified incubator at 
37 °C. Loss of Actin was calculated based on a) presence of rounded C2C12 cells and 
b) on signal strength of Actin fibres. 
After the treatment with the toxin, the medium was removed quickly and immediately 
the afterwards the cells were fixed in 4% PFA containing additional Triton-X-100 to 
0.25%. For recovery of the actin fibers, latrunculin B treated cells were incubated in 
fresh growth or differentiation medium for a specified amount of time. After recovery, 
the cells were fixed in 4% PFA with added 0.25% Triton-X-100.  
Subsequently, fixed cells were processed for immuno-histochemistry as described in 
section 2.2.26. 
 
2.2.28 Protein extraction from mammalian cells 
 
Mammalian cells were cultured in Nunc EasYFlask 75cm
2 
flasks (Thermo Scientific, 
Fisher Scientific UK Ltd, Loughborough, UK) as described in section 2.2.20 and 2.2.21. 
Before lysis, the cells were washed twice in PBS and trypsinised as described in section 
2.2.23. Once the cells detached from the surface of the flask, the enzymatic activity of 
trypsin was stopped by adding 1ml of cell culture medium to each flask. The cells were 
resuspended in the added medium and subsequently aliquoted into a sterilised eppendorf 
tube. The flasks were then rinsed with further 500 μl of cell culture medium to catch 
residual cells. The harvested mammalian cells were subsequently pelleted by 
centrifugation at 3000 rpm for 5 minutes. Obtained cell pellets were kept on ice to slow 
down protein degradation. The supernatant was completely removed and cells were 
lysed in 200 μl of RIPA protein lysis buffer on ice for 30 minutes. Samples were mixed 
by vortexing every 5-10 minutes. For the extraction of Klhl31 protein from mammalian 
cells, a mild lysis buffer was used including additional inhibitors of proteases, such as 
PMSF and sodium vanadate. Cells that were lysed with the mild lysis buffer were 
incubated on ice for 30 minutes without mixing or shaking.  
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To separate the cell debris from the protein solution, the lysis mixture was spun down at 
4 °C for 10 minutes at 13000 rpm. The protein solution was pipetted into a clean 
eppendorf tube and stored at - 20°C. The concentration of the protein was measured by 
using the Bradford assay. 
 
2.2.29 Measurement of protein concentration  
 
The Bradford protein assay was developed by Marion Bradford and uses a colorimetric 
approach to calculate the concentration of proteins in a solution (Bradford, 1976). The 
Bradford solution, usually coloured red, will change to a blue colour upon binding of 
proteins. The strength of colour can be measured as the absorbance at 595 nm and is an 
indicator for the amount of protein present. 
The protein concentration of the obtained samples was calculated based on a bovine 
serum albumin (BSA) standard. For the preparation of the BSA standard, a stock 
solution of 10 mg/ ml BSA in water was prepared. The stock solution was then further 
diluted to give a range of protein solutions with varying concentrations from 1 – 8 mg/ 
ml of BSA. 1μl of each BSA solution was then pipetted into a 1.5 ml disposable cuvette 
containing 1 ml of 1x Bradford reagent (Bio-Rad Laboratories Ltd., Hemel Hempstead, 
UK). The solution were gently mixed and incubated at room temperature for up to 2 
minutes to allow development of the colour reaction. The absorbance of each sample 
was then measured at 595 nm using a bench-top spectrophotometer (Biochrom Ltd, 
St.Albans, UK). Based on measured absorbance values, a standard curve was drawn and 
the linear trendline and equation were calculated. 
The protein lysate samples were prepared for the Bradford assay as described for the 
BSA standard and the absorbance measured at 595 nm. The approximate concentration 
of the protein lysates were calculated based on the values obtained for the BSA protein 
standard. 
 
 
 
107 
 
2.2.30  Preparation of Acrylamide Gel for SDS-PAGE  
 
Depending on the sizes of proteins, which should be separated using a SDS-PAGE, 
different percentages of Acrylamide/bisacrylamide can be used when preparing the 
lower or protein separating polyacrylamide (PAA) gel. 
For a standard 8% PAA gel the mixture was prepared as follows: 
4.6 ml   dH20 
2.7 ml  Acrylamide/Bisacrylamide mixture (ProtoGel 30%, AGTC Bioproducts 
t/a National Diagnostics UK, Hessle, UK) 
2.5 ml 1.5 M Tris pH 8.8 
0.1 ml  10% SDS 
0.1 ml 10% APS 
10  μl TEMED 
To prepare the gel, the glass slides for a 0.75 mm thick PAA gel were assembled using 
fitted casting frames and casting stands as described by the manufacturer (Bio-Rad 
Laboratories Ltd., Hemel Hempstead, UK).  
In a 50 ml beaker water, the Acrylamide mixture, Tris, SDS and APS were mixed 
together and TEMED was added to induce polymerisation. The solution was carefully 
filled into the glass plates up to a height of 2/3 of the glass plates without developing 
any air bubbles in the gel. The gel was then topped up with isopropanol and left to settle 
and polymerise.  
Once the gel was set, the isopropanol was completely removed and the upper gel 
solution was added on top of the lower, protein separation gel. The upper gel is used to 
collect the samples and to make sure that protein samples enter the lower gel at the same 
time. 
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The mixture for the upper gel was prepared as described below: 
3.4   ml  dH20 
0.83 ml  Acrylamide/Bisacrylamide mixture (ProtoGel 30%, AGTC Bioproducts 
t/a National Diagnostics UK, Hessle, UK) 
0.63 ml 1 M Tris pH 6.8 
0.05 ml  10% SDS 
0.05 ml 10% APS 
     5 μl TEMED 
A 10-well comb (Bio-Rad Laboratories Ltd., Hemel Hempstead, UK) was placed into 
the upper gel and the gel was left to polymerise. Poured gels could be stored at 4 °C 
wrapped in wet paper for up to two days. 
 
2.2.31 Protein sample preparation for SDS-PAGE 
 
Up to 50 μg of protein was freshly prepared for SDS-PAGE. The protein solution was 
added in a ratio of 4 : 1 to a 5x protein loading buffer. The sample was mixed 
thoroughly by vortexing and incubated for 10 minutes at 70 °C. The samples were 
subsequently spun down at 13000 rpm for 2 minutes and immediately loaded on a PAA 
gel. 
 
2.2.32 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 
The SDS-PAGE is a well establish method to separate proteins based on their size and 
their charge. SDS is used in this method to introduce further negative charges to the 
proteins proportional to the size of protein. 
The prepared gels were placed into a Mini Protean 3 Gel tank (Bio-Rad Laboratories 
Ltd., Hemel Hempstead, UK) and the tank was filled with SDS-PAGE running buffer 
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5 μl of Precision Plus Protein™ All Blue Standard (Bio-Rad Laboratories Ltd., Hemel 
Hempstead, UK) was loaded in one well of the PAA gel and usually 50 μg of total 
protein were loaded for each sample. The SDS-PAGE was usually carried out at 200 V 
for 45 minutes or until the blue loading dye was just about to move out of the bottom of 
the gel. The SDS-PAGE was stopped and the gel was either stained with Coomassie 
Blue or processed further for western blotting. 
 
2.2.33 Coomassie-Blue staining 
 
The gel used in the SDS-PAGE was carefully removed from the glass plates and rinsed 
once with PBS. The gel was then immediately fixed in fixing solution for 10 minutes at 
room temperature under constant moderate shaking. After the fixing the PAA Gel was 
stained with staining solution containing Coomassie brilliant blue R-250 for 15 minutes 
or up to several hours at room temperature. Coomassie staining of PAA gel is reversible 
and excess stain can eventually be removed by washing the stained gel several times in 
Destain solution. Once the gel was destained to the desired amount, the gel was placed 
on a transilluminator and a picture was taken with a standard digital camera. Images 
were labelled by using Adobe Photoshop (Adobe Systems Europe Ltd, Maidenhead, 
UK). 
 
2.2.34 Western Blotting 
 
The western blot is a method used to detect specific proteins in lysates or other protein 
mixtures. In the first part of the method, proteins are separated by an SDS-PAGE as 
described in 2.2.32, before they are transferred onto a membrane. 
 Preparation of the membrane and the electro-blotting chamber 
For the preparation of the blotting process, a piece of a Polyvinylidene fluoride (PVDF) 
(Bio-Rad Laboratories Ltd., Hemel Hempstead, UK) membrane with approximately the 
size of the lower gel was activated by incubation in 100 % methanol for 5 minutes. 
Once it was activated, the membrane was then incubated in western blotting transfer 
buffer. The lower gel from the SDS-PAGE (after being carefully removed from the 
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glass plates), as well as pieces of Whatman filter paper and the foam pads were also 
incubated in transfer buffer. 
 Assembly of  a wet electro-blotting chamber and western blotting 
The western blot uses an electric current to move proteins out of the gel and unto the 
PVDF membrane. Therefore the proteins on the membrane will resemble the proteins as 
separated in the lower PAA gel. As proteins are negatively charged, they move towards 
the cathode or negative pole in a wet electro-blotting chamber.  
The wet electro-blotting chamber, the Mini Trans-blot® cell (Bio-Rad Laboratories 
Ltd., Hemel Hempstead, UK), was prepared as described below. 
Firstly, the gel holder cassettes were assembled in following fashion: 
Cathode (+) 
Foam pad 
3 x Whatman filter paper (Whatman plc, Maidstone,UK) 
Activated PVDF membrane (Bio-Rad Laboratories Ltd., Hemel 
Hempstead, UK 
Lower PAA gel 
3 x Whatman filter paper (Whatman plc, Maidstone, UK) 
Foam pad   
Anode (-) 
The cassettes were then placed in the right orientation into the electrode-frame, which in 
turn was then placed into the tank. The tank was subsequently filled with transfer buffer 
and a cooling unit was placed into the tank.  
The electroblotting was carried out at 100 V for 1 hour. The success of protein transfer 
was analysed by Ponceau-Red staining.  
 Ponceau Red Staining 
The Ponceau Red staining is a sensitive and reversible staining method for proteins on a 
PVDF or nitrocellulose membrane. For staining, the membrane was washed twice in 
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water and then incubated in the Ponceau-staining solution until bands became visible. 
The red staining could be completely removed by washing the membrane in water. The 
water was changed when saturated with the red stain.  
 Blocking of the PVDF membrane and incubation with primary antibodies 
After the red stain was completely removed the PVDF membrane was blocked with 
10% milk (Marvel dried milk powder) diluted in TBST or 3 % BSA diluted in PBS 
depending on the primary antibody used. Blocking was carried out for 2 h at room 
temperature on a slow rocker. Subsequently the membrane was incubated in the desired 
primary antibodies, as listed in table 2.8. 
Table 2.8:  Primary Antibodies used for western blotting 
Following list contains information about primary antibodies, their dilution factors and blocking solutions 
used for western blotting  
name species detection dilution 
blocking 
solution 
incubation 
solution 
manufacturer 
ab62181 rabbit Klhl31 "1:1000" 
10% 
milk 
(TBST) 
1.25-2.5% 
milk 
(TBST) 
abcam®, 
Cambridge,UK 
ab290 rabbit GFP 
1:2000 -   
1:5000" 
3% 
BSA 
(PBS) 
3% BSA 
(PBS) 
abcam®, 
Cambridge,UK 
ab3280 mouse Actin "1:5000" 
10% 
milk 
(TBST) 
1.25-5% 
milk 
(TBST) 
abcam®, 
Cambridge,UK 
NB2 mouse Nebulin "1:400" 
10% 
milk 
(TBST) 
1.25-2.5% 
milk 
(TBST) 
abcam®, 
Cambridge,UK 
 
The membrane was incubated in the primary antibody overnight at 4 °C whilst shaking. 
The next morning the membrane was washed 6 times, each for 10 minutes, either in 
TBST or PBS depending on the primary antibody used, before being incubated in the 
secondary antibody. 
 Treatment with the secondary antibody 
For secondary antibodies, we used a horseradish peroxidise (HRP) conjugated antibody, 
which was able to detect the primary antibody based on the species the primary 
antibody was raised in.  Antibodies used were either an anti-mouse 
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Immunoglobulins/HRP antibody or an anti-rabbit Immunoglobulins/HRP antibody 
(DakoCytomation Denmark A/S, Glostrup, Denmark). The secondary antibodies were 
diluted (1:1000 for the α-mouse HRP and 1:5000 for the α-rabbit HRP) in the same 
incubation solution as described for the treatment with the primary antibody. The 
incubation was carried out for one hour at room temperature. After treatment with the 
secondary antibody, the membrane was washed 6 times for 10 minutes each, either in 
TBST or PBS depending on the used primary antibody. After the washing steps, the 
membrane was prepared for the signal development.  
 Signal development by ECL detection 
Enhanced chemiluminescence (ECL) is a highly sensitive method to detect proteins 
from a western blot. The protein which has been detected with a primary antibody and 
which has been then further recognized by the secondary antibody can be visualised on 
the membrane by the oxidation of luminol by the horseradish peroxidise attached to the 
secondary antibody. Emitted light from the oxidation of the substrate by the HRP is then 
detected and visualizes a specific band on the membrane.  
For the ECL reaction, the substrate solutions (western blot colour development solution 
1 containing 0.1M Tris pH 8.8, 2.5mM Luminol, 0.4mM p-Coumaric acid and western 
blot colour development solution 2 made up with 0.1M Tris pH 8.5, 0.02% v/v H2O2) 
were prepared and stored in the dark. In the meantime the dark chamber of the LAS-
3000 Imaging System (Fujifilm Medical Systems, Stamford, USA) was cooled down to 
-30 °C. Once cooled down, the membrane was taken out of the washing solution, briefly 
dried on paper and immediately incubated for one minute in the freshly mixed western 
blot colour development solution 1 and western blot colour development solution 2. 
Following the incubation with the oxidation substrates, the membrane was briefly dried, 
carefully wrapped in clingfilm and the protein marker labelled with a lumocolor pen. 
The membrane was immediately placed on a tray in the dark chamber and focused. 
Once the ECL signal was detected, a picture was taken by the LAS-3000 Imaging 
system (Fujifilm Medical Systems, Stamford, USA) with an inbuilt CCD camera. 
Images were exported into Adobe Photoshop (Adobe Systems Europe Ltd, Maidenhead, 
UK) for labelling purposes. 
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2.2.35 Stripping a membrane for reprobing 
 
The method of stripping can be used to remove primary and secondary antibodies from 
the membrane, making it possible to use the same membrane to stain for a different 
protein. Therefore one protein was detected on a western blot as described in section 
2.2.34, followed by the gentle removal of all bound antibodies from the membrane 
without affecting the transferred proteins. For this method, the membrane was washed 3 
times in PBS after the ECL detection and subsequently incubated for 10 minutes in mild 
stripping buffer (0.2M Glycine, 0.1% w/v SDS, 1% v/v Tween-20, pH 2.2) at room 
temperature whilst gently rocking. The buffer was removed and replaced by a fresh 
volume of mild stripping buffer. After further incubation of 10 minutes, the membrane 
was twice washed for 10 minutes in PBS followed by two washes in TBST for 5 
minutes each. The membrane was then ready to be blocked and incubated in a primary 
antibody as described in section 2.2.34. 
 
2.2.36 Glutathione S-transferase (GST) pull downs 
 
Interaction of proteins can be verified by using a GST-pull down. GST-proteins are in 
E.coli expressed fusion proteins which contain a GST-tag. This GST can be used to 
purify the GST-protein by affinity chromatography on immobilised glutathione, as it 
forms strong dimers with the GST-tag. Contamination can then easily be removed by 
washing the glutathione. Incubating the purified GST-protein with cell or other protein 
lysates will eventually lead to the binding of interaction partners to the GST-protein, 
which can then be purified and gently be removed from the glutathione phase. Obtained 
samples can then be analysed by mass spectrometry or western blot to identify 
interaction partners.  
 Preparation of the GST-Klhl31 protein 
The first part of the preparation was the production of a stable GST-Klhl31 Fusion 
protein. We have cloned a pGEX-5X-1 Klhl31 construct having the GST fused to the N-
term of the Klhl31 protein (see section 2.2.18). In the pGEX- vectors the expression of 
the GST-Fusion protein is controlled by a tac promoter, which can be activated by 
IPTG.  
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Competent cells (DH5α) were transformed with either pGEX-5X-1 or with pGEX-5X-
1-Klhl31 as described in section 2.2.1. A 5 ml pre-culture was grown for each construct 
and stored at 4 °C. The evening before the IPTG induction a 50 ml culture for each 
construct was started by adding 50 μl of each pre-culture. The cells were shaken 
overnight at 200 rpm and 37 °C. The next morning the whole 50 ml culture was added 
to 500 ml of fresh medium and cells were grown for 3 hours at 37 °C to achieve an 
optical density of 0.3-0.6. The medium was cooled down to 21 °C and the expression of 
the GST or GST-Fusion protein was induced by the addition of IPTG to a final 
concentration of 1 mM. The two E.coli cultures were shaken at 21 °C for further 3 
hours. After the incubation, the cells were pelleted from the medium by centrifugation 
at 4500 rpm using 50 ml falcon tubes. Each falcon tube contained a cell pellet from at 
least 100 ml of cell culture. The cell pellets were stored at -20 °C until processed for 
purification of the fusion proteins.  
 Purification of the GST-Fusion protein 
The frozen cells containing the overexpressed proteins, either GST only or GST-Klhl31 
FL, were thawed on ice and lysed with 9 ml STE-Buffer (0.1M NaCl, 10mM Tris pH 
8.0, 1mM EDTA pH 8.0) containing 50 μg of lysozyme (50 μl of 100 mg/ml stock 
solution). From this point onwards, both samples, the GST and the GST-Klhl31 FL 
lysates were treated exactly the same. The bacterial cells were incubated in the lysis 
buffer for 15 minutes on ice without mixing or shaking. Following the lysis step 
Sarkosyl (10% in STE-Buffer) was added to the lysate to a final concentration of 2%, as 
well as DTT to a final concentration of 1 mM and PSMF was also added to 1 mM final 
concentration. The cells were then further disrupted by french pressing and the lysate 
was centrifuged at 15000 rpm for 5 minutes. The supernatant was subsequently placed 
into a clean 10 ml Falcon tube. 50 μl of supernatant were kept for analysis by SDS-
PAGE, whilst Triton X-100 was added to the supernatant in the falcon tube to a final 
concentration of 1%.  500 μl of GST-beads slurry (Glutathione Sepharose High 
Performance beads, GE Healthcare Life Sciences, little Chalfont, UK) were added to 
each sample and incubated for up to 2 hours in the cold room at 4 °C on a slow shaker. 
The proteins should have now bound to the glutathione Sepharose beads. A sample of 
50 μl was removed from the suspension and the beads were gently spun down at a 
maximum of 2000 rpm for 1 minute. The supernatant was removed and discarded. The 
beads were then washed 6 times for each 5 minutes in PBS. The GST and GST-Klhl31 
bound beads were be kept in the fridge at 4°C for up to 3 weeks. To approximate the 
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amount of proteins on the beads, specified volumes between 5 – 20 μl of bead 
suspension were analysed on a 1% PAA gel next to a gradient of known BSA 
concentration of 1-5 mg/ml (as described in section 2.2.32).  
 Lysis of C2C12 myoblast and C2C12 myotubes 
C2C12 cells were cultured and differentiated as described in section 2.2.21. For a GST-
Pull down C2C12 cells were lysed in 2 ml of mild lysis buffer (50mM Tris pH 7.5, 
150mM NaCl, 5mM EDTA pH7.5, 1% v/v NP-40, 10% v/v Glycerol, 1mM Na3VO4, 
1mM PMSF, 1 Complete Mini, EDTA-free Protease inhibitor cocktail tablet (Roche 
Diagnostics Ltd, Burgess Hill, UK) per 10ml of buffer) for 30 minutes on ice without 
shaking. The protein lysate was obtained as described in section 2.2.28 and immediately 
processed further for the GST-pull down.  
Fresh PMSF was added to the C2C12 protein lysate and 100μl of GST or GST-Klhl31 
beads were added to the lysate. The suspension was incubated for up to 1 hour on a 
rocker at 4 °C. The supernatant was then removed from the beads and kept as a control 
for further analysis, whilst the beads were washed 6 times in mild washing buffer at 4 
°C. The beads were pelleted down by centrifugation between each washing step, using 
3000 rpm at 4 °C. After the 6
th
 wash the buffer was removed until only 100μl of slurry 
was left. As the GST-beads suspension was higher concentrated compared to the GST-
Klhl31 bound beads, the GST beads were further diluted in PBS to give equal amounts 
of GST-Klhl31 to GST. 100μl of each suspension was prepared for SDS-PAGE by 
adding protein loading buffer to 1x and DTT to 1mM. The protein samples were heated 
up to 70 °C for 10 minutes and immediately run on a large (17 x 15 cm) 10% PAA Gel, 
which were subsequently processed for silver staining, or on normal sized 10% PAA 
gels for western blotting (as described in section 2.2.33). 
 Preparing a V15.17 10 % PAA gel 
To give proteins from the GST-pull down enough space to separate during SDS-PAGE, 
we chose to use a larger (17 x 15 cm) 10% PAA gel based on the BRL Vertical Gel 
electrophoresis apparatus model V15.17 (Biometra, THISTLE SCIENTIFIC LTD, 
Glasgow, UK). The apparatus was kindly lent to us by Dr. Tracey Swingler, BMRC. 
For the preparation of the gel, the glass plates were assembled and the sides of the glass 
plates were taped and clipped to keep them tight. The glass plates were then placed into 
a large, square dish and sealed in an approximately 1cm high layer of 1 % agarose. A 
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lower gel was prepared based on the mixture as described for the PAA gel as described 
in sub chapter 2.2.30. After letting the gel set, the upper gel was prepared as described 
previously (section 2.2.30) and poured on top of the lower gel. A 20 well comb was 
added and the gel left to polymerize. Gels could be stored in the fridge at 4 °C wrapped 
in wet tissue for one day. To run the SDS-PAGE the gel was placed into the gel 
chamber with the comb facing inwards resting on the orange sponges. The gel was 
pressed tightly against the sponges and spaces between glass plates and chamber closed 
with Vaseline. Running buffer was filled into the upper tray and if no leakage was 
observed the lower tray was filled up as well. Up to 100 μl of sample could be loaded 
per well. The SDS-PAGE was run as described in section 2.2.32. 
 Protein visualisation in a PAA gel by Silver Stain and mass spectrometry 
Silver staining is a method to detect proteins in a PAA gel. This method is up to 50 
times more sensitive when compared to Coomassie Blue staining (Kerenyi and Gallyas, 
1973; Switzer and others, 1979). To prevent contamination, the gel was only touched 
with tweezers or when wearing fresh gloves, as proteins from the skin will be detected 
by the silver stain. Using Pierce® Silver Stain for Mass Spectrometry (Thermo Fisher 
Scientific, Cramlington, UK), borrowed from Dr. Samuel Fountain, the gel was 
prepared and stained as described by the manufacturer’s instructions. After the staining, 
interesting protein bands were excised from the gel and stored in a clean eppendorf tube 
at -80 °C. Excised bands were analysed by mass spectrometry, carried out by the 
FingerPrints Proteomics Facility at the College of Life Sciences (University of Dundee, 
UK). 
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3. Results 
 
Klhl31 associates with the actin cytoskeleton in mouse myoblasts 
 
3.1 Introduction 
 
3.1.1 C2C12 cells are a well-characterized model for myogenesis 
 
C2C12 cells are subclones of C2 mouse myoblasts, which have the ability to 
differentiate into myotubes or osteoblasts based on culturing in different conditioned 
media. First obtained by Yaffe and Saxel in 1977 from satellite cells generated from the 
thigh muscle of C3H mice (Yaffe and Saxel, 1977) C2C12 have been shown to be a 
good tool for studying myogenesis and osteogenesis on a cellular level.  
Differentiation into osteoblasts is triggered by BMP-2 signalling, which has been shown 
to inhibit myotube formation whilst inducing the expression of osteoblast markers, such 
as various alkaline phosphatases and osteocalcin (Katagiri and others, 1994). Myotube 
formation is achieved by starvation of C2C12 myoblasts from various growth factors, 
for example TGF-β (Brennan and others, 1991; Furutani and others, 2011; Vaidya and 
others, 1989) and β-catenin dependent or canonical Wnt ligands, such as Wnt3a 
(Tanaka and others, 2011). Serum Starvation will lead to the expression of late 
myogenic markers in C2C12, switching myoblasts from a proliferative state towards 
differentiation (see figure 3.1). This process is characterised by the withdrawal from cell 
cycle followed by elongation of the myoblasts and fusion of these to form 
multinucleated myotubes (Andres and Walsh, 1996; Walsh and Perlman, 1997).  
As C2C12 cells have been shown to express endogenous Klhl31 (Abou-Elhamd), we 
chose this cell line as a model to study Klhl31 expression during muscle development. 
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Figure 3.1: Schematic outline and time course of differentiation of C2C12  
(a) Multiple steps are involved in the differentiation of C2C12 myoblasts 
 
Upon starvation from growth factors C2C12 start to express the late myogenic marker myogenin 
followed by expression of p21 leading to cell cycle withdrawal. C2C12 myoblasts will then 
undergo major cytoskeletal changes including elongation and subsequent fusion to form 
multinucleated myotubes.                 
Scheme taken from (Andres and Walsh, 1996) 
 
(b) Differentiation of C2C12 myoblasts 
C2C12 were grown on coverslips and stained with DAPI to visualize DNA in the nucleus. On 
Day 0 C2C12 myoblasts are single cells, either polygonal (b’), which proliferate and upon 
growth factor removal start to elongate, indicated by * (b’’). After approximately four to five 
days of differentiation multinucleated myotubes (indicated by *) are formed (b’’’).  
 a 
 b 
 
* 
* 
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As differentiation of C2C12 is well described, both on genetic and molecular level, we use this myogenic 
cell line to study the localisation and function of Klhl31 during the cellular processes of myogenesis. 
 
3.1.2 Cytoskeletal changes during differentiation of C2C12 
 
Cytoskeletal dynamics in C2C12 myoblasts have been intensively studied. The 
cytoskeleton is involved in generating, stabilising and changing the shape of cells. 
Microfilaments, microtubules as well as intermediate filaments and cell surface 
receptors all play key roles in cytoskeletal changes (Alberts, 2008; Mermelstein and 
others, 2003).  
A major part of the cytoskeleton is composed of Actin fibres (Alberts, 2008; Pellegrin 
and Mellor, 2007; Tojkander and others, 2012). These fibres are formed by two-
stranded helices. In fibroblasts, Actin bundles are attached to each other by alpha-
actinin (Lazarides and Burridge, 1975), an Actin crosslinking protein, that is also 
involved in the organisation of Actin to the Z-discs of sarcomeres (Crawford and 
Horowits, 2011; Lazarides, 1975). Changes in Actin fibres can be mediated by 
signalling from integrins and other cell surface receptors, which interact with Actin at 
focal adhesion sites in the cell (Arora and others, 1999; Hinz, 2006; Sandbo and Dulin, 
2011). As Actin fibres are polarised structures it has been shown that various myosin 
motor proteins use the Actin fibres to transport cargo throughout the cell (Kapitein and 
Hoogenraad, 2011). 
Microtubules have also been studied as a vital part of the cytoskeleton being also 
involved in cell shape formation and stabilisation (de Forges and others, 2012; Suzuki 
and others, 2012). Microtubules are dynamic structures constantly assembling and de-
assembling to adapt to cellular changes (Alberts, 2008). They are made of α-tubulin and 
β-tubulin dimers, which polymerize to form Microtubules (Alberts, 2008). Microtubules 
also play an important role in intracellular transport (Stehbens and others, 2009). Active 
transport is carried out by motor proteins, kinesin and dynein, which travel along 
microtubules in a polarity–driven fashion. For example kinesin moves along 
microtubules in an anterograde orientation, whilst dynein moves along microtubules 
towards their minus-end (Vale, 2003; Welte, 2004) 
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The cytoskeleton undergoes various changes during differentiation of C2C12 (Ohtake 
and others, 2006). Studies carried out by immuno-fluorescence, as well as electron 
microscopy, have given detailed insight into myoblast differentiation and cytoskeletal 
changes (Burattini and others, 2004; Kontrogianni-Konstantopoulos and others, 2006). 
Analysing the Actin cytoskeleton it was shown that in undifferentiated C2C12 cells, 
Actin seems to be diffusely distributed throughout the cytoplasm with thicker Actin 
bundles appearing at the periphery of the cell (Burattini and others, 2004). Using 
antibodies against α-sarcomeric and cardiac Actin it was shown that both Actin 
isoforms are expressed at high levels in C2C12 myoblasts (Burattini and others, 2004).  
Around day two or day three of differentiation (labelled as intermediate differentiation 
stage by Burattini et al. in 2004) C2C12 cells elongate and intercellular spaces seem to 
narrow down. Phalloidin labelling revealed that the Actin fibres become denser and 
align in fibrillar orientation until Actin fibres are seen along the whole myotube 
(Burattini and others, 2004). Analysing the cytoplasm of myocytes in more detail, initial 
myofibrils can be seen by electron microscopy. Thin filament organization can be 
observed as well as premature Z-bodies (see figure 3.2). Premyofibrils have been 
described previously in C2C12 (Sanger and others, 2002). These authors also described 
structures termed minisarcomeres in C2C12 cells and avian primary muscle cells. They 
found that in differentiating primary muscle cells premature Z-bodies (termed primitive 
Actin anchoring structures by Sanger et al., 2002) are formed of alpha-actinin attaching 
Actin to itself, as well as to mini-A-bands comprising non-muscular myosin II 
filaments. 
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Figure 3.2: The intermediate differentiation stage of C2C12 
Using reverted microscopy (A) as well as scanning electron microscop y (B),  C2C12 can 
be seen to  elongate. Analysing C2C12 myocytes by t ransmission electron microscopy 
revealed the presence of premature myofibrils and Z -bodies (indicated by arrows) 
Legend: A, bar = 50 μm; B, bar = 20 μm; C, bar = 0.5 μm  
Figure taken from (Buratt ini and others, 2004) 
 
Sanger et al. further investigated the formation of mature myofibrils. Myofibrils are 
established by the alignment of primitive myofibrils (Rhee and others, 1994; Sanger and 
others, 2002). Furthermore, it was described that early Z-bodies fuse and non-muscle 
myosin II is removed from the minisarcomeres as titin and muscle myosin II are added 
to the myofibrils. Analysing fully differentiated C2C12 by transmission electron 
microscopy, sarcomeres and myofibrils can be observed as described by (Rhee and 
others, 1994; Sanger and others, 2002). 
During C2C12 differentiation the foundation is laid for the formation of mature 
sarcomeres.  In differentiated C2C12 myotubes thin and thick filament containing 
structures are already present, showing a similar organization to mature myofibrils 
(Burattini and others, 2004; Sanger and others, 2002). The differentiation process of 
C2C12 can therefore be used to study the tightly regulated process of early 
myofibrillogenesis. 
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3.1.3 Expression analysis of Klhl31 by RT-PCR  
 
We used the ability of C2C12 to differentiate into myotubes to investigate the role of 
endogenous Klhl31 during differentiation of C2C12 and fusion of myocytes into 
myotubes. After transfer of C2C12 into differentiation medium (section 2.2.21), we 
collected RNA from each day between day 0 (non-differentiated) and day 4 inclusive 
(early myotubes). Transcribing 2   of collected RNA into cDNA (section 2.2.13) we 
assessed the quality and relative quantity of the obtained cDNA by analysing the 
presence of an abundant gene, mouse β-Actin (see figure 3.3). 
 
 
Figure 3.3: Quality control of cDNA of C2C12 Differentiation time course 
cDNA obtained from C2C12 cells  undergoing different iat ion were  tested for relat ive 
quant ity and qualit y.  Using mouse β -Act in primers a 480 bp PCR product  was amplified . 
As a posit ive control for the PCR we used a previously established sample of chick 
cDNA and pr imers against  chick β -Act in amplifying a 400 bp PCR product.  Water was 
used as a negat ive control.  cDNA obtained from 3T3 mouse embryonic fibroblasts were 
used as a posit ive control for the mouse β -Act in primers.  
Legend: M - marker, + - posit ive control (chick cDNA), -  -  negat ive control,  D0- Day 0,  
D1 – Day1, D2 –  Day2, D3 – Day3, D4 – Day4 
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Examination of generated cDNA for the presence of mouse β-Actin suggested that a 
similar amount of C2C12 cDNA had been obtained for each day of the differentiation 
time course (see figure 3.3; D0-D4). We then moved on to analyse the expression of 
Klhl31 during myotube formation. 
Klhl31 expression was only detected at Day 3 and Day 4 of differentiation of C2C12 
myoblasts showing an increase in the PCR product obtained for Klhl31 as 
differentiation progressed (see figure 3.4). 
 
 
Figure 3.4: Klhl31 expression during differentiation of C2C12  
We used primers designed against  mouse Klhl31 to  detect  gene expression for Klhl31  
during C2C12 different iat ion. The predicted size for the DNA fragment  was 1177 bp. 
3T3 were used as a negat ive control.   
Legend: M - marker, D0- Day 0, D1 – Day1, D2 – Day2, D3 – Day3, D4 – Day4  
 
Klhl31 expression was not detected during early differentiation of C2C12 myocytes 
(figure 3.4; D0-D2). However, Klhl31 expression seemed to increase significantly 
during later stages of differentiation of C2C12 (see figure 3.4; D3-D4). In 3T3 mouse 
fibroblasts the Klhl31 PCR product was not detected (figure 3.4; 3T3). 
As Klhl31 mRNA levels seemed to increase after day 2 of C2C12 differentiation, we 
wondered if protein levels of Klhl31 also increase during C2C12 elongation and fusion.  
 
      M      D0    D1    D2   D3   D4    3T3 
3   kb 
2   kb 
1.5kb 
1   kb 
0.5kb 
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3.1.4 Klhl31 protein levels increased during differentiation of C2C12 
 
To investigate protein levels of Klhl31 during myotube formation, we collected protein 
samples at different time points of C2C12 differentiation as described in section 2.2.28. 
50 μg of whole protein lysate was loaded onto a 10 % PAA Gel, transferred to a PVDF 
membrane and subsequently blotted for Klhl31. The membrane was then stripped and 
re-probed with an Actin antibody as a loading control (see 2.2.35). 
The western blot against Actin revealed that similar amounts of proteins were loaded 
onto the gel (see figure 3.5). Blotting the membrane against Klhl31 showed a low level 
of Klhl31 proteins in myoblasts. However, the protein amount for Klhl31 increased 
during myotube formation (see figure 3.5; a). Stripping and reprobing the western blot 
with an anti-Actin antibody revealed loading of similar protein amounts per sample 
(figure 3.5; b). 
 
 
 
 
 
 
 
 
Figure 3.5: Klhl31 protein levels during Differentiation of C2C12  
(a) Protein lysates obtained dur ing a 5-day t ime course of C2C12 different iat ion were 
analysed by western blot incubated with an ant ibody against  Klhl31.  
(b) Blott ing against  Act in was used as a protein loading control.   
Legend: M - marker, D0- Day 0, D1 – Day1, D2 – Day2, D3 – Day3, D4 – Day4  
 
Overall, data from both the RT-PCR as well as the Western Blot revealed an increase of 
Klhl31 expression during C2C12 differentiation.  
(b) 
(a) 
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3.2 The sub-cellular localisation of Klhl31 during differentiation of C2C12 
 
3.2.1 Klhl31 was localised in the cytosol in undifferentiated C2C12, but changed its 
localisation during myotube formation 
 
Data from a recent publication reported a localisation of Klhl31 in the cytosol and 
around the nucleus of COS-7 and HeLa cells based on GFP-labelled fusion-proteins (Yu 
and others, 2008). To determine the localization of Klhl31 protein in C2C12 cells we 
used an immuno-staining approach to detect endogenous Klhl31 during a five-day time 
course of differentiation (from undifferentiated myoblasts to differentiated myotubes) of 
C2C12. It could be shown, that Klhl31 was localised in the cytoplasm of myoblasts (see 
figure 3.7: a and a’) in a punctate pattern. A potential punctate, nuclear localisation of 
Klhl31 could also be observed in some C2C12 myoblasts (see figure 3.6: a’).  In 
elongating C2C12 these puncta remained visible. Furthermore, they seemed to increase 
in quantity and then align to generate a filamentous pattern (figure 3.6: b and b’). After 
myotube formation Klhl31 puncta followed straight, well-organized lines similar to 
fibrillar structures inside the C2C12 myotubes (figure 3.6: c and c’). 
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Figure 3.6: Localization of Klhl31 protein during C2C12 differentiation 
Endogenous Klhl31 was detected with a polyclonal rabbit  ant i- human Klhl31 ant ibody 
and visualised with a secondary Alexa Fluor 488 ant ibody (green).  Nucleic DNA was 
labelled with DAPI (blue).   
Klhl31 levels changed during the differentiation of C2C12.  An increase of Klhl31 was 
observed at mRNA and protein level by PCR and Western blot. Furthermore, Klhl31 
localization was dynamic during C2C12 differentiation. These changes seem to 
correlate with major changes in the shape and structure of C2C12 cells themselves.  
 
3.2.2 Klhl31 co-localises with Actin fibres, but not with Microtubules 
 
We have seen that Klhl31 forms puncta that are organized in a linear pattern in 
differentiated C2C12 cells (figure 3.6). This organised Klhl31 localisation seems to be 
established around the time point in C2C12 differentiation that is defined by the 
changes of Actin leading to the formation of premature myofibrils. Based on the 
described localisation pattern, similar to motor proteins and previous data stating that 
members of the Kelch-like family bind to Actin (Hara and others, 2004; Robinson and 
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Cooley, 1997; Stogios and Prive, 2004), we were wondering if Klhl31 could associate 
to the cytoskeleton in C2C12 myotubes. 
We analysed the possible co-localisation of Klhl31 with cytoskeletal components using 
immuno-histochemistry. Double immuno-staining was carried out detecting Klhl31 
either together with Actin or α-tubulin in myoblasts and during the differentiation 
process of C2C12. 
Using either Texas-Red labelled phalloidin (red) or an Alexa-Fluor 488 conjugated 
phalloidin (green) we were able to reproduce the cytosolic localisation described for 
Actin in myoblasts, as well as in differentiating C2C12 myocytes (Burattini and others, 
2004). In addition, we were able to visualize the changes of the Actin cytoskeleton 
during differentiation of C2C12 mouse myoblasts (figure 3.7).  
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Figure 3.7: Klhl31 co-localizes with Actin, but only in differentiating 
myocytes 
The figure shows the localisat ion of Klhl31 and Act in in C2C12 during different iat ion. 
Endogenous Klhl31 was detected with a polyclonal rabbit  ant i-human Klhl31 ant ibody 
and visualised with a secondary Alexa Fluor 488 ant ibody (green).  Act in was visualized 
using Texas-Red-Phallo idin (red). Nuclear DNA was labelled with DAPI (blue).  Single 
channel images for either Klhl31 (d ,e,  f)  and for Act in (d’ ,e’, f’) are shown in grayscale 
and have been merged in images d’’ ,e’’ and f’’.   
Scale bars: (a, b, c) – 50 µm, (d ,e, f, d’, e’, f’, d’’, e’’, f’’) – 10 µm 
 (a,  d,  d’,  d’’) Klhl31 and Act in localisat ion in C2C12 myoblasts ( Day0) using a 20x 
object ive (a) and a 63x object ive (d ,  d’, d’’)  
(b,  e,  e’,  e’’) Klhl31 and Act in localisat ion during the intermediate stage of C2C12 
different iat ion (Day2) using a 20x object ive (b) and  a 63x object ive (e, e’, e’’)  
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 (c, f,  f’,  f’’) Klhl31 and Act in localisat ion in more mature different iat ing C2C12 (Day4) 
using a 20x object ive (c) and a 63x object ive (f,  f’,  f’’)  
 
In C2C12 myoblasts Actin fibres can be seen in the cytoplasm spanning the polygonal 
cell in a non-organised fashion, but linear pattern (figure 3.7; a and d’). However around 
day 2 of C2C12 differentiation Actin fibres elongate in correlation with elongation of 
the cells and the Actin fibres now reveal a parallel pattern, as the cell itself has now 
changed its form to resemble a more tube-like phenotype (figure 3.7; b and e’). In 
further differentiated, tube-like C2C12 myocytes the Actin fibres span the whole 
cytoplasm in a parallel pattern (figure 3.7; c and f’). Furthermore, the Actin density 
seem to have increased during differentiation, as also described by (Burattini and others, 
2004).  
In undifferentiated C2C12 myoblasts Klhl31 did not co-localize with Actin (figure 3.7; 
a and d’’). Again, a nuclear staining for Klhl31 could be observed (figure 3.7; d). 
However in more mature, differentiating C2C12 myocytes and in fully differentiated 
myotubes, Klhl31 was found to align to Actin fibres (see figure 3.7; c, f’’, figure 3.8). 
The co-localisation seemed to be established during the intermediate stage of 
differentiation (see figure 3.7; b, e’’) when the foundation for primitive myofibrils is 
laid down and Actin is incorporated into early Z-bodies (Rhee and others, 1994; Sanger 
and others, 2002). Furthermore it was again observed that the protein levels of Klhl31 
increased during C2C12 differentiation (figure 3.7; a-c). 
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Figure 3.8: Klhl31 co-localizes to Actin fibres in myotubes 
Endogenous Klhl31 was detected with a  polyclonal rabbit  ant i-human Klhl31 ant ibody 
and visualised with a secondary Alexa Fluor 568 ant ibody (red).  Act in was visualized 
using an Alexa-Fluor 488-Phallo idin (green).                                                                                                                       
The image was taken with a 100x object ive  of a single,  fully different iated C2C12 
myotube. Images a and b,  respect ively show single channel frames of the same myotube 
for Klhl31 (a) and Act in (b). Both single channel images were merged in image c.  
Scale bar (a, b, c) – 10 µm 
Next, the possible association of Klhl31 with microtubules was investigated. 
As before double immuno-staining was used, this time for Klhl31 and α-tubulin (see 
figure 3.9). We observed similar localisation patterns of microtubules in C2C12 
myoblasts and myotubes as described previously by Tassin (1985). Microtubules in 
C2C12 myoblasts span the whole cell with an organised network of fibres around the 
nucleus, from where the tubulin organisation centre originates. In myotubes however 
the microtubules exhibit longitudinal structures parallel to the sarcolemma (Azakir and 
others, 2010; Tassin and others, 1985).  
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Figure 3.9: Klhl31 might co-localize with microtubules 
Endogenous Klhl31 was detected with a polyclonal rabbit  ant i-human Klhl31 ant ibody 
and visualised with a secondary Alexa Fluor 568 ant ibody (red).  Mic rotubules were 
detected with a rat  ant i-α-tubulin ant ibody and visualized with a secondary Alexa -Fluor 
488 ant ibody (green). Nuclear DNA was labelled with DAPI (blue).  
Scale bar (a, b) – 10 µm 
 
 
Klhl31 co-localization with microtubules was not as clear as seen for Klhl31 with Actin, 
either in C2C12 myoblasts or in differentiating myocytes (see figure 3.9; a, b). Most of 
the Klhl31 did not seem to co-localise with α-tubulin. However some yellow 
fluorescence signal was observed indicating a close localisation of Klhl31 and 
microtubules. Co-localisation is difficult to analyse using an upright microscope and 
confocal images would help investigating the interaction of Klhl31 with microtubules 
during C2C12 differentiation. As we did not observe a strong close alignment of Klhl31 
to α-tubulin in C2C12 cells as compared to seen co-localisation for Klhl31 and Actin, 
we therefore assumed that Klhl31 is mainly associated with the Actin cytoskeleton. 
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To further investigate the relationship between Klhl31 and Actin, we decided to analyse 
the effects of Latrunculin B on both the Actin cytoskeleton and Klhl31. 
 
3.2.3 Latrunculin B treatment of C2C12 myoblasts disrupts Klhl31 localisation 
 
Latrunculin A and latrunculin B are both toxins that are produced by red sea sponges of 
the latrunculia family (I. Neeman, 1975; Spector and others, 1983). One molecule of 
latrunculin can bind one Actin monomer and prevent it from polymerising (Coue and 
others, 1987; Spector and others, 1983). Not only is Actin -polymerisation disabled by 
latrunculin A and latrunculin B, both drugs also depolymerise the existing Actin-
cytoskeleton. The process is fast and reversible after latrunculin removal (Coue and 
others, 1987; Morton and others, 2000; Spector and others, 1983). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.1: Optimization of Latrunculin B experiments 
As we have not  used Latrunculin B on C2C12 before,  we first  opt imized t reatment  
condit ions for each cell culture type, C2C12 myoblasts (table 3.1a) and C2C12 myotubes 
(table 3.1b) .  We tested various concentration, as well as different  incubat ion t imes with 
the drug and different  recovery t ime after treatment  to find the best  sett ings to carry out 
the final experiments.  The table shows how experiments were planned and the results we 
gathered from it .  The table also contains informat ion about  the microscopy sett ings used 
for image acquisit ion.  
 
Abbreviations: LaB – Latrunculin B
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table 3.1a experimental settings 
 
microscope setting results 
Number cells dish 
concen-
tration 
LaB 
(2mM 
stock) 
treatment  
time 
(min) 
recovery 
time    (min) 
negatives control Fix 
GFP 
exposure 
time 
568 
exposure 
time 
objective     
1 
titration 
C2C12 
growth 
12 
well/ 
1ml 
1:10000         
1:5000         
1:2000 
15/30 
15/30        
15 
60   
non 
treated 
C2C12 
PFA + 
0.25% 
Triton 
X-100 
1.9 sec 14 sec 20x/100x 
C2C12 loose actin 
and recover, best 
choice 1:2000 for 15 
min 
2 
C2C12 
growth 
12 
well/ 
1ml 
"1:2000" 15 60 
phalloidin 
only 
non 
treated 
C2C12 
PFA + 
0.25% 
Triton 
X-100 
4 sec 
non-
treated/ 
12 sec 
treated 
10 sec 
fixed 
20x/100x 
C2C12 loose actin 
but Klhl31 needs 
more recovery time 
3 
C2C12 
growth 
12 
well/ 
1ml 
"1:2000" 15 
30/60/120/   
180/240/300 
phalloidin 
only 
non 
treated 
C2C12 
PFA + 
0.25% 
Triton 
X-100 
no GFP 
17 sec 
fixed 
20x/100x 
fixing did not work/ 
phalloidin not visible 
4 
C2C12 
Growth 
12 
well/ 
0.5ml 
 "1:2000" 15 60/180/300 
phalloidin 
only 
non 
treated 
C2C12 
PFA + 
0.25% 
Triton 
X-100 
8 sec 
18 sec 
fixed 
100x 
Actin recovers after 
1 h, Kelchlike 31 
after 3 h 
5 
C2C12 
growth 
12 
well/ 
0.5ml 
 "1:2000" 15 60/180/300 
phalloidin 
only 
non 
treated 
C2C12 
PFA + 
0.25% 
Triton 
X-100 
7 sec 
18 sec 
fixed 
20x/100x 
Double Immuno 
Klhl31/ Actin 
QUANTIFICATION 
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table 3.1b experimental settings 
 
microscope setting results 
Number cells dish 
concen-
tration LaB            
(2mM 
stock) 
treatment  
time 
(min) 
recovery 
time    
(min) 
negatives control Fix 
GFP 
exposure 
time 
568 
exposure 
time 
objective 
   
1 
titration 
C2C12 
Diff 
12 
well/ 
1ml 
1:5000         
1:2000         
1:1000 
30                   
15/30        
15/30 
60   
non 
treated 
C2C12 
PFA + 
0.25% 
Triton 
X-100 
2 sec 11 sec 20x/100x 
C2C12 loose actin 
and do not recover 
2 
C2C12 
Diff 
12 
well/ 
1ml 
"1:1000" 
"1:2000" 
15/30 60 
phalloidin 
only 
non 
treated 
C2C12 
PFA + 
0.25% 
Triton 
X-100 
no GFP 
14 sec 
fixed 
20x/100x 
fixing did not work/ 
phalloidin not visible 
3 
C2C12 
Diff 
12 
well/ 
1ml 
"1:1000" 
"1:2000" 
15/30 60 
phalloidin 
only 
non 
treated 
C2C12 
PFA + 
0.25% 
Triton 
X-100 
3-5 sec 
8 sec 
fixed 
20x/100x 
different PFA, 
1:2000 LaB 15 min- 
cells recover 
4 
C2C12 
Diff  
12 
well/ 
0.5ml 
 "1:2000" 15 60/180/300 
phalloidin 
only 
non 
treated 
C2C12 
PFA + 
0.25% 
Triton 
X-100 
2.5 sec 
12 sec 
fixed 
100x 
Actin did not 
completely recover 
after 5h, Klhl31 
seems to have been 
affected by LaB 
treatment, 
accumulations 
5 
C2C12 
Diff  
12 
well/ 
0.5ml 
 "1:2000" 15 60/180 
tubulin 
only 
non 
treated 
C2C12 
PFA + 
0.25% 
Triton 
X-100 
4-5 sec 
14 sec 
fixed 
20x/100x 
Double Immuno 
Klhl31/ alpha 
Tubulin 
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6 
C2C12 
Diff  
12 
well/ 
0.5ml 
 "1:2000" 15 60/180/300 
phalloidin 
only 
non 
treated 
C2C12 
PFA + 
0.25% 
Triton 
X-100 
4-5 sec 
15 sec 
fixed 
20x/100x 
Double Immuno 
Klhl31/ Actin 
QUANTIFICATION 
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We tested the best conditions for Latrunculin B treatment in both C2C12 myoblasts and 
myotubes, but later only used Latrunculin B to disrupt the Actin components of the 
cytoskeleton in C2C12 myotubes, as we could only see co-localisation of Klhl31 to 
Actin in differentiated C2C12.  Firstly the best conditions for usage of Latrunculin B on 
fully differentiated C2C12 cells were tested (see table 3.1b). We found that completely 
disrupting the Actin cytoskeleton (table 3.1; number 1; 1/1000 dilution of 2 mM stock: 
2 μM for 30 minutes; Phalloidin-staining gave only background signal, but no Actin 
fibres were visualised) led to a non-recoverable collapse of cell structures followed by 
detachment of the C2C12 myotubes from the coverslips, potentially due to cell death 
(see figure 3.10: b, c). However, in cells that remained attached to the coverslips, the 
immuno-staining revealed a dense accumulation of Klhl31 protein in the condensed 
cytosol. In the periphery of the cells, Klhl31 protein could still be seen to have the 
previously observed punctate phenotype, although more condensed (figure 3.10: b’, c’) 
 
Figure 3.10: Latrunculin B treatment of C2C12 myotubes 
C2C12 myotubes after 5 days of different iat ion were t reated with 2μM of Latrunculin B 
for 30 minutes and then left  to  recover for further 60 minutes.  Cells were then processed 
for Immuno-histochemistry.  (a,  b,  c) Endogenous Klhl31 was detected with a polyclonal 
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rabbit  ant i-human Klhl31 ant ibody and visualised with a secondary Alexa Fluor 568 
ant ibody (red).  (a’,  b’,  c’) Actin was visualised using Alexa Fluor 488-conjugated 
Phallo idin (green) . Nuclear DNA was labelled with DAPI (blue).  Pictures a’’-c’’ are 
merged images for Klhl31 and Act in.  
Scale bar (a-c’’) – 10 µm 
 
C2C12 myotubes treated with high concentration of Latrunculin B did not recover from 
the loss of the Actin cytoskeleton. However, Klhl31 could still be detected with high 
levels in the cytosol of the cells (figure 3.10: c, c’’). The observed high levels of Klhl31 
were potentially due to concentration of the cytosol due to cell structure collapse. 
Differentiated myotubes seemed to break down without the Actin fibres, which led to a 
rounded cell phenotype (see figure 3.10: b, c). Similar observations were made by other 
groups, when using Actin-depolymerising drugs (Nowak and others, 2009). 
 
Previous data suggested that treatment of differentiating C2C12 with Latrunculin B led 
to elongation of C2C12, whilst fusion of the cells was inhibited due to loss of Actin and 
therefore lack of filopodia and lamellipodia formation (Nowak and others, 2009). 
Furthermore it was shown that cell migration was negatively affected. Nowak et al. also 
reported that after treating differentiated C2C12 with either Latrunculin B or 
cytochalasin D, they could observe large, rounded myoblast bodies. These authors 
claimed that this phenotype appeared because cell contact with the dish or coverslip was 
diminished, but these cells were not undergoing apoptosis (Nowak and others, 2009).  
 
Complete Actin repolymerisation was never observed, when using Latrunculin B at a 
concentration of 2 μM for 30 minutes. Once the Actin fibres were depolymerised 
C2C12 cells did not re-establish their cell shape and kept the rounded appearance. Also, 
treated C2C12 cells seemed to lose the attachment to the coverslip and were washed off 
during the immuno-staining preparation steps. 
Based on these findings, we therefore decided to use lower concentrations of 
Latrunculin B preventing complete depolymerisation of Actin fibres in differentiating 
myocytes and potentially allowing repolymerisation to occur. The best condition for 
incomplete depolymerisation of Actin fibres was determined as treatment of myocytes 
with 1 μM Latrunculin B (1/2000 dilution of a 2mM stock) for 15 minutes (see table 
3.1b, experiment number 3). However, the effects of Latrunculin B treatment were 
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variable. Some C2C12 myotubes were affected more by Latrunculin B and therefore 
lost more Actin fibres compared to others. In general, a high percentage of C2C12 
differentiated cells (>70%) were left with enough Actin fibres to be able to recover, and 
all treated and processed cells on coverslips were shown to rebuild their Actin 
cytoskeleton in a time course of up to five hours (figure 3.11, c-e).  
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Figure 3.11: Latrunculin B treatment of C2C12 myotubes leads to the disorganisation of Klhl31 localisation  
 
 
   
* 
* 
* 
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Figure 3.11: Latrunculin B treatment of C2C12 myotubes leads to the 
disorganisation of  Klhl31 localisation 
Differentiated C2C12 myotubes were treated with 1μM Latrunculin B for 15 minutes (b). Treated cells 
were fixed and processed for immuno-staining (b) or left to recover from 1-5 hours in fresh medium (c-e) 
and then fixed and stained. Untreated C2C12 were processed as controls (a). Endogenous Klhl31 was 
detected with a polyclonal rabbit anti- human Klhl31 antibody and visualised with a secondary Alexa 
Fluor 568 antibody (red). Actin was visualised using an Alexa Fluor 488-conjugated Phalloidin (green). 
Nucleic DNA was labelled with DAPI (blue), but the DAPI channel is not enabled in magnified images 
(a’-e’). Images were taken with a 63x objective.                                                                                                                                                                         
 
In untreated C2C12 myotubes Klhl31 was shown to associate to Actin fibres (figure 
3.11; a). Treatment with Latrunculin B lead to a slight reduction of the Actin 
cytoskeleton and the loss of Klhl31 localisation to Actin fibres (figure 3.11: b), as well 
as a general disorganized accumulation of Klhl31 in the cytosol (figure 3.11: b’, *). 
These Klhl31 accumulations (potentially indicating Klhl31 protein aggregates (figure 
3.11: b’, c’, e’) were observed at any stage during a recovery time course of up to 5 
hours. Although C2C12 myotubes recovered and their Actin fibres repolymerized (see 
figure 3.11: c-e), Klhl31 did not seem to re-localise to the newly build fibres, rather 
Klhl31 protein remained cytosolic still displaying a disorganized distribution and 
cytosolic protein aggregates (figure 3.11: c-e). 
Having characterised Klhl31 during C2C12 myotube formation, we then decided to 
investigate potential interaction partners for Klhl31. Finding interacting proteins would 
help us to further analyse a role for Klhl31 during C2C12 differentiation. 
  
141 
 
 
4. Generation of Klhl31- fusion proteins as tools to study 
function in C2C12 
 
4.1 Introduction 
 
4.1.1 Structure and function of proteins of the Kelch-like family 
 
Kelch-like proteins all show the same structural properties (see figure 4.1). They have 
three main functional domains: The amino-terminal broad complex/ tram-track/ bric-a-
brac (BTB) or poxvirus and zinc finger (POZ) domain, a central linking domain, called 
the BACK domain and the carboxy-terminal Kelch repeats (Stogios and others, 2005; 
Stogios and Prive, 2004). Various members of the Kelch -like protein family have been 
shown to bind to Actin via their Kelch β-propeller (Aromolaran and others, 2009; 
Aromolaran and others, 2012; Kelso and others, 2002), whilst the BTB-domain is 
involved in binding substrate proteins as part of E3 Ubiquitin Ligase complexes 
(Furukawa and others, 2003; Geyer and others, 2003; Stogios and others, 2005; Xu and 
others, 2003).  Also, via their BTB-domain, Kelch-like proteins have been shown to 
form homodimers (Geyer and others, 2003).  
 
 
Figure 4.1: Structure of Klhl31 
Human and chick Klhl31 have been reported to display an N-terminal BTB domain (light blue), a central 
BACK domain (beige) and 6 C-terminal Kelch repeats (light violet) (Abou-Elhamd and others, 2009; Yu 
and others, 2008). 
 
        Kelch-like 
repeats 
BTB BACK 
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Klhl31 was identified in zebrafish and a human and a chick homologue was reported 
recently (Abou-Elhamd and others, 2009; Wu and Gong, 2004; Yu and others, 2008). 
Both, human and chick Klhl31 encode a protein of 634 amino acids with a predicted 
size of 70 kDa (Abou-Elhamd and others, 2009; Yu and others, 2008). Furthermore, 
sequence analysis revealed that chick and human Klhl31are highly conserved displaying 
84.4% sequence homology (Abou-Elhamd).  
 
4.2 Results 
 
4.2.1 Cloning and analysis of an amino-terminal GFP-Klhl31 Fusion-protein 
 
Previous work in our laboratory described the expression of Klhl31 in developing chick 
embryos and also examined how the expression was regulated during myogenesis 
(Abou-Elhamd; Abou-Elhamd and others, 2009). By analysing the localisation of 
Klhl31 in C2C12, we found that Klhl31 seems to localise to the Actin cytoskeleton, but 
only in differentiated myotubes (figure 3.9). This co-localisation was established at a 
stage of differentiation (see figure 3.8), which was proposed to lead to changes in the 
Actin cytoskeleton in formation of primitive myofibrils (Burattini and others, 2004; 
Kontrogianni-Konstantopoulos and others, 2006; Sanger and others, 2002).   
We decided to generate GFP-Fusion proteins of Klhl31, which would enable us to use it 
as a tool to study interactions in the C2C12 cell line by analysing localisation patterns, 
as well as studying protein dynamics using live-imaging. Another approach could also 
be to find direct interaction partners of Klhl31 by using the GFP as an anchor that can 
be pulled down with an immobilized GFP-binding protein (GBP)  (Angers and others, 
2006). 
Kelch-like proteins have two distinct structural domains, which both have specific 
function in binding substrates: the BTB domain at the amino terminus and the Kelch 
repeats at the C-terminus (Stogios and others, 2005). Preliminary data for Klhl31 
suggests that both domains are necessary for the functionality of Klhl31, although the 
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BTB-domain seems to be the domain that is involved in binding substrates destined for 
ubiquitinylation and subsequently proteasomal degradation. 
We created a fusion protein, which would have an EGFP-tag attached at the Klhl31 
amino-terminus to the BTB-domain of the protein (see scheme in figure 4.2). As vector 
backbone, we used the pEGFP-C1 vector (Clontech Laboratories Inc., Mountain View, 
CA, USA). A full-length version of Klhl31 (EGFP-Klhl31 FL, 1.9 kb), as well as a 
mutant version lacking the Kelch-repeat domains (EGFP-Klhl31 ΔKR, 0.9kb) were 
cloned from chick cDNA. A second mutant with deletion of the BTB domain (EGFP-
Klhl31 ΔBTB, 1.4 kb) was previously generated and sub-cloned from pCaβ Klhl31 
ΔBTB IRES-GFP. For the cloning protocol and primers, see section 2.2.16. 
 
 
Figure 4.2: Schematic representation of EGFP-Klhl31 fusion proteins 
We created Klhl31 fusion protein tagged with an N-terminal EGFP-protein. EGFP-Klhl31 FL comprising 
of the full length protein sequence of Klhl31 fused to the EGFP-tag, whilst the EGFP-Klhl31 ΔBTB 
protein lacks the N-terminal BTB binding domain. The EGFP-Klhl31 ΔKR protein does not include the 
Kelch-repeats.  
 
Once the sequences were verified (see Appendix), we transfected C2C12 myoblasts 
with the different pEGFP-C1-Klhl31 constructs and examined GFP-expression in 
C2C12 myoblasts and myotubes. 
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Figure 4.3: Overexpression of pEGFP-C1 Klhl31 constructs in C2C12 
C2C12 were transfected with either pEGFP-C1 (a, e), pEGFP-C1 Klhl31 FL (b, f), pEGFP-C1 Klhl31 
ΔBTB (c, g) or pEGFP-C1 Klhl31 ΔKR (d, h), respectively. Transfected cells were either fixed after 24 h 
in growth medium (GM, a-d) or left to differentiate for 5 days in differentiation medium (DM, e-h). 
Figure showing grayscale images for Klhl31 only (a-h) and merged with DAPI to further visualize 
cellular localisation (a’-h’). 
Scale bar (a – h’) – 10 µm 
 
The N-terminal pEGFP-C1 Fusion-protein of Klhl31 did not recapitulate the observed 
localisation of endogenous Klhl31 to the Actin-cytoskeleton (figure 3.7). Instead, 
EGFP-Klhl31 FL and EGFP-Klhl31 ΔBTB protein (see figure 4.3: b, c, f and g) both 
showed a localisation that is similar to that described for inclusion bodies (Goldberg, 
2003) or lysosomes (Chimote and others, 2012), which contain misfolded proteins. The 
potential vesicular localisation can observed strongly for EGFP-Klhl31 FL in C2C12 
myotubes, where the accumulation of GFP-fluorescent protein was seen to localise 
around multiple nuclei, which themselves are close together (figure 4.3; f). Furthermore, 
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nuclei appeared to be enlarged in transfected C2C12, which might be due to increased 
stress on cultured cells or might indicate diminished health of used C2C12 myoblasts.  
Non-functional proteins stored in vesicles are usually subsequently degraded by the 
proteasome (Goldberg, 2003; Tyedmers and others, 2010). Observing both the full 
length Klhl31 protein as well as the BTB mutant of Klhl31 in structures resembling 
vesicles potentially containing misfolded proteins, suggested the possibility that our 
fusion-proteins are non-functional and therefore degraded by the cell.  The ΔKR mutant 
could be seen to be mainly cytosolic (figure 4.3: d, h). As the Kelch-repeats have been 
shown to be responsible for the binding of Kelch-like proteins to Actin (Adams and 
others, 2000; Aromolaran and others, 2009; Aromolaran and others, 2012; Kelso and 
others, 2002), it might be that the loss of the kelch-propeller is responsible for the 
diffuse cytosolic localisation. 
To test the functionality of the fusion proteins, we then used a Luciferase assay 
approach. 
It has been shown in our laboratory that Klhl31 can antagonize β-catenin dependant 
Wnt-signalling (Abou-Elhamd). In a Luciferase reporter assay, it was shown that Klhl31 
full length and Klhl31 ΔKR can both inhibit the Wnt-3a mediated induction of a 
LEF/TCF responsive promoter (TOPFLASH, kindly given to us by R. Moon), which 
drives luciferase expression. Klhl31 ΔBTB was not able to do so. Inducing LEF/TCF 
luciferase reporter vectors by β-catenin also induced the expression of luciferase, which 
was inhibited by around 20% by both Klhl31 FL, as well as Klhl31 ΔKR. Klhl31 ΔBTB 
was again not able to antagonize β-catenin induced luciferase activity (see figure 1.13).  
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Figure 4.4: Analysing the pEGFP-C1 Klhl31 constructs by Luciferase assay 
3T3 cells were transfected with either pEGFP-C1, pEGFP-C1 Klhl31 FL, pEGFP-C1 Klhl31 ΔBTB, 
pEGFP-C1 Klhl31 ΔKR, as well as either TOPFLASH or FOPFLASH vector, β-catenin and Renilla as 
internal control. Error bars were calculated based on the standard deviation. Signal strength is indicated in 
% compared to Luciferase signal of 3T3 cell transfected with vector only (set as 100%). As a positive 
control we used pCaβ-GFP (as vector only) and pCaβ-GFP Klhl31FL encoding for an untagged Klhl31 
FL protein. Luciferase reporter activity was inhibited by 18% by pCaβ-GFP Klhl31 FL, which was shown 
to be statistically significant (*).This experiments was carried out three times, which each sample being 
prepared and measured as triplicates (n=9) 
 
Compared to the results of Luciferase assays for Klhl31 carried out previously (Abou-
Elhamd), the pEGFP-C1 constructs did not reproduce inhibition of β-catenin induced 
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147 
 
Luciferase activity. In fact, pEGFP-Klhl31 FL seemed to enhance the Luciferase signal 
and pEGFP-Klhl31 ΔKR and pEGFP-Klhl31 ΔBTB were both not able to inhibit β-
catenin induced Luciferase reading to a statistical significance (see figure 4.4).  
Unfortunately the Luciferase reading varied extensively between experiments, which 
could potentially be explained by contamination or other issues related to the used 
pEGFP-C1 vector. Therefore obtained data is preliminary and issues associated with the 
plasmids need further investigation. The BTB domain has previously been described to 
be the mediator of the biological function of Kelch-like proteins (Albagli and others, 
1995; Geyer and others, 2003; Perez-Torrado and others, 2006; Pintard and others, 
2003; Xu and others, 2003). It is possible that this might also be the case for Klhl31. 
This would be consistent with the finding that the loss of the BTB-domain after deletion 
renders the protein unable to inhibit canonical Wnt signalling (Abou-Elhamd). The sub-
cellular localisation of EGFP-Klhl31 fusion proteins did not recapitulate the localization 
of endogenous Klhl31 protein (compare figure 4.4 and 3.5), indicating that the GFP 
may interfere with the function of Klhl31, potentially by interfering with the BTB 
domain. 
 
In summary, both the overexpression experiment in C2C12 as well as the results 
obtained from the Luciferase Assay indicated that the pEGFP-C1 Klhl31 Fusion 
constructs did not produce a functional Klhl31 protein and could therefore not be used 
to investigate potential interaction partners. 
 
4.2.2 Cloning and Analysis of carboxy-terminal DsRed- or GFP-Klhl31 Fusion-protein 
 
 
Next, we decided to generate fusion-proteins with the tag placed at the carboxy terminus 
of Klhl31 adjacent to the kelch repeats (unless deleted). We used pEGFP-N1 or 
pDsRed-N1 vectors (Clontech Laboratories Inc., Mountain View, CA, USA) to 
construct plasmids encoding the following proteins : Klhl31 FL-GFP/DsRed, Klhl31 
ΔBTB-GFP/DsRed or Klhl31 ΔKR-GFP/DsRed (see figure 4.5). We amplified the 
constructs from cDNA (for Klhl31 FL, Klhl31 ΔKR) or from pCaβ Klhl31 ΔBTB 
IRES-GFP, as described in chapter 2.2.16. 
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Figure 4.5: Schematic representation of C-terminal EGFP or DsRed Klhl31 
fusion proteins 
Klhl31 Fusions proteins were generated comprising an EGFP or DsRed tag at the carboxy terminus of the 
Klhl31 protein. Klhl31FL-EGFP/DsRed contains all binding domains of Klhl31, whilst Klhl31ΔBTB-
EGFP/DsRed is lacking the N-terminal BTB domain. Deletion of the C-terminal Kelch-repeats leads to 
the generation of Klhl31ΔKR-EGFP/DsRed. 
 
The functionality of the C-terminal fusion proteins was examined by Luciferase assay. 
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Figure 4.6: Analysing the pDsRed-N1 Klhl31 constructs by Luciferase assay 
3T3 cells were transfected with either pDsRed-N1, pDsRed-N1Klhl31 FL, pDsRed-N1Klhl31 ΔKR, 
pDsRed-N1 Klhl31 ΔBTB, as well as either TOPFLASH or FOPFLASH vector, β-catenin and Renilla as 
internal control. As a positive control we used pCaβ-GFP (as vector only) and pCaβ-GFP Klhl31FL 
encoding for an untagged Klhl31 FL protein. Luciferase reporter activity was normalised against pCaβ-
GFP and was shown to be inhibited by 22% by pCaβ-GFP Klhl31 FL, which was statistically significant 
(*) 
The data shown is based on four experiments each carried out in triplicates (n=12). Error bars were 
calculated based on the standard deviation. Signal strength is indicated in % compared to Luciferase 
signal of 3T3 cell transfected with β-catenin and vector only (set as 100%). 
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Klhl31 FL-DsRed was able to inhibit β-catenin induced Luciferase signal by around 
20%. The observed inhibition was statistically significant (* p<0.05). Data shown is 
similar to previous data obtained with pCaβ Klhl31 FL IRES-GFP, which does not 
generate a fusion protein (see figure 1.13). A similar inhibition could be observed when 
transfecting 3T3 cells with β-catenin, TOPFLASH vector and pDsRed-N1 Klhl31 ΔKR, 
again consistent with results obtained with non-tagged Klhl31 ΔKR. Klhl31 ΔBTB-
DsRed was not able to reduce β-catenin induced Luciferase signal significantly, as 
previously described (Abou-Elhamd). This indicated that C-terminal fusion did not 
negatively affect Klhl31 functionality. 
We therefore transfected C2C12 myocytes with these constructs to analyse the 
localisation of fusion proteins in the cells (see figure 4.7).  
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Figure 4.7: Overexpression of pDsRed-N1 Klhl31 constructs in C2C12 
C2C12 were transfected with either pDsRed-N1 (a, e), pDsRed-N1 Klhl31 FL (b, f), pDsRed-N1 Klhl31 
ΔBTB (c, g) or pDsRed-N1 Klhl31 ΔKR (d, h), respectively. Transfected cells were either fixed after 24 
h in growth medium (GM) or left to differentiate for 5 days in differentiation medium (DM). Images a’-h’ 
show localisation of the fusion proteins in relation to the nuclei (DAPI, blue). 
Scale bar (a - h’) – 10 µm 
 
Although the dsRed-N1 Klhl31 constructs were shown to be active in Luciferase assay, 
they could only partially reproduce the localisation of Klhl31 in C2C12 when compared 
to localisation of endogenous Klhl31 in C2C12 myoblasts. Non-transfected C2C12 cells 
used as a negative control during the imaging process showed a moderately strong red 
background signal (as described in section 2.2.26 making it rather difficult to 
distinguish between real DsRed-signal and auto-fluorescence. Although the red 
fluorescence for Klhl31 FL-DsRed and Klhl31 ΔKR-DsRed was barely stronger then 
C2C12 auto-fluorescence, Klhl31 FL-DsRed in undifferentiated C2C12 could be 
observed to display a cytosolic localisation (figure 4.7; b and d, respectively) similar to 
the one observed of endogenous Klhl31 (see figure 3.6). Klhl31 ΔKR-DsRed was also 
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observed to be localised in the cytosol of the myoblast similar to Klhl31 FL-DsRed. 
Interestingly the localisation pattern of Klhl31 ΔBTB-DsRed resembled strongly the 
localisation observed for pEGFP-C1 Klhl31 FL (figure 4.3; b). Protein expressed by the 
DsRed-N1 Klhl31 ΔBTB construct seemed to be accumulated in vesicles surrounding 
the nucleus (figure 4.7; c).  
 
Overexpression of the pDsRed-N1 Klhl31 constructs in differentiating C2C12 myocytes 
was even harder to analyse, as the red auto-fluorescence of C2C12 was even stronger in 
myocytes than in myoblasts. Also, it had previously been shown that expression of 
plasmid DNA decreases significantly after three days of C2C12 differentiation (Dodds 
and others, 1998). No fluorescence signal above background level was observed for 
Klhl31 FL-DsRed and Klhl31 ΔKR-DsRed (figure 4.7; f, h), whilst Klhl31 ΔBTB-
DsRed was still observed to be accumulated in vesicles around nuclei (figure 4.7; g). 
Not only could the lack of signal be due to a very strong background signal, the DsRed-
N1 vector itself can lead to some extent to diminished fluorescence, as it has been 
shown that the folding itself of the DsRed-tag takes significantly longer compared to a 
GFP tag, which might have also been a cause for the absent Klhl31-DsRed signal.  
 
The characterisation of the cloned pDsRed-N1 Klhl31 constructs using Luciferase 
reporter assays indicated the production of functional Klhl31 proteins with a C-terminal 
DsRed tag, either as a full length protein or as a Klhl31 mutant lacking the Kelch-
repeats (figure 4.6). Also proteins encoded by the pDsRed-N1 Klhl31 FL and pDsRed-
N1 Klhl31 ΔKR plasmids displayed a cytosolic, punctate localisation in the cytosol of 
C2C12 myoblasts (figure 4.7; b, d) comparable to the localisation of endogenous Klhl31 
(figure 3.8). 
Transfection of pDsRed-N1 Klhl31 ΔBTB expressing a protein lacking the BTB-
domain was not able to inhibit β-catenin induced Luciferase activity (see figure 4.7) and 
seemed to accumulate into vesicles (figure 4.7; c, g) both in C2C12 myoblasts, as well 
as after induced differentiation for about 5 days. Klhl31 FL-DsRed or Klhl31 ΔKR-
DsRed was never detected in differentiating C2C12 myocytes.  
 
As we could not investigate the localisation of Klhl31-DsRed tagged proteins in C2C12, 
we decided to analyze generated Klhl31-GFP expressing constructs.  
The pEGFP-N1 Klhl31 constructs were first examined by the luciferase assay. 
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Figure 4.8: Analysing the pEGFP-N1 Klhl31 constructs by Luciferase assay 
3T3 cells were transfected with either pEGFP-N1, pEGFP-N1Klhl31 FL, pEGFP-N1 Klhl31 ΔKR, 
pEGFP-N1 Klhl31 ΔBTB, as well as either TOPFLASH or FOPFLASH vector, β-catenin and Renilla as 
internal control.  As a positive control we used pCaβ-GFP (as vector only) and pCaβ-GFP Klhl31FL 
encoding for an untagged Klhl31 FL protein. Luciferase reporter activity was normalised against pCaβ-
GFP and was shown to be inhibited by 18% by pCaβ-GFP Klhl31 FL, which was statistically significant 
(*). Data is based on three experiments each carried out in triplicates (n=9). Error bars were calculated 
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based on the standard deviation. Signal strength is indicated in % compared to Luciferase signal of 3T3 
cell transfected with pEGFP –N1 vector and β-catenin only (set as 100%).  
 
The obtained data from the Luciferase assay showed the expression of potential active 
proteins for all three cloned constructs (figure 4.8). Klhl31 FL-GFP, as well as Klhl31 
ΔKR-GFP inhibited β-catenin induced Luciferase activity by around 20%. Again this 
inhibition was statistically significant (*p <0.05). 
Similar percentage of inhibition have been described previously for Klhl31 FL-DsRed 
and  Klhl31-DsRed ΔKR (see figure 4.6), as well as for untagged Klhl31 full length 
protein and Klhl31 ΔKR protein (Abou-Elhamd). 
Surprisingly, pEGFP-N1 Klhl31 ΔBTB was also shown to inhibit β-catenin by around 
12%. This inhibition was shown to be statistically significant as well (p<0.05). 
However, this experiment is still consistent with the previous observations, which 
indicated that loss of the BTB-domain leads to the potential loss of function of Klhl31. 
 
As we could verify the activity of all our pEGFP-N1 Klhl31 constructs, we then 
transfected C2C12 with these constructs and analysed the localisation of the GFP-
Fusion proteins in myoblasts and myocytes. 
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Figure 4.9: Overexpression of pEGFP-N1 Klhl31 constructs in C2C12 
C2C12 myoblasts were transfected with either pEGFP-N1 (a, e), pEGFP-N1 Klhl31 FL (b, f), pEGFP-N1 
Klhl31 ΔBTB (c, g) or pEGFP-N1 Klhl31 ΔKR (d, h), respectively. Transfected cells were either fixed 
after 24 h culturing in growth medium (GM) or left to differentiate for 5 days in differentiation medium 
(DM).  Images a’-h’ show the localisation of the Fusionprotein in comparison to nuclear staining (DAPI, 
blue). 
Scale bar (a -h’) – 10 µm 
 
Overexpression studies of the pEGFP-N1 constructs revealed a similar localisation as 
described for the dsRed-N1 constructs. Klhl31 FL-GFP could be observed as having a 
punctate localisation pattern in C2C12 myoblasts (figure 4.9; b). However, the puncta 
appear larger compared to endogenous Klhl31 (figure 3.7). Klhl31 ΔKR-GFP (figure 
4.9; d) was observed to display a cytosolic localisation in C2C12 myoblasts comparable 
to localisation of GFP expressed from the parental vector (figure 4.9; a), whilst Klhl31 
ΔBTB was again observed in to localise into vesicular structures surrounding the 
nucleus (figure 4.9; c), as previously described for Klhl31 ΔBTB-DsRed (figure 4.7; c). 
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In differentiating myocytes a diffused punctate localisation was observed for Klhl31 
FL-GFP (figure 4.9; f), again unlike the localisation described for endogenous Klhl31 
(figure 3.7). However, most of the times differentiating C2C12 myocytes did not reveal 
any GFP signal indicating the absence of GFP-tagged Klhl31 protein, as seen for Klhl31 
ΔBTB-GFP and Klhl31 ΔKR-GFP (figure 4.9; g and h, respectively).  
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4.3 Biochemical analysis of the Klhl31-GFP/DSRED Fusion proteins 
 
4.3.1 Investigating the stability of Klhl31 Fusion proteins 
 
 
It was not clear why we could only see a weak signal of overexpressed fusion-proteins 
in proliferating C2C12 myoblasts. Next, we wanted to analyze if we could detect Klhl31 
protein on a western blot, which would help us to investigate a possible degradation of 
Klhl31 when over-expressed in C2C12 myoblasts. We transfected C2C12 with the 
pEGFP-N1 Klhl31 FL construct as the encoded protein was shown to be functionally 
active and seemed to resemble the localisation pattern as observed for endogenous 
Klhl31. Also, we would then be able to detect proteins on a western blot with either a 
GFP antibody or Klhl31 antibody. Unfortunately we were not able to detect Klhl31 
proteins on a western blot (data not shown), neither when using a polyclonal anti-GFP 
antibody or with a polyclonal anti-Klhl31 antibody. This was surprising as we could test 
the constructs for their functionality and were able to look at their localisation in C2C12 
myoblasts. To increase the transfection efficiency and hopefully be able to express a 
higher amount of proteins, we then decided to use a different cell line to transfect 
Klhl31 overexpression constructs into; 3T3 mouse fibroblasts cells. These cells do not 
express endogenous Klhl31 (figure 3.3). But again, we could not detect the fusion-
proteins on a western blot, although GFP only was detected (see figure 4.10). 
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Figure 4.10: Western blot of cell lysates obtained from 3T3 cells transfected 
with plasmids encoding GFP-Klhl31 FL and Klhl31 FL-GFP 
Protein lysates were obtained from cells transfected with pEGFP-C1, pEGFP-C1 Klhl31 FL, pEGFP-N1 
or pEGFP-N1 Klhl31 FL and run on a PAA-Gel, transferred to a PVDF membrane and blotted with a 
GFP polyclonal antibody.  
Legend: M- Marker, lane 1-4; Protein lysates: 1 – 3T3 cells transfected with pEGFP-C1, 2 – 3T3 cells 
transfected with pEGFP-C1 Klhl31, 3-3T3 cells transfected with pEGFP-N1, 4 – 3T3 cells transfected 
with pEGFP-N1 Klhl31 FL. The Actin band (loading control) can be observed at around 50 kDa. 
 
Analysing proteins lysates from 3T3 mouse fibroblasts overexpressing GFP only 
(pEGFP-C1 and pEGFP-N1), GFP-Klhl31 FL or Klhl31 FL-GFP revealed that GFP was 
detected in both cell lines transfected with the empty vectors, while GFP was never 
detected in cells transfected with any of the GFP-Klhl31 Fusion proteins (figure 4.10). 
It has been shown that Kelch-like proteins form homodimers (Geyer and others, 2003), 
but could Klhl31 dimerize with another Klhl31 protein? And could this homodimers be 
involved in targeting Klhl31 for degradation? 
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4.3.2 Klhl31 could initially be degraded via a proteasome-independent process 
 
 
To investigate a potential degradation of Klhl31 after overexpression, we transfected 
HEK293 cells with pEGFP-N1 Klhl31 FL and treated the transfected cells with a 
proteasome inhibitor, MG 132 (Lee and Goldberg, 1998). MG 132 has been described 
to reduce the degradation of ubiquitin-conjugated proteins (Arora and others, 2005). 
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Figure 4.11: Treatment of cells with proteasome inhibitors allows the 
detection of Klhl31 FL-GFP with a) an antibody against Klhl31 and b) an 
antibody against GFP 
* 
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Western blot showing the effect of treatment with MG 132 on the expression of pEGFP-Klhl31 fusion 
proteins. 50 μg of total protein was loaded per sample and proteins were either detected by blotting 
against Klhl31 (a) or GFP (b). An antibody raised against Actin was used as a protein loading control (c).   
As a negative control, non-transfected HEK293 cells were either incubated for 48 h in DMEM (lane 1), or 
cultured in DMEM with the addition of MG 132 for either 6h (lane 2) or 24h (lane3). As a GFP-control, 
HEK 293 cells were transfected with pEGFP-N1. Cells were left to recover for 24h and then incubated in 
fresh medium for further 24h (lane 4) or cells were incubated in fresh medium with added MG 132 for 
either 6 h or 24 h, (lane 5 and 6) respectively. To investigate possible degradation of Klhl31 FL-GFP, 
HEK 293 cells were transfected with pEGFP-N1-Klhl31 FL. Transfected cells were also left to recover 
for 24h followed by incubation in fresh medium for further 24h (lane 7). To inhibit the proteasome, 
transfected HEK293  cells were cultured in fresh medium with added MG 132 for either 6 h or 24 h, (lane 
8 and 9) respectively.  
The visualisation of Actin showed a consistent protein amount loaded for each sample.  
Legend: M- Marker 
 
HEK293 cells were transfected with either pEGFP-N1 or pEGFP-N1 Klhl31 FL and 
treated with MG 132 (see figure 4.11). 
The treatment with MG 132 had no obvious effect on GFP levels, as can be seen in 
figure 4.11, blot b, lanes 4-6. Interestingly we were able to detect a GFP Klhl 31 fusion 
protein with both, the Klhl31 antibody, as well as the GFP antibody in protein lysates 
obtained from untreated and treated HEK293 cells (see figure 4.11, blot a and blot b, 
lanes 7-9). However, the size of the fusion protein was smaller than expected. A full 
length Klhl31-GFP protein should have the size of 96 kDa; 70 kDa for Klhl31 plus 26 
kDa for the GFP tag. 
Furthermore, when using the GFP antibody we were able to identify additional protein 
bands smaller than 75 kDa (figure 4.11, blot b, lanes 7-9, *). Observed bands were not 
detected by using the anti-Klhl31 antibody.  
Interestingly, the strength of the smaller bands seemed to increase slightly with longer 
incubation time in medium containing an additional proteasome inhibiting drug.  
Based on our obtained data, it seemed that initial degradation of Klhl31 might not be 
mediated by the proteasome, as we could never observe a 96 kDa Klhl31 FL-GFP 
protein, not even when inhibiting the proteasome, but the additional, smaller protein 
bands seemed to appear stronger in the samples treated with MG 132, indicating that the 
treatment with the proteasome-inhibiting drug might prevent further degradation. We 
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therefore suggested that although the first cleavage might not be mediated by the 
proteasome, subsequent degradation might however be proteasome dependant. 
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5. Investigating interaction partners of Klhl31 during 
myogenesis 
 
5.1 Introduction 
 
5.1.1 Candidate interaction partners for Klhl31 
 
We know from previous data, that some members of the Kelch-like family have been 
shown to bind to Actin (Adams and others, 2000; Kelso and others, 2002; Robinson and 
Cooley, 1997; Xue and Cooley, 1993). This also could be the case for Klhl31, as 
immuno-histochemistry revealed a close correlation of Klhl31 with Actin-fibres in 
differentiated C2C12 (see chapter 3.3.2). Results obtained from our Luciferase assays 
(see chapter 4.1.1 and chapter 4.2.1) suggest that additional potential interacting 
partners for Klhl31 may be found in the canonical Wnt-signalling pathway. In addition 
to TOPFLASH luciferase assays, there is supporting evidence previously obtained in 
our laboratory. In the African clawed frog, Xenopus laevis, a secondary body axis can 
be induced by overexpressing components of the β-catenin dependent Wnt-pathway 
(Guger and Gumbiner, 1995; Sokol and others, 1991). When injecting Wnt-ligands or β-
catenin together with Klhl31 into Xenopus laevis embryos, formation of the secondary 
axis could be inhibited (Abou-Elhamd and Garcia-Morales). Based on these 
experiments and our Luciferase assays, we can conclude that an inhibition of canonical 
Wnt-signalling by Klhl31 potentially takes place at the level of β-catenin or downstream 
of it. Our next aim was to identify interaction partners for Klhl31. 
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5.1.2 Designing a Yeast-2-Hybrid screen to find interaction partners for Klhl31 
 
As our cloned pEGFP-N1 and pEGFP-C1 Klhl31 Fusion constructs have been shown to 
be either non-active (for pEGFP-C1 Klhl31, see chapter 4.1) or degraded (pEGFP-N1 
Klhl31, see chapter 4.2 and chapter 4.3), it was clear that we would not be able to use 
them to pull down interaction partners as originally planned via a GFP-binding protein 
(GBP), also called GBP-Nanotrap (Rothbauer and others, 2008).  
We therefore chose a different approach, the Yeast-2-Hybrid screen, which would 
enable us to screen specific libraries, without actually using mammalian cells (Fields 
and Song, 1989). 
The Yeast-2-Hybrid system was developed around the properties of the yeast 
transcriptional factor, GAL4. In general, eukaryotic transcriptional activators, including 
GAL4, contain two distinct domains, the DNA binding domain (DB) at the amino-
terminus and the C-terminal transcription activation domain (AD). When the DB binds 
to its recognized DNA sequence, the AD will subsequently enable transcription of a 
reporter gene downstream of the DB domain by assembling a RNA polymerase II 
transcription complex (Chien and others, 1991; Fields and Song, 1989). This system 
was modified by Fields and Song to generate two specific hybrid proteins, one of which 
was fused to the GAL4 DNA binding domain, whilst the other protein was tagged with 
the GAL4 activation domain. As protein-protein interaction occurred, both domains 
came into close proximity leading to the transcription of a reporter gene (Fields and 
Song, 1989) (for a schematic overview of the Yeast-2-Hybrid screen see figure 5.1).   
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Figure 5.1: The Yeast-2-Hybrid system: a schematic overview 
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The Yeast-2-Hybrid allows the detection of potential interaction partners for a protein of interest. When a 
bait-protein X labelled with a GAL4-binding domain does not interact with a bait-protein Y fused to an 
activation domain, the reporter gene will not be expressed (a). However, when two proteins interact with 
each other and their BD and AD come into close vicinity, the transcription of the reporter gene is 
activated (b). Positive clones obtained from mating yeast cells expressing the bait-DB protein with a 
library of proteins tagged with an AD can grow on substrate deficient media (c). Positive clones can then 
be analysed by PCR and subsequently sequenced.  
Figure taken from (Pandey and Mann, 2000) 
Since then, the method has advanced further and can nowadays be used to screen cDNA 
libraries to detect potential novel interaction partners for proteins of interest (Bruckner 
and others, 2009).  The detection of protein-interaction is carried out in living yeast 
cells. One set of yeast cell will be expressing the protein of interest, also called the bait 
protein, which is fused to the DNA binding domain, whilst the activation domain is 
fused to a library of other proteins, called prey proteins. As for the cDNA library 
approach, prey proteins can contain a pool of proteins, as well as fragments of proteins, 
all derived from cDNA from a specific tissue or a mixture of specific tissues (Auerbach 
and others, 2002). It was suggested that the inclusion of full length ORFs, as well as 
fragmented cDNA sequences would increase the possibility to cover the full 
transcriptome, therefore reducing the chance of false negatives. However, it was also 
shown that screening libraries would increase the chances of detecting false positives or 
wrongly identified proteins (Bruckner and others, 2009).  
The bait protein is usually introduced to the prey proteins by mating of yeast cells, 
although transformation of yeast cells have also been described (Bruckner and others, 
2009). Once interaction between a bait protein and a prey protein is established, i.e. 
when the protein of interest has bound to a potential interacting partner, the close 
proximity of the BD and the AD will allow transcription of a reporter gene. This 
reporter gene can either be used to mediate a colour reaction, allow growth on a 
substrate deficient media or induce a specific antibiotic resistance (Bruckner and others, 
2009), enabling the selection of potential positive clones. However, these clones need to 
be analysed by PCR and sequencing.  
The early Yeast-2-Hybrid screens were limited in their approach due to technical 
limitations (Fields and Song, 1989), but  In recent years, the Yeast-2-Hybrid screens 
have been modified and developed to cater for different types of proteins and screening 
properties (for a list of current Y-2-H approaches, see (Bruckner and others, 2009). 
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The Yeast-2-Hybrid system is now an established tool to analyse protein-protein 
interactions.  
For our Yeast-2-Hybrid screen, we decided to use Hybrigenics services, a company that 
claimed to be a leader in the field of protein interaction studies, as well as being the 
most reliable protein interaction service (http://www.hybrigenics-services.com/). We 
decided to screen a library for human muscle specific tissues derived from adult and 18-
19 week fetal tissue using a full-length human Klhl31 as our bait protein (Image clone 
9021264 obtained from Source BioScience LifeSciences, UK). Based on our previous 
experience with tagged Klhl31 proteins, we decided that the GAL4 binding domain 
should be fused to the carboxy-terminus of the Klhl31 protein, as this did not seem to 
affect the functionality of the protein or the BTB domain. Our previous data suggested 
that fusing a tag, in our case GFP, to the N-terminus of the Klhl31 protein would create 
a dysfunctional Klhl31 protein, which may be due to blockage of the BTB-domain (see 
chapter 4.1.2).  
In summary, we decided to use a C-terminal fusion of the GAL4-binding domain to the 
human full length-Klhl31 protein. Possible interaction partners should be pulled out 
from a library containing protein or protein fragments derived from the transcriptome/ 
cDNA of fetal and adult muscle tissues. 
 
5.1.3 Analysing the data obtained from the Yeast-2-Hybrid screen 
 
Unfortunately for us, our Yeast-2-Hybrid screen did not progress completely without 
problems. The first more stringent approach did apparently fail and the second screen at 
reduced stringency did not reveal many positive interactions either. 
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Figure 5.2: The Yeast-2-Hybrid system: how to read your results 
Hybrigenics services classified potential protein interactions based on protein structure predictions, 
toxicity and previous experiences. Classes A-C can usually be established as being true interaction, whilst 
interaction partners classified as group D have to be analysed with caution, as they might contain false-
positives. Interaction partners classified in group E and F can usually be described at non-relevant, most 
likely false positives, either due to high connectivity of the prey protein itself or due to technical artefacts. 
Picture modified from Hybrigenics Services. 
 
As mentioned previously, we did not find a lot “most likely” real interaction partners as 
classified by Hybrigenics Services under groups A-C (see figure 5.2).  Only one out of 
37 predicted interactions was classified as B claiming high confidence in the interaction 
(see Appendix, A.3). When we analysed the DNA sequence of the interacting protein, it 
was shown to be a non-protein coding RNA sequence transcribing for JPX, a Xist 
activator. Xist, a non-coding RNA is involved in X chromosome inactivation 
(Brockdorff, 2011). It has been shown to coat the X-chromosome and recruits polycomb 
protein to its interacting site with the X-chromosome. Jpx is encoded by the X-
inactivation centre and has been shown to be an activator for Xist (Tian and others, 
2010). 
Why we pulled out a non-coding RNA in protein-protein interaction screen is somehow 
puzzling and cannot really be described as a valid positive interaction between two 
proteins, one of which being Klhl31, the other one being a artificial creation based on a 
non coding RNA sequence. Also we were only given the short 5’ sequence of the 
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fragment without any further information about the length of the sequence or the 
complete sequence of the fragment, which might limit us in terms of finding an open 
reading frame within the sequence, which might be translated into a protein fragment in 
yeast. However, we still tried to analyse the amino acid sequence to find clues with 
respect to structural properties or specific binding sites of Klhl31 binding partners. 
When we translated the given sequence into amino acids, a further problem occurred. 
We had no information about the frame of translation of the nucleotide sequence. So we 
looked at the amino acid sequence for all three possibilities. No matter what translation 
frame was used (reading frame 1, 2 or 3), we never found a continuous amino acid 
sequence. Sequences were always fragmented by stop-codons. Blasting a human protein 
data base against the different amino acid sequences revealed hundreds of hits, some 
known protein, some unknown, most of them with rather small similarity (for an 
example, see Appendix: blast of frame 1 of nc RNA (Jpx) transcribed into amino acid 
sequence). The longest non-disrupted amino acid chain was obtained from transcription 
in frame one. Although many proteins that were found in the screen had only around 
50-70 % similarity with the blasted amino acid sequence (see Appendix), a potential 
binding domain was detected containing the highly conserved GVQW motif (Marchler-
Bauer and others, 2011). The GVQW motif has been found so far in around 300 known 
proteins (Gerhard and others, 2004; Kanehori and others, 2003), but its functionality 
still needs to be verified. Examples of proteins obtained from the blast that contain the 
GVQW motif are the ubiquitously transcribed tetratricopeptide repeat protein Y-linked 
(UTY) (Accession number ABC87286.1) (Laaser and others, 2005) and the ubiquitin-
conjugating enzyme E2D 4 (Accession number EAW94179.1) (David and others, 
2010).  
Proteins of the Kelch-like family have been described as being part of the E3 ubiquitin 
ligase complex (Furukawa and others, 2003; Geyer and others, 2003; Xu and others, 
2003). Before the ubiquitin is bound to the target protein, it has to be activated first by 
an E1 or ubiquitin-activating enzyme, followed by transfer to an E2 ubiquitin-
conjugating enzyme and subsequently attachment to the target protein via the E3 
ubiquitin ligase (Neutzner and Neutzner, 2012). Therefore an interaction with an E2 
ubiquitin-conjugating enzyme would make sense in terms of protein ubiquitinylation. 
UTY as mentioned before is not as well described. UTY has a homologue on the X-
Chromosome called UTX (Greenfield and others, 1998). Whilst UTX has been shown to 
demethylate trimethylated lysine-residue on position 27 on histone 3 (H3K27
me3
) 
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(Agger and others, 2007; Lan and others, 2007)  reversing repression of gene activity 
(Lee and others, 2007; Martin and Zhang, 2005), UTY is not a functional demethylase 
for H3K27
me3
 (Hong and others, 2007; Lan and others, 2007; Shpargel and others, 
2012).  Recent publications have indicated a role for UTX and UTY in transcriptional 
regulation independent of the function as a demethylase (Shpargel and others, 2012). 
Also recently heart defects were reported in UTX-deficient mice and embryonic stem 
cells (Lee and others, 2012). Whilst ESCs lacking UTX did not acquire rhythmic 
contraction when cultured in cardiac differentiation inducing medium, UTX null mice 
displayed severe heart defects and died before birth. It was also shown that 
demethylation of H3K27
me3
 is activated by binding of cardiac-specific enhancer genes 
to UTX (Lee and others, 2012). Further evidence for a role of UTX and UTY in heart 
development has been collected in co-immunoprecipitation studies. It was shown that 
both UTY and UTX can form complexes with BRG1, a chromatin remodelling factor, 
and various heart transcription factors, e.g. Tbx5 and Nkx2.5 (Lee and others, 2012; 
Shpargel and others, 2012).  
Although both of the genes containing the GVQW motif could be interesting in terms of 
binding to Klhl31, as they both have been described to be involved in heart 
development or the ubiquitinylation process of target proteins, the evidence based for 
this interaction from the Yeast-2-Hybrid screen is too faint to consider a real interaction. 
The chances that the short amino acid fragments, which we analysed in the blast against 
a human protein database, would actually be a true interaction partner for Klhl31 is very 
small. The amino acid fragment was very small in size and identity to potential similar 
protein was not very high either (63% overall identity for UTY and 67% identity to 
E2D4), making it unlikely that we have identified a potential interacting partner based 
on a nc RNA sequence, even if the interaction was classified as highly likely by the 
company, which conducted our Yeast-2-Hybrid screen. 
As we had to rule out our main best hit for a potential Klhl31 interaction partner, we 
then went on to analyse the hits from the screen classified as members of group D: to be 
analyzed with cautions, due to the possibility of false positives or toxicity issues (see 
figure 5.2).  
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5.2 Results 
 
5.2.1 Background research on potential novel interaction partners for Klhl31 
 
Although we obtained only one highly likely interaction partner for Klhl31 (class B 
interaction see Appendix), 35 interactions found were grouped into class D. 
Class D interactions could contain false-positives as well as artificial products due to 
toxic side effects created by the overexpression of the bait-protein. We analysed all 35 
interactions for the possibility to bind to Klhl31 on the basis of their verified DNA 
sequence. When searching a human genome database, 27 out of these 35 interaction 
partners were shown to be derived from introns of different genes. One further sequence 
was shown to span an intron-exon site within a gene, whilst two sequences were shown 
to be non-coding RNA and another nucleotide fragment was unidentifiable. These 
results were unexpected as the muscle library was based on cDNA derived from 
mRNA. It is possible that the screened library was contaminated with genomic DNA.  
As we could not pursue any of these findings any further, we decided to investigate the 
three hits that were representing actual proteins. 
 
5.2.2 NEDD9 has been identified as a potential interaction partner for Klhl31 
 
Neural precursor expressed, developmentally down-regulated 9 (NEDD9) encodes for a 
protein called enhancer of filamentation 1, also known as HEF-1 or CAS-L. It is a 
member of the Cas-protein family based on a conserved structure of its protein-protein 
binding domain (Astier and others, 1997; Singh and others, 2007). Proteins of the Cas 
family have been shown to be adhesion docking proteins involved in cell migration and 
other cellular processes (Zhong and others, 2012). Recently NEDD9 became a protein 
of interest based on evidences that its expression is increased in metastatic cancers 
(Donninger and others, 2004; Iwata and others, 2005; O'Neill and others, 2007). 
Furthermore, it has been suggested that NEDD9 itself is a marker for metastasis, as 
increased NEDD9 expression was reported in human and mouse melanoma cells lines 
(Kim and others, 2006), in lung and breast cancer (Minn and others, 2005) and in 
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glioblastomas (Natarajan and others, 2006).  In colorectal cancer NEDD9 has also been 
described in mediating cancer migration (Li and others, 2011).  
Recently it has been shown that metastasis in WM1361 melanoma cell is increased by 
elevated NEDD9 expression (Ahn and others, 2012). It was also reported, that NEDD9 
protein levels were depending on integrin β3 signalling and led to phosphorylation of 
the integrin β3, subsequently activating Scr and FAK, as well as reducing ROCK 
activity (Ahn and others, 2012).  
That NEDD9 mediates cell migration by promoting integrin β1 receptor activity has 
also been reported in mouse embryonic fibroblasts (Zhong and others, 2012). Integrin 
signalling has been shown to regulate cell movement by binding to ligands of the 
extracellular matrix, such as fibronectin and collagen and by coupling the extracellular 
signals to the intracellular microfilaments. However, integrin receptors do not contain 
Actin-binding properties and changes in Actin cytoskeleton are therefore mediated by 
interaction of integrins with various Actin-binding proteins and the focal adhesion 
kinase (FAK) (Carragher and Frame, 2004; Hynes, 2002; Lo, 2006; Schlaepfer and 
others, 1999; Sieg and others, 1999; Wehrle-Haller, 2012). 
Although we could detect a close proximity of Klhl31 to Actin fibres, this co-
localisation was seen along the whole Actin filaments across the whole myotube (see 
figure 3.7 in chapter 3.3.2). Furthermore, we were never able to detect Actin Klhl31 co-
localisation in myoblasts, which also are migrating cells. Klhl31 expression did not 
seem specific to focal adhesion sites. Also, NEDD9 has never been reported to have a 
direct link to Actin fibres, rather it seems to influence cytoskeletal changes by 
enhancing signals from the integrin receptors (Zhong and others, 2012).  
However we have not looked in more detail at localisation of components of the focal 
adhesions, such as FAK and integrin receptors in relation to Klhl31. As these 
components are associated to the cell membrane and we detected Klhl31 either in the 
cytosol or associated to Actin fibres along myotubes, we did not gather any obvious 
evidence for association of Klhl31 to focal adhesion sites.  
We concluded that with respect to this project, the function of Klhl31 during 
myogenesis, NEDD9 would not be investigated any further. Also, advice given by the 
specialist from Hybrigenics Services, suggested that NEDD9 is a protein, which is 
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pulled out quite often in Yeast-2-Hybrid screens and therefore might indicate the 
possibility of being a false-positive. 
Based on our data, we decided not to pursue further experiments to validate a potential 
interaction for NEDD9 with Klhl31 at this stage. 
 
5.2.3 FKPB15 has been identified as a potential interaction partner for Klhl31 
 
FKBP15, also known as FKBP133, was first identified in mouse as a homologue of the 
FK506-binding proteins (Nakajima and others, 2006). FK506-binding proteins belong 
to immunophilins (Kawashima and others, 1988; Warty and others, 1988), a highly 
conserved family of proteins, which can bind immunosuppressive drugs, such as FK506 
and rapamycin (for an overview of FKBP proteins see (Kang and others, 2008). 
Members of the FKBP protein family display two distinct domains, the FKBP domain 
and the tetratricopeptide repeats (TPR) (Kang and others, 2008). The FKBP domain 
contains peptidylprolyl isomerase (PPIase) activity (Maki and others, 1990), which 
catalyzes cis-trans isomerisation of peptidylprolyl bonds and is involved in assisting 
protein folding (Fischer and Aumuller, 2003; Fruman and others, 1994). The C-terminal 
TPR domain has been shown to mediate protein-protein interactions (Scheufler and 
others, 2000). Although, as mentioned before, members of the FKBP family all contain 
the FKBP and the TRP domain (Kang and others, 2008), the number of the domains 
varies from protein to protein. For example FKBP38 contains one FKBP domain, but 
three TRP domains (Lam and others, 1995), whilst FKBP52 contains two tandem FKBP 
domains and also three TRP domains (Davies and Sanchez, 2005). Other members of 
the family can also contain additional different protein binding domains (Kay, 1996) 
determining their function and localisation in the cell.  
FK506-binding proteins have been shown to be involved in various intracellular events. 
For example, the best described member of the FKBP family, FK506-binding protein 51 
(also known as FKBP5) is expressed in various cancers, where hyperexpression of 
FKBP51 has been shown to sustain malignancy, whilst also promoting resistance to 
medical treatments (Romano and others, 2011). FKBP38, however, has got a 
completely different function. It has been shown to be involved in apoptosis, as well as 
regulation of the formation of the neural tube (Edlich and Lucke, 2011). 
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FKBP15, also known as FKBP133 due to its size of 133 kDa, has been described to be 
expressed in the developing nervous system of mice. It contains a domain, which is 
similar to Wiskott-Aldrich syndrome protein (WASP) homology region 1 (WH1) at the 
N-terminus, as well as the FK506-binding protein domain (Nakajima and others, 2006) 
in the centre of the protein. This protein does not contain a TRP domain, but a further 
Band4.1-Ezrin-Radixin-Moesin (FERM) domain (Nakajima and others, 2006). Based 
on the presence of the FKBP domain and homology to FKBP12, FKBP15 was termed 
being a member of the FKBP protein family (Nakajima and others, 2006).  Enzymatic 
test revealed that FKBP15 does not display PPIase activity unlike many other FKBP 
family members and it also is not able to bind to FK506 (Nakajima and others, 2006). 
Interestingly though, it has been shown to localise to F-Actin in growth cones of 
neurons in the dorsal root ganglion. It has also been described that overexpression of 
FKBP133 led to increased size of the growth cones, as well as leading to elevating 
numbers of filopodia. These changes were potentially mediated by the WH1 domain, as 
overexpression of a deletion mutant for the WH1 domain led to a reduced growth cone 
size and less filopodia (Nakajima and others, 2006). Furthermore, Nakajima et al. 
reported that FKBP15 does not influence changes in the Actin fibres of the growth 
cones directly, instead it stabilises the F-Actin cytoskeleton by preventing Semaphorin 
3A induced Actin depolymerisation.  
Recently, a different protein also containing the WH1 domain and the FKBP domain 
has been identified from biopsies taken from colons of patients with inflammatory 
bowel diseases (Viklund and others, 2008). Just as FKBP15, the discovered protein has 
been described to be transcribed by the DNA of the gene KIAA0674 (see 
http://www.ncbi.nlm.nih.gov/gene/23307).  
Based on its similarity to both proteins of the WASP family and the FKBP family, the 
described newly discovered protein was named WAFL (WASP and FKBP-like).  
As previously mentioned, WAFL also shows high structural similarity with FKBP15  as 
both proteins contain the WH1 and the FKBP domain at their N-termini (Nakajima and 
others, 2006; Viklund and others, 2009; Viklund and others, 2008). Alignment of the 
amino acid sequences for WAFL and FKBP15 revealed that both proteins share 75% 
identity and within the WH1 and FKBP domain the identity is even higher (82%). Also 
both proteins contain the predicted Klhl31 binding site. Therefore we can assume that 
Klhl31 could interact with both, FKBP15 and WAFL.  
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Figure 5.3: Structural organisation of WAFL 
The WASP and FKBP-like (WAFL) protein contains 4 distinct domains. Close together at the N-terminus 
it contains a WH1 and FKBP domain. In the centre of the protein it reveals a Coiled-coil domain, whilst 
C-terminal it contains a stretch of acidic amino-acids.                                                                                                                                                                                       
Figure redrawn after (Viklund and others, 2008) 
 
Further studies revealed a role of WAFL in endocytosis as a GFP-WAFL –fusion 
protein has been shown to interact with endosomes, as well as being localised along 
microtubules (Viklund and others, 2009). Movement of WAFL along microtubules was 
inhibited by treatment with nocodazole, which prevents polymerisation of microtubules. 
But when treated with Latrunculin A, movement was not decreased revealing that 
trafficking of WAFL-linked endosomes did mainly take place along microtubules 
(Viklund and others, 2009). Co-immunoprecipitation studies, however, revealed a direct 
interaction of WAFL with Actin and the WASP-interacting protein, suggesting a role 
for WAFL in the Actin polymerization during vesicle motility (Viklund and others, 
2009).  
The alignment of the Hybrigenics clone protein sequence of FKBP15, which was said to 
interact with Klhl31, to the amino-acid sequence of FKBP15/WAFL revealed that the 
Hybrigenics fragment overlaps with amino acids 336 to 559 of full length 
FKBP15/WAFL. The WH1 domain would contain amino-acid 71-159 (or 69-171), 
whilst amino-acids 178-289 (or 178-290) make up the FK506-binding domain as 
described by Nakajima et al., 2008 (or Viklund et al., 2008). Therefore the binding 
fragment for Klhl31 does not seem to be part of the published conserved binding 
domains.  
As WAFL has been described to interact directly with Actin (Viklund and others, 2009) 
and as we have observed punctate localisation of Klhl31 along Actin fibres in C2C12 
    WH1 FKBP Coiled-Coil Acidic 
End 
69-171 178-290 ~600 - ~950 1185-1219 
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myotubes (see figure 3.7; section 3.3.2), Klhl31 might interact with WAFL to promote 
Actin polymerization as described by Viklund et al., 2009. A real interaction between 
FKBP15/WAFL and Klhl31 needs to be verified first and more evidence needs to be 
gathered about functions of Klhl31 and FKBP15/WAFL before a potential role for 
Klhl31 together with WAFL can be hypothesised.  However, as Klhl31 expression 
seems to be restricted to striated muscles and FKBP15/WAFL expression has not been 
reported in muscular tissue so far, it seems unlikely that Klhl31 and FKBP15/WAFL 
could interact.    
Based on the differences in their expression patterns, we did not investigate a potential 
role of Klhl31 together with FKBP15/ WAFL any further. 
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5.3 Nebulin as a novel interaction partner for Klhl31 
5.3.1 The giant protein Nebulin and its role in striated muscle 
 
Nebulin seemed to be the most promising protein being discovered in the Yeast-2-
Hybrid screen. Not only did we identify two different isoforms of Nebulin, isoform 2 
and isoform 3 as potential interaction candidates for Klhl31; Nebulin has also been 
described to play important roles in embryonic and adult muscle tissues.  
Nebulin was firstly seen in rabbit skeletal myofibrils in 1980 and described as band 3 
protein, which remains near the Z-discs (Wang and Williamson, 1980). Later it was 
shown to be a giant protein between 600 – 900 kDa large, which was eventually termed 
Nebulin due to its nebulous size and the fact that it was difficult to purify (Wang, 1982). 
Further studies revealed that Nebulin would potentially make up between 3-4% of total 
myofibrillar proteins in striated muscles (Locker and Wild, 1986). Since its 
identification, Nebulin has been studied extensively.  Members of the Nebulin family 
can be found in invertebrates, such as chordates, and vertebrates, such as chimpanzee 
and humans and PCR data from various species led to the suggestion that the Nebulin 
gene family has expanded from a chordate ancestor gene during evolution (Bjorklund 
and others, 2010; Hanashima and others, 2009).  
The Nebulin gene has so far been best described for humans (Donner and others, 2004; 
Jin and Wang, 1991a) and mice (Kazmierski and others, 2003). 
Human Nebulin spans a genomic sequence of 249 kb and contains 183 exons (Donner 
and others, 2004), whilst the mouse Nebulin contains 165 exons spanning 202 kb of 
genomic DNA. In human Nebulin the translation initiation codon has been described to 
be in exon 3, whilst exon 183 contains the stop codon and the 3’UTR (Donner and 
others, 2004). Donner et al also identified alternatively spliced exons. Alternative 
splicing sites have been described for exons 63-66, exons 82-105 and exons 166-167, 
which alone can give rise to at least 20 different transcripts in the human adult tibialis 
anterior muscle (Donner and others, 2004). Exon 143 and exon 144 also contain an 
alternative splice site and only one of these exons seems to be present in each Nebulin 
isoform (Donner and others, 2006; Donner and others, 2004). Expression studies for 
exon 143/ 144 revealed that expression varies between muscle isoforms, but more 
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interestingly for us between developmental stages of muscles (Donner and others, 2004) 
with exon 144 being expressed more often in muscles of older mice. In mouse Nebulin, 
exons 127/ 128 have been described to be homologues to human Nebulin exons 143/ 
144 (Donner and others, 2006). It was further speculated that mouse Nebulin exons 
127/128 (or human 143/ 144) might function as developmental regulators mediating 
progression from growing muscle fibres (expressing exon 127 or 143) to mature 
muscles (expressing exon 128 or 144) (Buck and others, 2011; Donner and others, 
2006).  
Although there is a high homology between mouse and human Nebulin, mouse Nebulin 
displays a few differences when compared to human Nebulin. It has been reported that 
the mouse Nebulin contains 16 exons, which have no homologue in the human gene, as 
well as containing a protein binding domain similar to human protein ZO-1 in the 16
th
 
of the novel exons (Kazmierski and others, 2003).  
As mentioned in the previous section, alternative splicing sites have been reported for 
Nebulin across different species (Donner and others, 2004; Joo and others, 2004; 
Kazmierski and others, 2003). This alternative splicing leads to the translation of 
proteins with different sizes. It was thought for a long time that the size of Nebulin 
might serve as a ruler for thin filament length specification, as different types of 
muscles had different length of thin filaments, which in turn was proportional to the size 
of the Nebulin protein present in the muscle’s sarcomere (Kruger and others, 1991; 
Labeit and others, 1991; Wang, 1996). It was further reported that a single molecule of 
Nebulin spans the whole length of the thin filaments in sarcomeres with its C-terminus 
being localised to the Z-disc (Millevoi and others, 1998; Wang and Wright, 1988) (see 
figure 5.5). The N-terminus of Nebulin has been described to extend and potentially 
interact with the thin filament pointed ends via binding to tropomodulin (McElhinny 
and others, 2001).  Recently the interaction of the C-terminus of Nebulin with the (thin 
filament) barbed end capping protein CapZ has been reported (Pappas and others, 2008; 
Witt and others, 2006) giving even more evidence of a role for Nebulin in thin filament 
length regulation. But Nebulin has also been shown to interact with the Actin monomers 
as part of the thin filament directly (Labeit and others, 1991).  
Nebulin displays a highly repetitive protein structure, in which the central polypeptides 
are arranged in 153 modules (M9-M162) consisting of between 30 – 35 amino acids 
each (Jin and Wang, 1991b; Labeit and others, 1991; Labeit and Kolmerer, 1995a). 
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Each module contains a conserved SDXXYK Actin binding domain, so that each of the 
central modules can bind one Actin monomer (Jin and Wang, 1991b; Labeit and others, 
1991).  An overview to the structural organisation of Nebulin and its localisation in the 
sarcomere can be seen in figure 5.4. 
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Figure 5.4: Structural organisation of Nebulin and its localisation in sarcomeres  
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Figure 5.4: Structural organisation of Nebulin and its localisation in 
sarcomeres 
The giant protein Nebulin is associated to thin filaments in sarcomeres (top section). Nebulin binds to 
Actin via its central super repeats. With its C-terminus Nebulin has been shown to interact with titin and 
myopalladin, as well as CapZ and Desmin. The N-terminus of Nebulin contains binding sites for 
tropomodulin.   
Figure taken from (Ottenheijm and Granzier, 2010) 
Recent work by Pappas et al. (2010) described a more indirect role for Nebulin in length 
specification of the thin filament, as overexpression of a designed small protein of 
Nebulin, called Mini-Nebulin, was unable to restrict the length of the Actin  filament 
(Pappas and others, 2010). Treatment of Nebulin-deficient myocytes and control 
myocytes with the Actin depolymerising toxin Latrunculin A, revealed that the presence 
of Nebulin prevents the binding of Latrunculin A to Actin  monomers, which in turn 
prevents depolymerisation of the thin filament (Pappas and others, 2010). It was 
therefore suggested that Nebulin stabilises Actin-Actin monomer bonds in the thin 
filament rather than regulating its association and length (Pappas and others, 2010). It 
was also shown by Pappas et al. (2010) that the Actin monomers were more prone to 
substitution, when Nebulin was depleted using siRNA in the myocytes, again revealing 
a lack of Actin-polymer stabilisation. Also far earlier then Pappas et al. a stabilisation 
mechanism of Actin polymers has been indicated by work from Gonsior et al. It was 
reported that a recombinant human Nebulin fragment generated based on 5-6 modules 
from the N-terminal region was able to crosslink Actin monomers (Gonsior and others, 
1998). It was also suggested that binding of Actin monomers by Nebulin can be used as 
a scaffold along which further addition of Actin monomers can occur. Strong evidence 
against a role of Nebulin as thin filament length regulator was published in 2009 by 
Castillo et al. It was reported that  Nebulin does not extend to the pointed ends of the 
thin filament and would therefore not be able to interact with tropomodulin (Castillo 
and others, 2009). It was also reported that the length of the thin filament correlated 
with the size of the present titin isoform rather than Nebulin, thereby further 
highlighting that Nebulin does not regulate Actin filament length in striated muscles 
(Castillo and others, 2009)  
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As previously mentioned, Nebulin contains 153 Actin-binding modules. These modules 
themselves are further clustered into 22 super repeats (SR), each one consisting of a 
conserved binding domain comprising the motif WLKGIGW (Jin and Wang, 1991b; 
Labeit and others, 1991; Labeit and Kolmerer, 1995a). These binding domains have 
been implicated to associate with the troponin/tropomyosin complex (Labeit and 
Kolmerer, 1995a; Wang and others, 1996). As the troponin/tropomyosin complex is 
involved in regulating muscle contraction (Farah and Reinach, 1995) and Nebulin had 
been shown to inhibit actomyosin ATPase activity in an in vitro motility assay (Root 
and Wang, 1994), it was thought that Nebulin might also be involved in muscle 
contraction regulation. Further evidence for a role in Nebulin during muscle movement 
came from data obtained from Nebulin knock-out mice. It was shown that in Nebulin 
KO mice thin filament sizes are reduced (Bang and others, 2006; Witt and others, 
2006). As contraction is based on the length of the filaments (Gordon and others, 1966; 
Granzier and others, 1991), as well as the ratio of overlapping of the thin filament with 
the thick filament, also known as the cross-bridge theory (Huxley and Simmons, 1971), 
shorter thin filaments meant that the active tension was highly reduced in Nebulin KO 
mice (Gokhin and others, 2009; Witt and others, 2006). Furthermore it was reported that 
Nebulin might regulate muscle contraction by changing cross-bridge activity between 
Actin and myosin (Bang and others, 2009; Chandra and others, 2009). 
The C-terminus of Nebulin contains a serine-rich domain as well as a SRC homology 3 
(SH3) domain (Labeit and Kolmerer, 1995a). It has been shown that the C-terminus of 
Nebulin aligns to the Z-disc of the sarcomere (Millevoi and others, 1998; Wang and 
Wright, 1988). Recent data revealed the association of the SH3 domain with 
myopalladin linking Nebulin directly to the Z-disc (Bang and others, 2001; Ma and 
Wang, 2002). Interestingly, it was also shown that the SH3 domain does not only bind 
to the PEVK domain in myopalladin, it can also link Nebulin to another giant protein, 
Titin (otherwise known as Connectin ;(Ma and Wang, 2002). Based on their finding, 
Ma and Wang proposed that Titin together with myopalladin would be able to localise 
Nebulin to the Z-disc during myofibrillogenesis. Analysing the C-terminal Serine-rich 
domain of Nebulin, led to the speculation, that Nebulin could be involved in signalling 
pathways taking place close to the Z-disc due to the presence of potential 
phosphorylation sites in the serine-rich domain (Bang and others, 2006). The C-
terminus of Nebulin has also recently been implied to interact with the intermediate 
filament Desmin (Bang and others, 2002).  
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Figure 5.5: Localisation of Nebulin and interacting proteins  
Sections of myofibrils from quadriceps muscle fibres from wt-mice have been labelled for α-actinin 
(green) as a marker for Z-discs and various other proteins (red); (A) Nebulin, (B) myosin heavy chain, (C) 
myopalladin, (D) CapZ and (E) tropomodulin 1. Nebulin is detected at the Z-disc, where it potentially 
localises to α-actinin, myopalladin and CapZ. Also (A) lower picture, electron microscopy of muscle 
section labelled for Nebulin. 
Figure modified from (Witt and others, 2006) 
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5.3.2 A role for Nebulin during myofibrillogenesis 
 
Nebulin is not only expressed in adult muscles, it has also been reported that Nebulin 
plays an important role during muscle development. 
Data obtained for a function of Nebulin during myofibrillogenesis has been obtained by 
experiments using Nebulin knock-out mice and also by using cell culture.  
Evidence that Nebulin might play a role in myofibrillogenesis came from immuno-
fluorescence studies using primary cultures of skeletal muscle cells dissected out of 
pectoralis muscle from 10-12 days old chicken embryos. Firstly, Moncman and Wang 
(1996) analysed the temporal expression and assembly of sarcomeric proteins during 
myofibrillogenesis. Desmin was expressed first, followed by α-Actin, myosin, titin and 
Nebulin  (Moncman and Wang, 1996). However, looking at the assembly of expressed 
protein it was described that Myosin was shown to align first followed by titin, Nebulin, 
Actin and Desmin (Moncman and Wang, 1996).  
Nebulin was firstly detected in the cytoplasm of chick skeletal myocytes at the time 
point when cells started to differentiate and its localisation was described to be diffused, 
similar to that of muscular myosin and titin (Moncman and Wang, 1996). However, 
whilst muscle specific myosin and titin eventually became associated to nascent 
myofibrils and displayed striated patterns, Nebulin was still seen to be mainly 
cytoplasmic (Moncman and Wang, 1996). Nebulin was shown to be added to the 
myofibrils once myosin and titin had assembled in striations, but before the organisation 
of Actin into defined thin filaments with uniform lengths (Moncman and Wang, 1996). 
Moncman and Wang (1996) therefore concluded that the assembly of Nebulin requires 
the formation of the nascent I-Z-I complex containing the Z-disc as well as premature 
thin and thick filaments. They suggested that Nebulin is involved in organising Actin 
into the thin filaments as well as restricting the length of the Actin fibres (Moncman and 
Wang, 1996). Similar observations were also published by (Shimada and others, 1996). 
Furthermore, Shimada et al. also claimed that Nebulin is not needed in establishing a 
scaffold for other sarcomeric proteins to locate to during formation of myofibrils, but is 
potentially involved in the organisation of Actin to the premature sarcomeres (Shimada 
and others, 1996).  
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This is inconsistent with observations by Gonsior et al. (1998), who reported that 
Nebulin could potentially act as a scaffold for Actin polymerization. It was also reported 
that Nebulin did display a low affinity to bind to Actin monomers (Gonsior and others, 
1998). Based on their observation that Nebulin crosslinks Actin monomers, as well as 
Actin bundles and based on previously described expression patterns for Nebulin after 
the formation of primitive Z-discs, Gonsior et al. (1998) speculated that Nebulin would 
not be able to assemble on its own into thin filament associated striations. They 
suggested that either a peritranslational assembly mechanism is involved in Nebulin 
localisation to Actin fibres or that another protein, similar to a chaperone, would assist 
Nebulin during incorporation into sarcomeric thin filaments (Gonsior and others, 1998). 
Further evidence for Nebulin as a scaffold for Actin polymerization was published by 
Nwe et al. in 1999. It was reported that in premyofibrils Nebulin located along linear 
Actin filaments in a punctate fashion, although some Nebulin puncta were also observed 
to be scattered between the filament (Nwe and others, 1999). In developing myofibrils 
however Actin was shown to localise to the Z-disc and the edges of I-Z-I regions, whilst 
Nebulin was strongly expressed overlapping with Actin at the Z-disc (Nwe and others, 
1999). Once the myofibril had fully developed, Actin was still seen to display strong 
fluorescence at the Z-disc, while Nebulin proteins were found on either side of the 
Actin-staining flanking the Z-disc (Nwe and others, 1999).  Based on observed 
localisation of Nebulin to Actin, it was suggested that the punctate, but also linear 
Nebulin structures might build a scaffold upon which actin monomers can assemble to 
form non-striated Actin bundles in the first instance (Nwe and others, 1999). 
Furthermore, Nwe et al. studied the kinetics of Actin-assembly by Nebulin.  During 
early myofibrillogenesis Actin filaments were not closely linked to Nebulin, as the 
exchange rate of Actin monomers was reported as being rapid in comparison to mature 
myofibrils, whilst in mature myofibrils Actin was tightly associated to Nebulin (Nwe 
and others, 1999). Nwe and co-workers therefore distinguished between different types 
of Nebulin during myofibrillogenesis. The first type of Nebulin, the immature Nebulin, 
has a role in attaching the Actin monomers to the Z-disc (Nwe and others, 1999). As the 
bond between Nebulin and Actin is not very strong in premyofibrillar cells, the fluent 
exchange rates allow the incorporation of Actin monomers into the Z-disc (Nwe and 
others, 1999). As myofibrillogenesis progresses, the link between Nebulin and Actin 
becomes tighter, which leads to the stabilisation of Actin fibres by Nebulin in the 
striations of mature sarcomeres (Nwe and others, 1999).  
186 
 
Recently, Nebulin-silencing experiments also revealed a role for Nebulin during 
myofibrillogenesis.  During differentiation, the foetal rat skeletal myocytes were treated 
with siRNA to reduce Nebulin levels in the cells (McElhinny and others, 2005). In 
comparison to non-treated myocytes, Nebulin depleted rat muscle cells differentiated 
slower and fusion was delayed (McElhinny and others, 2005). When comparing the 
assembly of myofibrils in control myocytes with siRNA treated myocytes during a 5-
day time course of differentiation, it was shown that the Z-disc did not form properly, 
nor in fact had the striated pattern of the thin and thick filaments been established 
(McElhinny and others, 2005).  
Myofibrillogenesis was also studied in Nebulin knock-out mice. Although mouse 
embryos and new born rodents showed fully assembled myofibrils, the sarcomeric 
structure was shown to dissociate under muscle contraction (Bang and others, 2006; 
Gokhin and others, 2009; Witt and others, 2006).  
Nebulin knock-out rodents displayed normal myofibrils, the thin filament capping 
proteins, CapZ and Tropomodulin (Tmod1), as well as myopalladin were affected by 
the absence of Nebulin (Witt and others, 2006). Labelling of myopalladin at the Z-disc 
revealed a reduced and diffused localisation compared to wt myopalladin labelling (Witt 
and others, 2006). Similar data was also obtained for CapZ and Tmod1 (Witt and others, 
2006). Furthermore Tmod1 was also shown to be located closer to the Z-disc when 
compared to wt-Tmod1 (Witt and others, 2006). It was also shown that the length of the 
thin filament was greatly reduced (Witt and others, 2006). Based on their data, Witt et 
al. (2006) confirmed the suggested role for Nebulin in thin filament length specification. 
Similar observation were also made by (Bang and others, 2006), who reported that 
Nebulin would not be needed for the assembly of sarcomeres (Bang and others, 2006). 
But as they found shorter thin filaments in Nebulin deficient mice, misaligned Z-discs 
and the degradation of sarcomeric structures in active muscles, they also described a 
role for Nebulin in the stabilisation and maintenance of myofibrils (Bang and others, 
2006) 
In summary, Nebulin plays an important part in the organisation and stabilisation of 
myofibrils, as well as in mediating muscle contraction. 
Recently, Nebulin has also been shown to be expressed in the heart, stomach and brain 
in adult chicken (Joo and others, 2004). Nebulin expression in cardiomyocytes was 
further reported in other species, but protein levels are significantly less for cardiac 
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Nebulin compared to skeletal muscle Nebulin (Donner and others, 2004; Fock and 
Hinssen, 1999; Kazmierski and others, 2003). It was thought that the role of Nebulin in 
striated muscle was carried out in heart musculature by Nebulette, a 107 kDa 
homologue of Nebulin (Moncman and Wang, 1995). Further data seemed to confirm an 
essential role for Nebulette in cardiomyocytes, as a knock-down of Nebulette in 
cardiomyocytes lead to a thin filament phenotype similar to that of thin filament in 
Nebulin depleted skeletal muscle (Moncman and Wang, 2002). It was shown that 
Nebulette also interacts with thin filament capping proteins indicating that Nebulette 
might stabilize the length of the Actin filament in a similar way to Nebulin (Bonzo and 
others, 2008). 
 
5.3.3 Analysis of Nebulin as a potential new binding partner for Klhl31  
 
As mentioned earlier, the Yeast-2-Hybrid screen identified two Nebulin isoforms as 
potential binding partners for Klhl31. When the amino-acid sequences of both Nebulin 
fragments (Isoform 2 and Isoform 3) were aligned, we discovered that both amino acid 
sequences contained a similar, potential conserved binding site for Klhl31 (see 
alignment below). The protein alignment was done by using the software Clustal2W 
(EMBL-EBI tools).   
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-----------------------------------------------DTVSDVKYKEDLT 13 
 
DALDIVYHRKVTDDISKIKYKENYMSQLGIWRSIPDRPEHFHHRAVTDTVSDVKYKEDLT 60 
                                                                         
************** 
       
 
WLKGIGCYAYDTPDFTLAEKNKTLYSKYKYKEVFERTKSDFKYVADSPINRHFKYATQLM 73 
 
WLKGIGCYAYDTPDFTLAEKNKTLYSKYKYKEVFERTKSDFKYVADSPINRHFKYATQLM 120 
                   
************************************************************ 
       
 
NERKYKSSAKMFLQHGCNEILRPDMLTALYNSHMWSQIKYRKNYEKSKDKFTSIVDTPEH 133 
 
NEKKYRADYEQRKDKYHLVVDEPRHLLAKTAGDQISQIKYRKNYEKSKDKFTSIVDTPEH 180 
 
**:**::. :   ::    : .*  * *   ..  ************************* 
 
LRTTKVNKQISDILYK 149 
 
LRTTKVNKQISDILYK 196 
 
**************** 
 
Legend: Fragment Nebulin Variation 2, Fragment Nebulin Variation 3. 
Potential Actin binding domains (SDXXYK) are underlined. 
 
Also, both Nebulin isoforms are substantially different from each other due to 
alternative splicing, with for example Nebulin isoform 3 being significantly smaller 
than isoform 2.  Some of these differences can also be seen in the sequences of the 
fragments. However, when aligning the fragments to the full length DNA or amino acid 
sequence and comparing the obtained data to the already known DNA organisation of 
the Nebulin genes, it became clear that both fragments, which were identified to be a 
potential Klhl31 binding partner, are located in a mRNA sequence, which contains exon 
144 (for alignment and additional information, see Appendix).  
Exon 144 has been described to be a marker for adult muscle tissues (Buck and others, 
2011; Donner and others, 2006). As we have screened a library which contained 
proteins from adult and foetal muscular tissues, it was possible to detect proteins that 
might link Klhl31 to mature rather than developing muscles. We knew from previous 
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studies that Klhl31 was expressed in nearly all striated muscles in chick embryos, as 
well as in embryonic heart and skeletal muscle tissues of humans (Abou-Elhamd and 
others, 2009; Yu and others, 2008), but we have not analysed Klhl31 protein levels in 
adult muscle tissues. Nebulin has been very well described in muscle fibres, where it 
has been detected in striations localising to actin fibres along the Z-disc (see figure 5.7; 
(Pappas and others, 2008)and figure 5.6; (Witt and others, 2006) 
 
5.3.4 Nebulin partially co-localises with Klhl31 in mouse muscles  
 
To find out, whether Klhl31 is actually expressed in adult muscles and if it would co-
localise to Nebulin, we decided to use an immuno-staining approach on mouse adult 
muscle sections. 
Localisation of both, Nebulin and Klhl31, were analysed by immuno-staining for both 
proteins in mouse tibialis anterior muscle. The preparation of mouse sections, as well as 
the immuno-staining was done in collaboration with Christina Stratford. 
Nebulin localisation in myofibrils has been very well described for different types of 
muscles and species (Millevoi and others, 1998; Pappas and others, 2008; Wang and 
Wright, 1988; Witt and others, 2006).  Klhl31 localisation however has not been 
analysed in adult muscle so far.  
 
Figure 5.6: Nebulin in chick skeletal myotubes 
Chick skeletal myotubes were stained with an antibody against Nebulin or were stained with Phalloidin to 
visualise Actin. Nebulin can be seen close to the Z-disc, where it co-localises to actin.                                                                          
Figure taken from (Pappas and others, 2008) 
190 
 
 
Immuno-staining for Klhl31 in adult mouse muscle revealed its presence in mature 
muscles.  
In transverse sections of mouse tibialis anterior, Klhl31 was shown to display a punctate 
localisation in muscle fibres (see figure 5.8, b and c). 
* 
Figure 5.7: Expression of Nebulin and Klhl31 in mouse tibialis anterior  
Immuno-staining for Klhl31 (a-c) and Nebulin (d-f) was carried out on transverse sections of wildtype 
mouse tibialis anterior. Images a and d were taken with a 20x objective, whilst images b-c and e-f were 
taken by using a 63x objective. Nuclei stained blue with Hoechst are visualized at the periphery of the 
muscle fibres.  
 
a 
b 
c 
d 
e 
f 
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Therefore we found that Klhl31 is not only expressed during development (Abou-
Elhamd and others, 2009), but also in adult muscle tissues. Comparing Immuno-staining 
for Klhl31 with Phalloidin-staining of frozen muscle biopsies from either rectus 
abdominus or quadriceps (see figure 5.8; (Ilkovski and others, 2004), it could be shown 
that both localisation pattern for Klhl31 and Actin are very similar. Although we have 
not analysed Actin and Klhl31 co-localisation in adult muscle ourselves, the similar 
localisation of Klhl31 to Actin (as seen in mouse tibialis anterior (figure 5.6) and human 
rectus abdominus or quadriceps (figure 5.8)) together with the evidence for partial co-
localisation of Klhl31 with actin fibres in C2C12 myotubes (chapter 3.3.2, figure 3.8) 
might indicate a possible interaction for both proteins in mature muscles.  Each punctate 
expression signal of Klhl31 is potentially labelling a single myofibril, as up to 1000 
myofibrils can make up a single muscle fibre (Martini, 2005). Sometimes Klhl31 
expression seemed to look a bit circular or wave-like (as seen in figure 5.7, b). This 
might be due to shifting of the muscle tissue during the embedding process. Therefore 
the muscle might not have been sectioned in a transverse fashion, but slightly changed 
towards longitudinal section. This would mean that we would detect Klhl-31 
localisation as a mixture of punctate staining (transverse section) and linear staining 
(longitudinal section). 
Immuno-labelling for Nebulin in tibialis anterior (figure 5.7, d-f) showed a similar 
localisation of Nebulin when compared to the localisation of Klhl31 in the muscle 
fibres. Nebulin also displayed a punctate localisation, potentially labelling single 
myofibrils in a single muscle fibre. Unfortunately, the immuno-staining for Nebulin in 
transverse sections of human muscles as reported by (Ilkovski and others, 2004) (see 
figure 5.8) appears diffuse and can therefore not be used for a comparison with the 
Nebulin localisation in tibialis anterior (figure 5.7).  
 
↓ 
* 
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Figure 5.8: Expression of Nebulin and Actin in human muscle  
Immuno-labelling for Actin (A and D) and Nebulin (B and E) of frozen biopsies from healthy human 
beings from either a quadriceps (A and B) or rectus abdominalis (D and E) revealed a punctate 
localisation for Actin in muscle fibres. The localisation for Nebulin appears diffuse, but was described as 
normal myofibril labelling.  
Figure modified from (Ilkovski and others, 2004) 
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We could show that Klhl31 is expressed in mature muscle tissues in mice. But would 
Klhl31 co-localise with Nebulin in the muscle, too?  
 
  
Figure 5.9: Nebulin and Klhl31 partially co-localise in mouse tibialis 
anterior 
Double immuno-staining for Klhl31 and Nebulin was carried out on sections of wildtype mouse tibialis 
anterior as described previously. Images were taken with a 20x objective (a) or a 63x objective (b). 
Klhl31 was visualised by using an α-rabbit Alexa fluor 568 conjugated secondary antibody (red), whilst 
Nebulin was labelled with a α-mouse Alexa fluor 488 secondary antibody (green). Negative samples were 
prepared as described in section 2.2.26. Strong fluorescence in the skeletal muscle basement membrane is 
possibly due to accumulation of the secondary antibodies, as it was also observed in the negative controls. 
 
Double immuno-histochemistry for Klhl31 and Nebulin on mouse tibialis anterior 
sections revealed that Klhl31 and Nebulin are closely localised at or along myofibrils in 
muscle fibres (see figure 5.9; b, yellowish coloured spots).  
The NB2 antibody we used to detect Nebulin was characterised in 1988 by Furst et al. 
The antibody recognises an epitope in the Nebulin protein, which localises to the N2 
lines in the sarcomere, a region which is not part of the alternative splicing sites of the 
Nebulin gene (Furst and others, 1988). Therefore we assumed we would be able to 
detect all present Nebulin isoforms in the muscle section. 
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However, we observed staining exclusively for either Nebulin or Klhl31 as single green 
or single red puncta. Muscles have been shown to express different isoforms of Nebulin 
(Donner and others, 2004; Joo and others, 2004; Kazmierski and others, 2003). For 
human tibialis anterior alone over 20 different transcripts have been predicted due to 
alternative splicing (Donner and others, 2004). We can therefore assume that mouse 
anterior tibialis also expresses different isoforms of Nebulin. As Klhl31 seems to be 
binding to an amino acid motif between super repeat 20 and super repeat 21 found in 
exon 128 (mouse) or exon 144 (human) in genomic DNA, we have to consider the 
presence of Nebulin isoforms lacking exon 128 in mouse tibialis anterior muscle. This 
could explain why we could see Nebulin staining on myofibrils, which do not localise 
with Klhl31.   
Based on observed co-localisation of Klhl31 to Nebulin in myofibrils, we suggested that 
Klhl31 might co-localise with Nebulin in adult musculature.  
 
5.3.5 Nebulin is expressed in differentiating C2C12 myoblasts  
 
Nebulin has various important functions in adult muscle tissues and during 
myofibrillogenesis (as described in the chapter 5.3.1 and 5.3.2).  
We have shown that Klhl31 localises close to Nebulin in adult muscles. Next we wanted 
to study potential interaction of Klhl31 and Nebulin in developing muscles. 
To analyze a potential association of Klhl31 with Nebulin during C2C12 differentiation 
in more detail, we firstly wanted to identify the presence of Nebulin during C2C12 
myotube formation. We collected total protein lysates during a 5 day time course of 
differentiation of mouse myoblasts as described in chapter 3.1.3. By using a 10% PAA 
gel, we could detect a band using a Nebulin antibody, but only on one day during the 5 
days of differentiation, between day one and day two (figure 5.10).   
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Figure 5.10: Nebulin is expressed on the onset of C2C12 differentiation  
The expression of Nebulin during C2C12 different iat ion was analysed by western 
blott ing using a mouse monoclonal ant ibody against  Nebulin.  A band was detected of 
approximately 130kDa was detected at  day 1 of C2C12 different iat ion.  An Act in 
ant ibody was used to detect the total Act in  levels as a loading control.  
Legend: M - marker, D0- Day 0, D1 – Day1, D2 – Day2, D3 – Day3, D4 – Day4  
The protein band, which was detected with the NB2 Nebulin antibody, was only 
observed at the beginning of elongation of myocytes around day one during the 
differentiation time course of C2C12 cells. Comparing the expression of a potential 
Nebulin-protein with Klhl31 expression it was observed that the detected 130kDa 
protein seemed to be expressed before the expression of Klhl31 is upregulated (around 
day 2, see chapter 3.1.3).  The published larger Nebulin protein bands (~700 kDa as 
described in the review by (McElhinny and others, 2003) could not be detected as the 
acrylamide percentage of the gel used for SDS-PAGE was not high enough to permit 
separation of large proteins.  
As we have seen that a protein detectable with a Nebulin antibody is expressed in 
C2C12 during differentiation we wanted to analyse its localisation during C2C12 
myotube formation. 
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5.3.6 Nebulin localises to Actin fibres in differentiating myocytes  
 
A potential Nebulin-protein was shown to be expressed at the onset of 
myofibrillogenesis in differentiating C2C12 myocytes, slightly before Klhl31 
expression was elevated (as described in the previous chapter). We wanted to know if 
Klhl31 could co-localise with the Nebulin-protein just as we had seen in adult muscle 
tissue (chapter 5.3.3). But before investigating Klhl31 and potential Nebulin localisation 
in C2C12 cells we wanted to compare Nebulin localisation to a well described part of 
myofibrils, the Actin cytoskeleton.  
In adult muscle Nebulin has been described to align to the whole thin filament by 
binding Actin-monomers via its central modules (Jin and Wang, 1991b; Labeit and 
others, 1991; Labeit and Kolmerer, 1995a) and cell culture experiments led to the 
suggestion that Nebulin assists Actin monomers during the organisation of the thin 
filaments during myofibrillogenesis (Moncman and Wang, 1996; Nwe and others, 1999; 
Shimada and others, 1996) 
Using a double immuno-staining approach we could show that Nebulin aligns to Actin 
fibres exclusively in differentiating C2C12 myocytes (see figure 5.11). 
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Figure 5.11: Nebulin localises to Actin fibres during the differentiation of C2C12 myocytes  
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Figure 5.11: Nebulin localises to Actin fibres during the differentiation of 
C2C12 myocytes 
C2C12 myocytes (Day 0),  early different iat ing myocytes (Day 2) and late different iat ing 
myocytes (Day 4) were labelled for Nebulin (green, Alexa -Fluor 488 secondary ant ibody) 
and Act in (red, Texas-red phallo idin).   
We observed that Nebulin again was only present in early differentiating C2C12 
myocytes, where it displayed a fibrillar localisation pattern, closely associated to Actin 
fibres (figure 5.11, day 2). Nebulin was not detected in undifferentiated or late 
differentiating C2C12.  
As described previously for chick skeletal myocytes (Moncman and Wang, 1996; Nwe 
and others, 1999; Shimada and others, 1996), Nebulin was also shown to localise to 
Actin fibres in differentiating mouse myocytes.  
Comparing our localisation data to previously described western blotting data for a 
protein detectable with a Nebulin antibody, Nebulin again was only detected between 
day 1 and day 2 of incubation of C2C12 cells in differentiation medium (DM).  
Based on this narrow time frame of expression, we therefore decided to look in more 
detail at Nebulin expression during differentiation of C2C12. 
As not all C2C12 cells did respond to DM at the same time and therefore differentiated 
differently we wanted to characterise the time frame of Nebulin expression in 
differentiating C2C12 more closely. Culturing and starving mouse myoblasts as 
described before (in chapter 5.3.5), we detected expression of a potential Nebulin-
protein during a 24 hour time frame between day 1.5 and day 2.5 of C2C12 
differentiation (see figure 5.12). 
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Figure 5.12: Nebulin is expressed between day 1.5 and day 2.5 of 
differentiation of C2C12 
The expression of a potent ial Nebulin-protein dur ing C2C12 different iat ion was analysed 
by western blott ing using a mouse monoclonal ant ibody against  Nebulin.  A protein band  
was detected between day 1.5 and day 2.5 of the different iat ion t ime course. The 
strongest  band displayed a proximal size of 130 kDa, whilst  other lower bands were also 
detected. Act in levels were to compare loaded protein samples.  
Legend: M - marker, D0- Day 0,  D0.5- Day 0.5, D1 – Day1, D1.5 –  Day1.5,  D2 – Day2, 
D2.5 – Day 2.5 and D3 – Day 3  
Analysing samples taken every 12 hours during C2C12 myotube formation revealed 
that a protein detectable with a Nebulin antibody was expressed between day 1.5 and 
day 2.5 during a time course of C2C12 differentiation (see figure 5.12). Observed 
protein expression was therefore consistent with previous described data from western 
blotting and immuno-histochemistry (as reported in chapters 5.3.5 and 5.3.6)  revealing 
a timeframe of potential Nebulin expression of 24 hours at during early C2C12 
differentiation. Furthermore, the protein detected was again to small in its size 
(compared with the published size of Nebulin of around 700 kDa; (McElhinny and 
others, 2003), raising the question whether the detected protein might be unspecific or 
whether it could be a degradation product of Nebulin.  Again, we were not able to detect 
full-length Nebulin as the PAA Gel used in the experiments did not have the needed 
acrylamide concentration to allow protein separation for Nebulin. 
200 
 
Next we wanted to compare localisation of Klhl31 to localisation of Nebulin during 
C2C12 differentiation, as Nebulin was identified as an interaction partner for Klhl31 in 
the Yeast-2-Hybrid screen (see chapter 5.1). Also we had already shown that Klhl31 co-
localised to Actin in adult musculature (see figure 5.9).  
Therefore, we decided again to use a double-immuno staining approach to compare the 
expression and localisation of Klhl31 with Nebulin during myotube formation. 
 
5.3.7 Nebulin and Klhl31 are both expressed in the differentiating myoblasts 
 
C2C12 mouse myoblasts were cultured on coverslips, differentiated as described 
previously and stained for Klhl31 and Nebulin, Nebulin and Actin or Actin and Klhl31. 
We decided to immuno-label C2C12 cells during a 5 day time course of differentiation, 
with samples taken every 12 hours between day one and day three based on our 
previous expression data obtained for a potential Nebulin protein.  
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Figure 5.13: Nebulin and Klhl31 are expressed in the same differentiating myoblasts  
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Figure 5.13: Nebulin and Klhl31 are expressed in the same differentiating 
myoblasts 
(a,b,c) Double immuno-staining for Klhl31 (green, Alexa-Fluor 488) and Act in 
(red, Texas-red Phallo idin) during a 5-day t ime course of C2C12 different iat ion  
(d-j)  Double immuno-staining for Nebulin (green, Alexa-Fluor 488) and Act in 
(red, Texas-red Phallo idin) during a 5-day t ime course of C2C12 different iat ion  
(k-q) Double immuno-staining for Nebulin (green, Alexa-Fluor 488) and Klhl31 
(red, Alexa-Fluor 568) during a 5-day t ime course of C2C12 different iat ion  
 Nuclear DNA was stained with DAPI 
Images were taken with a 63x object ive .  Legend: scale bar – 10 μm 
 
We could observe upregulation of Klhl31 expression during C2C12 differentiation, as 
well as co-localisation of Klhl31 to Actin fibres in early differentiating and late 
differentiating C2C12, which is consistent with the expression profile for Klhl31 as 
described in previously (figure 3.8 and figure 5.13; a-c).  
The double Immuno-staining approach further revealed a potential Nebulin expression 
firstly detected around day 1 (figure 5.13; e and l, similar to previous obtained data for 
Nebulin expression, see figure 5.12) displaying a diffused and punctate localisation in 
the cytosol. Nebulin exhibited the diffused localisation until approximately day 2 when 
it aligned to Actin fibres still displaying puncta (figure 5.13; g). A potential Nebulin 
expression was not detected after day 3 of C2C12 differentiation (figure 5.13; h,i,j and 
q). Furthermore, potential Nebulin expression was mostly observed in cells with 
elevated protein levels of Klhl31 (figure 5.13; l,m,n and p), although occasional Nebulin 
positive cells were observed during early differentiation (figure 5.13; l). Klhl31 protein 
levels stayed elevated whilst detected Nebulin protein levels decreased (figure 5.13; q) 
consistent with previously described data for potential Nebulin expression and Klhl31 
expression (figure 5.12 and 3.4, respectively). During later stages of differentiation 
Nebulin seemed to be localised at the edges of elongated pre-fusion myoblasts close to 
enriched Klhl31 levels (figure 5.13; p) 
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Figure 5.14: Nebulin aligns to actin fibres in elongated myoblasts  
Higher magnification image of C2C12 cells during early differentiation. 
Images are as shown in figure 5.13, but were further magnified using image processing software. 
Further magnifying images obtained from the double immuno-staining approach (figure 
5.13, g,b and n) were used to analyse a potential co-localisation of Klhl31 to Nebulin. 
Nebulin was observed to align to Actin fibres in pre-fusion mouse myoblasts (figure 
5.14; a’’) in a punctate fashion, where it also seemed to be accumulated at the edges of 
the cell. As previously described, Klhl31 aligned along the whole length of Actin fibres 
in differentiating C2C12 cells (figure 5.14; b’’). Higher magnified images also revealed 
a partial localisation of a possible Nebulin-protein with Klhl31 (figure 5.14; c’’) 
As reported previously by other groups (Moncman and Wang, 1996; Shimada and 
others, 1996), we also observed that Nebulin displayed a diffused localisation in the 
cytosol before eventually aligning into a fibrillar structure closely associated to the actin 
fibres (figure 5.13; e-g, figure 5.14; a’). However, co-localisation of Nebulin with 
Klhl31 was not as clear, which is partially due to a rapidly fading Alexa Fluor 568 
secondary antibody, which made it difficult to visualise Klhl31. When Nebulin 
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expression was observed first, it seemed to be expressed prior to enhanced Klhl31 
expression (figure 5.13; l) displaying a diffused localisation in the cytosol of C2C12 
myoblasts. After day 1.5 of the differentiation time course all Nebulin positive cells also 
showed elevated Klhl31 staining (figure 5.13; m, n, p and figure 5.14; c). Once 
myoblasts became elongated Nebulin partially co-localised or aligned close to fibrillar 
Klhl31 structures (figure 5.13; m, figure 5.14; c). We could see Nebulin puncta, which 
did not localise to Klhl31 fibrillar structures (figure 5.14; c’’). This might be due to 
either the fading signal of the Alexa-Fluor 568 antibody or due to the loss of weaker 
Alexa-fluor 568 signal during image processing (e.g. subtracting the background 
obtained with Alexa-Fluor 568 secondary antibody in absence of a primary antibody, as 
described in materials and methods, section 2.2.26). Very rarely we observed Nebulin 
staining after day 2.5 of C2C12 differentiation. However, later during  C2C12 
differentiation (day 2+), we observed that Nebulin expression was although diffused 
confined to the edges of the elongated cell close to strong levels of Klhl31 (figure 5.13; 
p). 
During later stages of C2C12 differentiation, when C2C12 cells started to fuse into 
myotubes, Nebulin was not detected anymore.  
Although there seemed to be a close proximity between Klhl31 and Nebulin, we have so 
far not verified a potential direct interaction between the two proteins. We therefore 
decided to use a GST-pull down approach to investigate if Klhl31 can bind to Nebulin. 
 
5.3.8 Klhl31 can bind to Actin and form homodimers 
 
When we decided which approach to use to investigate interaction partners for Klhl31 
we had the issue that it had been difficult to create fusion-proteins for Klhl31, as the 
added protein tags seemed to impair function of the fusion-protein (chapter 4.1.2). 
Furthermore we found that overexpressed Klhl31 fusion-proteins seemed to be 
degraded in mammalian cells (see chapter 4.3.2).  
The GST approach would enable us to overexpress a GST-Klhl31 protein in a bacterial 
environment using low expression temperatures, which would make it possible to 
generate stable Klhl31 fusion proteins by preventing degradation.  
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We created an N-terminal GST-Klhl31 protein by cloning human Klhl31 (image clone 
9021264) into a pGEX-5X-I vector. The gene expression was induced by IPTG. Using 
different induction temperatures revealed that we could produce stable GST-Klhl31 
proteins in sufficient amounts at low temperatures (see figure 5.15). We observed the 
best results when inducing GST-Klhl31 expression at 21 °C for 3 hours.  
 
Figure 5.15: Stable overexpression of GST-Klhl31fusion protein 
Samples of GST-Klhl31 expressing bacteria lysates were run on a 10% PAA Gel and 
stained with Coomassie br illiant  blue.  Approximate protein concentrat ion for GST -
Klhl31 was est imated by compar ison to  a BSA protein standard.  Stable GST -Klhl31 was 
successfully expressed in E.coli at  lower temperatures which prevented de gradat ion of 
the fusion protein.  
Legend: M – marker 
Once we had purified the GST-Klhl31 proteins (as described in chapter 2.2.36), we used 
them to carry out pull-down experiments using C2C12 lysates from different time 
points of differentiation (see chapter 2.2.36). GST only served as control for these 
experiments. 
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Figure 5.16: Finding interaction partner for Klhl31 using a GST-pull down 
approach 
(a) Silver staining of a 10 % PAA gel.  Pull downs with GST Beads (1,3,5,7)  and 
GST-Klhl31 (2,4,6,8) incubated with either PBS (1,2) or in C2C12 lysates (3 -8) 
are shown. A band potent ially containing endogenous Klhl31 (←, lane 4 and 6) 
was pulled out by GST-Klhl31 from C2C12 lysates of early different iat ion t ime 
points.  Act in however seemed enr iched in samples obtained dur ing late 
different iat ion (lane 6 and 8).  Bands surrounded by coloured rectangles were 
analysed by mass spectrometry.  
(b)  Western blot  against  Klhl31 (upper blot) or Act in ( lower blot) further ident ify 
some of the bands seen in the silver staining. Endogenous Klhl31 was pulled out 
of lysates from myoblasts or different iat ing  C2C12 cells (lanes 4 and 6),  whilst  
Act in was shown to be enr iched in samples obtained from different iated C2C12 
myotubes (lane 6 and 8) 
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Legend: M –  marker,  1 -  GST in PBS (negat ive control for GST only),  2 -  GST-Klhl31 in 
PBS (negat ive control for GST-Klhl31),  3 -  GST in C2C12 lysate (Day 0),  4 -  GST-
Klhl31 in C2C12 lysate (Day 0),  5 -  GST in C2C12 lysate (Day 2),  6 -  GST-Klhl31 in 
C2C12 lysate (Day 2), 7 -  GST in C2C12 lysate (Day 4),  8 - GST-Klhl31 in C2C12 lysate 
(Day 4). 
After running the samples acquired from the GST-pull downs on a PAA gel and 
subsequently staining with silver stain as a more sensitive staining compared to 
Coomassie, we could see that we were able to extract bands from C2C12 lysates when 
using the GST-Klhl31 fusion protein (see figure 5.16, a; lanes 4,6 and 8). More 
interestingly for us was that the pulled out protein bands showed variations between day 
0, day 2 and day 4 of myoblast differentiation, suggesting that Klhl31 interacts with 
different proteins at the onset of differentiation compared to later stages of C2C12 
differentiation (figure 5.16, a).  
Furthermore we saw an enrichment of a protein displaying the size of endogenous 
Klhl31 pulled down by GST-Klhl31 (figure 5.16, a;  ←), but only during the early 
stages of C2C12 differentiation (between day 0 and day 2). The binding of GST-Klhl31 
to endogenous Klhl31 was verified by western blot (figure 5.16, b; ←). In summary, we 
could show that endogenous Klhl31 seems to be an interaction partner for GST-Klhl31 
during early differentiation. It has been reported that proteins of the Kelch-like family 
can form homodimers (Geyer and others, 2003; Stogios and others, 2005). Our pull-
down assays suggest that Klhl31 is also able to form homodimers during early 
differentiation of C2C12, before Klhl31 aligns completely to Actin fibres (see chapter 
3.3.2).  
Using the GST-pull down we also observed that Actin was enriched with GST-Klhl31, 
indicating that it may interact with Actin directly (figure 5.16, a and b; lane 6 and 8). 
However, as Actin was also enriched in the GST only samples, although weaker when 
compared to GST-Klhl31, this result needs to be interpreted with caution. Interaction 
with the Actin cytoskeleton has previously been reported for various members of the 
Kelch-like protein family as well (Adams and others, 2000; Kelso and others, 2002; 
Robinson and Cooley, 1997; Xue and Cooley, 1993). GST-Klhl31 pull-down did not 
lead to enrichment of Actin in undifferentiated C2C12 (figure 5.16, and b; lane 4) in 
agreement with our localisation studies (chapter 3.3.2). Only once C2C12 had passed 
the intermediate state of differentiation as defined by (Burattini and others, 2004), 
Klhl31 localised to Actin filaments. As we only pulled-down Actin bands from C2C12 
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lysates of day 2 or day 4 (resembling later stages of C2C12 differentiation), we can 
assume that localisation of Klhl31 to Actin also involves a direct interaction between 
Klhl31 and Actin.  
 
5.3.9 Mass spectrometry analysis of excised bands 
 
Next, we tried to identify additional proteins of interest pulled down using GST-Klhl31. 
Some of the clearer protein bands were excised from silver stained gels obtained from 
GST-pull down assays and the samples indicated by green and red rectangles in figure 
5.16 were analysed by mass spectrometry at the FingerPrints Proteomics facility 
(University of Dundee). Hits were identified by using the Mascot database.  
Interestingly, the verified hits indicate that Klhl31 can bind to various other proteins of 
the contractile muscle apparatus. The excised bands contained proteins, which were not 
pulled down from undifferentiated C2C12 lysates (Day 0). The bands were only 
observed during C2C12 differentiation (Day 2) and in late differentiating C2C12 
myocytes (Day 4).  
Table 5.1: Proteins identified in the excised protein bands from the GST - 
pull down 
The table shows the top 5 hits identified by mass spectrometry from the <17 kDa excised protein band 
(red rectangular) and the ~35 kDa excised protein band (green rectangular) as seen in figure 5.16.  
 
Protein  
size 
(kDa) 
  
 
Protein  
size 
(kDa) 
~ band 
size 
  15-17   
~ band 
size 
  ~ 35 
  
myosin 
regulatory light 
chain, B-like 
~20     
Isoform 1 of 
Tropomyosin alpha-1 
chain 
32 
  Myl12b ~20     
Isoform 2 of 
Tropomyosin alpha-1 
chain 
32 
  Myl9 ~20     
F-actin-capping protein 
subunit alpha-2 (Capza2) 
~32 
  Calmodulin 17     Annexin 36 
  
Actin-related 
protein 2/3 
complex subunit 
3 (Arpc3) 
21     
F-actin-capping protein 
subunit alpha-1 (Capza1) 
~32 
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First, an excised protein band displaying a size of approximately 15-17 kDa was 
analysed (figure 5.16; a - red box). Calmodulin (17kDa) and myosin regulatory light 
chain isoforms (around 20 kDa large, e.g. myosin regulatory light chain (homo sapiens), 
myosin regulatory light chain B-like, Myl12b, Myl9 (all mus musculus). Myosin 
regulatory light chains are involved in mediating muscle contraction in adult muscle and 
in myofibrillogenesis in developing muscle fibres (Du and others, 2003; Gordon and 
others, 2000; Kamm and Stull, 2011). Also a subunit of the Actin-related protein 2/3 
complex was identified.  The Arp2/3 complex mediates the nucleation of Actin, the first 
step during de-novo Actin polymerisation by assisting the formation of Actin dimers or 
trimers (Soderling, 2009). The Arp2/3 complex consists of 7 subunits, two of which, 
Arp2 and Arp3 (identified in the GST-pull down), can mimic Actin dimers when 
aligning to already existing Actin fibres (Pollard, 2007). Addition of further Actin 
monomers by the Arp2/3 complex has been described to stimulate Actin polymerisation 
(Robinson and others, 2001; Volkmann and others, 2001).  Also interesting, the Arp2/3 
complex is activated by members of the Wiskott-Aldrich syndrome protein (WASP) 
family (Panchal and others, 2003). Furthermore, in striated muscle the Arp2/3 complex 
is also involved in Actin polymerization along the edges of the myoblast prior to fusion 
(Blanchoin and others, 2001; Richardson and others, 2007). 
Identified proteins from a ~35 kDa band (figure 5.16, a – green box) revealed the 
presence of tropomyosin α-chain (32 kDa). Tropomyosin α and tropomyosin β are 
mainly expressed in skeletal and cardiac muscle, where they form dimers and associate 
to the actin filament (Bailey, 1948; Kalyva and others, 2012; Perry, 2001). The formed 
tropomyosin dimer in association with troponin has been shown to mediate muscle 
contraction (for an overview of muscle contraction and function of tropomyosin see 
chapter 1.9 or (Farah and Reinach, 1995; Gordon and others, 2000). Furthermore it had 
been reported that tropomyosin can interact with tropomodulin in regulating actin 
filament lengths by capping the slow growing end of Actin fibres (Casella and others, 
1986; Gregorio and others, 1995; Kostyukova, 2008; Weber and others, 1994). Also by 
mass spectrometry analysis of the ~35 kDa protein band, CapZ had been identified to be 
pulled out of C2C12 lysates by Klhl31. CapZ is also a capping protein for the Actin 
filament, however it caps the fast-growing or barbed ends of Actin fibres (Caldwell and 
others, 1989).  
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Annexin was also identified by mass spectrometry. Annexins are involved in various 
cellular processes, such as membrane organisation, membrane traffic and the regulation 
of the activity of ion channels (Gerke and Moss, 2002). Furthermore, some Annexins 
have been described to be Actin-binding proteins and were thought to be involved in 
regulating changes to the membrane-associated cytoskeleton (Alvarez-Martinez and 
others, 1997; Gerke and Moss, 2002). Recently, a role for Annexin in skeletal muscle 
differentiation and membrane repair has been described (Bizzarro and others, 2010a; 
Bizzarro and others, 2010b). It was shown that Annexin 1 enhanced myoblast cell 
proliferation by promoting satellite cell migration (Bizzarro and others, 2010b). 
We also identified NEDD8-conjugating enzyme Ubc12 (21 kDa), an E2 ubiquitin-
conjugating enzyme as a potential interaction partner for Klhl31 in the GST-pull down.   
Further experiments are needed in order to determine whether Nebulin is a direct 
interaction partner for Klhl31 in the GST pull down assays. 
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6. Klhl31 expression during heart development 
 
6.1 Introduction to early cardiogenesis 
 
6.1.1 Formation of the primary heart tube 
 
The heart is the first organ to form during the development of vertebrates. It is 
important as its contractions transport nutrients and oxygen throughout the embryo. 
Cardiac progenitor cells are derived from the mesoderm (Garcia-Martinez and 
Schoenwolf, 1992; Kinder and others, 1999) and emerge from the anterior part of the 
primitive streak during gastrulation (Garcia-Martinez and Schoenwolf, 1993). These 
cells eventually give rise to all layers of the heart tube: the endocardium, myocardium 
and the parietal pericardium (Garcia-Martinez and Schoenwolf, 1993; Schoenwolf and 
others, 1992).  
Recent studies showed that the prospective heart cells ingress through the primitive 
streak to form a bilateral heart field on the left and the right side of the axial midline 
(Garcia-Martinez and Schoenwolf, 1993; Rawles, 1943; Rosenquist, 1970). This cell 
population was termed the lateral plate mesoderm, also known as the bilateral 
cardiogenic mesoderm (Garcia-Martinez and Schoenwolf, 1993; Munsterberg and Yue, 
2008; Yang and others, 2002). The lateral plate mesoderm will eventually split into two 
layers, the splanchnic and the somatic mesoderm (Linask, 1992; Linask and others, 
1997). Myocardial progenitor cells originate exclusively from the splanchnic mesoderm 
and form the cardiogenic mesoderm in the bilateral heart fields (Linask and others, 
1997).  
Cells residing in the bilateral heart field eventually move medially to the ventral midline 
of the embryo, where they fuse to form the primitive heart tube (Moorman and others, 
2003; Stalsberg and DeHaan, 1969). The group of cells that contribute to the primary 
heart tube are called the primary heart field (Abu-Issa and others, 2004; De La Cruz and 
others, 1989). 
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6.1.2 Cells from the secondary heart field contribute to the outflow tract 
 
After the primary heart tube in chick has formed at HH stage 9 and the heart continues 
to grow, it was reported that further heart progenitor cells from the splanchnic 
mesoderm are recruited to the anterior pole of the primary heart  (de la Cruz and others, 
1977). This population of cells was named the secondary source of myocardium or 
secondary heart field and was shown to add to the outflow tract myocardium, as well as 
the right ventricle and both, the right and left atrium (Abu-Issa and others, 2004; Kelly, 
2012; Waldo and others, 2001) (for a scheme of the location of cells of the secondary 
heart field in the heart see figure 6.1). 
It was further reported that cells contributing to the outflow tract have also been derived 
from the pharyngeal mesenchyme or prepharyngeal mesoderm (Kelly and others, 2001; 
Mjaatvedt and others, 2001; Waldo and others, 2001).  
Further data revealed that cardiac neural crest cells also contributed to the outflow tract 
(Kirby and others, 1983). These cells migrate through the pharyngeal mesoderm before 
addition to the outflow tract (for a review see (Keyte and Hutson, 2012).  
 
  
 
Figure 6.1: The secondary heart field during heart development  
The scheme shows the localisation of cells from the secondary heart field in the mature chick heart as 
described by (Kelly, 2012) . The secondary heart field is labelled in green and cells of the primary heart 
field are labelled in red. At the cardiac crescent stage cells from the primary and secondary heart field 
reside in close proximity. At E8.0 cells from the secondary heart field reside close to the pharyngeal 
Arches (Pha) next to the primitive heart tube. In the mature heart (E10.5) cells of the secondary heart field 
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can be found in the outflow tract (OFT), the right ventricle (RV), as well as the left and right atrium (LA, 
RA).  Figure modified from (Laugwitz and others, 2008). 
 
 
Recently it was shown that both the primary and the secondary heart field are part of a 
single heart cell population, which migrate towards the midline in two distinct waves 
(Camp and others, 2012; Meilhac and others, 2003).  
 
After the formation of the primary heart and addition of cells from the secondary heart 
field to the tube, the heart undergoes further growth and development to eventually form 
a contracting four-chambered heart (Anderson and others, 2003; Wagner and Siddiqui, 
2007).  
 
6.1.3 Signalling pathways involved in early cardiogenesis 
 
Heart development is an important and highly complex process during vertebrate 
development. Many well known signal pathways have significant roles during early 
cardiac development. Ablation of the anterior endoderm has been shown to lead to 
incomplete specification of the myocardium in Xenopus (Nascone and Mercola, 1995). 
A role in inducing cardiogenesis has also been described for the endoderm in chick 
embryogenesis (Alsan and Schultheiss, 2002), revealing that a member of the fibroblast 
growth factor (FGF) family FGF8 secreted from the endoderm is important for inducing 
and maintaining the cardiogenic fate. Also secreted from the anterior endoderm is the 
bone morphogenetic protein (BMP)-2, which was shown to be able to induce heart 
formation (Andree and others, 1998). A similar role has been described for BMP-4, 
BMP-5 and BMP-7 (Schultheiss and others, 1997; Solloway and Robertson, 1999). 
Noggin was identified as an inhibitor to BMPs in cardiogenesis, thereby preventing 
myocardial differentiation (Schlange and others, 2000). BMP-2 and FGF-10 as well as 
Sonic Hedgehog (Shh) have not only been described to be involved in the activation of 
cardiogenic mesoderm, but have also significant roles in the induction of the secondary 
heart field (Kelly and others, 2001; Waldo and others, 2001). A further important signal 
pathway in cardiac development is the pathway of the wingless-int (Wnt) family, which 
has been said to be the earliest signalling affecting the cardiac induction (Dyer and 
Kirby, 2009). 
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Studies in the primary heart field of chick embryos suggested a role for Wnt-signalling 
during differentiation of the myocardium. Inhibition of Wnt3a or Wnt8c signalling in the 
anterior lateral mesoderm led to the formation of a heart, whilst overexpression of Wnt 
in the posterior lateral mesoderm promoted blood formation (Marvin and others, 2001). 
Further data proved a function of Wnt in heart induction, showing that inhibition of Wnt 
signalling in explants of paraxial mesoderm led to the development of beating cardiac 
mesoderm (Tzahor and Lassar, 2001). Inhibitions of Wnt in the ventral marginal zone in 
X. laevis have also been shown to induce heart formation in non-cardiac specific tissues 
(Schneider and Mercola, 2001). Further analysis showed that Wnt3a and Wnt8 are 
responsible for the promotion of cardiogenesis in X. laevis, revealing similarities 
between frog and chick heart development. When focusing on the role of β-catenin 
during cardiogenesis, Schneider and Mercola showed that a deletion of β-catenin via 
expression of GSK3 β, a part of the degradation complex of β-catenin, also was able to 
promote heart formation in the ventral mesoderm. Ablation of β-catenin in the 
endoderm of mouse embryos led to a phenotype displaying ectopic heart formation 
(Lickert and others, 2002). It was described that the cells lacking β-catenin developed 
into cardiac mesodermal cells instead of being endodermal. It was therefore suggested 
that β-Catenin dependent Wnt signalling must be inhibited in order for cardiogenesis to 
occur. Inhibition of Wnt signalling has been found to be caused by binding of the 
secreted Wnt-antagonist Crescent to several Wnt-proteins (Marvin and others, 2001). 
Crescent is predominantly expressed in the anterior mesendoderm and therefore able to 
inhibit Wnt in the mesodermal cells. A role for Dikkopf-1 (Dkk-1), being expressed in 
the posterior lateral mesoderm, has also been described in antagonizing Wnt signalling 
during heart formation. However inhibition of Wnt alone is not sufficient enough to 
induce cardiogenesis. BMP2 expressed in the anterior endoderm together with the 
inhibition of Wnt signalling has been shown induce heart formation (Andree and others, 
1998; Schultheiss and others, 1997) 
As described before the inhibition of β-Catenin mediated Wnt pathway is needed for the 
induction of cardiogenesis in the primary heart field. Recent data showed that cells of 
the secondary heart field, especially their differentiation and proliferation, seem to be 
affected by β-catenin dependent Wnt signalling as well. Conditional knock-out of β-
catenin in the secondary heart field of the cardiac crescent in mouse embryos led to a 
disruption of looping of the primary heart and the formation of a shortened outflow tract 
(Klaus and others, 2007). Atria and left ventricle seemed to have been developed 
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correctly, while the right ventricle somehow was reduced in size. Expression of Islet-1 
(Isl1), a marker for the secondary heart field,  in the β-Catenin knock-out mice has been 
analysed further to examine the role of β-catenin during differentiation of the cells. Isl1 
was significantly lower expressed in knock-out embryos in comparison to wildtype 
embryos, especially in the outflow tract and the splanchnic mesoderm. Overexpression 
of β-catenin also revealed disruptions in the primary heart tube leading to the formation 
of two separate clusters of cardiomyocytes (Klaus and others, 2007). It was suggested 
that the observed phenotype is due to a wrong or incomplete migration of both the 
primary and the secondary heart field. Nevertheless, Isl1 expression was enhanced upon 
β-catenin overexpression. Taking all described data together, β-catenin/Wnt signalling 
seem to be involved in the correctly induction of Isl1-positive cells and therefore in the 
induction of the secondary heart field.  
 
6.1.4 Expression of marker genes during cardiogenesis 
 
To be able to define and compare separate phases of heart development, expression of 
marker genes involved in cardiogenesis have been described. 
The first marker for cells with a cardiac fate is mesoderm posterior 1 (Mesp1) labelling 
early heart cells already in the primitive streak (Saga and others, 2000; Saga and others, 
1999). Mesp1 expression is switched off once cardiogenic cells populate the lateral plate 
mesoderm and subsequently NK2 transcription factor related, locus 5 (Nkx2.5) 
expression is switched on (Lints and others, 1993; Pandur and others, 2013; Schultheiss 
and others, 1995). Nkx2.5 expressing cells have now committed irreversibly to become 
heart cells (Pandur and others, 2013). Also Nkx2.5 labels cardiac progenitor cells both 
from the primary and secondary heart field (Chen and Schwartz, 1996; Lints and others, 
1993; Schultheiss and others, 1995), as well as endodermal and mesodermal cells (Lints 
and others, 1993; Lopez-Sanchez and others, 2009). However, after the primary heart 
tube has formed Nkx2.5 expression is restricted to the myocardium (Lints and others, 
1993; Schultheiss and others, 1995). 
 
Several heart markers have been described to label either the primary heart field or the 
secondary heart field. Two of those markers are Tbx5 and Isl1. Tbx5 (T-box 
transcription factor 5) is a marker for cells of the primary heart field and is first 
expressed in the cardiac crescent stage (mouse E 7.5 and chick HH 7) (Bruneau and 
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others, 1999; Chapman and others, 1996). Later Tbx5 expression is observed in the 
posterior heart tube, the left ventricle and atria (see figure 6.2), which are all structures 
derived from the primary heart field (Bruneau and others, 1999; Chapman and others, 
1996; Liberatore and others, 2000). LIM-homeodomain transcription factor  Islet 1 
(Isl1) however is a marker for the secondary heart field, which also can be seen to be 
expressed in the cardiac crescent or crescent shaped bilateral heart fields depending on 
developing organism (Watanabe and Buckingham, 2010). In chick Isl1 is expressed 
around HH stage 4 onwards in the rostrolateral mesoderm but expression is lost in cells 
which fuse to form the primary heart tube (Yuan and Schoenwolf, 2000).  At later 
stages of heart development Isl1 expression is restricted both in mouse and chick to the 
right ventricle, parts of both atria and more prominent the outflow tract (Pandur and 
others, 2013; Watanabe and Buckingham, 2010), which all derive from the secondary 
heart field (figure 6.1). 
 
As the heart loops rightwards after the formation of the primary heart tube (Brand, 
2003; Manasek and others, 1972), several genes have been described in establishing the 
left-right asymmetry of the heart. Paired-like homeodomain transcription factor 2 
(Pitx2) has been shown to be expressed exclusively in the left side of the bilateral heart 
field around the cardiac crescent stage (Campione and others, 2001). After the 
formation of the primary heart tube pitx2 expression was observed only in the left part 
of the heart tube and after looping pitx2 was shown to be expressed in the left atrium, 
the ventral part of the ventricles and the left side of the outflow tract (Campione and 
others, 2001). Further expression studies revealed that pitx2 is also a marker for 
mesodermal cell populations (Lopez-Sanchez and others, 2009). 
 
So far all previously mentioned heart marker genes label cells derived from the 
mesoderm, but there are also genes, which are specifically expressed in the endoderm. 
One of these markers is Hex. Hex expressing cells can firstly be observed around HH 
stage 7+ in the cardiac crescent (Lopez-Sanchez and others, 2009) and mark 
endodermal cells adjacent to the mesoderm in the bilateral heart field (Lopez-Sanchez 
and others, 2009). After fusion of the primary heart tube, Hex is still expressed in the 
underlying endoderm (Lopez-Sanchez and others, 2009). 
 
Ventricular myosin heavy chain (vMHC) is a marker for later phases of heart 
development. vMHC was shown to be expressed in the entire myocardium of the 
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primary heart tube (Bisaha and Bader, 1991; Somi and others, 2006). From around HH 
16 onwards the expression of vMHC becomes restricted to the ventricles as the 
expression levels for vMHC in the atria decrease (Somi and others, 2006) 
  
218 
 
 
6.2 Expression pattern for Klhl31 during early cardiogenesis 
 
6.2.1 Klhl31 is expressed in heart progenitor cells during cardiogenesis 
 
When Klhl31 was first described it was shown to be strongly expressed in embryonic 
muscle and heart tissue (Yu and others, 2008). In-situ hybridisation studies on chick 
embryos carried out in our laboratory revealed that Klhl31 is expressed in cardiogenic 
progenitor cells from HH stage 8 onwards (Abou-Elhamd and others, 2009), see figure 
6.2). It was also shown that Klhl31 is expressed in the primary heart tube (around HH 
10) and in heart tissue throughout embryonic development (Abou-Elhamd and others, 
2009), as seen in figure 6.2). 
 
 
Figure 6.2: The expression of Klhl31 during chick development  
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In situ hybridisation for Klhl31 in chick embryos revealed that Klhl31 is expressed predominantly in 
skeletal and cardiac muscle tissues.  
Legend: aip - anterior intestinal portal, ht - heart; EC - endocardium; MC - myocardium; EP - epicardium; 
R -  right auricle; RA - right atrium; La -  left auricle; LA - left atrium; RV - right ventricle; IV - 
interventricular septum; LV - left ventricle 
Figure modified from (Abou-Elhamd and others, 2009) 
 
6.2.2 Klhl31 expression during early heart development 
 
Based on our evidence that Klhl31 is expressed in heart muscle tissues, we wanted to 
examine Klhl31 expression during cardiogenesis in more detail. We therefore carried 
out in situ hybridisations for Klhl31 during different stages of heart development in 
chick embryos and compared the expression pattern of Klhl31 to expression pattern of 
heart markers, such as Isl1, Nkx2.5, Hex, vMHC and pitx2. 
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Figure 6.3: Expression of Klhl31 to the expression of heart markers at HH stage 10 of chick development  
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Figure 6.3: Expression of Klhl31 compared to the expression of heart 
markers at HH stage 10 of chick development  
Whole mount in situ hybridisation for Klhl31 mRNA compared to mRNA expression of heart markers 
during early heart development. Nkx2.5 and vMHC expression was observed throughout the whole 
myocardium (B’ and C’, respectively). Hex was expressed in the adjacent endoderm (D’), while pitx2 
expression in whole mount pictures was observed in the left omphalomesenteric vein close to the anterior 
intestinal portal (E). Cryosections also revealed the expression of pitx2 in the vitelline vein (E’). 
Expression for Isl1 was observed in mesenchymal structures to the left and to the right of the primary 
heart tube (F). Sectioning further specified Isl1 expression in the splanchnopleuric mesenchyme (F’). 
Klhl31 expression was observed in the heart (A) and the splanchnic mesoderm of chick embryos prior to 
fusion of the primary heart tube (A’) 
Legend: aip - anterior intestinal portal, ht - heart; en – endoderm; sm - splanchnic mesoderm; cm- 
cephalic mesenchyme; me – mesenchyme 
 
We first analysed the expression of Klhl31 during early cardiogenesis around HH stage 
10, when the primary heart tube is formed (Stalsberg and DeHaan, 1969). We observed 
the known expression pattern for Nkx2.5 (figure 6.3, B and B’) and vMHC (figure 6.3, C 
and C’) in the myocardium of the primary heart tube in chick embryos (Schultheiss and 
others, 1995; Somi and others, 2006). Hex was expressed in the endoderm underlying 
the two heart primordia prior to fusion (figure 6.3, D’). Hex has previously been 
reported to be a marker for adjacent endoderm during heart development (Lopez-
Sanchez and others, 2009). Therefore our findings for Hex are in agreement with 
published data. Pitx2 has been reported to be expressed in the left side of the primary 
heart tube (Campione and others, 2001). However, we were not able to reproduce the 
published expression pattern. Using  in situ labelling for pitx2 we detected restricted 
pitx2 expression to the left part of the omphalomesenteric vein (figure 6.3, E), which is 
connected to the primary heart tube and originates from the same cell population as the 
primary heart tube (Moreno-Rodriguez and others, 2006; van den Berg and Moorman, 
2011). When sectioning the embryo along the anterior intestinal portal, we could also 
observe pitx2 expression in the left side of the vitelline vein (figure 6.3, E’). The reason 
for this discrepancy is currently unresolved. 
Isl1 expression was observed as previously reported (Pandur and others, 2013). In our in 
situ hybridisation study Isl1 expression was restricted to the splanchnic mesoderm 
adjacent to the primary heart tube (figure 6.3, F and F’). In comparison to observed 
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heart marker expression, Klhl31 was expressed in the primary heart tube and in the 
splanchnic mesoderm prior to the fusion of the primary heart tube (figure 6.3, A and A’ 
respectively), similar to the expression of Nkx2.5. 
 
6.2.3 Klhl31 expression during later heart development (HH 17-18) 
 
After the primary heart tube is formed cells from the secondary heart field are added to 
the primary heart tube and the heart undergoes morphological changes (Buckingham 
and others, 2005; Christoffels and others, 2000). We therefore analysed Klhl31 
expression during later cardiogenesis. 
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Figure 6.4: Expression of Klhl31 to the expression of heart markers at HH stage 17 -18 of chick development 
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Figure 6.4: Expression of Klhl31 compared to the expression of heart 
markers at HH stage 17-18 of chick development 
Whole mount in situ hybridisation for Klhl31 mRNA compared to mRNA expression of heart markers 
during later heart development. Nkx2.5 was still expressed in the whole myocardium (B and B’) whilst 
vMHC expression was only observed in the ventricle of the heart (C’). Hex expression was observed in 
liver progenitor cells (D▲) as well as in cells that will contribute to the thyroid (D▼). In cryosections of 
chick embryos Hex expression was shown to be close to cells that belong to the dorsal mesocardium 
underlying the foregut (D’). Pitx2 expression was observed in tissue surrounding the foregut (E’), but not 
in the heart (E). Isl1 expression was also not observed in the heart (F, F’), but was expressed in tissues 
belonging to the aortic arches and the pharyngeal arches (F▼). Klhl31 expression was detected in the 
myotome of the somites (A) and in the myocardium (A and A’) 
 Legend: nt – neural tube, myo – myotome, fg – forgut, da – dorsal aorta, a – atrium, v – ventricle, dm – 
dorsal mesocardium, ht - heart 
 
At HH stage 17-18 chick embryos have turned to the left and have early limb buds, as 
well as showing a fully formed optic cup (Hamburger and Hamilton, 1992). The heart 
has looped rightwards and a distinct atrium and ventricle can be observed (Martinsen, 
2005). Klhl31 expression was still very similar to Nkx2.5 expression as described by 
Schultheiss et al. (1995). Transcripts for both genes were detected in the myocardium 
(see figure 6.4; A and A’ for Klhl31 and figure 6.4; B and B’ for Nkx2.5). Klhl31 
expression could also be observed in the myotome (figure 6.4; A’) as previously 
reported (Abou-Elhamd and others, 2009). Furthermore, Klhl31 expression seems to be 
confined to the developing atrioventricular canal. vMHC expression is now restricted to 
the ventricle (figure 6.4; C’) in conclusion with other published expression patterns for 
vMHC, which described a decrease of vMHC levels in the atrium and stable expression 
levels in the ventricle (Bisaha and Bader, 1991; Somi and others, 2006). As mentioned 
before, during early heart development Hex is a marker for underlying endoderm 
(Lopez-Sanchez and others, 2009). However in later stages of chick and mouse 
development (from mouse E9.5 onwards and in chick from HH stage 12 onwards) Hex 
is a marker for the hepatic progenitor cell population and the thyroid primordium 
(Crompton and others, 1992; Keng and others, 1998; Thomas and others, 1998; Yanai 
and others, 2005). Hex is expressed throughout the development of the liver and the 
thyroid and is also shown to be expressed in the foetal lung (Keng and others, 1998; 
Yanai and others, 2005). We could observe Hex expression in the thyroid primordium 
(figure 6.4; D▼) and the hepatic anlage (figure 6.4; D▲), but when we looked at 
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cryosections (figure 6.4; D’) we did see expression of Hex in cells underlying the 
foregut close to the dorsal mesocardium. Hex expression has been published by many 
groups and although all of them describe expression for Hex in the thyroid and the liver, 
some report additional expression patterns for Hex. Thomas et al. (1998) reported 
expression of Hex in the ventral foregut endoderm, the allantois and in the posterior 
lateral mesoderm in chick embryos at HH stage 9-10 (Thomas and others, 1998). At HH 
stage 15-16 Hex expression was observed in the thyroid and liver primordia, as well as 
in the roof of the dorsal aorta and the ventral gut endoderm (Thomas and others, 1998). 
Our probe against Hex might therefore as well have labelled endodermal cells of the 
foregut. However, the probe we used has to be characterised further to be able to 
analyse the expression of Hex in more detail. In situ staining for different stages of 
chick development between HH 12-HH18 would give us more data to analyse Hex 
expression over a distinct period of development and would help us identify the cells 
which are expressing Hex. Pitx2 was observed to be expressed predominately on the left 
side of the embryo (figure 6.4; E). However, pitx2 expression was not seen in the heart 
as reported previously (Campione and others, 2001). Furthermore we observed 
expression of pitx2 in the foregut (figure 6.4; E’), which is unlike to any previous 
described pitx2 expression pattern. The reason for this is unclear at present and it will 
need to be confirmed whether our probe detects pitx2 mRNA. Comparing Isl1 
expression as observed in our in-situ hybridisation study to Isl1 expression as published 
on GEISHA (Id ISL1.UApcr and Id Islet2.UApcr, GEISHA Gallus Expression In Situ 
Hybridisation Analytics, University of Arizona, USA), we could observe expression of 
Isl1 in the cranial ganglion and the pharyngeal arches (figure 6.4; F) as described by 
GEISHA. Islet1 expression was not observed in the chick heart at HH stage 17-18.  
 
6.2.4 Klhl31 expression during later heart development (HH 20-21) 
 
Chick embryos at Hamburger Hamilton stage 20 are defined by the segmentation of 
nearly the whole embryo (somites can be seen along the dorsal side of the embryo 
except for the tip of the tail), enlarged limb buds and the presence of the allantois. 
Pigmentation in the eye is starting (Hamburger and Hamilton, 1992). The lung buds are 
formed, both atrium and ventricle grow in size and the conus arteriosus and sinus 
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venosus are formed (Martinsen, 2005). However, at this time during development the 
heart chambers have so far not been separated. 
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Figure 6.5: Expression of Klhl31 compared to the expression of heart markers at HH stage 20 -21 of chick development 
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Figure 6.5: Expression of Klhl31 compared to the expression of heart 
markers at HH stage 20-21 of chick development 
Whole mount in situ hybridisation for Klhl31 mRNA compared to mRNA expression of heart markers 
during later heart development. Nkx2.5 was shown to be expressed in the myocardium of the ventricle 
and the heart (B’ and B, respectively). vMHC expression could be observed in the ventricle of the heart 
(C’) and weak in the atrium (C) and conus arteriosus (C’). Hex expression was still observed in liver 
primordia (D▲, D’) and in the thyroid progenitor cells (D▼). Pitx2 expression was seen along the left 
side of the embryo (E). The cryosection of a pitx2 labelled chick embryo revealed pitx2 expression in the 
left side of the gut and the liver (E’), but not in the heart (E and E’). Isl1 expression was again not 
observed in the heart (F, F’), but was expressed in the pharyngeal arches (F). In the corresponding 
cryosection expression of Isl1 was observed in the spinal cord labelling motor neurons (F’▲). Klhl31 was 
expressed in the myotome of the somites (A) and in the heart (A), as well as in the myocardium of the 
ventricle and conus arteriosus (A’) 
Legend: nt – neural tube, nc – notochord, lub – lung buds, myo – myotome, da – dorsal aorta, v – 
ventricle, ca – conus arteriosus, sv – sinus venosus, g – gut, es – esophagus, t – trachea, a – atrium, l – 
liver, ta – truncus arteriosus, ht  - heart, lb – limb buds, t - telencephalon 
 
Expression of Nkx2.5 was observed in the heart (figure 6.5; B) and in the myocardium 
of the ventricle (figure 6.5; B’). As Nkx2.5 has been described to be a marker for the 
myocardium throughout heart development (Lints and others, 1993; Schultheiss and 
others, 1995), our observed expression pattern is comparable to published data. At HH 
stage 20-21 Klhl31 expression still resembles expression of Nkx2.5 and Klhl31 was also 
shown to be expressed in the myocardium of the ventricle (figure 6.5: A’). As 
previously described (Abou-Elhamd and others, 2009) Klhl31 is also expressed in the 
myotome of the somites (figure 6.5; A and A’). Strong vMHC expression was detected 
in the ventricle and weak vMHC expression was seen in the adjacent conus arteriosus 
(figure 6.5; C’) matching published expression patterns for vMHC (Bisaha and Bader, 
1991; Somi and others, 2006). The observed expression for Hex further highlighted the 
role for Hex as a marker for liver and thyroid development (Keng and others, 1998; 
Yanai and others, 2005). In situ hybridisation for Hex in HH stage 20 chick embryos 
revealed labelling for Hex mRNA in the liver and thyroid primordia (figure 6.5; D) A 
strong signal for Hex mRNA was also noted in the liver in cryosections of chick 
embryos analysed for Hex  expression (figure 6.5; D’). In situ hybridisation for pitx2 of 
HH stage 20 chick embryos was again not able to reproduce published gene expression 
pattern marking the left side of the heart (Campione and others, 2001). We were only 
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able to detect pitx2 mRNA in the left part of the gut and tissues surrounding the liver 
(figure 6.5; E’) leaving us questioning the reliability of the probe. Isl1 expression was 
again observed to be similar to published data (Id ISL1.UApcr and Id Islet2.UApcr, 
GEISHA, University of Arizona, USA). Islet 1 was shown to be expressed in the 
pharyngeal arches in whole mount chick embryos, as well as in the pancreas (figure 6.5; 
F▲), but not in the heart. Interestingly Isl1 has been described to be a marker for motor 
neurons in the spinal cord (Tsuchida and others, 1994; Wang and others, 2011). We 
were able to reproduce the described expression pattern for Isl1 in motor neurons 
(figure 6.5, F’▲). 
In summary, by comparing the expression of Klhl31 to the expression of other well 
described marker genes, we could show that Klhl31 is a potential marker for the 
myocardium during cardiogenesis.  
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7. Discussion 
 
7.1 A novel role for Klhl31 during myogenesis 
 
7.1.1 Klhl31 as a potential mediator of myogenesis 
 
We previously have reported a potential role for Klhl31 during myogenesis (Abou-
Elhamd and others, 2009).  
Here we provide some evidence supporting the hypothesis that Klhl31 has a role during 
de novo myofibrillogenesis. Further experiments are needed to substantiate this idea and 
I will discuss some of these below.  
 
7.1.2 Klhl31 expression is linked to Actin filament changes during C2C12 
differentiation 
 
Differentiation of C2C12 cells involves similar processes as occurring during the 
differentiation of the myotome in the somite. 
C2C12 differentiation is dependent on canonical Wnt-signalling, which has also been 
shown to activate myogenesis in somites (Tajbakhsh and others, 1998; Tanaka and 
others, 2011). Furthermore, both C2C12 differentiation and myotome differentiation is 
marked by MRFs expression. Undifferentiated C2C12 myoblasts already express Myf 5 
and MyoD (Braun and others, 1989; Yoshida and others, 1998) and myogenin 
expression is activated in C2C12 myocytes around 20 hours of differentiation (Andres 
and Walsh, 1996) followed by MRF4 expression (Janot and others, 2009). Once the 
cells have entered the differentiation process, cultured mouse myoblasts and muscle 
cells in the myotome start to express p21 and withdraw from the cell cycle (Andres and 
Walsh, 1996; Braun and Gautel, 2011; Manceau and others, 2008). Furthermore, the 
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cells then elongate, fuse and eventually form multinucleated myotubes. Also, both in the 
myotome and in C2C12 myocytes expression of sarcomeric proteins is activated and de-
novo myofibrillogenesis occurs (Andres and Walsh, 1996; Buckingham, 2001; 
Kontrogianni-Konstantopoulos and others, 2006; Pownall and others, 2002; Sanger and 
others, 2002; Sanger and others, 2010).  
Analysis of C2C12 differentiation on cellular levels revealed the temporal and spatial 
organisation of myofibrillogenesis from premyofibrils to mature myofibrils in more 
detail (Burattini and others, 2004; Kontrogianni-Konstantopoulos and others, 2006). 
Premature Z-discs and M-bands already assembled after only 24h in differentiation 
medium, whilst after 48h of differentiation an early organisation of mature myofibrils 
was observed (Burattini and others, 2004; Kontrogianni-Konstantopoulos and others, 
2006). After 72 h, C2C12 myocytes have begun to accumulate muscular myosin into 
their myofibrils and after 96 hours the myotubes contained mature myofibrils (Burattini 
and others, 2004; Kontrogianni-Konstantopoulos and others, 2006) (see figure 3.7).  
Using immuno-staining experiments in differentiating C2C12 myocytes, we were able 
to reproduce the actin filament staining during early differentiation as described by 
Burattini et al (2004). We therefore assumed that changes in Actin and other Actin-
associated proteins we observed were directly affected by de-novo myofibrillogenesis in 
C2C12 myocytes. However, our used C2C12 cell line was substantially older and less 
reliable then the cell line used in described publication by Burratini et al. (2004), which 
resulted in low differentiation potential. Unfortunately, we therefore were only able to 
culture our C2C12 myoblasts for a short amount of time, which restricted the 
experiments we aimed to do in terms of lengths of time course and expression studies. 
Also our C2C12 experiments cannot be completely be compared to Burratinis work, as 
their cell line already displayed mature myotubes after 96 hours in differentiation 
medium, whilst we never saw mature myotubes in our cultures in the same timeframe. 
We therefore need to assume that myofibrillogenesis occurred slower in our cell lines 
compared to published data for C2C12.  
We studied Klhl31 expression and localisation during differentiation of C2C12 mouse 
myoblasts. The first interesting observation was that Klhl31 mRNA levels as well as 
protein levels were low in myoblasts, but increased around day 2 – day 3 during C2C12 
differentiation (figure 3.4 and figure 3.5, respectively). Furthermore Klhl31 localisation 
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also changed during differentiation of mouse myoblasts from a punctate and cytosolic 
localisation to a fibrillar, but still punctate pattern (figure 3.6).  
Further experiments revealed that the observed puncta of Klhl31 in C2C12 myotubes 
was closely localised with Actin fibres (figure 3.8, c and f, figure 3.9), but not with 
microtubules (figure 3.10). 
Co-localisation of Klhl31 with Actin fibres was established around day 2 of C2C12 
differentiation (figure 3.8; b, e and e’) correlating with the observed increase in 
transcript and protein levels for Klhl31 and potentially linking enhanced Klhl31 
expression with early myofibrillogenesis (Kontrogianni-Konstantopoulos and others, 
2006; Sanger and others, 2002; Sanger and others, 2010).  
Various members of the Kelch-like family have already been described to directly 
interact with Actin; Kelch, Klhl20 (KLEIP) and Klhl17 (Actinfilin) amongst others 
(Hara and others, 2004; Robinson and Cooley, 1997; Salinas and others, 2006; Stogios 
and Prive, 2004; Xue and Cooley, 1993). We therefore analysed if Klhl31 was also able 
to bind directly to Actin. 
We used Latrunculin B to further test a potential direct interaction between Klhl31 and 
the Actin filament (as explained in section 3.3.3).  Klhl31 localisation was affected by 
Latrunculin B treatment, as we observed diffused Klhl31 accumulations in the cytosol 
of treated C2C12 cells (see figure 3.12; b and b’). Furthermore, Klhl31 localisation to 
Actin fibres could also not been recovered (see figure 3.12; c’-e’). We therefore 
suggested that Klhl31 might associate directly to Actin fibres.  
A potential direct interaction between Klhl31 and Actin fibres was found by using a 
GST-pull down approach. Actin was isolated from C2C12 lysates by using a GST-
Klhl31 fusion protein and visualised both on a silver stained PAA Gel (figure 5.17, a) 
and on a western blot (figure 5.17, b). The actin bands in the GST-Klhl31 lanes are 
stronger than in the GST control lanes indicating that the observed interaction might be 
true. This would be consistent with the localisation studies for Klhl31 and Actin, thus 
strengthening the idea that the interaction between Klhl31 and the Actin filament was 
established during early myofibrillogenesis in C2C12 myocytes.  However, it might also 
be that Actin is bound to a protein, which forms a complex with Klhl31 and therefore 
the observed interaction is an indirect one. A crucial experiment, which needs to be 
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done in order to prove that Klhl31 is involved in myofibrillogenesis is the verification 
of published expression patterns and expression timeframes relating to 
myofibrillogenesis. This should include the analysis and comparison of the sarcomeric 
Z-line protein α-actinin and other key sarcomeric proteins with the expression pattern 
for Klhl31. To further analyse a potential function for Klhl31 during myofibrillogenesis, 
we decided to use fluorescence-labelled Klhl31 fusion proteins.  
7.1.3 The BTB domain and the Kelch-repeats of Klhl31 have specific cellular functions 
 
Proteins of the Kelch-like family contain two highly conserved binding sites, the BTB 
domain and the Kelch-repeats (as described in chapter 1.12; (Stogios and others, 2005; 
Stogios and Prive, 2004).  We carried out molecular and biochemical experiments to 
further analyse the function of both domains for Klhl31. We found that both Klhl31 FL, 
as well as Klhl31 ΔKR can significantly inhibit β-catenin induced luciferase reporter 
activity, while Klhl31 lacking the BTB domain did not show inhibition in the luciferase 
assays (see figure 4.6). The data is consistent with data previously obtained in our lab 
(Abou-Elhamd), see figure 1.13).  It was suggested that substrates bound to the BTB-
domain in Klhl31 might be targeted for degradation, possibly as part of an E3 ubiquitin 
ligase complex, as has been described for many other substrates targeted by members of 
the Kelch-like family (Geyer and others, 2003; Xu and others, 2003). Furthermore it 
was also described that β-catenin itself is targeted for proteasomal degradation by an E3 
ubiquitin ligase, β-Transducin repeats-containing protein (β-Trcp) (Hart and others, 
1999; Marikawa and Elinson, 1998). We have gathered information that Klhl31 could 
be associated with E3 ubiquitin ligase complexes, as we extracted an E2 ubiquitin 
conjugating enzyme, NEDD8-conjugating enzyme Ubc12, in our GST-pull down 
experiment. However, we have to be cautious as we do not know how likely this 
interaction is, as NEDD8-conjugating enzyme Ubc12 was not under the top 10 hits of 
the mass spectrometry data of proteins identified from the excised band. It is unlikely 
though that Klhl31 could interact with β-Trcp as well, as  β-Trcp belongs to the Skp1-
Cullin-1-F-box-type E3 ubiquitin ligase, whilst Kelch-like proteins have been shown to 
mainly associate to Cullin3-RING ubiquitin ligases (Canning and others, 2013; Fuchs 
and others, 2004). However finding that Klhl31 could interact with an E2 ubiquitin 
conjugating enzyme might indicate a role for Klhl31 in protein turnover regulations not 
only during Wnt-signalling but also during myofibrillogenesis. 
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Further experiments need to be carried out to analyse a potential role for Klhl31 as part 
of an E3 ubiquitin ligase complex.  Determining whether Klhl31 can interact directly 
with associated ubiquitin-ligase complex proteins, such as Cullin3, could shed more 
light on potential functions of Klhl31. Nonetheless comparison of published literature 
together with the identification of an E2 ubiquitin-conjugating enzyme as potential 
interaction partner could suggest that Klhl31 could also play a part in ubiquitin-
mediated proteasomal degradation and could therefore target components of the 
canonical Wnt-pathway, as well as sarcomeric proteins for ubiquitinylation and 
subsequent degradation.  
To analyse potential Klhl31 functions, we created GFP and DsRed fusion proteins of 
Klhl31. We were able to reproduce previously described functionality for Klhl31 in 
inhibiting β-Catenin mediated Wnt-signalling (Abou-Elhamd), but only for fusion 
proteins for Klhl31 tagged at the carboxy terminus (see chapter 4.2.1).  We therefore 
assumed that we had generated functional Klhl31-fusion proteins. Furthermore it was 
again shown that the loss of the BTB domain led to limited functionality of the protein.  
N-terminal tagged Klhl31 fusion proteins did not inhibit β-Catenin induced luciferase 
signalling (see luciferase assay for pEGFP-C1 Klhl31, figure 4.3). We observed similar 
decrease in functionality when using an N-terminal tagged fusion protein for Klhl31 as 
compared to luciferase readings for Klhl31 ΔBTB-GFP/DsRed. We therefore wondered 
if a GFP-tag at the N-term of Klhl31 would disturb or block the structure of the Klhl31 
protein, especially the BTB-domain. Circular dichroism analysis for an N-terminal 
tagged Klhl31 fusion protein could reveal if and to what extent GFP-tag could interact 
with the BTB-domain and would also shed light on whether this interaction could 
inhibit functionality of the fusion protein, as our data suggests.  
Furthermore, we observed that the N-terminal tagged Klhl31 fusion proteins displayed a 
vesicular localisation in C2C12 cells (as described and discussed in sections 4.2.1 and 
4.2.2), indicating that these Fusion-proteins might be degraded by the cell. However, we 
need to carry out lysosome-labelling experiments together with overexpression of the 
Klhl31-fusion proteins to be able to verify co-localisation. Also staining for 
ubiquitinylation could be used to validate a potential Klhl31 degradation.  
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Based on our data from the luciferase assays we could conclude that structural 
disturbances of the BTB domain potentially lead to a non functional Klhl31 protein. 
As mentioned previously, Klhl31 fusion proteins tagged at the carboxy-terminus were 
active in our luciferase assays. However, we were not able to successfully overexpress 
most of the Klhl31 constructs in C2C12 myoblasts. Transfection efficiency for the used 
pEGFP-N1 or pDsRed-N1 constructs was never observed to be higher than 20% 
(consistent with a described optimal transfection efficiency of a maximum of around 
25% by(Dodds and others, 1998) and signals for the C-terminal GFP tagged Kelch-like 
proteins only displayed very weak fluorescence (figure 4.9) making it difficult to 
observe real fluorescence of the fusion proteins. Only Klhl31-FL-GFP displayed a 
cellular localisation in C2C12 myoblasts, although different to the localisation observed 
for endogenous Klhl31 (figure 4.9, b). Klhl31-FL-GFP was not seen in C2C12 
myotubes (figure 4.9, f). Klhl31 ΔKR-GFP was also only detected in C2C12 myoblasts 
revealing a diffused cytosolic localisation (figure 4.9, d) similar to the observed 
localisation for EGFP-Klhl31 ΔKR (figure 4.4; d). Similar cytosolic localisation of 
EGFP-Klhl31 ΔKR was also observed in myotubes (figure 4.4; h), but not for Klhl31 
ΔKR-GFP (figure 4.9; h). It was reported that members of the Kelch-like family bind 
cellular Actin fibres via its Kelch-repeats (Hara and others, 2004; Robinson and Cooley, 
1997; Salinas and others, 2006; Stogios and Prive, 2004). As Klhl31 seems to bind to 
Actin in C2C12 myotubes, a cytosolic localisation of EGFP-Klhl31 ΔKR can be 
explained by the loss of association to Actin fibres due to a lack of the C-terminal 
Kelch-propellers. However, endogenous Klhl31 in C2C12 myoblasts displayed a 
punctate localisation in the cytosol (figure 3.8), which could not be reproduced by 
overexpression of pEGFP-C1 Klhl31 ΔKR (figure 4.4; d) and pEGFP-N1 Klhl31 ΔKR 
(figure 4.9; d). It might be that localisation of Klhl31 is also mediated by the Kelch-
repeats in undifferentiated C2C12 cells, but might not involve the Actin fibres. Proteins 
containing Kelch-repeats have been shown to localise to membranes, the cytosol and 
sperm acrosomal vesicles without being directly associated to Actin (for a review see 
(Adams and others, 2000). It could be possible that Klhl31 is associated to other cellular 
components in C2C12 myoblasts compared to myotubes. Another possibility might be 
that the plasmid DNA used for transfection was contaminated, which either led to less 
expression and therefore non-observable fluorescence or overexpression of only the 
fluorophore. This could explain why overexpressed Klhl31ΔKR-GFP localisation and 
236 
 
signal strength seemed to be highly similar to localisation and fluorescence signal of 
GFP expressed from the parental vector (figure 4.9, a). 
As we were able to detect a similar localisation for Klhl31 FL GFP in myoblasts 
compared to endogenous Klhl31, we expected to also be able to visualise C-terminal 
DsRed-tagged Klhl31 (see figure 4.7). But unfortunately, we could not observe 
fluorescence signal for any of the constructs except for Klhl31 ΔBTB-DsRed, which 
again displayed a vesicular pattern, both in myoblasts and myotubes (figure 4.7, c and 
g). This could partially be explained by known problems of DsRed-constructs in terms 
of correct folding of generated fusion-proteins.  
A further possibility why we did not observe our overexpression constructs, either 
Klhl31-GFP or Klhl31-DsRed could be that the fusion proteins were degraded over the 
differentiation time-course of C2C12 starvation. During differentiation of C2C12 
myocytes apoptosis is occurring (Cerone and others, 2000; Wang and Walsh, 1996), 
keeping up the right balance between proliferating and differentiating cells (Burattini 
and others, 2004). Apoptosis is only affecting myoblasts, differentiated C2C12 do not 
undergo programmed cell death (Wang and Walsh, 1996). As we only transfected a low 
percentage of cells (~20%) followed by the induction of apoptosis in some myoblasts by 
promoting C2C12 differentiation, we potentially loose more protein expression over the 
5 days of differentiation time course. We therefore have to assume that by the end of 
our time-course of C2C12 differentiation fusion-protein levels are too low to be 
detectable in myotubes, which did negatively affect both, DsRed and GFP-tagged 
Klhl31 fusion proteins. 
7.1.4 Klhl31 is downregulated in mammalian cell cultures possibly by targeting itself 
for degradation 
 
We could show that overexpression of Klhl31 fusion proteins in C2C12 was possible, 
but the levels of transcribed fusion proteins seemed to be very low.  
Although we were not able to detect GFP-Fusion proteins on a western blot, we were 
able to see GFP on its own (figure 4.10) revealing that the transfection of C2C12 should 
have been successful. A further interesting clue regarding Klhl31 overexpression in 
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C2C12 was observed by Dr. Katarzyna Goljanek-Whysall in our laboratory. It was 
previously reported that expression of canonical Wnt-ligands in C2C12 keep C2C12 
cells in a proliferative state and that inhibition of β-catenin mediated Wnt-signalling is a 
prerequisite for the induction of C2C12 differentiation (Nakashima and others, 2005; 
Tanaka and others, 2011; Zhang and others, 2012). Previous work from our group had 
already indicated that Klhl31 can inhibit canonical Wnt-signalling (Abou-Elhamd and 
Garcia-Morales).  
When Dr. Katarzyna Goljanek-Whysall silenced Klhl31 expression in C2C12 myoblasts 
she observed that proliferation was increased and differentiation delayed. This 
observation was supporting the suggestion that Klhl31 is an inhibitor for β-catenin 
dependent Wnt-signalling. However, C2C12 cells were also observed to proliferate 
more when transfected with Klhl31. C2C12 myoblast expressing ectopic Klhl31 did not 
differentiate as efficiently compared to controls.  
Based on our findings, that Klhl31 levels in C2C12 myoblasts were very low, only 
increasing during the intermediate phase of differentiation and that overexpression of 
Klhl31 did surprisingly not induce myotube formation, we were wondering if Klhl31 
levels need to be low and therefore might be regulated by the cellular environment. 
Another possibility could be that Klhl31 mediates its own downregulation in C2C12 
myoblasts, as a negative feed-back, to prevent increased Klhl31 protein levels.  
If Klhl31 is in fact downregulated by targeted degradation, we might be able to prevent 
degradation by inhibiting the proteasome. First we decided to increase our transfection 
efficiency by choosing HEK293 cells, which do not endogenously express Klhl31. We 
overexpressed Klhl31 FL-GFP in HEK293 cells and treated transfected cells with MG 
132. We observed a 75 kDa protein band in HEK293 cells, both treated and untreated 
with MG132. However, this protein band was smaller than expected for a full-length 
Klhl31 FL-GFP protein.  As we could detect the C-terminal tagged GFP-fusion protein 
with a GFP-antibody, we assumed that a full length protein was produced in the cell. 
The smaller size may therefore indicate that the fusion protein was cleaved near the 
amino-terminus. Using MG132 did not seem to prevent this reduction in size and 
presumed cleavage. However, after MG132 treatment, we observed a weak stabilisation 
of some smaller fragments of the cleaved Klhl31 fusion protein, which ran below the 
main band (figure 4.11 and figure 4.12, lanes 7-9).  
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It has recently been shown that other members of the Kelch-like family have also been 
initially degraded by a so far unknown process which does not involve the proteasome 
(Zhang and others, 2005). KEAP-1 (Klhl19) degradation is due to the formation of 
homodimers, which triggers the ubiquitinylation of KEAP-1 and subsequently leads to 
the degradation of this Kelch-like protein (Zhang and others, 2005). Zhang et al. (2005) 
also claimed that the switch from substrate to substrate adaptor ubiquitinylation is 
important for the regulation and control of steady-state protein levels of both, substrates 
and adaptor proteins, in the cellular environment.  
Could Klhl31 also not only control protein levels of its substrates, but also its own 
protein levels based on potentially self-targeted or self-induced degradation? It has been 
suggested that in theory all members of the Kelch-like family should be able to form 
homodimers (Geyer and others, 2003).  
We used a GST-pull down approach to find interaction partners for Klhl31 specifically 
in C2C12 cells and we found that GST-Klhl31 was detected together with a protein 
band displaying the size of endogenous Klhl31 on a PAA gel (figure 5.17, a; ←). 
Furthermore, the potential interaction of Klhl31 with itself was further verified by 
detection of both endogenous Klhl31 and GST-Klhl31 with a Klhl31-antibody on a 
western blot (figure 5.17, b; ←). 
Being able to show that Klhl31 can eventually interact with itself, possibly as 
homodimers, further highlights a function for a self-regulation of protein levels of 
Klhl31.  
7.1.5 Identifying interaction partners for Klhl31 
 
To identify potential interactions for Klhl31 in skeletal muscle tissues, we 
commissioned a Yeast-2-Hybrid screen (see chapter 5.1.2). The Yeast-2-Hybrid screen 
in general has not been very successful and included sequences derived from non 
protein-coding RNA or intronic DNA sequences (chapter 5.1.3) suggesting 
contaminations with genomic DNA in the screened libraries.  
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All four proteins identified as potential interaction partners were classified as category 
D, which contains potentially false positives (figure 5.2). We had designed our bait 
construct for Klhl31 in consultation with Hybrigenics. Based on our GFP/DSRed fusion 
proteins, it seemed likely that a tag at the BTB domain would impair function (as 
discussed in chapter 7.1.3). We therefore decided to use a C-terminal LexA/GAL4-
Klhl31 fusion protein for Klhl31. C-terminal tagged fusion proteins were shown to be 
functional and seemed to localise similar to endogenous Klhl31 in C2C12 myoblasts. 
Thus we were confident that a C-terminal tagged bait protein could successfully be used 
in a Yeast-2-Hybrid screen. However, we have also seen that overexpressed Klhl31 in 
cell culture was potentially degraded, potentially initiated by the cellular environment 
and maybe even targeted by itself (chapter 7.1.4). To what extent this might have been 
an issue in Yeast cells we do not know.  
The screen identified three potential new interaction partners for Klhl31. NEDD9 
(described in chapter 5.2.2), FKBP15 (described in chapter 5.2.3) and two isoforms of 
Nebulin (chapter 5.3). NEDD9 and FKBP15 have been discussed previously (section 
5.2.2 and 5.2.3, respectively) and will not be analysed any further. The possible 
interaction with Nebulin will be discussed in the following chapter (7.2). 
We wondered why the Yeast-2-Hybrid screen did not identify a possible interaction of 
Klhl31 with Actin. We had previously shown that Klhl31 localises closely to Actin 
fibres and we were able to verify a direct interaction by a GST-pull down approach. We 
questioned if the GAL4/LexA domain fused to the carboxy terminus in Klhl31 for the 
Yeast-2-Hybrid Screen might have diminished the binding capacity of the Kelch-
repeats. Also we wondered if a potential structural blockage or rearrangement of the C-
terminus might also have had an impact on the N-terminus of the Klhl31 fusion protein 
again speculating that the Yeast-2-Hybrid screen might have missed some interactions 
for Klhl31. 
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7.2 Nebulin and Klhl31 might both be involved in mediating 
myofibrillogenesis  
 
7.2.1 Nebulin and Klhl31 co-localise in adult muscle tissues 
 
As the Y-2-H had identified two isoforms of the giant sarcomeric protein Nebulin and 
as it was reported that Nebulin has function both in embryonic and adult muscle tissues, 
we decided to further investigate Nebulin as a potential new interacting partner for 
Klhl31. First we compared both fragments of the Nebulin isoforms with each other. We 
found that both isoforms contained the same amino acid sequence, which potentially 
could be a conserved binding site for Klhl31 (see alignment of both fragments in 
chapter 5.3.1). 
Using an immuno-histochemistry approach we showed that both Klhl31 and Nebulin 
are expressed in adult mouse striated muscles (see figure 5.7). Both Klhl31 and Nebulin 
could be observed to label punctate structures in myofibres, potentially single 
myofibrils. Using double immuno-staining for Klhl31 and Nebulin on tibialis anterior 
sections revealed a close association of Nebulin and Klhl31, as both proteins were 
detected in the majority of myofibrils (yellow staining, see figure 5.8; b).  Observing 
this close localisation suggested that Klhl31 and Nebulin might be able to interact 
directly with each other, as predicted by the Yeast-2-Hybrid screen. However, we have 
also observed myofibrils that were either Nebulin positive (green), but not Klhl31 
positive, as well as myofibrils, which were only labelled for Klhl31 (red), but not for 
Nebulin. Various isoforms for Nebulin have been reported to be expressed in different 
muscle tissues and during different developmental stages (Donner and others, 2004; Joo 
and others, 2004; Kazmierski and others, 2003). It was predicted that over 20 different 
Nebulin transcripts could be generated by alternative splicing in the human tibialis 
anterior muscle alone (Donner and others, 2004) and therefore we have to assume that 
the tibialis anterior muscle in mice also expresses various Nebulin isoforms. Having 
observed Nebulin-positive myofibrils, which were negative for Klhl31, we could 
assume that Klhl31 does not interact with all of the potential present Nebulin isoforms. 
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This observation would be in line with the data analysis for a potential binding domain 
for Klhl31 within the super-repeat domain of Nebulin, which is different for each 
isoform due to alternative splicing sites within the Nebulin gene. We know that the 
antibody, which we used to detect Nebulin was raised against an epitope found in the 
conserved C-terminal region of Nebulin, which is localised close to the Z-disc in the 
sarcomere and which is not affected by alternative splicing (Furst and others, 1988). 
The Nebulin antibody should therefore label all present Nebulin isoforms within the 
mouse muscle. Having observed Klhl31 expressing myofibrils, which were not labelled 
for Nebulin leads to the question whether Klhl31 is closely associated to Nebulin and 
whether Klhl31 could also associate to other sarcomeric proteins, which are not located 
in the Nebulin-containing area of the sarcomere. We therefore have to consider that 
Nebulin and Klhl31 might not associate with each other along the whole myofibrillar 
structure. We know that Nebulin is associated to thin filaments, but not the thick 
filaments (Millevoi and others, 1998; Wang and Wright, 1988). It could be that Klhl31 
also aligns to specific parts of the myofibrils. We propose that Klhl31 is associated to 
Actin (see figure 5.16) and an interaction with Nebulin was predicted in the Yeast-2-
Hybrid screen (chapter 5.3.1), leading to the suggestion that Klhl31 is localised to the 
thin filaments, maybe also associated to Nebulin. However, we need to undertake more 
experiments to identify localisation and function for Klhl31 in mature muscles, 
potentially by using longitudinal sections. Immuno-staining for Nebulin, Actin and 
Klhl31 could further clarify if Klhl31 is only found along the thin filament, whilst 
comparing the localisation of further sarcomeric proteins (such as α-actinin or proteins 
of the M-band) with the localisation of Klhl31 could also shed more light on a potential 
function for Klhl31 in adult muscle. 
Unfortunately we were not able to verify Nebulin-Klhl31 interaction by using a GST-
Klhl31 fusion protein in pull-down assays in C2C12 lysates during C2C12 
differentiation. 
This could be explained in that observed Nebulin levels were very low in the C2C12 
lysates. Also we still have to remember that we could not detect full length Nebulin by 
Western blotting, as we have chosen to use a too low concentrated PAA gel. We 
therefore cannot confirm nor deny a potential interaction of Klhl31 with Nebulin. 
Another possibility is that Klhl31 could target Nebulin for degradation as part of a 
potential E3-Ubiquitin-ligase complex. When we analysed Nebulin protein expression 
by western blotting, the antibody against Nebulin detected a protein band of 130 kDa 
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(see section 5.3.7). This is far too small to be a full length Nebulin protein, as Nebulin 
has been described to be between 600-900 kDa large (Labeit and Kolmerer, 1995a; 
McElhinny and others, 2003).  At this moment we cannot confirm, whether Klhl31 
could potentially assist in the ubiquitinylation of Nebulin. We firstly need to identify 
full-length Nebulin protein on an appropriate SDS-PAGE, followed by characterisation 
of the observed 130 kDa protein band, before we can investigate this suggestion any 
further. Ubiquitination assays could further help highlighting if Nebulin is degraded 
during myofibrillogenesis. At this moment, we probably have to assume that the 
detected protein band might only be an unspecific protein, which cross-reacted with our 
used Nebulin antibody. We could use other anti-Nebulin antibodies to further clarify the 
identity of the detected protein band. 
 
7.2.2 Nebulin and Klhl31 might function in myofibrillogenesis in C2C12 mouse 
myoblasts 
 
Nebulin has also been described to play an important role during myofibrillogenesis (as 
explained in chapter 5.3.2).  
As described previously, Nebulin during C2C12 differentiation was only expressed for 
approximately 24 h between day 1.5 and day 2.5 (see figure 5.10 and figure 5.12).  
Comparing the expression of Nebulin to the expression of Klhl31 during C2C12 
differentiation, it was seen that Nebulin expression seemed to be expressed before or at 
the same time that Klhl31 protein levels increased (as described in chapter 3.1.3) at the 
time point during differentiation that was marked by the formation of primitive Z-discs 
and was described as the onset of C2C12 myofibrillogenesis (Burattini and others, 
2004; Kontrogianni-Konstantopoulos and others, 2006). 
However, previous data reported a constant expression of Nebulin during 
myofibrillogenesis and in adult muscle tissues (McElhinny and others, 2005; Moncman 
and Wang, 1996; Nwe and others, 1999). Therefore we were wondering, why we were 
not able to detect Nebulin throughout differentiation of mouse myocytes. It could be 
that the antibody we used to label Nebulin with does not detect all Nebulin isoforms. 
Therefore we maybe had only detected one specific isoform of Nebulin, which only 
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functions during early myogenesis. But as mentioned before, the Nebulin antibody used 
is very well characterised and should not selectively detect specific Nebulin-isoforms.  
Also it seemed like that the C2C12 cell culture used was unhealthy and maybe even a 
bit too old. Therefore we cannot exclude that the differentiation potential of the used 
C2C12 cells was diminished, especially towards later stages of differentiation, so that a 
lack of constant Nebulin expression is not due to a real absence of Nebulin, it might be 
rather be due to undefined cellular processes within the C2C12 myocytes originating 
from high stress levels or diminished health.  
This problem could also have affected the observations made in our Latrunculin B 
experiments (as described in chapter 3.3.3) to some extend. In published literature, it 
has been reported that Actin filaments associated to Nebulin cannot be depolymerised 
under Latrunculin B treatment (Pappas and others, 2010). However differentiated 
C2C12, which were treated with Latrunculin B in our experiments, lost all their Actin 
filaments and eventually the cell structure collapsed (see figure 3.11) raising the 
possibility that the Actin filament was not stabilised by Nebulin or that again due to 
poor health our C2C12 cells were not able to recover from additional stress caused by 
treatment with the drug. 
Also, we could not test C2C12 myotubes, which have differentiated for more than 5 
days, for expression of Nebulin. This was due to technical problems with the C2C12 
cell culture. Mature myotubes in culture tend to detach and reform constantly leading to 
a huge number of cells being lost from the plates or coverslips (already after 5-6 days in 
differentiation medium), which might also have been increased in our cell culture due to 
mentioned age and health-related issues. Published data for Nebulin expression during 
C2C12 differentiation stated a constant expression of Nebulin from early 
myofibrillogenesis on and even in fully mature myotubes (Burattini and others, 2004; 
Sanger and others, 2010). In fully mature C2C12 myotubes (around day 10 of 
differentiation) Nebulin was even shown to display striations in myofibrils just as 
described for adult muscles (Cooper and others, 2004). We have tested whether our 
C2C12 myoblasts could differentiate into striated myofibrils. However, as this was not 
the case, we have to assume that our C2C12 cells were potentially not healthy enough to 
undergo a normal differentiation process compared to healthy myoblasts.   
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Further expression data, for both Nebulin mRNA and protein, needs to be obtained in 
healthy C2C12 myoblasts in order to be able to clearly indentify the time frame of 
Nebulin expression, as well as Klhl31 expression during C2C12 differentiation.  
Following the analysis of Nebulin expression in C2C12, we studied the localisation of 
Nebulin in elongating C2C12 cells. In conclusion with published literature, we also 
found that Nebulin aligns to Actin fibres during differentiation of muscle cells (figure 
5.11 and figure 5.13) (Moncman and Wang, 1996; Shimada and others, 1996). Although 
Nebulin seemed to form fibrillar structures, it could be seen that some of this fibrillar 
structures displayed a punctate pattern. Also punctate staining was observed in the 
cytosol and not attached to Actin fibres (figure 5.11, day 2). A similar pattern was 
observed by Nwe et al. (1999).  
As differentiation of C2C12 cells progressed, we could observe Nebulin staining in a 
punctate and accumulated pattern restricted to the edges of the elongating cells (see 
figure 5.13; g and p) with few puncta still observed along Actin fibres (see also figure 
5.14, a). Nwe et al. (1999) published that Actin during later myocyte differentiation 
localised to Z-discs, where it overlapped with high levels of Nebulin. As we were able 
to observe accumulation of Actin and Nebulin at the edges of the cell we were 
wondering if this localisation could be close to primitive Z-discs in C2C12. Co-staining 
for Nebulin with sarcomeric α-actinin would clarify if we have Nebulin localisation 
along the Z-discs in differentiating C2C12 cells. Based on our obtained data for Nebulin 
during C2C12 differentiation and published literature for Nebulin, we could assume that 
Nebulin is involved in C2C12 mouse myoblasts, potentially by assisting the association 
of Actin filaments to the primitive Z-discs.  
Unfortunately, once Nebulin staining has been refined to the edges of the cells 
expression decreases and was not detected anymore during the subsequent days of 
C2C12 differentiation. This observation has not been made in any other cell line or 
model organism (as described previously) leaving us again wondering whether the 
health or age of our C2C12 cell line was inhibiting our ability to investigate the late 
differentiation of mouse myoblasts. 
Having analysed Nebulin and Actin, as well as Klhl31 and Actin localisation during 
C2C12 differentiation, we then compared Klhl31and Nebulin localisation. 
245 
 
Klhl31 and Nebulin both aligned to Actin fibres in similar stages of C2C12 myotube 
formation (see figure 5.13; k-q), from day 1 until around day 2. We were also able to 
show a weak, partial co-localisation of Nebulin puncta to Klhl31 fibres (see figure 5.14; 
c) but only in elongated myocytes after day 1.5 of C2C12 differentiation.  However, we 
also detected a higher number of Nebulin puncta that did not align to Klhl31 structures 
(figure 5. 14; c), which is likely to be observed due to the instability of the red signal 
from the secondary antibody (as described in material and methods, section 2.2.26). 
Compared to previous Klhl31 staining (see figure 3.8), we only observed a few Klhl31 
fibres in differentiating mouse myoblasts indicating that we had potentially detected less 
Klhl31 than were actually present in the cell. Based on previous immuno-staining in 
C2C12 for Actin and Klhl31, as well as for Actin and Nebulin, we have to assume that 
Klhl31 and Nebulin would be in close proximity in elongating myoblasts. However 
again, we need to repeat the experiment in young, healthy mouse myoblasts and we also 
need to co-stain for other well defined sarcomeric proteins, like α-actinin to further 
clarify the regions within the premyofibril the proteins, especially Klhl31 and Nebulin, 
localise to. 
We also need to repeat some of the expression profiling experiments, so we can further 
clarify the temporal expression pattern, both on mRNA and protein level) of Klhl31 
compared to other well-described sarcomeric genes during C2C12 differentiation in 
order to be able to describe a potential function for Klhl31 during myofibrillogenesis.  
Our data obtained from the cell culture experiments can also not be used to explain why 
Klhl31 is still localised to Actin fibres during late myofibrillogenesis and in adult 
muscles, as well as that we also have no idea what the function of Klhl31 is both in 
developing and mature muscles. We have evidence from in-situ hybridisation in chick 
embryo (Abou-Elhamd and others, 2009), as well as from our data obtained in 
myoblasts that Klhl31 could play a key part during myofibrillogenesis in the myotome, 
which requires association with the Actin filament. But so far we have not gathered 
enough evidence to specify this role.   
We have identified CapZ and tropomyosin as potential interacting partners for Klhl31 in 
differentiating C2C12 myoblasts. Various publications had suggested a role for Nebulin 
in stabilisation of the thin filament in striated muscles (Kruger and others, 1991; Labeit 
and others, 1991; McElhinny and others, 2005; Moncman and Wang, 1996; Pappas and 
others, 2010). As we could observed an association between Nebulin and Klhl31 and as 
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we have identified CapZ, as well as tropomyosin (both, tropomyosin, by binding to 
tropomodulin, and CapZ are involved in capping of the Actin filament in striated 
muscles (Bailey, 1948; Caldwell and others, 1989; Kostyukova, 2008; Perry, 2001; 
Weber and others, 1994)) as being able to bind to Klhl31, as well as being able to bind 
to Nebulin (McElhinny and others, 2001; Pappas and others, 2008), we could 
hypothesise that Klhl31 might be involved in thin filament assembly and stabilisation 
(probably in association with Nebulin), maybe even in length specification. This might 
be a potential function for Klhl31, as we also have identified the Arp2/3 complex as a 
potential interaction partner for Klhl31 during C2C12 differentiation and potential 
myofibrillogenesis. Nebulin was recently shown to form a complex with N-WASP, 
which was able to induce Actin nucleation without the assistance of the Arp2/3 complex 
(Takano and others, 2010). We have identified FKBP15/WAFL, a member of the 
Wiskott–Aldrich Syndrome protein (WASP) family as a potential interaction partner for 
Klhl31 in the Yeast-2-Hybrid screen. Although a direct interaction between Klhl31 and 
FKBP15/WAFL needs to be verified, it could be interesting to test, whether a member 
of the WASP family is involved in Actin polymerization together with potentially 
Nebulin and Klhl31.  
Furthermore, we pulled down the myosin regulatory light chains Myl9 and Myl12b. 
Myl9 and Myl12 b are be part of Myosin II in non-muscle cell tissues, where they play 
a crucial role in cell adhesion, cell division and migration (Park and others, 2011). 
Furthermore, Myl9 has also been reported to be expressed in smooth muscle (Kumar 
and others, 1989). Myl9 and Myl12b have not been reported to be expressed in adult 
skeletal muscle. 
However, immuno-histochemistry studies and protein extraction studies revealed the 
presence of both Myl9  and Myl12b in C2C12 cells (http://www.scbt.com/datasheet-
19848-p-MYL9-thr-18-antibody.html, (Sharma and others, 2012), which could mean 
that both RLCs have actual functions in the sarcomeric structures of C2C12 cells. 
During myofibrillogenesis it was reported that non-muscular myosin II is initially 
assembled into premyofibrils and is later replaced by muscle-specific myosins (Sanger 
and others, 2002; Sanger and others, 2010). This also includes the associated non-
muscle myosin regulatory light chains (Du and others, 2003). It was reported that 
myosin II and its associated myosin regulatory light chain Myl12b are expressed during 
early myofibrillogenesis. Furthermore phosphorylation of non-muscle myosin 
regulatory light chains is essential for premyofibril assembly, as the inhibition of non-
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muscle myosin regulatory light chain led to the complete loss of premyofibrils in 
precardiac mesoderm explants (Du and others, 2003). Having observed that Klhl31 
might bind to components of non-muscle myosin II during early myofibrillogenesis 
might reveal a role for Klhl31 during myofibril assembly, not only for the thin filament, 
but also for the thick filament. However, we can only speculate here, as we do not have 
enough evidence to support our idea. Our immuno-staining for Klhl31 during C2C12 
differentiation contradicts the idea of a potential role for Klhl31 during thin and thick 
filament assembly, as we have only observed an interrupted staining for Klhl31, whilst 
we probably would expect a continuous staining inside the myocytes if Klhl31 would 
associate to both the actin and the myosin filament. Again, we need to carry out further 
experiments directed towards the question whether Klhl31 might be involved in 
myofibrillogenesis, assisting both the thin and the thick filament to assemble.  
The data from the mass spectrometry might also give clues towards a role for Klhl31 in 
mature sarcomeres. Based on having identified CapZ and tropomyosin as interaction 
partners for Klhl31 by GST-pull down and co-localisation of both proteins, Klhl31 and 
Nebulin in adult muscle, we could suggested that Klhl31 together with Nebulin might 
be involved in stabilising the Actin thin filament in mature muscles.  
Furthermore, tropomyosin as an interacting partner for Klhl31 could also link Klhl31 to 
muscle contraction, as troponin/tropomyosin complexes have been reported to mediate 
muscle contraction by translating elevated Ca 
2+
 signals into actomyosin interactions 
and subsequent movement (Catterall, 1995; Farah and Reinach, 1995; Gordon and 
others, 2000; Zhi and others, 2005). This idea could furthermore be emphasized by the 
identification of Calmodulin from the GST-pull down. However, we have no clear 
evidence or in fact any supporting material for this hypothesis and I therefore emphasize 
here again, that this is only a speculation of what Klhl31 might be involved in at this 
point in time.   
So far we have only analysed the low sized proteins from the silver stained PAA-Gel by 
mass spectrometry. Further bands have been excised and are still kept at – 80 °C. We 
could possibly find other interesting candidates in the other excised protein bands.   
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7.2.3 Nebulin, Actin and tropomyosin mutations in nemaline myopathy 
 
Nemaline myopathies are congenital, inheritable neuromuscular disorders characterized 
by the presence of rod-like structures in skeletal muscle fibres.  
Patients with nemaline myopathies show signs of hypotonia and biopsies of affected 
muscles reveal unusual rod-shaped structures or myogranules, also known as nemaline 
bodies (Conen and others, 1963; Sanoudou and Beggs, 2001; Shy and others, 1963).  
Most nemaline myopathies originate during development caused by mutations of 
various sarcomeric proteins (Wallgren-Pettersson and others, 2011).  
Mutation in ACTA1, encoding skeletal muscle α-Actin, Nebulin, TPM2, expressing β-
tropomyosin, TPM3, which encodes α-tropomyosin, TNNT1, expressing slow skeletal 
muscle troponin T as well as CFL2, encoding muscle specific cofilin have been shown 
to be responsible for nemaline myopathies (Agrawal and others, 2007; Donner and 
others, 2002; Johnston and others, 2000; Laing and others, 1995; Nowak and others, 
1999; Pelin and others, 1999). More recently a gene of the Kelch/BTB family has been 
described to also be mutated in patients displaying nemaline myopathy, KBTBD13 
(Sambuughin and others, 2010). 
In comparison to the other genes affected in nemaline myopathies, Actin and Nebulin 
mutations seem to be the most common mutations (Wallgren-Pettersson and others, 
2011). How mutations in sarcomeric proteins lead to a myopathy, remains unclear. 
Based on present knowledge, two hypotheses have been formulated. The first one being 
that mutations in sarcomeric proteins interfere directly with muscle contractile apparatus 
or that, claimed in hypothesis two, the presence of nemaline bodies would decrease the 
number of functional sarcomeres (Ravenscroft and others, 2011a; Ravenscroft and 
others, 2011b) 
Components and structure of nemaline bodies have been analyzed in biopsies and by 
using transgenic mice. It was shown that nemaline bodies are extensions of Z-discs and 
mainly consist of α-actinin, myotilin and sarcomeric α-Actin (Jockusch and others, 
1980; Schroder and others, 2003; Wallgren-Pettersson and others, 1995; Witt and 
others, 2006; Yamaguchi and others, 1982). Accumulations of filamentous proteins and 
desmin have also been described (Ravenscroft and others, 2011b).  
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In the context of this project, we were wondering if mutations in Klhl31 could also 
cause nemaline myopathy or otherwise if mutations in Actin, Nebulin and other 
sarcomeric proteins could alter Klhl31 expression during nemaline myopathy. Our 
obtained data indicated a potential role for Klhl31 during myofibril assembly as it has 
been predicted to bind to Nebulin and has been shown to interact with Actin and 
tropomyosin. However, a mutation in Klhl31 in nemaline myopathy has not been 
reported so far. Interestingly though, a mutation in a different member of the Kelch-
BTB protein family, KBTBD13, causing nemaline myopathy has been published 
recently (Sambuughin and others, 2010). KBTBD13 similar to Klhl31 is mainly 
expressed in skeletal and cardiac muscle. Furthermore it was shown that mutations in 
KBTBD13 that promote nemaline myopathy were found in the kelch-propeller domain 
potentially changing the structure of the carboxy-terminus of KBTBD13. We were 
wondering if KBTBD13 might have similar function like Klhl31. However, a function 
for KBTBD13 has not been described so far. Recently it was reported that KBTBD13 
might function as a E3 ubiquitin ligase (Sambuughin and others, 2012). Based on 
known data, we were wondering if Klhl31 and KBTBD13 could be structurally related. 
However, when aligned KBTBD13 and Klhl31 do not share a high homology on DNA 
and protein level (see Appendix A.6).  
We therefore cannot compare Klhl31 with KBTBD13. However, based on predicted and 
observed interactions of Klhl31 with Actin, tropomyosin and Nebulin, it would be 
interesting to see if mutations of Klhl31 could also play a role in nemaline myopathies. 
Analysing Klhl31 expression and localisation in fibres affected by nemaline myopathy 
could potentially also give further insight into the role of Klhl31 in sarcomeres and 
maybe further clarify a role of Klhl31 during myofibrillogenesis. 
 
7.3 Klhl31 expression and potential function during cardiogenesis  
 
7.3.1 Klhl31 is expressed in the myocardium during chick development 
 
We compared expression of Klhl31 to the expression patterns for published heart 
marker genes during early heart development of chick embryos.  
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We observed that Klhl31 was expressed in the same tissues as the myocardium-marker 
Nkx2.5 throughout all analysed stages of chick development. However, in contrast to 
Nkx2.5, Klhl31 was not expressed in cardiac progenitor cells prior to fusion of the 
primary heart tube. Fusion of the primary heart tube in chick correlates with the 
differentiation of myocytes (Colas and others, 2000; Yuan and Schoenwolf, 2000). It is 
therefore possible that Klhl31 might have similar function as proposed for C2C12 
skeletal myocytes.  
Sarcomeres in cardiac muscle display similar organisation to skeletal muscle myofibrils 
(thick and thin filaments, Z-discs, M-bands) and are comprised of some of the same 
structural proteins (e.g. Actin, myosin, tropomyosin, and troponin). Furthermore 
processes regulating cardiac myofibril assembly and stability seem to be similar (Rudy 
and others, 2001; Sanger and others, 2010), also explained in chapter 1.3).  
However, cardiomyocytes express Nebulette, a relatively small homologue of the 
Nebulin gene family (Moncman and Wang, 1995). Just as Nebulin, Nebulette also 
contains the central repeat domain through which Nebulette can associate with Actin 
monomers (Jin and Wang, 1991a; Jin and Wang, 1991b; Millevoi and others, 1998; 
Moncman and Wang, 1995; Moncman and Wang, 1999). Also similar to Nebulin, 
Nebulette contains a C-terminal SH3 domain and has been shown to interact via the C-
terminus with α-actinin, titin, myopalladin and desmin (Bang and others, 2001; Esham 
and others, 2007; Grunewald and Butt, 2008; Wang and others, 2002). Recently the 
interaction of the central repeat domain of Nebulette with the tropomyosin/troponin 
complex has also been revealed (Bonzo and others, 2008; Ogut and others, 2003). 
Based on the similarity of Nebulin and Nebulette, it was suggested that Nebulette 
carries out the role that Nebulin mediates in skeletal muscle (Bonzo and others, 2008; 
Moncman and Wang, 1995).  
Evidence that Nebulette might be involved in myofibrillogenesis in heart muscle was 
reported by Moncman and Wang (1995, 1999). It was shown that Nebulette binds to 
sarcomeric α-actinin already in premature myofibrils and stays associated to the Z-disc 
in mature myofibrils, leading to the suggestion that Nebulette might be involved in 
myofibrillogenesis by connecting the Actin filament to the Z-disc (Moncman and 
Wang, 1995; Moncman and Wang, 1999).  
It was furthermore described that Nebulette might also stabilise the thin filament in a 
similar way as described for Nebulin (Moncman and Wang, 2002; Pappas and others, 
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2010). Although Nebulette in comparison to Nebulin seems to be too small to be able to 
span the whole Actin filament and Nebulette only associates to Actin-fibres in the Z-
disc, silencing studies in cardiomyocytes have been reported to generate a reduced size 
of the thin filament revealing that Nebulette can stabilise thin filaments longer then 
Nebulette itself (Moncman and Wang, 2002). Further data seemed to confirm an 
essential role for Nebulette in thin filament length specification, as a knock-down of 
Nebulette in cardiomyocytes lead to a thin filament phenotype similar to that of reduced 
thin filament seen in Nebulin depleted skeletal muscle (Bang and others, 2006; Bonzo 
and others, 2008; Witt and others, 2006).  
Nebulette does also interact with the thin filament capping protein tropomyosin (Bonzo 
and others, 2008), which might further indicate a role for Nebulette in thin filament 
length specification. 
Furthermore, Nebulette also seems to be involved in muscle contraction, as Nebulette 
deficient cardiomyocytes display weaker heart beats compared to wt cardiomyocytes 
(Moncman and Wang, 2002).  
Based on published data, we can assume that Nebulette functions as Nebulin 
counterpart in cardiomyocytes. However, Nebulin is also expressed in the heart, but its 
expression levels are lower compared to levels in skeletal muscle (Bang and others, 
2006; Kazmierski and others, 2003).  
It was therefore suggested that Nebulin and Nebulette have overlapping functions in 
cardiomyocytes (Pappas and others, 2011). 
Based on our observation of Klhl31 expression in the myocardium exclusively during 
myogenic differentiation and based on data that Klhl31 might interact with Nebulin and 
that Klhl31 does interact with Actin, Actin-capping proteins and components of myosin 
II, we assume that Klhl31 might also be involved in myofibril assembly and thin 
filament stabilisation during heart development. But we do not know yet, if Klhl31 can 
also interact with Nebulette. Based on sequence analysis of Nebulette, we did not find 
the potential binding site for Klhl31, but we were not able to further investigate the 
structural organisation of this domain. It was reported that both Nebulin and Nebulette 
display structural similarities in their super-repeat domains (Bjorklund and others, 
2010). It might be that the Klhl31 binding site contains a specific structural motif, 
which would allow Klhl31 to associate with it, both in Nebulin and Nebulette. As the 
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Klhl31 binding site lies within the boundary of two super-repeat domains, which has 
been reported to contain conserved binding sites for Actin and tropomyosin/troponin 
complexes (Labeit and Kolmerer, 1995a; Pfuhl and others, 1996), we wondered if the 
Klhl31 binding domain or structure could also be found in other domains, both in 
Nebulin and Nebulette proteins other than predicted super-repeat 20 and 21. Although 
we have no direct evidence at present, it might be interesting to see if Klhl31 could 
interact with Nebulette during heart development.  
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8. Conclusion 
 
Klhl31 has previously been described as a novel protein involved in myogenesis (Abou-
Elhamd and others, 2009).  
In this report we suggest a potential role for Klhl31 during myocyte differentiation and 
myofibrillogenesis.  
We studied Klhl31 expression in C2C12 mouse myoblast and found increasing 
expression levels for Klhl31 during the intermediate stage of differentiation, potentially 
correlating with myofibrillogenesis in mouse myoblasts. We also observed that Klhl31 
closely aligned to Actin fibres during C2C12 differentiation. This interaction was later 
verified by GST-pull down approaches. Nebulin, a giant sarcomeric protein, which 
binds and stabilises Actin polymers in striated muscles (Pappas and others, 2011), was 
identified as a potential binding partner for Klhl31 in a Yeast-2-Hybrid screen. 
Furthermore a close localisation for both Nebulin and Klhl31 was observed in 
differentiating C2C12 mouse myoblasts and mouse tibialis anterior muscles. Possible 
interactions of Klhl31 with Nebulin and Actin indicated a potential novel role for 
Klhl31 within the thin filament of striated muscles. More information about the 
potential novel function was obtained by the identification of further interaction partners 
for Klhl31. Thin filament capping protein CapZ and tropomyosin (Fowler, 1996) were 
pulled down by GST-Klhl31. Taking together our observed localisation pattern for 
Klhl31 during C2C12 differentiation, the identified possible binding partners for 
Klhl31, as well as published data for Nebulin, we hypothesised that Klhl31 might be 
involved in myofibrillogenesis, potentially by either regulating the thin filament length 
in collaboration with Nebulin or by assisting the assembly of the thin filament to the Z-
discs. Klhl31 might even be involved in the assembly of premyofibrils as it also seems 
to interact with non-muscle myosin II. 
Further interacting proteins identified in the GST-pull downs could shed a light of a role 
for Klhl31 in mature striated muscles. Calmodulin and tropomyosin were found to 
associate with Klhl31. Together with the observed interaction of Klhl31 with Actin, this 
data indicates that Klhl31 might be associated to the contractile apparatus in fully 
developed sarcomeres. 
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As Klhl31 was shown to be expressed both in the somite after the commitment towards 
a myogenic fate and in cardiac progenitor cells at the onset of differentiation, we could 
assume, that Klhl31 might have similar roles in cardiac and skeletal muscle.  
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Appendix 
 
A.1 Klhl31 Sequences (gallus gallus) 
 
This chapter contains information of DNA and protein sequences for Klhl31 with a 
legend highlighting the functional domains. Primer information is also available for 
cloned Klhl31 constructs. 
A1.1 Klhl31 (DNA) 
 
atggcacctaagaagaagaacgtgaagaagaacaaagcagcagatatcagtgaaatgactatcattgtggaagatggcccc
ctcagtaaactaaatggcttgaatggactcttagatggaggcaatggtttcagctgcgtctcatctgaagtttctgacccatcatat
agcccaaatctcttggaaggtctaagcagaatgagactagaaaattttctttgtgacttgactatcagtaccaaaaccaaatctttc
agtgttcataaggtggtgatggcttcaatcagtgactactttcacaacatcttaaagaaagatccatccactcaaagagtagacct
caatgatgtatccccattgggtctagctactgttatcacctatgcttacactggaaagctcactctctcactttatacaataggtagt
attatttccaccgcgatttatcttcagattcacacccttgtaaagatgtgctgtgattttctaacccaagaaatcagtgttgagaattg
tatgtatattgccaatattgcagaaacgtacggactaaaaacaaccaaggaagctgcacacaaatttattagagacaacttcatt
gaattttcagaaacagatcagttcttaaaactcacttttgatcagattaatgaacttcttgcagatgatgacttgcagttgccttctga
aattgttgcattccagattgcaataaaatggctggaatttgaccaaaaaagagtaaagtttgctgctgatctcttaggtaacattcgt
tttggtactatctcagctcaagacctcgtcaattatgtccaaactgttccgagaatgatgcaagatgcagattgccataaactcctg
gtagatgccatgaactatcatttgcttccctatcatcagaatacacttcagtctagaagaacaaggattcgtggaggattcagagt
gttagttactgttggcggacgccctgctttaacagaaaagtctcttagcagagacatcttgtacagagatcctgaaaatggatgg
aagaagcttagtgaaatgcccgctaaaagttttaaccagtgcgtgacggtgatggatgggtttctctacgtggccggtggggaa
gaccagaatgatgccaggaaccaagccaagcatgcagtcagcaacttctgcagatacgatcctcgtttcaacacctggattca
cctggcaaatatgaatcagaagcgcacccacttcagcctgaatgtattcaatggcctcctttttgcagtgggtggtcgcaacttg
gagggttgtctctcctcgatggagtgctacgtgcctgcaactaatcagtggcagatgaaggcacccctggaggtgcccaggtg
ctgccatgccagtgctgtggtggatggtaggatcctggtcacgggaggttacattaataatgcttactctcgttcagtgtgcatgt
atgaccccagcaatgatagctggcaagataagtccagtcttagcaccccacgagggtggcactgtgccgtgtccctgctgga
gagggtctatgtcatgggtgggtctcaactgggggggagaggggaaagggtcgacgttctccctgtggagtgttacagccctt
acacagggcagtggagttatgtggcaccccttcaaactggagttagcacagccggtgcttcgatgctggatgggaaaatttact
tagtggggggctggaatgagatagagaaaaaatataagaagtgcattcagtgctataacccagatctcaatgagtggacgga
ggaagacgagctgcctgaagccactgtgggagtatcctgttgtactatatccatgcccaacaccaagacaagggagtccaga
gcaagctcagtctcttctgtaccagtcagtatttaa  
 
Legend: 
Start/Stop-Codon 
BTB-Domain 
Kelch-repeats 
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A1.2 Klhl31 (protein) 
 
MAPKKKNVKKNKAADISEMTIIVEDGPLSKLNGLNGLLDGGNGFSCVSSEVSD
PSYSPNLLEGLSRMRLENFLCDLTISTKTKSFSVHKVVMASISDYFHNILKKD
PSTQRVDLNDVSPLGLATVITYAYTGKLTLSLYTIGSIISTAIYLQIHTLVKM
CCDFLTQEISVENCMYIANIAETYGLKTTKEAAHKFIRDNFIEFSETDQFLKLT
FDQINELLADDDLQLPSEIVAFQIAIKWLEFDQKRVKFAADLLGNIRFGTISAQD
LVNYVQTVPRMMQDADCHKLLVDAMNYHLLPYHQNTLQSRRTRIRGGFRVL
VTVGGRPALTEKSLSRDILYRDPENGWKKLSEMPAKSFNQCVTVMDGFLY
VAGGEDQNDARNQAKHAVSNFCRYDPRFNTWIHLANMNQKRTHFSLNVF
NGLLFAVGGRNLEGCLSSMECYVPATNQWQMKAPLEVPRCCHASAVVDG
RILVTGGYINNAYSRSVCMYDPSNDSWQDKSSLSTPRGWHCAVSLLERVYV
MGGSQLGGRGERVDVLPVECYSPYTGQWSYVAPLQTGVSTAGASMLDGK
IYLVGGWNEIEKKYKKCIQCYNPDLNEWTEEDELPEATVGVSCCTISMPNT
KTRESRASSVSSVPVSI 
Legend: 
Start Methionine 
BTB-Domain 
Kelch-repeats 
 
A1.3 pEGFP-N1 / dsRED-N1 Klhl31 constructs 
 
 
pEGFP-N1 Klhl31 FL 
dsRED-N1 Klhl31 FL 
 
pEGFP-N1 as well as dsRED-N1 share the same multiple cloning site. 
 
All used pEGFP-N1/C1 and dsRED-N1 constructs are not manufactured anymore by 
Clontech. 
 
Vector information and map for pEGFP-N1  
GenBank Accession #55762 
Clontech Catalog number #6085-1 
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Vector map and multiple cloning site for pEGFP-N1 
 
 
 
 
Vector information for pDsRed-Express-N1  
GenBank Accession n/a 
Clontech Catalog number 632429 
Same multiple cloning site as for pEGFP-N1 
 
 
Primer information 
 
forward primer – ctcgagatggcacctaagaagaagaac 
restriction enzyme  – XhoI 
 
reverse primer -  gaattccaatactgactggtacagaaga 
restriction enzyme -  EcoRI 
 
 
ctcgagatggcacctaagaagaagaacgtgaagaagaacaaagcagcagatatcagtgaaatgactatcattgtggaagatg
gccccctcagtaaactaaatggcttgaatggactcttagatggaggcaatggtttcagctgcgtctcatctgaagtttctgaccca
tcatatagcccaaatctcttggaaggtctaagcagaatgagactagaaaattttctttgtgacttgactatcagtaccaaaaccaaa
tctttcagtgttcataaggtggtgatggcttcaatcagtgactactttcacaacatcttaaagaaagatccatccactcaaagagta
gacctcaatgatgtatccccattgggtctagctactgttatcacctatgcttacactggaaagctcactctctcactttatacaatag
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gtagtattatttccaccgcgatttatcttcagattcacacccttgtaaagatgtgctgtgattttctaacccaagaaatcagtgttgag
aattgtatgtatattgccaatattgcagaaacgtacggactaaaaacaaccaaggaagctgcacacaaatttattagagacaact
tcattgaattttcagaaacagatcagttcttaaaactcacttttgatcagattaatgaacttcttgcagatgatgacttgcagttgcctt
ctgaaattgttgcattccagattgcaataaaatggctggaatttgaccaaaaaagagtaaagtttgctgctgatctcttaggtaaca
ttcgttttggtactatctcagctcaagacctcgtcaattatgtccaaactgttccgagaatgatgcaagatgcagattgccataaac
tcctggtagatgccatgaactatcatttgcttccctatcatcagaatacacttcagtctagaagaacaaggattcgtggaggattca
gagtgttagttactgttggcggacgccctgctttaacagaaaagtctcttagcagagacatcttgtacagagatcctgaaaatgg
atggaagaagcttagtgaaatgcccgctaaaagttttaaccagtgcgtgacggtgatggatgggtttctctacgtggccggtgg
ggaagaccagaatgatgccaggaaccaagccaagcatgcagtcagcaacttctgcagatacgatcctcgtttcaacacctgg
attcacctggcaaatatgaatcagaagcgcacccacttcagcctgaatgtattcaatggcctcctttttgcagtgggtggtcgcaa
cttggagggttgtctctcctcgatggagtgctacgtgcctgcaactaatcagtggcagatgaaggcacccctggaggtgccca
ggtgctgccatgccagtgctgtggtggatggtaggatcctggtcacgggaggttacattaataatgcttactctcgttcagtgtgc
atgtatgaccccagcaatgatagctggcaagataagtccagtcttagcaccccacgagggtggcactgtgccgtgtccctgct
ggagagggtctatgtcatgggtgggtctcaactgggggggagaggggaaagggtcgacgttctccctgtggagtgttacagc
ccttacacagggcagtggagttatgtggcaccccttcaaactggagttagcacagccggtgcttcgatgctggatgggaaaatt
tacttagtggggggctggaatgagatagagaaaaaatataagaagtgcattcagtgctataacccagatctcaatgagtggac
ggaggaagacgagctgcctgaagccactgtgggagtatcctgttgtactatatccatgcccaacaccaagacaagggagtcc
agagcaagctcagtctcttctgtaccagtcagtattggaattc  
 
 
 
pEGFP-N1 Klhl31 ΔBTB 
dsRED-N1 Klhl31 ΔBTB 
 
Primer information 
 
forward primer – ctcgagatggcacctaagaagaagaac 
restriction enzyme  – XhoI 
 
reverse primer -  gaattccaatactgactggtacagaaga 
restriction enzyme -  EcoRI 
 
ctcgagatggcacctaagaagaagaacgtgaagaagaacaaagcagcagatatcagtgaaatgactatcattgtggaagatg
gccccctcagtaaactaaatggcttgaatggactcttagatggaggcaatggtttcagctgcgtctcatctgaagtttctgaccca
tcatatagcccaaatctcttggaaggttacggactaaaaacaaccaaggaagctgcacacaaatttattagagacaacttcattg
aattttcagaaacagatcagttcttaaaactcacttttgatcagattaatgaacttcttgcagatgatgacttgcagttgccttctgaa
attgttgcattccagattgcaataaaatggctggaatttgaccaaaaaagagtaaagtttgctgctgatctcttaggtaacattcgtt
ttggtactatctcagctcaagacctcgtcaattatgtccaaactgttccgagaatgatgcaagatgcagattgccataaactcctg
gtagatgccatgaactatcatttgcttccctatcatcagaatacacttcagtctagaagaacaaggattcgtggaggattcagagt
gttagttactgttggcggacgccctgctttaacagaaaagtctcttagcagagacatcttgtacagagatcctgaaaatggatgg
aagaagcttagtgaaatgcccgctaaaagttttaaccagtgcgtgacggtgatggatgggtttctctacgtggccggtggggaa
gaccagaatgatgccaggaaccaagccaagcatgcagtcagcaacttctgcagatacgatcctcgtttcaacacctggattca
cctggcaaatatgaatcagaagcgcacccacttcagcctgaatgtattcaatggcctcctttttgcagtgggtggtcgcaacttg
gagggttgtctctcctcgatggagtgctacgtgcctgcaactaatcagtggcagatgaaggcacccctggaggtgcccaggtg
ctgccatgccagtgctgtggtggatggtaggatcctggtcacgggaggttacattaataatgcttactctcgttcagtgtgcatgt
atgaccccagcaatgatagctggcaagataagtccagtcttagcaccccacgagggtggcactgtgccgtgtccctgctgga
gagggtctatgtcatgggtgggtctcaactgggggggagaggggaaagggtcgacgttctccctgtggagtgttacagccctt
acacagggcagtggagttatgtggcaccccttcaaactggagttagcacagccggtgcttcgatgctggatgggaaaatttact
tagtggggggctggaatgagatagagaaaaaatataagaagtgcattcagtgctataacccagatctcaatgagtggacgga
ggaagacgagctgcctgaagccactgtgggagtatcctgttgtactatatccatgcccaacaccaagacaagggagtccaga
gcaagctcagtctcttctgtaccagtcagtattggaattc  
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pEGFP-N1 Klhl31 ΔKR 
dsRED-N1 Klhl31 ΔKR 
 
Primer information 
 
forward primer – ctcgagatggcacctaagaagaagaac 
restriction enzyme  – XhoI 
 
reverse primer -  gaattcctctgaatcctccacgaatcct 
restriction enzyme -  EcoRI 
 
 
ctcgagatggcacctaagaagaagaacgtgaagaagaacaaagcagcagatatcagtgaaatgactatcattgtggaagatg
gccccctcagtaaactaaatggcttgaatggactcttagatggaggcaatggtttcagctgcgtctcatctgaagtttctgaccca
tcatatagcccaaatctcttggaaggtctaagcagaatgagactagaaaattttctttgtgacttgactatcagtaccaaaaccaaa
tctttcagtgttcataaggtggtgatggcttcaatcagtgactactttcacaacatcttaaagaaagatccatccactcaaagagta
gacctcaatgatgtatccccattgggtctagctactgttatcacctatgcttacactggaaagctcactctctcactttatacaatag
gtagtattatttccaccgcgatttatcttcagattcacacccttgtaaagatgtgctgtgattttctaacccaagaaatcagtgttgag
aattgtatgtatattgccaatattgcagaaacgtacggactaaaaacaaccaaggaagctgcacacaaatttattagagacaact
tcattgaattttcagaaacagatcagttcttaaaactcacttttgatcagattaatgaacttcttgcagatgatgacttgcagttgcctt
ctgaaattgttgcattccagattgcaataaaatggctggaatttgaccaaaaaagagtaaagtttgctgctgatctcttaggtaaca
ttcgttttggtactatctcagctcaagacctcgtcaattatgtccaaactgttccgagaatgatgcaagatgcagattgccataaac
tcctggtagatgccatgaactatcatttgcttccctatcatcagaatacacttcagtctagaagaacaaggattcgtggaggattca
gaggaattc 
 
 
 
A1.4 pEGFP-C1 Klhl31 constructs  
 
Vector information and map for pEGFP-C1  
GenBank Accession #55763 
Clontech Catalog number #6084-1 
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Vector map and multiple cloning site for pEGFP-C1 
 
 
 
 
pEGFP-C1 Klhl31 FL 
 
Primer information 
 
 
forward primer – tccggaatggcacctaagaagaac 
restriction enzyme  – BspEI 
 
reverse primer -  gaattctcaagcgtaatctggaacatcgtatgggtaaatactgactggtacagaag 
restriction enzyme -  EcoRI 
 
 
tccggaatggcacctaagaagaagaacgtgaagaagaacaaagcagcagatatcagtgaaatgactatcattgtggaagatg
gccccctcagtaaactaaatggcttgaatggactcttagatggaggcaatggtttcagctgcgtctcatctgaagtttctgaccca
tcatatagcccaaatctcttggaaggtctaagcagaatgagactagaaaattttctttgtgacttgactatcagtaccaaaaccaaa
tctttcagtgttcataaggtggtgatggcttcaatcagtgactactttcacaacatcttaaagaaagatccatccactcaaagagta
gacctcaatgatgtatccccattgggtctagctactgttatcacctatgcttacactggaaagctcactctctcactttatacaatag
gtagtattatttccaccgcgatttatcttcagattcacacccttgtaaagatgtgctgtgattttctaacccaagaaatcagtgttgag
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aattgtatgtatattgccaatattgcagaaacgtacggactaaaaacaaccaaggaagctgcacacaaatttattagagacaact
tcattgaattttcagaaacagatcagttcttaaaactcacttttgatcagattaatgaacttcttgcagatgatgacttgcagttgcctt
ctgaaattgttgcattccagattgcaataaaatggctggaatttgaccaaaaaagagtaaagtttgctgctgatctcttaggtaaca
ttcgttttggtactatctcagctcaagacctcgtcaattatgtccaaactgttccgagaatgatgcaagatgcagattgccataaac
tcctggtagatgccatgaactatcatttgcttccctatcatcagaatacacttcagtctagaagaacaaggattcgtggaggattca
gagtgttagttactgttggcggacgccctgctttaacagaaaagtctcttagcagagacatcttgtacagagatcctgaaaatgg
atggaagaagcttagtgaaatgcccgctaaaagttttaaccagtgcgtgacggtgatggatgggtttctctacgtggccggtgg
ggaagaccagaatgatgccaggaaccaagccaagcatgcagtcagcaacttctgcagatacgatcctcgtttcaacacctgg
attcacctggcaaatatgaatcagaagcgcacccacttcagcctgaatgtattcaatggcctcctttttgcagtgggtggtcgcaa
cttggagggttgtctctcctcgatggagtgctacgtgcctgcaactaatcagtggcagatgaaggcacccctggaggtgccca
ggtgctgccatgccagtgctgtggtggatggtaggatcctggtcacgggaggttacattaataatgcttactctcgttcagtgtgc
atgtatgaccccagcaatgatagctggcaagataagtccagtcttagcaccccacgagggtggcactgtgccgtgtccctgct
ggagagggtctatgtcatgggtgggtctcaactgggggggagaggggaaagggtcgacgttctccctgtggagtgttacagc
ccttacacagggcagtggagttatgtggcaccccttcaaactggagttagcacagccggtgcttcgatgctggatgggaaaatt
tacttagtggggggctggaatgagatagagaaaaaatataagaagtgcattcagtgctataacccagatctcaatgagtggac
ggaggaagacgagctgcctgaagccactgtgggagtatcctgttgtactatatccatgcccaacaccaagacaagggagtcc
agagcaagctcagtctcttctgtaccagtcagtatttacccatacgatgttccagattacgcttgagaattc 
 
 
 
pEGFP-C1 Klhl31 ΔBTB 
 
Primer information 
 
 
forward primer – tccggaatggcacctaagaagaac 
restriction enzyme  – BspEI 
 
reverse primer -  gaattctcaagcgtaatctggaacatcgtatgggtaaatactgactggtacagaag 
restriction enzyme -  EcoRI 
 
 
tccggaatggcacctaagaagaagaacgtgaagaagaacaaagcagcagatatcagtgaaatgactatcattgtggaagatg
gccccctcagtaaactaaatggcttgaatggactcttagatggaggcaatggtttcagctgcgtctcatctgaagtttctgaccca
tcatatagcccaaatctcttggagtacggactaaaaacaaccaaggaagctgcacacaaatttattagagacaacttcattgaatt
ttcagaaacagatcagttcttaaaactcacttttgatcagattaatgaacttcttgcagatgatgacttgcagttgccttctgaaattg
ttgcattccagattgcaataaaatggctggaatttgaccaaaaaagagtaaagtttgctgctgatctcttaggtaacattcgttttgg
tactatctcagctcaagacctcgtcaattatgtccaaactgttccgagaatgatgcaagatgcagattgccataaactcctggtag
atgccatgaactatcatttgcttccctatcatcagaatacacttcagtctagaagaacaaggattcgtggaggattcagagtgtta
gttactgttggcggacgccctgctttaacagaaaagtctcttagcagagacatcttgtacagagatcctgaaaatggatggaag
aagcttagtgaaatgcccgctaaaagttttaaccagtgcgtgacggtgatggatgggtttctctacgtggccggtggggaagac
cagaatgatgccaggaaccaagccaagcatgcagtcagcaacttctgcagatacgatcctcgtttcaacacctggattcacctg
gcaaatatgaatcagaagcgcacccacttcagcctgaatgtattcaatggcctcctttttgcagtgggtggtcgcaacttggagg
gttgtctctcctcgatggagtgctacgtgcctgcaactaatcagtggcagatgaaggcacccctggaggtgcccaggtgctgc
catgccagtgctgtggtggatggtaggatcctggtcacgggaggttacattaataatgcttactctcgttcagtgtgcatgtatga
ccccagcaatgatagctggcaagataagtccagtcttagcaccccacgagggtggcactgtgccgtgtccctgctggagagg
gtctatgtcatgggtgggtctcaactgggggggagaggggaaagggtcgacgttctccctgtggagtgttacagcccttacac
agggcagtggagttatgtggcaccccttcaaactggagttagcacagccggtgcttcgatgctggatgggaaaatttacttagt
ggggggctggaatgagatagagaaaaaatataagaagtgcattcagtgctataacccagatctcaatgagtggacggaggaa
gacgagctgcctgaagccactgtgggagtatcctgttgtactatatccatgcccaacaccaagacaagggagtccagagcaa
gctcagtctcttctgtaccagtcagtatttacccatacgatgttccagattacgcttgagaattc 
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pEGFP-C1 Klhl31 ΔKR 
 
Primer information 
 
 
forward primer – tccggaatggcacctaagaagaac 
restriction enzyme  – BspEI 
 
reverse primer -  gaattctcaagcgtaatctggaacatcgtatgggtatctgaatcctccacgaatcc 
restriction enzyme -  EcoRI 
 
 
tccggaatggcacctaagaagaagaacgtgaagaagaacaaagcagcagatatcagtgaaatgactatcattgtggaagatg
gccccctcagtaaactaaatggcttgaatggactcttagatggaggcaatggtttcagctgcgtctcatctgaagtttctgaccca
tcatatagcccaaatctcttggaaggtctaagcagaatgagactagaaaattttctttgtgacttgactatcagtaccaaaaccaaa
tctttcagtgttcataaggtggtgatggcttcaatcagtgactactttcacaacatcttaaagaaagatccatccactcaaagagta
gacctcaatgatgtatccccattgggtctagctactgttatcacctatgcttacactggaaagctcactctctcactttatacaatag
gtagtattatttccaccgcgatttatcttcagattcacacccttgtaaagatgtgctgtgattttctaacccaagaaatcagtgttgag
aattgtatgtatattgccaatattgcagaaacgtacggactaaaaacaaccaaggaagctgcacacaaatttattagagacaact
tcattgaattttcagaaacagatcagttcttaaaactcacttttgatcagattaatgaacttcttgcagatgatgacttgcagttgcctt
ctgaaattgttgcattccagattgcaataaaatggctggaatttgaccaaaaaagagtaaagtttgctgctgatctcttaggtaaca
ttcgttttggtactatctcagctcaagacctcgtcaattatgtccaaactgttccgagaatgatgcaagatgcagattgccataaac
tcctggtagatgccatgaactatcatttgcttccctatcatcagaatacacttcagtctagaagaacaaggattcgtggaggattca
gatacccatacgatgttccagattacgcttgagaattc 
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A.2 Klhl31 Sequence (homo sapiens) 
 
Klhl31 IMAGE Clone 9021264 
 
Clone obtained from Source BioScience Life Sciences 
Plasmid Information for IMAGE Clone 9021264 
Cross 
Reference 
Gene Symbol KLHL31 
Species Homo sapiens 
Technical 
Clone Data 
  
Library NIH_MGC_362 
Alternative Name 9021264 (IMAGE ID) 
Source Homo sapiens, tissue:'pool of cerebellum, 
kidney, placenta, testis, lung, colon, liver, 
heart, thyroid, bladder, uterus', organ:'mixed' 
Host DH10B TonA (Escherichia coli) 
Vector pCR4-TOPO 
Cloning Sites 5s: TA cloning, 3s: TA cloning 
Growth Conditions medium: LB ; antibiotics: Amp (50 µg/ml) ; 
alternative antibiotic: Kan (30 µg/ml) 
Sequence  accession: BC137267 
 
 
Vector information and map for pCR4-TOPO 
Invitrogen Catalog number K4575-02 
 
 
 
 
 
 
295 
 
Vector map and multiple cloning site for pCR®4-TOPO 
 
 
 
Sequence (DNA) 
atggcacccaaaaagaagattgtcaaaaagaacaaaggagatatcaatgagatgactataatcgtagaagatagccccctaaa
caaactgaatgctttgaatgggctcctagagggaggcaatggccttagctgcatttcttctgaactaacagatgcttcttatggcc
ccaacctcttggaaggtttaagtaaaatgcggcaggagaacttcttatgtgacttagtcattggtaccaaaaccaaatcctttgat
gttcataagtcagtcatggcttcatgcagtgagtatttttacaacatcctaaaaaaagacccgtcaattcagagggtggatctcaat
gatatctcaccactaggcctggccactgtcattgcatatgcctacactggaaagctcactctctccttgtatacaataggaagcat
tatttctgctgctgtttatcttcagatccatactcttataaagatgtgcagtgattttctgatacgggagatgagtgttgagaattgcat
gtatgttgttaatattgctgaaacatactccctaaaaaatgcaaaagcagcagcccagaaatttattcgggataacttccttgaattt
gcagaatcggatcagtttatgaaacttacatttgaacaaattaatgaacttcttatagatgatgacttacagttgccttctgagatagt
agcattccagattgcaatgaaatggttagaatttgaccaaaagagagtaaaatacgctgcagatcttttgagcaatattcgctttg
gtaccatctctgcacaagacctggtcaattatgttcaatccgtaccaagaatgatgcaagatgctgattgtcacagacttctcgta
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gatgctatgaactaccacttgcttccatatcatcaaaacacattgcaatctaggcgaacaagaatccgaggtggctgccgagtc
ctcgtcactgttgggggacgcccaggccttactgagaagtcccttagcagagacatcctgtatagagaccctgaaaatggatg
gagcaagcttacggaaatgccagccaaaagttttaatcagtgtgtggctgtgatggatggatttctttatgtagccggtggtgaa
gaccagaatgatgcaagaaatcaagccaagcatgcagtcagcaatttctgcagatacgatccccgcttcaacacctggataca
cctggccagcatgaaccagaagcgcacgcacttcagcctgagcgtgttcaacgggctcgtgtacgccgcgggcggccgca
acgcagaaggaagcctggcctcgctggagtgctacgtgccctccaccaatcagtggcagccgaagacgcccctggaggtg
gcgcgctgctgccacgctagcgcggtcgccgacggccgcgtgctggtgaccggaggctacatcgccaacgcctactcgcg
ctctgtgtgcgcctacgacccggccagcgaccgtggcaggagctgccgaacctcagcacaccccggggctggcactgcgc
ggtcacgctgagcgacagagtgtacgtgatgggcggcagccagctggggccgcgcggggagcgcgtggacgtgctcacc
gtggagtgctacagccccgcgaccggccagtggagctacgcggcgccgctgcaggtgggagtgagcactgcgggcgtct
cggcgctgcatggccgcgcctacctggtggggggctggaacgagggcgagaagaagtacaagaagtgcatccagtgcttc
agccccgagctcaacgagtggacggaggacgacgagctacccgaggccactgtcggcgtgtcctgctgcaccctctcgatg
cccaacaacgtgactcgggaatcccgggccagttcggtatcttctgtgccagtcagtatctgagcccaggtagatgcagggac
gcaggaa 
 
 
Sequence (Protein) 
 
MAPKKKIVKKNKGDINEMTIIVEDSPLNKLNALNGLLEGGNGLS 
CISSELTDASYGPNLLEGLSKMRQENFLCDLVIGTKTKSFDVHKSVMASCSEYF
YNILKKDPSIQRVDLNDISPLGLATVIAYAYTGKLTLSLYTIGSIISAAVYLQIHTL
IKMCSDFLIREMSVENCMYVVNIAETYSLKNAKAAAQKFIRDNFLEFAESDQFM
KLTFEQINELLIDDDLQLPSEIVAFQIAMKWLEFDQKRVKYAADLLSNIRFGTIS
AQDLVNYVQSVPRMMQDADCHRLLVDAMNYHLLPYHQNTLQSRRTRIRGGC
RVLVTVGGRPGLTEKSLSRDILYRDPENGWSKLTEMPAKSFNQCVAVMDGFLY
VAGGEDQNDARNQAKHAVSNFCRYDPRFNTWIHLASMNQKRTHFSLSVFNGL
VYAAGGRNAEGSLASLECYVPSTNQWQPKTPLEVARCCHASAVADGRVLVTG
GYIANAYSRSVCAYDPASDSWQELPNLSTPRGWHCAVTLSDRVYVMGGSQLG
PRGERVDVLTVECYSPATGQWSYAAPLQVGVSTAGVSALHGRAYLVGGWNE
GEKKYKKCIQCFSPELNEWTEDDELPEATVGVSCCTLSMPNNVTRESRASSVSS
VPVSI 
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A.3 Yeast-2-Hybrid Screen, Hybrigenics Services 
 
This chapter of the Appendix contains data from the Yeast-2-Hybrid Screen, as well as 
an example for alignment of retrieved hits from the screen to a human protein library. 
 
A.3.1 Yeast-2-Hybrid Result summary 
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Summary of the results obtained from the Yeast -2-Hybrid Screen 
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A3.2 Blast of a ncRNA Sequence transcribed into protein (based on translation frame 1)  
 
The amino acid sequence based on the RNA Sequence for Jpx was used to search a 
human protein data base for matching results.  
Given nucleotide sequence for Jpx-fragment (as obtained from Hybrigenics Services) 
CCCGGGTTCAAGCAATTCTCCTGCTTCAGCCTCCCGAGTAGCTGGGATTACTGGTGCCCATC
ACTGCACCCAGCTCATTTTTTTGTACTTTTAGTGGAGACAGGGTTTTACCATGTTGGCCAGGC
TGGTCTTGAACTCCTGACCTCATGATCCACCCGCCTCGGCCTCCCAAAGTGCTGGGATTACA
GACGTGAGCCACTGCGCCCAGCCAATAACGCATCTTAAACATGAAATATCTCCCCATTTATT
TTGGTCTTTTAAAATTTTCTTCAACAACATTGTGTAGCTTTCTTTATACAAATCTTGCAGGTGT
TTTGTTGAATTATTCCTAAAGATTTAGTCTTTTTGGTGCTATTTTGTATGGAATTGATTTCTTA
ATTTCATTTTTGGATCATTCATTGCTAG 
Translation into amino acid sequence by using ExPASy (SIB Bioinformatics Resource 
Portal) identified stop-codons and therefore fragmented proteins.                                      
Translation based on frame one (starting with nucleotide one), for example, contained 6 
distinct protein fragments and one single amino acid.  
Translated amino acid sequence based on Jpx-fragment (frame 1)  
PGFKQFSCFSLPSSWDYWCPSLHPAHFFVLLVETGFYHVGQAGLELLTS. 
STRLGLPKCWDYRREPLRPANNAS. 
T. 
NISPFILVF. 
NFLQQHCVAFFIQILQVFC. 
IIPKDLVFLVLFCMELIS. 
FHFWIIHC. 
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When searching a human protein data base with the described amino acid sequences, various 
proteins have been found. They all share limited percentage of identity with the blasted 
amino acid fragment and seem to have no common origin. However, for the first amino 
acid fragment of the translated nc RNA, a conserved potential binding domain was 
found. The GVQW domain can usually be found incorporated into longer functional 
domains. However, no function has been described for this domain yet, but its highly 
conserved GVQW motif indicates the potential of being a binding domain. Information 
about the GVQW domain was collected from the NCBI Conserved Domain Database 
(CDD) (Marchler-Bauer and others, 2011). 
Protein Sequence (128 letters)  
Results for: 
lcl|26936 None(128aa)
[?]  
Your BLAST job specified more than one input sequence. This box lets you choose 
which input sequence to show BLAST results for.  
Query ID  
lcl|26936  
lcl|26936  
Description  
None  
Molecule type  
amino acid  
Query Length  
128  
Database Name  
nr  
Description  
All non-redundant GenBank CDS translations+PDB+SwissProt+PIR+PRF 
excluding environmental samples from WGS projects See details  
Program  
BLASTP 2.2.27+ Citation  
 
Reference  
Stephen F. Altschul, Thomas L. Madden, Alejandro A. Schäffer, Jinghui Zhang, Zheng 
Zhang, Webb Miller, and David J. Lipman (1997), "Gapped BLAST and PSI-BLAST: a 
new generation of protein database search programs", Nucleic Acids Res. 25:3389-
3402. 
Reference - compositional score matrix adjustment  
Stephen F. Altschul, John C. Wootton, E. Michael Gertz, Richa Agarwala, Aleksandr 
Morgulis, Alejandro A. Schäffer, and Yi-Kuo Yu (2005) "Protein database searches 
using compositionally adjusted substitution matrices", FEBS J. 272:5101-5109. 
Graphic Summary  
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Show Conserved Domains  
 
 
Descriptions  
Accession Description 
Max 
score  
Total 
score  
Query 
cover
age  
E 
value  
Max 
iden
t  
BAC03563.1  
unnamed protein product [Homo 
sapiens] 
77.0 77.0 75% 2e-17 48% 
AAA36776.1  
transformation-related protein, 
partial [Homo sapiens] 
79.3 79.3 50% 3e-17 64% 
EAW56733.1  
similar to zinc finger protein 569, 
isoform CRA_a [Homo sapiens] 
72.8 72.8 39% 5e-16 72% 
AAB49034.1  
c-MYB [Homo sapiens] 
>gb|EAW47974.1| v-myb 
myeloblastosis viral oncogene 
homolog (avian), isoform 
CRA_h [Homo sapiens] 
76.3 110 52% 8e-16 73% 
CAF04484.1  
unnamed protein product [Homo 
sapiens] 
76.3 110 52% 9e-16 73% 
CAE55174.1  
v-myb myeloblastosis viral 
oncogene homologue (avian) 
[Homo sapiens] 
76.3 110 52% 1e-15 73% 
EAW47968.1  
v-myb myeloblastosis viral 
oncogene homolog (avian), 
isoform CRA_b [Homo sapiens] 
75.1 108 52% 1e-15 73% 
EAW82740.1  
hypothetical protein FLJ38101, 
isoform CRA_c [Homo sapiens] 
69.3 96.7 50% 5e-15 71% 
NP_001158011.1  
disrupted in schizophrenia 1 
protein isoform c [Homo sapiens] 
>gb|ACR40062.1| disrupted in 
schizophrenia 1 isoform 26 
[Homo sapiens] 
71.2 71.2 39% 5e-14 70% 
EAW74756.1  hCG1820410 [Homo sapiens] 66.2 96.3 50% 6e-14 76% 
EAW93409.1  hCG2039073 [Homo sapiens] 67.0 67.0 51% 8e-14 56% 
BAC85397.1  
unnamed protein product [Homo 
sapiens] 
66.6 66.6 38% 1e-13 69% 
AAG35515.1  PRO2550 [Homo sapiens] 65.9 94.3 54% 2e-13 70% 
Q0VDF0.1  
RecName: Full=Putative 
uncharacterized protein 
LOC65996 >gb|EAW72619.1| 
hypothetical protein MGC2752 
[Homo sapiens] 
66.6 99.7 54% 2e-13 67% 
BAC11494.1  
unnamed protein product [Homo 
sapiens] 
68.2 68.2 38% 3e-13 67% 
302 
 
Accession Description 
Max 
score  
Total 
score  
Query 
cover
age  
E 
value  
Max 
iden
t  
EAW91517.1  hCG1820395 [Homo sapiens] 63.5 63.5 39% 8e-13 68% 
BAC85329.1  
unnamed protein product [Homo 
sapiens] 
63.9 63.9 39% 9e-13 68% 
CAI40721.1  
emopamil binding protein-like 
[Homo sapiens] 
64.3 93.2 52% 9e-13 67% 
NP_689672.4  
UPF0764 protein C16orf89 
isoform 1 precursor [Homo 
sapiens] 
>sp|Q6UX73.2|CP089_HUMAN 
RecName: Full=UPF0764 
protein C16orf89; Flags: 
Precursor 
66.2 66.2 38% 1e-12 65% 
AAQ88847.1  
SARG904 [Homo sapiens] 
>gb|EAW85244.1| hypothetical 
protein MGC45438, isoform 
CRA_c [Homo sapiens] 
66.2 66.2 38% 2e-12 65% 
EAW85243.1  
hypothetical protein MGC45438, 
isoform CRA_b [Homo sapiens] 
66.2 66.2 38% 2e-12 65% 
AAF69605.1  PRO1722 [Homo sapiens] 62.8 62.8 40% 2e-12 67% 
BAH12031.1  
unnamed protein product [Homo 
sapiens] 
65.5 65.5 38% 2e-12 63% 
BAC86633.1  
unnamed protein product [Homo 
sapiens] 
63.2 63.2 39% 3e-12 68% 
BAC86261.1  
unnamed protein product [Homo 
sapiens] 
62.8 92.4 53% 4e-12 68% 
BAA91131.1  
unnamed protein product [Homo 
sapiens] 
62.4 62.4 67% 4e-12 48% 
EAW65573.1  hCG2039011 [Homo sapiens] 61.2 61.2 29% 5e-12 77% 
EAW55887.1  hCG1742852 [Homo sapiens] 62.8 62.8 39% 6e-12 68% 
ABC87286.1  
ubiquitously transcribed 
tetratricopeptide repeat protein 
Y-linked transcript variant 16 
[Homo sapiens] 
65.1 65.1 38% 9e-12 63% 
AAH07609.1  E2F2 protein [Homo sapiens] 59.7 59.7 39% 2e-11 68% 
EAX08445.1  hCG2019873 [Homo sapiens] 60.1 60.1 39% 2e-11 62% 
AAR84645.1  
alpha 1A adrenoceptor isoform 
2c [Homo sapiens] 
>gb|ACA05904.1| adrenergic, 
alpha-1A-, receptor variant 6 
[Homo sapiens] 
61.6 61.6 38% 4e-11 64% 
EAW62752.1  hCG2039002 [Homo sapiens] 58.9 58.9 38% 6e-11 61% 
Q6ZSR6.3  
RecName: Full=Putative 
uncharacterized protein 
FLJ45256 >dbj|BAC86880.1| 
59.7 59.7 31% 6e-11 70% 
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Accession Description 
Max 
score  
Total 
score  
Query 
cover
age  
E 
value  
Max 
iden
t  
unnamed protein product [Homo 
sapiens] 
AAH33883.1  
RBP7 protein, partial [Homo 
sapiens] 
59.7 59.7 39% 6e-11 66% 
CAI14684.1  
retinol binding protein 7, cellular 
[Homo sapiens] 
59.3 59.3 44% 6e-11 61% 
AAY68207.1  
ubiquitously transcribed 
tetratricopeptide repeat protein 
Y-linked transcript variant 6 
[Homo sapiens] 
61.2 61.2 38% 1e-10 58% 
EAW85402.1  hCG1778978 [Homo sapiens] 57.8 57.8 39% 1e-10 66% 
ABR09258.1  
ubiquitously transcribed 
tetratricopeptide repeat protein 
Y-linked transcript variant 8 
[Homo sapiens] 
61.6 61.6 38% 1e-10 58% 
EAW93800.1  
hypothetical protein MGC72075, 
isoform CRA_c [Homo sapiens] 
57.8 57.8 39% 1e-10 64% 
ABR09247.1  
ubiquitously transcribed 
tetratricopeptide repeat protein 
Y-linked transcript variant 9 
[Homo sapiens] 
61.2 61.2 38% 1e-10 58% 
ABV49427.1  
ubiquitously transcribed 
tetratricopeptide repeat protein 
Y-linked transcript variant 28 
[Homo sapiens] 
61.2 61.2 38% 1e-10 58% 
ABC75708.1  
ubiquitously transcribed 
tetratricopeptide repeat protein 
Y-linked transcript variant 27 
[Homo sapiens] 
61.2 61.2 38% 1e-10 58% 
BAF85547.1  
unnamed protein product [Homo 
sapiens] 
61.2 61.2 38% 1e-10 58% 
ABC87284.1  
ubiquitously transcribed 
tetratricopeptide repeat protein 
Y-linked transcript variant 29 
[Homo sapiens] 
61.2 61.2 38% 1e-10 58% 
ABC75709.1  
ubiquitously transcribed 
tetratricopeptide repeat protein 
Y-linked transcript variant 24 
[Homo sapiens] 
61.2 61.2 38% 1e-10 58% 
ABR09240.1  
ubiquitously transcribed 
tetratricopeptide repeat protein 
Y-linked transcript variant 18 
[Homo sapiens] 
61.2 61.2 38% 1e-10 58% 
ABR09243.1  
ubiquitously transcribed 
tetratricopeptide repeat protein 
61.2 61.2 38% 2e-10 58% 
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Accession Description 
Max 
score  
Total 
score  
Query 
cover
age  
E 
value  
Max 
iden
t  
Y-linked transcript variant 22 
[Homo sapiens] 
AAU87837.1  
ubiquitously transcribed 
tetratricopeptide repeat protein 
Y-linked transcript variant 11 
[Homo sapiens] 
61.2 61.2 38% 2e-10 58% 
NP_872601.1  
histone demethylase UTY 
isoform 1 [Homo sapiens] 
>gb|AAC51843.1| ubiquitous 
TPR motif, Y isoform [Homo 
sapiens] 
61.2 61.2 38% 2e-10 58% 
Q8WTZ3.1  
RecName: Full=Zinc finger 
protein ENSP00000375192 
>gb|AAH21822.1| ZNF99 
protein [Homo sapiens] 
>gb|EAW84927.1| hCG1796108 
[Homo sapiens] 
58.9 58.9 52% 2e-10 49% 
ABR09242.1  
ubiquitously transcribed 
tetratricopeptide repeat protein 
Y-linked transcript variant 4 
[Homo sapiens] 
61.2 61.2 38% 2e-10 58% 
ABR09253.1  
ubiquitously transcribed 
tetratricopeptide repeat protein 
Y-linked transcript variant 30 
[Homo sapiens] 
61.2 61.2 38% 2e-10 58% 
BAC05300.1  
unnamed protein product [Homo 
sapiens] >emb|CAH71256.1| 
tigger transposable element 
derived 1-like 2 [Homo sapiens] 
58.2 58.2 39% 2e-10 69% 
ABV49466.1  
ubiquitously transcribed 
tetratricopeptide repeat protein 
Y-linked transcript variant 23 
[Homo sapiens] 
61.2 61.2 38% 2e-10 58% 
ABR09257.1  
ubiquitously transcribed 
tetratricopeptide repeat protein 
Y-linked transcript variant 21 
[Homo sapiens] 
61.2 61.2 38% 2e-10 58% 
ABR09255.1  
ubiquitously transcribed 
tetratricopeptide repeat protein 
Y-linked transcript variant 25 
[Homo sapiens] 
61.2 61.2 38% 2e-10 58% 
ABR09237.1  
ubiquitously transcribed 
tetratricopeptide repeat protein 
Y-linked transcript variant 12 
[Homo sapiens] 
60.8 60.8 38% 2e-10 58% 
ABR09254.1  ubiquitously transcribed 60.8 60.8 38% 2e-10 58% 
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age  
E 
value  
Max 
iden
t  
tetratricopeptide repeat protein 
Y-linked transcript variant 19 
[Homo sapiens] 
EAW89455.1  hCG2039055 [Homo sapiens] 57.4 87.0 54% 3e-10 67% 
BAB14371.1  
unnamed protein product [Homo 
sapiens] >gb|EAW83838.1| 
ATP/GTP binding protein-like 3, 
isoform CRA_b [Homo sapiens] 
57.0 57.0 38% 4e-10 65% 
XP_003960524.1  
PREDICTED: putative 
uncharacterized protein 
LOC65996-like [Homo sapiens] 
55.8 55.8 37% 5e-10 63% 
ABV82621.1  
ubiquitously transcribed 
tetratricopeptide repeat protein 
Y-linked transcript variant 10 
[Homo sapiens] 
59.3 59.3 38% 7e-10 57% 
EAW94179.1  
ubiquitin-conjugating enzyme 
E2D 4 (putative), isoform 
CRA_b [Homo sapiens] 
55.8 55.8 39% 7e-10 66% 
EAW55348.1  
chromosome 6 open reading 
frame 79, isoform CRA_c [Homo 
sapiens] 
57.0 57.0 39% 9e-10 62% 
EAW62475.1  hCG2038077 [Homo sapiens] 55.5 55.5 39% 9e-10 62% 
BAB14934.1  
unnamed protein product [Homo 
sapiens] 
57.0 57.0 39% 1e-09 62% 
ACP43292.1  
ubiquitously transcribed 
tetratricopeptide repeat Y-linked 
isoform 3 [Homo sapiens] 
>gb|ACP43293.1| ubiquitously 
transcribed tetratricopeptide 
repeat Y-linked isoform 3 [Homo 
sapiens] >gb|ACP43294.1| 
ubiquitously transcribed 
tetratricopeptide repeat Y-linked 
isoform 3 [Homo sapiens] 
54.3 54.3 41% 2e-09 56% 
NP_001243358.1  
PDZ and LIM domain protein 5 
isoform i [Homo sapiens] 
>gb|AAR09142.1| PDZ and LIM 
domain 5 [Homo sapiens] 
54.7 54.7 39% 2e-09 64% 
BAG64432.1  
unnamed protein product [Homo 
sapiens] 
54.7 54.7 50% 2e-09 45% 
XP_003846407.1  
PREDICTED: putative 
uncharacterized protein 
LOC65996-like [Homo sapiens] 
>gb|AAF69654.1|AF119917_62 
PRO2822 [Homo sapiens] 
53.9 53.9 37% 2e-09 60% 
EAW98491.1  hCG2042307 [Homo sapiens] 53.9 53.9 50% 2e-09 48% 
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t  
EAW53691.1  hCG1747827 [Homo sapiens] 53.9 53.9 37% 2e-09 60% 
AAF77052.1  
ubiquitous TPR-motif protein Y 
isoform [Homo sapiens] 
55.5 55.5 39% 3e-09 57% 
EAW51245.1  hCG2044997 [Homo sapiens] 53.5 53.5 39% 3e-09 63% 
AAH28935.1  C3orf64 protein [Homo sapiens] 53.5 53.5 38% 4e-09 58% 
BAC86723.1  
unnamed protein product [Homo 
sapiens] 
53.9 53.9 53% 4e-09 43% 
BAC87102.1  
unnamed protein product [Homo 
sapiens] 
53.5 53.5 53% 5e-09 43% 
EAW67976.1  
cytoskeleton associated protein 5 
[Homo sapiens] 
56.2 56.2 30% 6e-09 69% 
EAW49158.1  
hCG1648656, isoform CRA_c 
[Homo sapiens] 
>gb|ACF23537.1| unknown 
[Homo sapiens] 
52.4 52.4 39% 9e-09 62% 
CAI12641.1  
caspase 7, apoptosis-related 
cysteine peptidase [Homo 
sapiens] >emb|CAI16007.1| 
caspase 7, apoptosis-related 
cysteine peptidase [Homo 
sapiens] 
53.1 53.1 39% 1e-08 58% 
EAX11403.1  
bromodomain adjacent to zinc 
finger domain, 2B, isoform 
CRA_a [Homo sapiens] 
51.6 51.6 40% 2e-08 56% 
ABR09248.1  
ubiquitously transcribed 
tetratricopeptide repeat protein 
Y-linked transcript variant 7 
[Homo sapiens] 
54.3 54.3 39% 2e-08 57% 
EAX07947.1  hCG1817231 [Homo sapiens] 52.0 52.0 39% 2e-08 59% 
EAX09874.1  hCG1820769 [Homo sapiens] 51.6 51.6 38% 2e-08 58% 
XP_003846420.1  
PREDICTED: putative calcium-
sensing receptor-like 1-like 
[Homo sapiens] 
51.2 80.5 52% 2e-08 69% 
XP_003403540.1  
PREDICTED: uncharacterized 
protein LOC100652894 [Homo 
sapiens] >ref|XP_003960858.1| 
PREDICTED: uncharacterized 
protein LOC100652894 [Homo 
sapiens] >dbj|BAC87615.1| 
unnamed protein product [Homo 
sapiens] 
52.8 52.8 56% 3e-08 46% 
XP_003846587.1  
PREDICTED: putative calcium-
sensing receptor-like 1-like 
[Homo sapiens] 
>ref|XP_003960517.1| 
51.2 80.5 52% 3e-08 69% 
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PREDICTED: putative calcium-
sensing receptor-like 1-like 
[Homo sapiens] 
>dbj|BAC86985.1| unnamed 
protein product [Homo sapiens] 
XP_003846686.1  
PREDICTED: LOW QUALITY 
PROTEIN: uncharacterized 
protein LOC100652894 [Homo 
sapiens] 
52.8 52.8 56% 3e-08 46% 
AAH31359.1  
Unknown (protein for 
IMAGE:4778855), partial [Homo 
sapiens] 
48.5 48.5 31% 9e-08 63% 
EAX03685.1  hCG2000628 [Homo sapiens] 48.1 48.1 32% 1e-07 60% 
EAX06532.1  hCG2031845 [Homo sapiens] 48.9 48.9 28% 1e-07 64% 
EAW83901.1  hCG2014257 [Homo sapiens] 50.1 50.1 35% 2e-07 58% 
BAE97422.1  
decay-accelerating factor splicing 
variant 1 [Homo sapiens] 
51.2 51.2 28% 2e-07 70% 
BAB71666.1  
unnamed protein product [Homo 
sapiens] 
48.1 48.1 39% 3e-07 60% 
EAW97718.1  
5'-nucleotidase domain 
containing 3, isoform CRA_d 
[Homo sapiens] 
48.1 48.1 51% 3e-07 46% 
EAW98472.1  hCG2015876 [Homo sapiens] 48.5 48.5 39% 3e-07 58% 
EAW70437.1  
hCG1641896, isoform CRA_b 
[Homo sapiens] 
48.9 48.9 39% 4e-07 52% 
AAC51145.1  
FAP protein, partial [Homo 
sapiens] 
48.5 48.5 28% 9e-07 62% 
EAX04784.1  
chloride channel 3, isoform 
CRA_c [Homo sapiens] 
46.6 46.6 39% 1e-06 56% 
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A.4 Analysis of the Nebulin Isoforms 
A.4.1 Amino Acid Alignment for Nebulin Isoform 2 and Nebulin Isoform 3  
The amino acid sequences for Nebulin Isoform 2 and Isoform 3 were aligned using 
Clustal2W software. The sequences of DNA fragments for clones from the Hybrigenics 
Y-2-H screen are indicated in grey (for Nebulin Isoform2) and in yellow (for Nebulin 
Isoform 3). 
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NebV2           
MADDEDYEEVVEYYTEEVVYEEVPGETITKIYETTTTRTSDYEQSETSKPALAQPALAQP 60 
NebV3           
MADDEDYEEVVEYYTEEVVYEEVPGETITKIYETTTTRTSDYEQSETSKPALAQPALAQP 60 
                
************************************************************ 
 
NebV2           
ASAKPVERRKVIRKKVDPSKFMTPYIAHSQKMQDLFSPNKYKEKFEKTKGQPYASTTDTP 120 
NebV3           
ASAKPVERRKVIRKKVDPSKFMTPYIAHSQKMQDLFSPNKYKEKFEKTKGQPYASTTDTP 120 
                
************************************************************ 
 
NebV2           
ELRRIKKVQDQLSEVKYRMDGDVAKTICHVDEKAKDIEHAKKVSQQVSKVLYKQNWEDTK 180 
NebV3           
ELRRIKKVQDQLSEVKYRMDGDVAKTICHVDEKAKDIEHAKKVSQQVSKVLYKQNWEDTK 180 
                
************************************************************ 
 
NebV2           
DKYLLPPDAPELVQAVKNTAMFSKKLYTEDWEADKSLFYPYNDSPELRRVAQAQKALSDV 240 
NebV3           
DKYLLPPDAPELVQAVKNTAMFSKKLYTEDWEADKSLFYPYNDSPELRRVAQAQKALSDV 240 
                
************************************************************ 
 
NebV2           
AYKKGLAEQQAQFTPLADPPDIEFAKKVTNQVSKQKYKEDYENKIKGKWSETPCFEVANA 300 
NebV3           
AYKKGLAEQQAQFTPLADPPDIEFAKKVTNQVSKQKYKEDYENKIKGKWSETPCFEVANA 300 
                
************************************************************ 
 
NebV2           
RMNADNISTRKYQEDFENMKDQIYFMQTETPEYKMNKKAGVAASKVKYKEDYEKNKGKAD 360 
NebV3           
RMNADNISTRKYQEDFENMKDQIYFMQTETPEYKMNKKAGVAASKVKYKEDYEKNKGKAD 360 
                
************************************************************ 
 
NebV2           
YNVLPASENPQLRQLKAAGDALSDKLYKENYEKTKAKSINYCETPKFKLDTVLQNFSSDK 420 
NebV3           
YNVLPASENPQLRQLKAAGDALSDKLYKENYEKTKAKSINYCETPKFKLDTVLQNFSSDK 420 
                
************************************************************ 
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NebV2           
KYKDSYLKDILGHYVGSFEDPYHSHCMKVTAQNSDKNYKAEYEEDRGKGFFPQTITQEYE 480 
NebV3           
KYKDSYLKDILGHYVGSFEDPYHSHCMKVTAQNSDKNYKAEYEEDRGKGFFPQTITQEYE 480 
                
************************************************************ 
 
NebV2           
AIKKLDQCKDHTYKVHPDKTKFTQVTDSPVLLQAQVNSKQLSDLNYKAKHESEKFKCHIP 540 
NebV3           
AIKKLDQCKDHTYKVHPDKTKFTQVTDSPVLLQAQVNSKQLSDLNYKAKHESEKFKCHIP 540 
                
************************************************************ 
 
NebV2           
PDTPAFIQHKVNAYNLSDNLYKQDWEKSKAKKFDIKVDAIPLLAAKANTKNTSDVMYKKD 600 
NebV3           
PDTPAFIQHKVNAYNLSDNLYKQDWEKSKAKKFDIKVDAIPLLAAKANTKNTSDVMYKKD 600 
                
************************************************************ 
 
NebV2           
YEKNKGKMIGVLSINDDPKMLHSLKVAKNQSDRLYKENYEKTKAKSMNYCETPKYQLDTQ 660 
NebV3           
YEKNKGKMIGVLSINDDPKMLHSLKVAKNQSDRLYKENYEKTKAKSMNYCETPKYQLDTQ 660 
                
************************************************************ 
 
NebV2           
LKNFSEARYKDLYVKDVLGHYVGSMEDPYHTHCMKVAAQNSDKSYKAEYEEDKGKCYFPQ 720 
NebV3           
LKNFSEARYKDLYVKDVLGHYVGSMEDPYHTHCMKVAAQNSDKSYKAEYEEDKGKCYFPQ 720 
                
************************************************************ 
 
NebV2           
TITQEYEAIKKLDQCKDHTYKVHPDKTKFTAVTDSPVLLQAQLNTKQLSDLNYKAKHEGE 780 
NebV3           
TITQEYEAIKKLDQCKDHTYKVHPDKTKFTAVTDSPVLLQAQLNTKQLSDLNYKAKHEGE 780 
                
************************************************************ 
 
NebV2           
KFKCHIPADAPQFIQHRVNAYNLSDNVYKQDWEKSKAKKFDIKVDAIPLLAAKANTKNTS 840 
NebV3           
KFKCHIPADAPQFIQHRVNAYNLSDNVYKQDWEKSKAKKFDIKVDAIPLLAAKANTKNTS 840 
                
************************************************************ 
 
NebV2           
DVMYKKDYEKSKGKMIGALSINDDPKMLHSLKTAKNQSDREYRKDYEKSKTIYTAPLDML 900 
NebV3           
DVMYKKDYEKSKGKMIGALSINDDPKMLHSLKTAKNQSDREYRKDYEKSKTIYTAPLDML 900 
                
************************************************************ 
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NebV2           
QVTQAKKSQAIASDVDYKHILHSYSYPPDSINVDLAKKAYALQSDVEYKADYNSWMKGCG 960 
NebV3           
QVTQAKKSQAIASDVDYKHILHSYSYPPDSINVDLAKKAYALQSDVEYKADYNSWMKGCG 960 
                
************************************************************ 
 
NebV2           
WVPFGSLEMEKAKRASDILNEKKYRQHPDTLKFTSIEDAPITVQSKINQAQRSDIAYKAK 1020 
NebV3           
WVPFGSLEMEKAKRASDILNEKKYRQHPDTLKFTSIEDAPITVQSKINQAQRSDIAYKAK 1020 
                
************************************************************ 
 
NebV2           
GEEIIHKYNLPPDLPQFIQAKVNAYNISENMYKADLKDLSKKGYDLRTDAIPIRAAKAAR 1080 
NebV3           
GEEIIHKYNLPPDLPQFIQAKVNAYNISENMYKADLKDLSKKGYDLRTDAIPIRAAKAAR 1080 
                
************************************************************ 
 
NebV2           
QAASDVQYKKDYEKAKGKMVGFQSLQDDPKLVHYMNVAKIQSDREYKKDYEKTKSKYNTP 1140 
NebV3           
QAASDVQYKKDYEKAKGKMVGFQSLQDDPKLVHYMNVAKIQSDREYKKDYEKTKSKYNTP 1140 
                
************************************************************ 
 
NebV2           
HDMFNVVAAKKAQDVVSNVNYKHSLHHYTYLPDAMDLELSKNMMQIQSDNVYKEDYNNWM 1200 
NebV3           
HDMFNVVAAKKAQDVVSNVNYKHSLHHYTYLPDAMDLELSKNMMQIQSDNVYKEDYNNWM 1200 
                
************************************************************ 
 
NebV2           
KGIGWIPIGSLDVEKVKKAGDALNEKKYRQHPDTLKFTSIVDSPVMVQAKQNTKQVSDIL 1260 
NebV3           
KGIGWIPIGSLDVEKVKKAGDALNEKKYRQHPDTLKFTSIVDSPVMVQAKQNTKQVSDIL 1260 
                
************************************************************ 
 
NebV2           
YKAKGEDVKHKYTMSPDLPQFLQAKCNAYNISDVCYKRDWYDLIAKGNNVLGDAIPITAA 1320 
NebV3           
YKAKGEDVKHKYTMSPDLPQFLQAKCNAYNISDVCYKRDWYDLIAKGNNVLGDAIPITAA 1320 
                
************************************************************ 
 
NebV2           
KASRNIASDYKYKEAYEKSKGKHVGFRSLQDDPKLVHYMNVAKLQSDREYKKNYENTKTS 1380 
NebV3           
KASRNIASDYKYKEAYEKSKGKHVGFRSLQDDPKLVHYMNVAKLQSDREYKKNYENTKTS 1380 
                
************************************************************ 
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NebV2           
YHTPGDMVSITAAKMAQDVATNVNYKQPLHHYTYLPDAMSLEHTRNVNQIQSDNVYKDEY 1440 
NebV3           
YHTPGDMVSITAAKMAQDVATNVNYKQPLHHYTYLPDAMSLEHTRNVNQIQSDNVYKDEY 1440 
                
************************************************************ 
 
NebV2           
NSFLKGIGWIPIGSLEVEKVKKAGDALNERKYRQHPDTVKFTSVPDSMGMVLAQHNTKQL 1500 
NebV3           
NSFLKGIGWIPIGSLEVEKVKKAGDALNERKYRQHPDTVKFTSVPDSMGMVLAQHNTKQL 1500 
                
************************************************************ 
 
NebV2           
SDLNYKVEGEKLKHKYTIDPELPQFIQAKVNALNMSDAHYKADWKKTIAKGYDLRPDAIP 1560 
NebV3           
SDLNYKVEGEKLKHKYTIDPELPQFIQAKVNALNMSDAHYKADWKKTIAKGYDLRPDAIP 1560 
                
************************************************************ 
 
NebV2           
IVAAKSSRNIASDCKYKEAYEKAKGKQVGFLSLQDDPKLVHYMNVAKIQSDREYKKGYEA 1620 
NebV3           
IVAAKSSRNIASDCKYKEAYEKAKGKQVGFLSLQDDPKLVHYMNVAKIQSDREYKKGYEA 1620 
                
************************************************************ 
 
NebV2           
SKTKYHTPLDMVSVTAAKKSQEVATNANYRQSYHHYTLLPDALNVEHSRNAMQIQSDNLY 1680 
NebV3           
SKTKYHTPLDMVSVTAAKKSQEVATNANYRQSYHHYTLLPDALNVEHSRNAMQIQSDNLY 1680 
                
************************************************************ 
 
NebV2           
KSDFTNWMKGIGWVPIESLEVEKAKKAGEILSEKKYRQHPEKLKFTYAMDTMEQALNKSN 1740 
NebV3           
KSDFTNWMKGIGWVPIESLEVEKAKKAGEILSEKKYRQHPEKLKFTYAMDTMEQALNKSN 1740 
                
************************************************************ 
 
NebV2           
KLNMDKRLYTEKWNKDKTTIHVMPDTPDILLSRVNQITMSDKLYKAGWEEEKKKGYDLRP 1800 
NebV3           
KLNMDKRLYTEKWNKDKTTIHVMPDTPDILLSRVNQITMSDKLYKAGWEEEKKKGYDLRP 1800 
                
************************************************************ 
 
NebV2           
DAIAIKAARASRDIASDYKYKKAYEQAKGKHIGFRSLEDDPKLVHFMQVAKMQSDREYKK 1860 
NebV3           
DAIAIKAARASRDIASDYKYKKAYEQAKGKHIGFRSLEDDPKLVHFMQVAKMQSDREYKK 1860 
                
************************************************************ 
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NebV2           
GYEKSKTSFHTPVDMLSVVAAKKSQEVATNANYRNVIHTYNMLPDAMSFELAKNMMQIQS 1920 
NebV3           
GYEKSKTSFHTPVDMLSVVAAKKSQEVATNANYRNVIHTYNMLPDAMSFELAKNMMQIQS 1920 
                
************************************************************ 
 
NebV2           
DNQYKADYADFMKGIGWLPLGSLEAEKNKKAMEIISEKKYRQHPDTLKYSTLMDSMNMVL 1980 
NebV3           
DNQYKADYADFMKGIGWLPLGSLEAEKNKKAMEIISEKKYRQHPDTLKYSTLMDSMNMVL 1980 
                
************************************************************ 
 
NebV2           
AQNNAKIMNEHLYKQAWEADKTKVHIMPDIPQIILAKANAINMSDKLYKLSLEESKKKGY 2040 
NebV3           
AQNNAKIMNEHLYKQAWEADKTKVHIMPDIPQIILAKANAINMSDKLYKLSLEESKKKGY 2040 
                
************************************************************ 
 
NebV2           
DLRPDAIPIKAAKASRDIASDYKYKYNYEKGKGKMVGFRSLEDDPKLVHSMQVAKMQSDR 2100 
NebV3           
DLRPDAIPIKAAKASRDIASDYKYKYNYEKGKGKMVGFRSLEDDPKLVHSMQVAKMQSDR 2100 
                
************************************************************ 
 
NebV2           
EYKKNYENTKTSYHTPADMLSVTAAKDAQANITNTNYKHLIHKYILLPDAMNIELTRNMN 2160 
NebV3           
EYKKNYENTKTSYHTPADMLSVTAAKDAQANITNTNYKHLIHKYILLPDAMNIELTRNMN 2160 
                
************************************************************ 
 
NebV2           
RIQSDNEYKQDYNEWYKGLGWSPAGSLEVEKAKKATEYASDQKYRQHPSNFQFKKLTDSM 2220 
NebV3           
RIQSDNEYKQDYNEWYKGLGWSPAGSLEVEKAKKATEYASDQKYRQHPSNFQFKKLTDSM 2220 
                
************************************************************ 
 
NebV2           
DMVLAKQNAHTMNKHLYTIDWNKDKTKIHVMPDTPDILQAKQNQTLYSQKLYKLGWEEAL 2280 
NebV3           
DMVLAKQNAHTMNKHLYTIDWNKDKTKIHVMPDTPDILQAKQNQTLYSQKLYKLGWEEAL 2280 
                
************************************************************ 
 
NebV2           
KKGYDLPVDAISVQLAKASRDIASDYKYKQGYRKQLGHHVGFRSLQDDPKLVLSMNVAKM 2340 
NebV3           
KKGYDLPVDAISVQLAKASRDIASDYKYKQGYRKQLGHHVGFRSLQDDPKLVLSMNVAKM 2340 
                
************************************************************ 
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NebV2           
QSEREYKKDFEKWKTKFSSPVDMLGVVLAKKCQELVSDVDYKNYLHQWTCLPDQNDVVQA 2400 
NebV3           
QSEREYKKDFEKWKTKFSSPVDMLGVVLAKKCQELVSDVDYKNYLHQWTCLPDQNDVVQA 2400 
                
************************************************************ 
 
NebV2           
KKVYELQSENLYKSDLEWLRGIGWSPLGSLEAEKNKRASEIISEKKYRQPPDRNKFTSIP 2460 
NebV3           
KKVYELQSENLYKSDLEWLRGIGWSPLGSLEAEKNKRASEIISEKKYRQPPDRNKFTSIP 2460 
                
************************************************************ 
 
NebV2           
DAMDIVLAKTNAKNRSDRLYREAWDKDKTQIHIMPDTPDIVLAKANLINTSDKLYRMGYE 2520 
NebV3           
DAMDIVLAKTNAKNRSDRLYREAWDKDKTQIHIMPDTPDIVLAKANLINTSDKLYRMGYE 2520 
                
************************************************************ 
 
NebV2           
ELKRKGYDLPVDAIPIKAAKASREIASEYKYKEGFRKQLGHHIGARNIEDDPKMMWSMHV 2580 
NebV3           
ELKRKGYDLPVDAIPIKAAKASREIASEYKYKEGFRKQLGHHIGARNIEDDPKMMWSMHV 2580 
                
************************************************************ 
 
NebV2           
AKIQSDREYKKDFEKWKTKFSSPVDMLGVVLAKKCQTLVSDVDYKNYLHQWTCLPDQSDV 2640 
NebV3           
AKIQSDREYKKDFEKWKTKFSSPVDMLGVVLAKKCQTLVSDVDYKNYLHQWTCLPDQSDV 2640 
                
************************************************************ 
 
NebV2           
IHARQAYDLQSDNLYKSDLQWLKGIGWMTSGSLEDEKNKRATQILSDHVYRQHPDQFKFS 2700 
NebV3           
IHARQAYDLQSDNLYKSDLQWLKGIGWMTSGSLEDEKNKRATQILSDHVYRQHPDQFKFS 2700 
                
************************************************************ 
 
NebV2           
SLMDSIPMVLAKNNAITMNHRLYTEAWDKDKTTVHIMPDTPEVLLAKQNKVNYSEKLYKL 2760 
NebV3           
SLMDSIPMVLAKNNAITMNHRLYTEAWDKDKTTVHIMPDTPEVLLAKQNKVNYSEKLYKL 2760 
                
************************************************************ 
 
NebV2           
GLEEAKRKGYDMRVDAIPIKAAKASRDIASEFKYKEGYRKQLGHHIGARAIRDDPKMMWS 2820 
NebV3           
GLEEAKRKGYDMRVDAIPIKAAKASRDIASEFKYKEGYRKQLGHHIGARAIRDDPKMMWS 2820 
                
************************************************************ 
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NebV2           
MHVAKIQSDREYKKDFEKWKTKFSSPVDMLGVVLAKKCQTLVSDVDYKNYLHQWTCLPDQ 2880 
NebV3           
MHVAKIQSDREYKKDFEKWKTKFSSPVDMLGVVLAKKCQTLVSDVDYKNYLHQWTCLPDQ 2880 
                
************************************************************ 
 
NebV2           
SDVIHARQAYDLQSDNMYKSDLQWMRGIGWVSIGSLDVEKCKRATEILSDKIYRQPPDRF 2940 
NebV3           
SDVIHARQAYDLQSDNMYKSDLQWMRGIGWVSIGSLDVEKCKRATEILSDKIYRQPPDRF 2940 
                
************************************************************ 
 
NebV2           
KFTSVTDSLEQVLAKNNAITMNKRLYTEAWDKDKTQIHIMPDTPEIMLARMNKINYSESL 3000 
NebV3            
KFTSVTDSLEQVLAKN-------------------------------------------- 2956 
****************                                             
 
NebV2           
YKLANEEAKKKGYDLRSDAIPIVAAKASRDIISDYKYKDGYCKQLGHHIGARNIEDDPKM 3060 
NebV3            
------------------------------------------------------------ 
                                                                             
 
NebV2           
MWSMHVAKIQSDREYKKDFEKWKTKFSSPVDMLGVVLAKKCQTLVSDVDYKNYLHEWTCL 3120 
NebV3           
------------------------------------------------------------ 
                                                                             
 
NebV2           
PDQSDVIHARQAYDLQSDNIYKSDLQWLRGIGWVPIGSMDVVKCKRATEILSDNIYRQPP 3180 
NebV3            
------------------------------------------------------------ 
                                                                             
 
NebV2           
DKLKFTSVTDSLEQVLAKNNALNMNKRLYTEAWDKDKTQIHIMPDTPEIMLARQNKINYS 3240 
NebV3            
-------------------NALNMNKRLYTEAWDKDKTQIHIMPDTPEIMLARQNKINYS 2997 
                                             
****************************************** 
 
NebV2           
ETLYKLANEEAKKKGYDLRSDAIPIVAAKASRDVISDYKYKDGYRKQLGHHIGARNIEDD 3300 
NebV3           
ETLYKLANEEAKKKGYDLRSDAIPIVAAKASRDVISDYKYKDGYRKQLGHHIGARNIEDD 3057 
                
************************************************************ 
 
NebV2           
PKMMWSMHVAKIQSDREYKKDFEKWKTKFSSPVDMLGVVLAKKCQTLVSDVDYKNYLHEW 3360 
NebV3           
PKMMWSMHVAKIQSDREYKKDFEKWKTKFSSPVDMLGVVLAKKCQTLVSDVDYKNYLHEW 3117 
                
************************************************************ 
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NebV2           
TCLPDQNDVIHARQAYDLQSDNIYKSDLQWLRGIGWVPIGSMDVVKCKRAAEILSDNIYR 3420 
NebV3           
TCLPDQNDVIHARQAYDLQSDNIYKSDLQWLRGIGWVPIGSMDVVKCKRAAEILSDNIYR 3177 
                
************************************************************ 
 
NebV2           
QPPDKLKFTSVTDSLEQVLAKNNALNMNKRLYTEAWDKDKTQVHIMPDTPEIMLARQNKI 3480 
NebV3           
QPPDKLKFTSVTDSLEQVLAKNNALNMNKRLYTEAWDKDKTQVHIMPDTPEIMLARQNKI 3237 
                
************************************************************ 
 
NebV2           
NYSESLYRQAMEEAKKEGYDLRSDAIPIVAAKASRDIASDYKYKEAYRKQLGHHIGARAV 3540 
NebV3           
NYSESLYRQAMEEAKKEGYDLRSDAIPIVAAKASRDIASDYKYKEAYRKQLGHHIGARAV 3297 
                
************************************************************ 
 
NebV2           
HDDPKIMWSLHIAKVQSDREYKKDFEKYKTRYSSPVDMLGIVLAKKCQTLVSDVDYKHPL 3600 
NebV3           
HDDPKIMWSLHIAKVQSDREYKKDFEKYKTRYSSPVDMLGIVLAKKCQTLVSDVDYKHPL 3357 
                
************************************************************ 
 
NebV2           
HEWICLPDQNDIIHARKAYDLQSDNLYKSDLEWMKGIGWVPIDSLEVVRAKRAGELLSDT 3660 
NebV3           
HEWICLPDQNDIIHARKAYDLQSDNLYKSDLEWMKGIGWVPIDSLEVVRAKRAGELLSDT 3417 
                
************************************************************ 
 
NebV2           
IYRQRPETLKFTSITDTPEQVLAKNNALNMNKRLYTEAWDNDKKTIHVMPDTPEIMLAKL 3720 
NebV3           
IYRQRPETLKFTSITDTPEQVLAKNNALNMNKRLYTEAWDNDKKTIHVMPDTPEIMLAKL 3477 
                
************************************************************ 
 
NebV2           
NRINYSDKLYKLALEESKKEGYDLRLDAIPIQAAKASRDIASDYKYKEGYRKQLGHHIGA 3780 
NebV3           
NRINYSDKLYKLALEESKKEGYDLRLDAIPIQAAKASRDIASDYKYKEGYRKQLGHHIGA 3537 
                
************************************************************ 
 
NebV2           
RNIKDDPKMMWSIHVAKIQSDREYKKEFEKWKTKFSSPVDMLGVVLAKKCQILVSDIDYK 3840 
NebV3           
RNIKDDPKMMWSIHVAKIQSDREYKKEFEKWKTKFSSPVDMLGVVLAKKCQILVSDIDYK 3597 
                
************************************************************ 
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NebV2           
HPLHEWTCLPDQNDVIQARKAYDLQSDAIYKSDLEWLRGIGWVPIGSVEVEKVKRAGEIL 3900 
NebV3           
HPLHEWTCLPDQNDVIQARKAYDLQSDAIYKSDLEWLRGIGWVPIGSVEVEKVKRAGEIL 3657 
                
************************************************************ 
 
NebV2           
SDRKYRQPADQLKFTCITDTPEIVLAKNNALTMSKHLYTEAWDADKTSIHVMPDTPDILL 3960 
NebV3           
SDRKYRQPADQLKFTCITDTPEIVLAKNNALTMSKHLYTEAWDADKTSIHVMPDTPDILL 3717 
                
************************************************************ 
 
NebV2           
AKSNSANISQKLYTKGWDESKMKDYDLRADAISIKSAKASRDIASDYKYKEAYEKQKGHH 4020 
NebV3           
AKSNSANISQKLYTKGWDESKMKDYDLRADAISIKSAKASRDIASDYKYKEAYEKQKGHH 3777 
                
************************************************************ 
 
NebV2           
IGAQSIEDDPKIMCAIHAGKIQSEREYKKEFQKWKTKFSSPVDMLSILLAKKCQTLVTDI 4080 
NebV3           
IGAQSIEDDPKIMCAIHAGKIQSEREYKKEFQKWKTKFSSPVDMLSILLAKKCQTLVTDI 3837 
                
************************************************************ 
 
NebV2           
DYRNYLHEWTCMPDQNDIIQAKKAYDLQSDSVYKADLEWLRGIGWMPEGSVEMNRVKVAQ 4140 
NebV3            
DYRNYLHEWTCMPDQNDIIQAKKAYDLQS------------------------------- 3866 
*****************************                                
 
NebV2           
DLVNERLYRTRPEALSFTSIVDTPEVVLAKANSLQISEKLYQEAWNKDKSNITIPSDTPE 4200 
NebV3            
------------------------------------------------------------ 
                                                                             
 
NebV2           
MLQAHINALQISNKLYQKDWNDAKQKGYDIRADAIEIKHAKASREIASEYKYKEGYRKQL 4260 
NebV3            
------------------------------------------------------------ 
                                                                             
 
NebV2           
GHHMGFRTLQDDPKSVWAIHAAKIQSDREYKKAYEKSKGIHNTPLDMMSIVQAKKCQVLV 4320 
NebV3            
------------------------------------------------------------ 
                                                                             
 
NebV2           
SDIDYRNYLHQWTCLPDQNDVIQAKKAYDLQSDNLYKSDLEWLKGIGWLPEGSVEVMRVK 4380 
NebV3            
------------------------------------------------------------ 
                                                                             
 
NebV2           
NAQNLLNERLYRIKPEALKFTSIVDTPEVIQAKINAVQISEPLYRDAWEKEKANVNVPAD 4440 
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NebV3            
------------------------------------------------------------ 
                                                                       
NebV2           
TPLMLQSKINALQISNKRYQQAWEDVKMTGYDLRADAIGIQHAKASRDIASDYLYKTAYE 4500 
NebV3            
------------------------------------------------------------ 
                                                                             
 
NebV2           
KQKGHYIGCRSAKEDPKLVWAANVLKMQNDRLYKKAYNDHKAKISIPVDMVSISAAKEGQ 4560 
NebV3            
------------------------------------------------------------ 
                                                                             
 
NebV2           
ALASDVDYRHYLHHWSCFPDQNDVIQARKAYDLQSDSVYKADLEWLRGIGWMPEGSVEMN 4620 
NebV3            
------------------------------------------------------------ 
                                                                             
 
NebV2           
RVKVAQDLVNERLYRTRPEALSFTSIVDTPEVVLAKANSLQISEKLYQEAWNKDKSNITI 4680 
NebV3            
------------------------------------------------------------ 
                                                                             
 
NebV2           
PSDTPEMLQAHINALQISNKLYQKDWNDTKQKGYDIRADAIEIKHAKASREIASEYKYKE 4740 
NebV3            
------------------------------------------------------------ 
                                                                             
 
NebV2           
GYRKQLGHHMGFRTLQDDPKSVWAIHAAKIQSDREYKKAYEKSKGIHNTPLDMMSIVQAK 4800 
NebV3            
------------------------------------------------------------ 
                                                                             
 
NebV2           
KCQVLVSDIDYRNYLHQWTCLPDQNDVIQAKKAYDLQSDNLYKSDLEWLKGIGWLPEGSV 4860 
NebV3            
------------------------------------------------------------ 
                                                                             
 
NebV2           
EVMRVKNAQNLLNERLYRIKPEALKFTSIVDTPEVIQAKINAVQISEPLYRNAWEKEKAN 4920 
NebV3            
------------------------------------------------------------ 
                                                                             
 
NebV2           
VNVPADTPLMLQSKINALQISNKRYQQAWEDVKMTGYDLRADAIGIQHAKASRDIASDYL 4980 
NebV3            
------------------------------------------------------------ 
                                                                             
 
NebV2           
YKTAYEKQKGHYIGCRSAKEDPKLVWAANVLKMQNDRLYKKAYNDHKAKISIPVDMVSIS 5040 
NebV3            
------------------------------------------------------------ 
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NebV2           
AAKEGQALASDVDYRHYLHHWSCFPDQNDVIQARKAYDLQSDSVYKADLEWLRGIGWMPE 5100 
NebV3            
------------------------------------------------------------ 
                                                                             
 
NebV2           
GSVEMNRVKVAQDLVNERLYRTRPEALSFTSIVDTPEVVLAKANSLQISEKLYQEAWNKD 5160 
NebV3            
------------------------------------------------------------ 
                                                                             
 
NebV2           
KSNITIPSDTPEMLQAHINALQISNKLYQKDWNDTKQKGYDIRADAIEIKHAKASREIAS 5220 
NebV3            
------------------------------------------------------------ 
                                                                             
 
NebV2           
EYKYKEGYRKQLGHHMGFRTLQDDPKSVWAIHAAKIQSDREYKKAYEKSKGIHNTPLDMM 5280 
NebV3            
------------------------------------------------------------ 
                                                                             
 
NebV2           
SIVQAKKCQVLVSDIDYRNYLHQWTCLPDQNDVIQAKKAYDLQSDNLYKSDLEWLKGIGW 5340 
NebV3            
------------------------------------------------------------ 
                                                                             
 
NebV2           
LPEGSVEVMRVKNAQNLLNERLYRIKPEALKFTSIVDTPEVIQAKINAVQISEPLYRDAW 5400 
NebV3            
------------------------------------------------------------ 
                                                                             
 
NebV2           
EKEKANVNVPADTPLMLQSKINALQISNKRYQQAWEDVKMTGYDLRADAIGIQHAKASRD 5460 
NebV3            
------------------------------------------------------------ 
                                                                             
 
NebV2           
IASDYLYKTAYEKQKGHYIGCRSAKEDPKLVWAANVLKMQNDRLYKKAYNDHKAKISIPV 5520 
NebV3            
------------------------------------------------------------ 
                                                                             
 
NebV2           
DMVSISAAKEGQALASDVDYRHYLHRWSCFPDQNDVIQARKAYDLQSDALYKADLEWLRG 5580 
NebV3            
-----------------------------------------------DALYKADLEWLRG 3879 
                                                               
************** 
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NebV2           
IGWMPQGSPEVLRVKNAQNIFCDSVYRTPVVNLKYTSIVDTPEVVLAKSNAENISIPKYR 5640 
NebV3           
IGWMPQGSPEVLRVKNAQNIFCDSVYRTPVVNLKYTSIVDTPEVVLAKSNAENISIPKYR 3939 
                
************************************************************ 
 
NebV2           
EVWDKDKTSIHIMPDTPEINLARANALNVSNKLYREGWDEMKAGCDVRLDAIPIQAAKAS 5700 
NebV3           
EVWDKDKTSIHIMPDTPEINLARANALNVSNKLYREGWDEMKAGCDVRLDAIPIQAAKAS 3999 
                
************************************************************ 
 
NebV2           
REIASDYKYKLDHEKQKGHYVGTLTARDDNKIRWALIADKLQNEREYRLDWAKWKAKIQS 5760 
NebV3           
REIASDYKYKLDHEKQKGHYVGTLTARDDNKIRWALIADKLQNEREYRLDWAKWKAKIQS 4059 
                
************************************************************ 
 
NebV2           
PVDMLSILHSKNSQALVSDMDYRNYLHQWTCMPDQNDVIQAKKAYELQSDNVYKADLEWL 5820 
NebV3           
PVDMLSILHSKNSQALVSDMDYRNYLHQWTCMPDQNDVIQAKKAYELQSDNVYKADLEWL 4119 
                
************************************************************ 
 
NebV2           
RGIGWMPNDSVSVNHAKHAADIFSEKKYRTKIETLNFTPVDDRVDYVTAKQSGEILDDIK 5880 
NebV3           
RGIGWMPNDSVSVNHAKHAADIFSEKKYRTKIETLNFTPVDDRVDYVTAKQSGEILDDIK 4179 
                
************************************************************ 
 
NebV2           
YRKDWNATKSKYTLTETPLLHTAQEAARILDQYLYKEGWERQKATGYILPPDAVPFVHAH 5940 
NebV3           
YRKDWNATKSKYTLTETPLLHTAQEAARILDQYLYKEGWERQKATGYILPPDAVPFVHAH 4239 
                
************************************************************ 
 
NebV2           
HCNDVQSELKYKAEHVKQKGHYVGVPTMRDDPKLVWFEHAGQIQNERLYKEDYHKTKAKI 6000 
NebV3           
HCNDVQSELKYKAEHVKQKGHYVGVPTMRDDPKLVWFEHAGQIQNERLYKEDYHKTKAKI 4299 
                
************************************************************ 
 
NebV2           
NIPADMVSVLAAKQGQTLVSDIDYRNYLHQWMCHPDQNDVIQARKAYDLQSDNVYRADLE 6060 
NebV3           
NIPADMVSVLAAKQGQTLVSDIDYRNYLHQWMCHPDQNDVIQARKAYDLQSDNVYRADLE 4359 
                
************************************************************ 
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NebV2           
WLRGIGWIPLDSVDHVRVTKNQEMMSQIKYKKNALENYPNFRSVVDPPEIVLAKINSVNQ 6120 
NebV3           
WLRGIGWIPLDSVDHVRVTKNQEMMSQIKYKKNALENYPNFRSVVDPPEIVLAKINSVNQ 4419 
                
************************************************************ 
 
NebV2           
SDVKYKETFNKAKGKYTFSPDTPHISHSKDMGKLYSTILYKGAWEGTKAYGYTLDERYIP 6180 
NebV3           
SDVKYKETFNKAKGKYTFSPDTPHISHSKDMGKLYSTILYKGAWEGTKAYGYTLDERYIP 4479 
                
************************************************************ 
 
NebV2           
IVGAKHADLVNSELKYKETYEKQKGHYLAGKVIGEFPGVVHCLDFQKMRSALNYRKHYED 6240 
NebV3           
IVGAKHADLVNSELKYKETYEKQKGHYLAGKVIGEFPGVVHCLDFQKMRSALNYRKHYED 4539 
                
************************************************************ 
 
NebV2           
TKANVHIPNDMMNHVLAKRCQYILSDLEYRHYFHQWTSLLEEPNVIRVRNAQEILSDNVY 6300 
NebV3           
TKANVHIPNDMMNHVLAKRCQYILSDLEYRHYFHQWTSLLEEPNVIRVRNAQEILSDNVY 4599 
                
************************************************************ 
 
NebV2           
KDDLNWLKGIGCYVWDTPQILHAKKSYDLQSQLQYTAAGKENLQNYNLVTDTPLYVTAVQ 6360 
NebV3           
KDDLNWLKGIGCYVWDTPQILHAKKSYDLQSQLQYTAAGKENLQNYNLVTDTPLYVTAVQ 4659 
                
************************************************************ 
 
NebV2           
SGINASEVKYKENYHQIKDKYTTVLETVDYDRTRNLKNLYSSNLYKEAWDRVKATSYILP 6420 
NebV3           
SGINASEVKYKENYHQIKDKYTTVLETVDYDRTRNLKNLYSSNLYKEAWDRVKATSYILP 4719 
                
************************************************************ 
 
NebV2           
SSTLSLTHAKNQKHLASHIKYREEYEKFKALYTLPRSVDDDPNTARCLRVGKLNIDRLYR 6480 
NebV3           
SSTLSLTHAKNQKHLASHIKYREEYEKFKALYTLPRSVDDDPNTARCLRVGKLNIDRLYR 4779 
                
************************************************************ 
 
NebV2           
SVYEKNKMKIHIVPDMVEMVTAKDSQKKVSEIDYRLRLHEWICHPDLQVNDHVRKVTDQI 6540 
NebV3           
SVYEKNKMKIHIVPDMVEMVTAKDSQKKVSEIDYRLRLHEWICHPDLQVNDHVRKVTDQI 4839 
                
************************************************************ 
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NebV2           
SDIVYKDDLNWLKGIGCYVWDTPEILHAKHAYDLRDDIKYKAHMLKTRNDYKLVTDTPVY 6600 
NebV3           
SDIVYKDDLNWLKGIGCYVWDTPEILHAKHAYDLRDDIKYKAHMLKTRNDYKLVTDTPVY 4899 
                
************************************************************ 
 
NebV2           
VQAVKSGKQLSDAVYHYDYVHSVRGKVAPTTKTVDLDRALHAYKLQSSNLYKTSLRTLPT 6660 
NebV3           
VQAVKSGKQLSDAVYHYDYVHSVRGKVAPTTKTVDLDRALHAYKLQSSNLYKTSLRTLPT 4959 
                
************************************************************ 
 
NebV2           
GYRLPGDTPHFKHIKDTRYMSSYFKYKEAYEHTKAYGYTLGPKDVPFVHVRRVNNVTSER 6720 
NebV3           
GYRLPGDTPHFKHIKDTRYMSSYFKYKEAYEHTKAYGYTLGPKDVPFVHVRRVNNVTSER 5019 
                
************************************************************ 
 
NebV2           
LYRELYHKLKDKIHTTPDTPEIRQVKKTQEAVSELIYKSDFFKMQGHMISLPYTPQVIHC 6780 
NebV3           
LYRELYHKLKDKIHTTPDTPEIRQVKKTQEAVSELIYKSDFFKMQGHMISLPYTPQVIHC 5079 
                
************************************************************ 
 
NebV2           
RYVGDITSDIKYKEDLQVLKGFGCFLYDTPDMVRSRHLRKLWSNYLYTDKARKMRDKYKV 6840 
NebV3           
RYVGDITSDIKYKEDLQVLKGFGCFLYDTPDMVRSRHLRKLWSNYLYTDKARKMRDKYKV 5139 
                
************************************************************ 
 
NebV2           
VLDTPEYRKVQELKTHLSELVYRAAGKKQKSIFTSVPDTPDLLRAKRGQKLQSQYLYVEL 6900 
NebV3           
VLDTPEYRKVQELKTHLSELVYRAAGKKQKSIFTSVPDTPDLLRAKRGQKLQSQYLYVEL 5199 
                
************************************************************ 
 
NebV2           
ATKERPHHHAGNQTTALKHAKDVKDMVSEKKYKIQYEKMKDKYTPVPDTPILIRAKRAYW 6960 
NebV3           
ATKERPHHHAGNQTTALKHAKDVKDMVSEKKYKIQYEKMKDKYTPVPDTPILIRAKRAYW 5259 
                
************************************************************ 
 
NebV2           
NASDLRYKETFQKTKGKYHTVKDALDIVYHRKVTDDISKIKYKENYMSQLGIWRSIPDRP 7020 
NebV3           
NASDLRYKETFQKTKGKYHTVKDALDIVYHRKVTDDISKIKYKENYMSQLGIWRSIPDRP 5319 
                
************************************************************ 
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NebV2           
EHFHHRAVTDTVSDVKYKEDLTWLKGIGCYAYDTPDFTLAEKNKTLYSKYKYKEVFERTK 7080 
NebV3           
EHFHHRAVTDTVSDVKYKEDLTWLKGIGCYAYDTPDFTLAEKNKTLYSKYKYKEVFERTK 5379 
                
************************************************************ 
 
NebV2           
SDFKYVADSPINRHFKYATQLMNERKYKSSAKMFLQHGCNEILRPDMLTALYNSHMWSQI 7140 
NebV3           
SDFKYVADSPINRHFKYATQLMNEKKYRADYEQRKDKYHLVVDEPRHLLAKTAGDQISQI 5439 
                 
************************:**::. :   ::    : .*  * *   ..  *** 
 
NebV2           
KYRKNYEKSKDKFTSIVDTPEHLRTTKVNKQISDILYKLEYNKAKPRGYTTIHDTPMLLH 7200 
NebV3           
KYRKNYEKSKDKFTSIVDTPEHLRTTKVNKQISDILYKLEYNKAKPRGYTTIHDTPMLLH 5499 
                
************************************************************ 
 
NebV2           
VRKVKDEVSDLKYKEVYQRNKSNCTIEPDAVHIKAAKDAYKVNTNLDYKKQYEANKAHWK 7260 
NebV3           
VRKVKDEVSDLKYKEVYQRNKSNCTIEPDAVHIKAAKDAYKVNTNLDYKKQYEANKAHWK 5559 
                
************************************************************ 
 
NebV2           
WTPDRPDFLQAAKSSLQQSDFEYKLDREFLKGCKLSVTDDKNTVLALRNTLIESDLKYKE 7320 
NebV3           
WTPDRPDFLQAAKSSLQQSDFEYKLDREFLKGCKLSVTDDKNTVLALRNTLIESDLKYKE 5619 
                
************************************************************ 
 
NebV2           
KHVKERGTCHAVPDTPQILLAKTVSNLVSENKYKDHVKKHLAQGSYTTLPETRDTVHVKE 7380 
NebV3           
KHVKERGTCHAVPDTPQILLAKTVSNLVSENKYKDHVKKHLAQGSYTTLPETRDTVHVKE 5679 
                
************************************************************ 
 
NebV2           
VTKHVSDTNYKKKFVKEKGKSNYSIMLEPPEVKHAMEVAKKQSDVAYRKDAKENLHYTTV 7440 
NebV3           
VTKHVSDTNYKKKFVKEKGKSNYSIMLEPPEVKHAMEVAKKQSDVAYRKDAKENLHYTTV 5739 
                
************************************************************ 
 
NebV2           
ADRPDIKKATQAAKQASEVEYRAKHRKEGSHGLSMLGRPDIEMAKKAAKLSSQVKYRENF 7500 
NebV3           
ADRPDIKKATQAAKQASEVEYRAKHRKEGSHGLSMLGRPDIEMAKKAAKLSSQVKYRENF 5799 
                
************************************************************ 
  
324 
 
 
NebV2           
DKEKGKTPKYNPKDSQLYKVMKDANNLASEVKYKADLKKLHKPVTDMKESLIMNHVLNTS 7560 
NebV3           
DKEKGKTPKYNPKDSQLYKVMKDANNLASEVKYKADLKKLHKPVTDMKESLIMNHVLNTS 5859 
                
************************************************************ 
 
NebV2           
QLASSYQYKKKYEKSKGHYHTIPDNLEQLHLKEATELQSIVKYKEKYEKERGKPMLDFET 7620 
NebV3           
QLASSYQYKKKYEKSKGHYHTIPDNLEQLHLKEATELQSIVKYKEKYEKERGKPMLDFET 5919 
                
************************************************************ 
 
NebV2           
PTYITAKESQQMQSGKEYRKDYEESIKGRNLTGLEVTPALLHVKYATKIASEKEYRKDLE 7680 
NebV3           
PTYITAKESQQMQSGKEYRKDYEESIKGRNLTGLEVTPALLHVKYATKIASEKEYRKDLE 5979 
                
************************************************************ 
 
NebV2           
ESIRGKGLTEMEDTPDMLRAKNATQILNEKEYKRDLELEVKGRGLNAMANETPDFMRARN 7740 
NebV3           
ESIRGKGLTEMEDTPDMLRAKNATQILNEKEYKRDLELEVKGRGLNAMANETPDFMRARN 6039 
                
************************************************************ 
 
NebV2           
ATDIASQIKYKQSAEMEKANFTSVVDTPEIIHAQQVKNLSSQKKYKEDAEKSMSYYETVL 7800 
NebV3           
ATDIASQIKYKQSAEMEKANFTSVVDTPEIIHAQQVKNLSSQKKYKEDAEKSMSYYETVL 6099 
                
************************************************************ 
 
NebV2           
DTPEIQRVRENQKNFSLLQYQCDLKNSKGKITVVQDTPEILRVKENQKNFSSVLYKEDVS 7860 
NebV3           
DTPEIQRVRENQKNFSLLQYQCDLKNSKGKITVVQDTPEILRVKENQKNFSSVLYKEDVS 6159 
                
************************************************************ 
 
NebV2           
PGTAIGKTPEMMRVKQTQDHISSVKYKEAIGQGTPIPDLPEVKRVKETQKHISSVMYKEN 7920 
NebV3           
PGTAIGKTPEMMRVKQTQDHISSVKYKEAIGQGTPIPDLPEVKRVKETQKHISSVMYKEN 6219 
                
************************************************************ 
 
NebV2           
LGTGIPTTVTPEIERVKRNQENFSSVLYKENLGKGIPTPITPEMERVKRNQENFSSILYK 7980 
NebV3            
LGTGIPTTVTPEIERVKRNQENFSSVLYKENLGKGIPTPITPEMERVKRNQENFS----- 6274 
                 
*******************************************************      
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NebV2           
ENLSKGTPLPVTPEMERVKLNQENFSSVLYKENVGKGIPIPITPEMERVKHNQENFSSVL 8040 
NebV3            
------------------------------------------------------------ 
                                                                             
 
NebV2           
YKENLGTGIPIPITPEMQRVKHNQENLSSVLYKENMGKGTPLPVTPEMERVKHNQENISS 8100 
NebV3            
------------------------------------------------------------ 
                                                                             
 
NebV2           
VLYKENMGKGTPLPVTPEMERVKHNQENISSVLYKENMGKGTPLAVTPEMERVKHNQENI 8160 
NebV3            
------------------------------SVLYKENMGKGTPLAVTPEMERVKHNQENI 6304 
                                              
****************************** 
 
NebV2           
SSVLYKENVGKATATPVTPEMQRVKRNQENISSVLYKENLGKATPTPFTPEMERVKRNQE 8220 
NebV3           
SSVLYKENVGKATATPVTPEMQRVKRNQENISSVLYKENLGKATPTPFTPEMERVKRNQE 6364 
                
************************************************************ 
 
NebV2           
NFSSVLYKENMRKATPTPVTPEMERAKRNQENISSVLYSDSFRKQIQGKAAYVLDTPEMR 8280 
NebV3           
NFSSVLYKENMRKATPTPVTPEMERAKRNQENISSVLYSDSFRKQIQGKAAYVLDTPEMR 6424 
                
************************************************************ 
 
NebV2           
RVRETQRHISTVKYHEDFEKHKGCFTPVVTDPITERVKKNMQDFSDINYRGIQRKVVEME 8340 
NebV3           
RVRETQRHISTVKYHEDFEKHKGCFTPVVTDPITERVKKNMQDFSDINYRGIQRKVVEME 6484 
                
************************************************************ 
 
NebV2           
QKRNDQDQETITGLRVWRTNPGSVFDYDPAEDNIQSRSLHMINVQAQRRSREQSRSASAL 8400 
NebV3           
QKRNDQDQETITGLRVWRTNPGSVFDYDPAEDNIQSRSLHMINVQAQRRSREQSRSASAL 6544 
                
************************************************************ 
 
NebV2           
SISGGEEKSEHSEAPDHHLSTYSDGGVFAVSTAYKHAKTTELPQQRSSSVATQQTTVSSI 8460 
NebV3           
SISGGEEKSEHSEAPDHHLSTYSDGGVFAVSTAYKHAKTTELPQQRSSSVATQQTTVSSI 6604 
                
************************************************************ 
 
NebV2           
PSHPSTAGKIFRAMYDYMAADADEVSFKDGDAIINVQAIDEGWMYGTVQRTGRTGMLPAN 8520 
NebV3           
PSHPSTAGKIFRAMYDYMAADADEVSFKDGDAIINVQAIDEGWMYGTVQRTGRTGMLPAN 6664 
                
************************************************************ 
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NebV2           YVEAI 8525 
NebV3           YVEAI 6669 
                ***** 
 
 
Nebulin Fragment Variation 2 
D T V S D V K Y K E D L T W L K G I G C Y A Y D T P D F T L A E K N K T L Y 
S K Y K Y K E V F E R T K S D F K Y V A D S P I N R H F K Y A T Q L M N E R 
K Y K S S A K M F L Q H G C N E I L R P 
Nebulin Fragment Variation 3 
D A L D I V Y H R K V T D D I S K I K Y K E N Y M S Q L G I W R S I P D R P E 
H F H H R A V T D T V S D V K Y K E D L T W L K G I G C Y A Y D T P D F T L 
A E K N K T L Y S K Y K Y K E V F E R T K S D F K Y V A D S P I N R H F K Y A 
T Q L M N E K K Y R A D Y E Q R K D K Y H L V V D E P R H L L A K T A G D 
Q I S Q I K Y R K N Y E K S K D K F T S I V D T P E H L R T T K V N K Q I S D I 
L Y K 
 
Nebulin exon 144 based on gene bank entry Z28496.1 (Donner and others, 2004) 
 
K X V A D S P I N R H F K Y A T Q L M N E X K Y K S S A K M F L Q H G C N E 
I L R P D M L T A L Y N S H M W S Q X K Y K K X K K  
 
Nebulin exon 144 based on gene bank entry AA099760 (Donner and others, 2004) 
 
G G P F L I V Q S I S T T E Q S L T Q S V X V K Y K E D L T W L K G I 
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Q H G C N E I L R P D M L T A L L Q F R I C G A R S N T X T X K T M 
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A.5 Analysis of the Nebulin Isoforms II 
A.5.1 Amino Acid Alignment for Nebulin Isoform 1 and Nebulin Isoform 2  
The amino acid sequences for Nebulin Isoform 2 and Isoform 3 were aligned using 
Clustal2W software. The sequences of DNA fragments for clones from the Hybrigenics 
Y-2-H screen are indicated in grey (for Nebulin Isoform2)  
 
CLUSTAL 2.1 multiple sequence alignment 
 
 
NebV1           MADDEDYEEVVEYYTEEVVYEEVPGETITKIYETTTTRTSDYEQSETSKPALAQPALAQP 
NebV2           MADDEDYEEVVEYYTEEVVYEEVPGETITKIYETTTTRTSDYEQSETSKPALAQPALAQP 
                ************************************************************ 
 
NebV1           ASAKPVERRKVIRKKVDPSKFMTPYIAHSQKMQDLFSPNKYKEKFEKTKGQPYASTTDTP 
NebV2           ASAKPVERRKVIRKKVDPSKFMTPYIAHSQKMQDLFSPNKYKEKFEKTKGQPYASTTDTP 
                ************************************************************ 
 
NebV1           ELRRIKKVQDQLSEVKYRMDGDVAKTICHVDEKAKDIEHAKKVSQQVSKVLYKQNWEDTK 
NebV2           ELRRIKKVQDQLSEVKYRMDGDVAKTICHVDEKAKDIEHAKKVSQQVSKVLYKQNWEDTK 
                ************************************************************ 
 
NebV1           DKYLLPPDAPELVQAVKNTAMFSKKLYTEDWEADKSLFYPYNDSPELRRVAQAQKALSDV 
NebV2           DKYLLPPDAPELVQAVKNTAMFSKKLYTEDWEADKSLFYPYNDSPELRRVAQAQKALSDV 
                ************************************************************ 
 
NebV1           AYKKGLAEQQAQFTPLADPPDIEFAKKVTNQVSKQKYKEDYENKIKGKWSETPCFEVANA 
NebV2           AYKKGLAEQQAQFTPLADPPDIEFAKKVTNQVSKQKYKEDYENKIKGKWSETPCFEVANA 
                ************************************************************ 
 
NebV1           RMNADNISTRKYQEDFENMKDQIYFMQTETPEYKMNKKAGVAASKVKYKEDYEKNKGKAD 
NebV2           RMNADNISTRKYQEDFENMKDQIYFMQTETPEYKMNKKAGVAASKVKYKEDYEKNKGKAD 
                ************************************************************ 
 
NebV1           YNVLPASENPQLRQLKAAGDALSDKLYKENYEKTKAKSINYCETPKFKLDTVLQNFSSDK 
NebV2           YNVLPASENPQLRQLKAAGDALSDKLYKENYEKTKAKSINYCETPKFKLDTVLQNFSSDK 
                ************************************************************ 
 
NebV1           KYKDSYLKDILGHYVGSFEDPYHSHCMKVTAQNSDKNYKAEYEEDRGKGFFPQTITQEYE 
NebV2           KYKDSYLKDILGHYVGSFEDPYHSHCMKVTAQNSDKNYKAEYEEDRGKGFFPQTITQEYE 
                ************************************************************ 
 
NebV1           AIKKLDQCKDHTYKVHPDKTKFTQVTDSPVLLQAQVNSKQLSDLNYKAKHESEKFKCHIP 
NebV2           AIKKLDQCKDHTYKVHPDKTKFTQVTDSPVLLQAQVNSKQLSDLNYKAKHESEKFKCHIP 
                ************************************************************ 
 
NebV1           PDTPAFIQHKVNAYNLSDNLYKQDWEKSKAKKFDIKVDAIPLLAAKANTKNTSDVMYKKD 
NebV2           PDTPAFIQHKVNAYNLSDNLYKQDWEKSKAKKFDIKVDAIPLLAAKANTKNTSDVMYKKD 
                ************************************************************ 
 
NebV1           YEKNKGKMIGVLSINDDPKMLHSLKVAKNQSDRLYKENYEKTKAKSMNYCETPKYQLDTQ 
NebV2           YEKNKGKMIGVLSINDDPKMLHSLKVAKNQSDRLYKENYEKTKAKSMNYCETPKYQLDTQ 
                ************************************************************ 
 
NebV1           LKNFSEARYKDLYVKDVLGHYVGSMEDPYHTHCMKVAAQNSDKSYKAEYEEDKGKCYFPQ 
NebV2           LKNFSEARYKDLYVKDVLGHYVGSMEDPYHTHCMKVAAQNSDKSYKAEYEEDKGKCYFPQ 
                ************************************************************ 
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NebV1           TITQEYEAIKKLDQCKDHTYKVHPDKTKFTAVTDSPVLLQAQLNTKQLSDLNYKAKHEGE 
NebV2           TITQEYEAIKKLDQCKDHTYKVHPDKTKFTAVTDSPVLLQAQLNTKQLSDLNYKAKHEGE 
                ************************************************************ 
 
NebV1           KFKCHIPADAPQFIQHRVNAYNLSDNVYKQDWEKSKAKKFDIKVDAIPLLAAKANTKNTS 
NebV2           KFKCHIPADAPQFIQHRVNAYNLSDNVYKQDWEKSKAKKFDIKVDAIPLLAAKANTKNTS 
                ************************************************************ 
 
NebV1           DVMYKKDYEKSKGKMIGALSINDDPKMLHSLKTAKNQSDREYRKDYEKSKTIYTAPLDML 
NebV2           DVMYKKDYEKSKGKMIGALSINDDPKMLHSLKTAKNQSDREYRKDYEKSKTIYTAPLDML 
                ************************************************************ 
 
NebV1           QVTQAKKSQAIASDVDYKHILHSYSYPPDSINVDLAKKAYALQSDVEYKADYNSWMKGCG 
NebV2           QVTQAKKSQAIASDVDYKHILHSYSYPPDSINVDLAKKAYALQSDVEYKADYNSWMKGCG 
                ************************************************************ 
 
NebV1           WVPFGSLEMEKAKRASDILNEKKYRQHPDTLKFTSIEDAPITVQSKINQAQRSDIAYKAK 
NebV2           WVPFGSLEMEKAKRASDILNEKKYRQHPDTLKFTSIEDAPITVQSKINQAQRSDIAYKAK 
                ************************************************************ 
 
NebV1           GEEIIHKYNLPPDLPQFIQAKVNAYNISENMYKADLKDLSKKGYDLRTDAIPIRAAKAAR 
NebV2           GEEIIHKYNLPPDLPQFIQAKVNAYNISENMYKADLKDLSKKGYDLRTDAIPIRAAKAAR 
                ************************************************************ 
 
NebV1           QAASDVQYKKDYEKAKGKMVGFQSLQDDPKLVHYMNVAKIQSDREYKKDYEKTKSKYNTP 
NebV2           QAASDVQYKKDYEKAKGKMVGFQSLQDDPKLVHYMNVAKIQSDREYKKDYEKTKSKYNTP 
                ************************************************************ 
 
NebV1           HDMFNVVAAKKAQDVVSNVNYKHSLHHYTYLPDAMDLELSKNMMQIQSDNVYKEDYNNWM 
NebV2           HDMFNVVAAKKAQDVVSNVNYKHSLHHYTYLPDAMDLELSKNMMQIQSDNVYKEDYNNWM 
                ************************************************************ 
 
NebV1           KGIGWIPIGSLDVEKVKKAGDALNEKKYRQHPDTLKFTSIVDSPVMVQAKQNTKQVSDIL 
NebV2           KGIGWIPIGSLDVEKVKKAGDALNEKKYRQHPDTLKFTSIVDSPVMVQAKQNTKQVSDIL 
                ************************************************************ 
 
NebV1           YKAKGEDVKHKYTMSPDLPQFLQAKCNAYNISDVCYKRDWYDLIAKGNNVLGDAIPITAA 
NebV2           YKAKGEDVKHKYTMSPDLPQFLQAKCNAYNISDVCYKRDWYDLIAKGNNVLGDAIPITAA 
                ************************************************************ 
 
NebV1           KASRNIASDYKYKEAYEKSKGKHVGFRSLQDDPKLVHYMNVAKLQSDREYKKNYENTKTS 
NebV2           KASRNIASDYKYKEAYEKSKGKHVGFRSLQDDPKLVHYMNVAKLQSDREYKKNYENTKTS 
                ************************************************************ 
 
NebV1           YHTPGDMVSITAAKMAQDVATNVNYKQPLHHYTYLPDAMSLEHTRNVNQIQSDNVYKDEY 
NebV2           YHTPGDMVSITAAKMAQDVATNVNYKQPLHHYTYLPDAMSLEHTRNVNQIQSDNVYKDEY 
                ************************************************************ 
 
NebV1           NSFLKGIGWIPIGSLEVEKVKKAGDALNERKYRQHPDTVKFTSVPDSMGMVLAQHNTKQL 
NebV2           NSFLKGIGWIPIGSLEVEKVKKAGDALNERKYRQHPDTVKFTSVPDSMGMVLAQHNTKQL 
                ************************************************************ 
 
NebV1           SDLNYKVEGEKLKHKYTIDPELPQFIQAKVNALNMSDAHYKADWKKTIAKGYDLRPDAIP 
NebV2           SDLNYKVEGEKLKHKYTIDPELPQFIQAKVNALNMSDAHYKADWKKTIAKGYDLRPDAIP 
                ************************************************************ 
 
NebV1           IVAAKSSRNIASDCKYKEAYEKAKGKQVGFLSLQDDPKLVHYMNVAKIQSDREYKKGYEA 
NebV2           IVAAKSSRNIASDCKYKEAYEKAKGKQVGFLSLQDDPKLVHYMNVAKIQSDREYKKGYEA 
                ************************************************************ 
 
NebV1           SKTKYHTPLDMVSVTAAKKSQEVATNANYRQSYHHYTLLPDALNVEHSRNAMQIQSDNLY 
NebV2           SKTKYHTPLDMVSVTAAKKSQEVATNANYRQSYHHYTLLPDALNVEHSRNAMQIQSDNLY 
                ************************************************************ 
 
NebV1           KSDFTNWMKGIGWVPIESLEVEKAKKAGEILSEKKYRQHPEKLKFTYAMDTMEQALNKSN 
NebV2           KSDFTNWMKGIGWVPIESLEVEKAKKAGEILSEKKYRQHPEKLKFTYAMDTMEQALNKSN 
                ************************************************************ 
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NebV1           KLNMDKRLYTEKWNKDKTTIHVMPDTPDILLSRVNQITMSDKLYKAGWEEEKKKGYDLRP 
NebV2           KLNMDKRLYTEKWNKDKTTIHVMPDTPDILLSRVNQITMSDKLYKAGWEEEKKKGYDLRP 
                ************************************************************ 
 
NebV1           DAIAIKAARASRDIASDYKYKKAYEQAKGKHIGFRSLEDDPKLVHFMQVAKMQSDREYKK 
NebV2           DAIAIKAARASRDIASDYKYKKAYEQAKGKHIGFRSLEDDPKLVHFMQVAKMQSDREYKK 
                ************************************************************ 
 
NebV1           GYEKSKTSFHTPVDMLSVVAAKKSQEVATNANYRNVIHTYNMLPDAMSFELAKNMMQIQS 
NebV2           GYEKSKTSFHTPVDMLSVVAAKKSQEVATNANYRNVIHTYNMLPDAMSFELAKNMMQIQS 
                ************************************************************ 
 
NebV1           DNQYKADYADFMKGIGWLPLGSLEAEKNKKAMEIISEKKYRQHPDTLKYSTLMDSMNMVL 
NebV2           DNQYKADYADFMKGIGWLPLGSLEAEKNKKAMEIISEKKYRQHPDTLKYSTLMDSMNMVL 
                ************************************************************ 
 
NebV1           AQNNAKIMNEHLYKQAWEADKTKVHIMPDIPQIILAKANAINMSDKLYKLSLEESKKKGY 
NebV2           AQNNAKIMNEHLYKQAWEADKTKVHIMPDIPQIILAKANAINMSDKLYKLSLEESKKKGY 
                ************************************************************ 
 
NebV1           DLRPDAIPIKAAKASRDIASDYKYKYNYEKGKGKMVGFRSLEDDPKLVHSMQVAKMQSDR 
NebV2           DLRPDAIPIKAAKASRDIASDYKYKYNYEKGKGKMVGFRSLEDDPKLVHSMQVAKMQSDR 
                ************************************************************ 
 
NebV1           EYKKNYENTKTSYHTPADMLSVTAAKDAQANITNTNYKHLIHKYILLPDAMNIELTRNMN 
NebV2           EYKKNYENTKTSYHTPADMLSVTAAKDAQANITNTNYKHLIHKYILLPDAMNIELTRNMN 
                ************************************************************ 
 
NebV1           RIQSDNEYKQDYNEWYKGLGWSPAGSLEVEKAKKATEYASDQKYRQHPSNFQFKKLTDSM 
NebV2           RIQSDNEYKQDYNEWYKGLGWSPAGSLEVEKAKKATEYASDQKYRQHPSNFQFKKLTDSM 
                ************************************************************ 
 
NebV1           DMVLAKQNAHTMNKHLYTIDWNKDKTKIHVMPDTPDILQAKQNQTLYSQKLYKLGWEEAL 
NebV2           DMVLAKQNAHTMNKHLYTIDWNKDKTKIHVMPDTPDILQAKQNQTLYSQKLYKLGWEEAL 
                ************************************************************ 
 
NebV1           KKGYDLPVDAISVQLAKASRDIASDYKYKQGYRKQLGHHVGFRSLQDDPKLVLSMNVAKM 
NebV2           KKGYDLPVDAISVQLAKASRDIASDYKYKQGYRKQLGHHVGFRSLQDDPKLVLSMNVAKM 
                ************************************************************ 
 
NebV1           QSEREYKKDFEKWKTKFSSPVDMLGVVLAKKCQELVSDVDYKNYLHQWTCLPDQNDVVQA 
NebV2           QSEREYKKDFEKWKTKFSSPVDMLGVVLAKKCQELVSDVDYKNYLHQWTCLPDQNDVVQA 
                ************************************************************ 
 
NebV1           KKVYELQSENLYKSDLEWLRGIGWSPLGSLEAEKNKRASEIISEKKYRQPPDRNKFTSIP 
NebV2           KKVYELQSENLYKSDLEWLRGIGWSPLGSLEAEKNKRASEIISEKKYRQPPDRNKFTSIP 
                ************************************************************ 
 
NebV1           DAMDIVLAKTNAKNRSDRLYREAWDKDKTQIHIMPDTPDIVLAKANLINTSDKLYRMGYE 
NebV2           DAMDIVLAKTNAKNRSDRLYREAWDKDKTQIHIMPDTPDIVLAKANLINTSDKLYRMGYE 
                ************************************************************ 
 
NebV1           ELKRKGYDLPVDAIPIKAAKASREIASEYKYKEGFRKQLGHHIGARNIEDDPKMMWSMHV 
NebV2           ELKRKGYDLPVDAIPIKAAKASREIASEYKYKEGFRKQLGHHIGARNIEDDPKMMWSMHV 
                ************************************************************ 
 
NebV1           AKIQSDREYKKDFEKWKTKFSSPVDMLGVVLAKKCQTLVSDVDYKNYLHQWTCLPDQSDV 
NebV2           AKIQSDREYKKDFEKWKTKFSSPVDMLGVVLAKKCQTLVSDVDYKNYLHQWTCLPDQSDV 
                ************************************************************ 
 
NebV1           IHARQAYDLQSDNLYKSDLQWLKGIGWMTSGSLEDEKNKRATQILSDHVYRQHPDQFKFS 
NebV2           IHARQAYDLQSDNLYKSDLQWLKGIGWMTSGSLEDEKNKRATQILSDHVYRQHPDQFKFS 
                ************************************************************ 
 
NebV1           SLMDSIPMVLAKNNAITMNHRLYTEAWDKDKTTVHIMPDTPEVLLAKQNKVNYSEKLYKL 
NebV2           SLMDSIPMVLAKNNAITMNHRLYTEAWDKDKTTVHIMPDTPEVLLAKQNKVNYSEKLYKL 
                ************************************************************ 
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NebV1           GLEEAKRKGYDMRVDAIPIKAAKASRDIASEFKYKEGYRKQLGHHIGARAIRDDPKMMWS 
NebV2           GLEEAKRKGYDMRVDAIPIKAAKASRDIASEFKYKEGYRKQLGHHIGARAIRDDPKMMWS 
                ************************************************************ 
 
NebV1           MHVAKIQSDREYKKDFEKWKTKFSSPVDMLGVVLAKKCQTLVSDVDYKNYLHQWTCLPDQ 
NebV2           MHVAKIQSDREYKKDFEKWKTKFSSPVDMLGVVLAKKCQTLVSDVDYKNYLHQWTCLPDQ 
                ************************************************************ 
 
NebV1           SDVIHARQAYDLQSDNMYKSDLQWMRGIGWVSIGSLDVEKCKRATEILSDKIYRQPPDRF 
NebV2           SDVIHARQAYDLQSDNMYKSDLQWMRGIGWVSIGSLDVEKCKRATEILSDKIYRQPPDRF 
                ************************************************************ 
 
NebV1           KFTSVTDSLEQVLAKNNAITMNKRLYTEAWDKDKTQIHIMPDTPEIMLARMNKINYSESL 
NebV2           KFTSVTDSLEQVLAKNNAITMNKRLYTEAWDKDKTQIHIMPDTPEIMLARMNKINYSESL 
                ************************************************************ 
 
NebV1           YKLANEEAKKKGYDLRSDAIPIVAAKASRDIISDYKYKDGYCKQLGHHIGARNIEDDPKM 
NebV2           YKLANEEAKKKGYDLRSDAIPIVAAKASRDIISDYKYKDGYCKQLGHHIGARNIEDDPKM 
                ************************************************************ 
 
NebV1           MWSMHVAKIQSDREYKKDFEKWKTKFSSPVDMLGVVLAKKCQTLVSDVDYKNYLHEWTCL 
NebV2           MWSMHVAKIQSDREYKKDFEKWKTKFSSPVDMLGVVLAKKCQTLVSDVDYKNYLHEWTCL 
                ************************************************************ 
 
NebV1           PDQSDVIHARQAYDLQSDNIYKSDLQWLRGIGWVPIGSMDVVKCKRATEILSDNIYRQPP 
NebV2           PDQSDVIHARQAYDLQSDNIYKSDLQWLRGIGWVPIGSMDVVKCKRATEILSDNIYRQPP 
                ************************************************************ 
 
NebV1           DKLKFTSVTDSLEQVLAKNNALNMNKRLYTEAWDKDKTQIHIMPDTPEIMLARQNKINYS 
NebV2           DKLKFTSVTDSLEQVLAKNNALNMNKRLYTEAWDKDKTQIHIMPDTPEIMLARQNKINYS 
                ************************************************************ 
 
NebV1           ETLYKLANEEAKKKGYDLRSDAIPIVAAKASRDVISDYKYKDGYRKQLGHHIGARNIEDD 
NebV2           ETLYKLANEEAKKKGYDLRSDAIPIVAAKASRDVISDYKYKDGYRKQLGHHIGARNIEDD 
                ************************************************************ 
 
NebV1           PKMMWSMHVAKIQSDREYKKDFEKWKTKFSSPVDMLGVVLAKKCQTLVSDVDYKNYLHEW 
NebV2           PKMMWSMHVAKIQSDREYKKDFEKWKTKFSSPVDMLGVVLAKKCQTLVSDVDYKNYLHEW 
                ************************************************************ 
 
NebV1           TCLPDQNDVIHARQAYDLQSDNIYKSDLQWLRGIGWVPIGSMDVVKCKRAAEILSDNIYR 
NebV2           TCLPDQNDVIHARQAYDLQSDNIYKSDLQWLRGIGWVPIGSMDVVKCKRAAEILSDNIYR 
                ************************************************************ 
 
NebV1           QPPDKLKFTSVTDSLEQVLAKNNALNMNKRLYTEAWDKDKTQVHIMPDTPEIMLARQNKI 
NebV2           QPPDKLKFTSVTDSLEQVLAKNNALNMNKRLYTEAWDKDKTQVHIMPDTPEIMLARQNKI 
                ************************************************************ 
 
NebV1           NYSESLYRQAMEEAKKEGYDLRSDAIPIVAAKASRDIASDYKYKEAYRKQLGHHIGARAV 
NebV2           NYSESLYRQAMEEAKKEGYDLRSDAIPIVAAKASRDIASDYKYKEAYRKQLGHHIGARAV 
                ************************************************************ 
 
NebV1           HDDPKIMWSLHIAKVQSDREYKKDFEKYKTRYSSPVDMLGIVLAKKCQTLVSDVDYKHPL 
NebV2           HDDPKIMWSLHIAKVQSDREYKKDFEKYKTRYSSPVDMLGIVLAKKCQTLVSDVDYKHPL 
                ************************************************************ 
 
NebV1           HEWICLPDQNDIIHARKAYDLQSDNLYKSDLEWMKGIGWVPIDSLEVVRAKRAGELLSDT 
NebV2           HEWICLPDQNDIIHARKAYDLQSDNLYKSDLEWMKGIGWVPIDSLEVVRAKRAGELLSDT 
                ************************************************************ 
 
NebV1           IYRQRPETLKFTSITDTPEQVLAKNNALNMNKRLYTEAWDNDKKTIHVMPDTPEIMLAKL 
NebV2           IYRQRPETLKFTSITDTPEQVLAKNNALNMNKRLYTEAWDNDKKTIHVMPDTPEIMLAKL 
                ************************************************************ 
 
NebV1           NRINYSDKLYKLALEESKKEGYDLRLDAIPIQAAKASRDIASDYKYKEGYRKQLGHHIGA 
NebV2           NRINYSDKLYKLALEESKKEGYDLRLDAIPIQAAKASRDIASDYKYKEGYRKQLGHHIGA 
                ************************************************************ 
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NebV1           RNIKDDPKMMWSIHVAKIQSDREYKKEFEKWKTKFSSPVDMLGVVLAKKCQILVSDIDYK 
NebV2           RNIKDDPKMMWSIHVAKIQSDREYKKEFEKWKTKFSSPVDMLGVVLAKKCQILVSDIDYK 
                ************************************************************ 
 
NebV1           HPLHEWTCLPDQNDVIQARKAYDLQSDAIYKSDLEWLRGIGWVPIGSVEVEKVKRAGEIL 
NebV2           HPLHEWTCLPDQNDVIQARKAYDLQSDAIYKSDLEWLRGIGWVPIGSVEVEKVKRAGEIL 
                ************************************************************ 
 
NebV1           SDRKYRQPADQLKFTCITDTPEIVLAKNNALTMSKHLYTEAWDADKTSIHVMPDTPDILL 
NebV2           SDRKYRQPADQLKFTCITDTPEIVLAKNNALTMSKHLYTEAWDADKTSIHVMPDTPDILL 
                ************************************************************ 
 
NebV1           AKSNSANISQKLYTKGWDESKMKDYDLRADAISIKSAKASRDIASDYKYKEAYEKQKGHH 
NebV2           AKSNSANISQKLYTKGWDESKMKDYDLRADAISIKSAKASRDIASDYKYKEAYEKQKGHH 
                ************************************************************ 
 
NebV1           IGAQSIEDDPKIMCAIHAGKIQSEREYKKEFQKWKTKFSSPVDMLSILLAKKCQTLVTDI 
NebV2           IGAQSIEDDPKIMCAIHAGKIQSEREYKKEFQKWKTKFSSPVDMLSILLAKKCQTLVTDI 
                ************************************************************ 
 
NebV1           DYRNYLHEWTCMPDQNDIIQAKKAYDLQSDSVYKADLEWLRGIGWMPEGSVEMNRVKVAQ 
NebV2           DYRNYLHEWTCMPDQNDIIQAKKAYDLQSDSVYKADLEWLRGIGWMPEGSVEMNRVKVAQ 
                ************************************************************ 
 
NebV1           DLVNERLYRTRPEALSFTSIVDTPEVVLAKANSLQISEKLYQEAWNKDKSNITIPSDTPE 
NebV2           DLVNERLYRTRPEALSFTSIVDTPEVVLAKANSLQISEKLYQEAWNKDKSNITIPSDTPE 
                ************************************************************ 
 
NebV1           MLQAHINALQISNKLYQKDWNDAKQKGYDIRADAIEIKHAKASREIASEYKYKEGYRKQL 
NebV2           MLQAHINALQISNKLYQKDWNDAKQKGYDIRADAIEIKHAKASREIASEYKYKEGYRKQL 
                ************************************************************ 
 
NebV1           GHHMGFRTLQDDPKSVWAIHAAKIQSDREYKKAYEKSKGIHNTPLDMMSIVQAKKCQVLV 
NebV2           GHHMGFRTLQDDPKSVWAIHAAKIQSDREYKKAYEKSKGIHNTPLDMMSIVQAKKCQVLV 
                ************************************************************ 
 
NebV1           SDIDYRNYLHQWTCLPDQNDVIQAKKAYDLQSDNLYKSDLEWLKGIGWLPEGSVEVMRVK 
NebV2           SDIDYRNYLHQWTCLPDQNDVIQAKKAYDLQSDNLYKSDLEWLKGIGWLPEGSVEVMRVK 
                ************************************************************ 
 
NebV1           NAQNLLNERLYRIKPEALKFTSIVDTPEVIQAKINAVQISEPLYRDAWEKEKANVNVPAD 
NebV2           NAQNLLNERLYRIKPEALKFTSIVDTPEVIQAKINAVQISEPLYRDAWEKEKANVNVPAD 
                ************************************************************ 
 
NebV1           TPLMLQSKINALQISNKRYQQAWEDVKMTGYDLRADAIGIQHAKASRDIASDYLYKTAYE 
NebV2           TPLMLQSKINALQISNKRYQQAWEDVKMTGYDLRADAIGIQHAKASRDIASDYLYKTAYE 
                ************************************************************ 
 
NebV1           KQKGHYIGCRSAKEDPKLVWAANVLKMQNDRLYKKAYNDHKAKISIPVDMVSISAAKEGQ 
NebV2           KQKGHYIGCRSAKEDPKLVWAANVLKMQNDRLYKKAYNDHKAKISIPVDMVSISAAKEGQ 
                ************************************************************ 
 
NebV1           ALASDVDYRHYLHHWSCFPDQNDVIQARKAYDLQSDSVYKADLEWLRGIGWMPEGSVEMN 
NebV2           ALASDVDYRHYLHHWSCFPDQNDVIQARKAYDLQSDSVYKADLEWLRGIGWMPEGSVEMN 
                ************************************************************ 
 
NebV1           RVKVAQDLVNERLYRTRPEALSFTSIVDTPEVVLAKANSLQISEKLYQEAWNKDKSNITI 
NebV2           RVKVAQDLVNERLYRTRPEALSFTSIVDTPEVVLAKANSLQISEKLYQEAWNKDKSNITI 
                ************************************************************ 
 
NebV1           PSDTPEMLQAHINALQISNKLYQKDWNDTKQKGYDIRADAIEIKHAKASREIASEYKYKE 
NebV2           PSDTPEMLQAHINALQISNKLYQKDWNDTKQKGYDIRADAIEIKHAKASREIASEYKYKE 
                ************************************************************ 
 
NebV1           GYRKQLGHHMGFRTLQDDPKSVWAIHAAKIQSDREYKKAYEKSKGIHNTPLDMMSIVQAK 
NebV2           GYRKQLGHHMGFRTLQDDPKSVWAIHAAKIQSDREYKKAYEKSKGIHNTPLDMMSIVQAK 
                ************************************************************ 
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NebV1           KCQVLVSDIDYRNYLHQWTCLPDQNDVIQAKKAYDLQSDNLYKSDLEWLKGIGWLPEGSV 
NebV2           KCQVLVSDIDYRNYLHQWTCLPDQNDVIQAKKAYDLQSDNLYKSDLEWLKGIGWLPEGSV 
                ************************************************************ 
 
NebV1           EVMRVKNAQNLLNERLYRIKPEALKFTSIVDTPEVIQAKINAVQISEPLYRNAWEKEKAN 
NebV2           EVMRVKNAQNLLNERLYRIKPEALKFTSIVDTPEVIQAKINAVQISEPLYRNAWEKEKAN 
                ************************************************************ 
 
NebV1           VNVPADTPLMLQSKINALQISNKRYQQAWEDVKMTGYDLRADAIGIQHAKASRDIASDYL 
NebV2           VNVPADTPLMLQSKINALQISNKRYQQAWEDVKMTGYDLRADAIGIQHAKASRDIASDYL 
                ************************************************************ 
 
NebV1           YKTAYEKQKGHYIGCRSAKEDPKLVWAANVLKMQNDRLYKKAYNDHKAKISIPVDMVSIS 
NebV2           YKTAYEKQKGHYIGCRSAKEDPKLVWAANVLKMQNDRLYKKAYNDHKAKISIPVDMVSIS 
                ************************************************************ 
 
NebV1           AAKEGQALASDVDYRHYLHHWSCFPDQNDVIQARKAYDLQSDSVYKADLEWLRGIGWMPE 
NebV2           AAKEGQALASDVDYRHYLHHWSCFPDQNDVIQARKAYDLQSDSVYKADLEWLRGIGWMPE 
                ************************************************************ 
 
NebV1           GSVEMNRVKVAQDLVNERLYRTRPEALSFTSIVDTPEVVLAKANSLQISEKLYQEAWNKD 
NebV2           GSVEMNRVKVAQDLVNERLYRTRPEALSFTSIVDTPEVVLAKANSLQISEKLYQEAWNKD 
                ************************************************************ 
 
NebV1           KSNITIPSDTPEMLQAHINALQISNKLYQKDWNDTKQKGYDIRADAIEIKHAKASREIAS 
NebV2           KSNITIPSDTPEMLQAHINALQISNKLYQKDWNDTKQKGYDIRADAIEIKHAKASREIAS 
                ************************************************************ 
 
NebV1           EYKYKEGYRKQLGHHMGFRTLQDDPKSVWAIHAAKIQSDREYKKAYEKSKGIHNTPLDMM 
NebV2           EYKYKEGYRKQLGHHMGFRTLQDDPKSVWAIHAAKIQSDREYKKAYEKSKGIHNTPLDMM 
                ************************************************************ 
 
NebV1           SIVQAKKCQVLVSDIDYRNYLHQWTCLPDQNDVIQAKKAYDLQSDNLYKSDLEWLKGIGW 
NebV2           SIVQAKKCQVLVSDIDYRNYLHQWTCLPDQNDVIQAKKAYDLQSDNLYKSDLEWLKGIGW 
                ************************************************************ 
 
NebV1           LPEGSVEVMRVKNAQNLLNERLYRIKPEALKFTSIVDTPEVIQAKINAVQISEPLYRDAW 
NebV2           LPEGSVEVMRVKNAQNLLNERLYRIKPEALKFTSIVDTPEVIQAKINAVQISEPLYRDAW 
                ************************************************************ 
 
NebV1           EKEKANVNVPADTPLMLQSKINALQISNKRYQQAWEDVKMTGYDLRADAIGIQHAKASRD 
NebV2           EKEKANVNVPADTPLMLQSKINALQISNKRYQQAWEDVKMTGYDLRADAIGIQHAKASRD 
                ************************************************************ 
 
NebV1           IASDYLYKTAYEKQKGHYIGCRSAKEDPKLVWAANVLKMQNDRLYKKAYNDHKAKISIPV 
NebV2           IASDYLYKTAYEKQKGHYIGCRSAKEDPKLVWAANVLKMQNDRLYKKAYNDHKAKISIPV 
                ************************************************************ 
 
NebV1           DMVSISAAKEGQALASDVDYRHYLHRWSCFPDQNDVIQARKAYDLQSDALYKADLEWLRG 
NebV2           DMVSISAAKEGQALASDVDYRHYLHRWSCFPDQNDVIQARKAYDLQSDALYKADLEWLRG 
                ************************************************************ 
 
NebV1           IGWMPQGSPEVLRVKNAQNIFCDSVYRTPVVNLKYTSIVDTPEVVLAKSNAENISIPKYR 
NebV2           IGWMPQGSPEVLRVKNAQNIFCDSVYRTPVVNLKYTSIVDTPEVVLAKSNAENISIPKYR 
                ************************************************************ 
 
NebV1           EVWDKDKTSIHIMPDTPEINLARANALNVSNKLYREGWDEMKAGCDVRLDAIPIQAAKAS 
NebV2           EVWDKDKTSIHIMPDTPEINLARANALNVSNKLYREGWDEMKAGCDVRLDAIPIQAAKAS 
                ************************************************************ 
 
NebV1           REIASDYKYKLDHEKQKGHYVGTLTARDDNKIRWALIADKLQNEREYRLDWAKWKAKIQS 
NebV2           REIASDYKYKLDHEKQKGHYVGTLTARDDNKIRWALIADKLQNEREYRLDWAKWKAKIQS 
                ************************************************************ 
 
NebV1           PVDMLSILHSKNSQALVSDMDYRNYLHQWTCMPDQNDVIQAKKAYELQSDNVYKADLEWL 
NebV2           PVDMLSILHSKNSQALVSDMDYRNYLHQWTCMPDQNDVIQAKKAYELQSDNVYKADLEWL 
                ************************************************************ 
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NebV1           RGIGWMPNDSVSVNHAKHAADIFSEKKYRTKIETLNFTPVDDRVDYVTAKQSGEILDDIK 
NebV2           RGIGWMPNDSVSVNHAKHAADIFSEKKYRTKIETLNFTPVDDRVDYVTAKQSGEILDDIK 
                ************************************************************ 
 
NebV1           YRKDWNATKSKYTLTETPLLHTAQEAARILDQYLYKEGWERQKATGYILPPDAVPFVHAH 
NebV2           YRKDWNATKSKYTLTETPLLHTAQEAARILDQYLYKEGWERQKATGYILPPDAVPFVHAH 
                ************************************************************ 
 
NebV1           HCNDVQSELKYKAEHVKQKGHYVGVPTMRDDPKLVWFEHAGQIQNERLYKEDYHKTKAKI 
NebV2           HCNDVQSELKYKAEHVKQKGHYVGVPTMRDDPKLVWFEHAGQIQNERLYKEDYHKTKAKI 
                ************************************************************ 
 
NebV1           NIPADMVSVLAAKQGQTLVSDIDYRNYLHQWMCHPDQNDVIQARKAYDLQSDNVYRADLE 
NebV2           NIPADMVSVLAAKQGQTLVSDIDYRNYLHQWMCHPDQNDVIQARKAYDLQSDNVYRADLE 
                ************************************************************ 
 
NebV1           WLRGIGWIPLDSVDHVRVTKNQEMMSQIKYKKNALENYPNFRSVVDPPEIVLAKINSVNQ 
NebV2           WLRGIGWIPLDSVDHVRVTKNQEMMSQIKYKKNALENYPNFRSVVDPPEIVLAKINSVNQ 
                ************************************************************ 
 
NebV1           SDVKYKETFNKAKGKYTFSPDTPHISHSKDMGKLYSTILYKGAWEGTKAYGYTLDERYIP 
NebV2           SDVKYKETFNKAKGKYTFSPDTPHISHSKDMGKLYSTILYKGAWEGTKAYGYTLDERYIP 
                ************************************************************ 
 
NebV1           IVGAKHADLVNSELKYKETYEKQKGHYLAGKVIGEFPGVVHCLDFQKMRSALNYRKHYED 
NebV2           IVGAKHADLVNSELKYKETYEKQKGHYLAGKVIGEFPGVVHCLDFQKMRSALNYRKHYED 
                ************************************************************ 
 
NebV1           TKANVHIPNDMMNHVLAKRCQYILSDLEYRHYFHQWTSLLEEPNVIRVRNAQEILSDNVY 
NebV2           TKANVHIPNDMMNHVLAKRCQYILSDLEYRHYFHQWTSLLEEPNVIRVRNAQEILSDNVY 
                ************************************************************ 
 
NebV1           KDDLNWLKGIGCYVWDTPQILHAKKSYDLQSQLQYTAAGKENLQNYNLVTDTPLYVTAVQ 
NebV2           KDDLNWLKGIGCYVWDTPQILHAKKSYDLQSQLQYTAAGKENLQNYNLVTDTPLYVTAVQ 
                ************************************************************ 
 
NebV1           SGINASEVKYKENYHQIKDKYTTVLETVDYDRTRNLKNLYSSNLYKEAWDRVKATSYILP 
NebV2           SGINASEVKYKENYHQIKDKYTTVLETVDYDRTRNLKNLYSSNLYKEAWDRVKATSYILP 
                ************************************************************ 
 
NebV1           SSTLSLTHAKNQKHLASHIKYREEYEKFKALYTLPRSVDDDPNTARCLRVGKLNIDRLYR 
NebV2           SSTLSLTHAKNQKHLASHIKYREEYEKFKALYTLPRSVDDDPNTARCLRVGKLNIDRLYR 
                ************************************************************ 
 
NebV1           SVYEKNKMKIHIVPDMVEMVTAKDSQKKVSEIDYRLRLHEWICHPDLQVNDHVRKVTDQI 
NebV2           SVYEKNKMKIHIVPDMVEMVTAKDSQKKVSEIDYRLRLHEWICHPDLQVNDHVRKVTDQI 
                ************************************************************ 
 
NebV1           SDIVYKDDLNWLKGIGCYVWDTPEILHAKHAYDLRDDIKYKAHMLKTRNDYKLVTDTPVY 
NebV2           SDIVYKDDLNWLKGIGCYVWDTPEILHAKHAYDLRDDIKYKAHMLKTRNDYKLVTDTPVY 
                ************************************************************ 
 
NebV1           VQAVKSGKQLSDAVYHYDYVHSVRGKVAPTTKTVDLDRALHAYKLQSSNLYKTSLRTLPT 
NebV2           VQAVKSGKQLSDAVYHYDYVHSVRGKVAPTTKTVDLDRALHAYKLQSSNLYKTSLRTLPT 
                ************************************************************ 
 
NebV1           GYRLPGDTPHFKHIKDTRYMSSYFKYKEAYEHTKAYGYTLGPKDVPFVHVRRVNNVTSER 
NebV2           GYRLPGDTPHFKHIKDTRYMSSYFKYKEAYEHTKAYGYTLGPKDVPFVHVRRVNNVTSER 
                ************************************************************ 
 
NebV1           LYRELYHKLKDKIHTTPDTPEIRQVKKTQEAVSELIYKSDFFKMQGHMISLPYTPQVIHC 
NebV2           LYRELYHKLKDKIHTTPDTPEIRQVKKTQEAVSELIYKSDFFKMQGHMISLPYTPQVIHC 
                ************************************************************ 
 
NebV1           RYVGDITSDIKYKEDLQVLKGFGCFLYDTPDMVRSRHLRKLWSNYLYTDKARKMRDKYKV 
NebV2           RYVGDITSDIKYKEDLQVLKGFGCFLYDTPDMVRSRHLRKLWSNYLYTDKARKMRDKYKV 
                ************************************************************ 
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NebV1           VLDTPEYRKVQELKTHLSELVYRAAGKKQKSIFTSVPDTPDLLRAKRGQKLQSQYLYVEL 
NebV2           VLDTPEYRKVQELKTHLSELVYRAAGKKQKSIFTSVPDTPDLLRAKRGQKLQSQYLYVEL 
                ************************************************************ 
 
NebV1           ATKERPHHHAGNQTTALKHAKDVKDMVSEKKYKIQYEKMKDKYTPVPDTPILIRAKRAYW 
NebV2           ATKERPHHHAGNQTTALKHAKDVKDMVSEKKYKIQYEKMKDKYTPVPDTPILIRAKRAYW 
                ************************************************************ 
 
NebV1           NASDLRYKETFQKTKGKYHTVKDALDIVYHRKVTDDISKIKYKENYMSQLGIWRSIPDRP 
NebV2           NASDLRYKETFQKTKGKYHTVKDALDIVYHRKVTDDISKIKYKENYMSQLGIWRSIPDRP 
                ************************************************************ 
 
NebV1           EHFHHRAVTDTVSDVKYKEDLTWLKGIGCYAYDTPDFTLAEKNKTLYSKYKYKEVFERTK 
NebV2           EHFHHRAVTDTVSDVKYKEDLTWLKGIGCYAYDTPDFTLAEKNKTLYSKYKYKEVFERTK 
                ************************************************************ 
 
NebV1           SDFKYVADSPINRHFKYATQLMNEKKYRADYEQRKDKYHLVVDEPRHLLAKTAGDQISQI 
NebV2           SDFKYVADSPINRHFKYATQLMNERKYKSSAKMFLQHGCNEILRPDMLTALYNSHMWSQI 
                ************************:**::. :   ::    : .*  * *   ..  *** 
 
NebV1           KYRKNYEKSKDKFTSIVDTPEHLRTTKVNKQISDILYKLEYNKAKPRGYTTIHDTPMLLH 
NebV2           KYRKNYEKSKDKFTSIVDTPEHLRTTKVNKQISDILYKLEYNKAKPRGYTTIHDTPMLLH 
                ************************************************************ 
 
NebV1           VRKVKDEVSDLKYKEVYQRNKSNCTIEPDAVHIKAAKDAYKVNTNLDYKKQYEANKAHWK 
NebV2           VRKVKDEVSDLKYKEVYQRNKSNCTIEPDAVHIKAAKDAYKVNTNLDYKKQYEANKAHWK 
                ************************************************************ 
 
NebV1           WTPDRPDFLQAAKSSLQQSDFEYKLDREFLKGCKLSVTDDKNTVLALRNTLIESDLKYKE 
NebV2           WTPDRPDFLQAAKSSLQQSDFEYKLDREFLKGCKLSVTDDKNTVLALRNTLIESDLKYKE 
                ************************************************************ 
 
NebV1           KHVKERGTCHAVPDTPQILLAKTVSNLVSENKYKDHVKKHLAQGSYTTLPETRDTVHVKE 
NebV2           KHVKERGTCHAVPDTPQILLAKTVSNLVSENKYKDHVKKHLAQGSYTTLPETRDTVHVKE 
                ************************************************************ 
 
NebV1           VTKHVSDTNYKKKFVKEKGKSNYSIMLEPPEVKHAMEVAKKQSDVAYRKDAKENLHYTTV 
NebV2           VTKHVSDTNYKKKFVKEKGKSNYSIMLEPPEVKHAMEVAKKQSDVAYRKDAKENLHYTTV 
                ************************************************************ 
 
NebV1           ADRPDIKKATQAAKQASEVEYRAKHRKEGSHGLSMLGRPDIEMAKKAAKLSSQVKYRENF 
NebV2           ADRPDIKKATQAAKQASEVEYRAKHRKEGSHGLSMLGRPDIEMAKKAAKLSSQVKYRENF 
                ************************************************************ 
 
NebV1           DKEKGKTPKYNPKDSQLYKVMKDANNLASEVKYKADLKKLHKPVTDMKESLIMNHVLNTS 
NebV2           DKEKGKTPKYNPKDSQLYKVMKDANNLASEVKYKADLKKLHKPVTDMKESLIMNHVLNTS 
                ************************************************************ 
 
NebV1           QLASSYQYKKKYEKSKGHYHTIPDNLEQLHLKEATELQSIVKYKEKYEKERGKPMLDFET 
NebV2           QLASSYQYKKKYEKSKGHYHTIPDNLEQLHLKEATELQSIVKYKEKYEKERGKPMLDFET 
                ************************************************************ 
 
NebV1           PTYITAKESQQMQSGKEYRKDYEESIKGRNLTGLEVTPALLHVKYATKIASEKEYRKDLE 
NebV2           PTYITAKESQQMQSGKEYRKDYEESIKGRNLTGLEVTPALLHVKYATKIASEKEYRKDLE 
                ************************************************************ 
 
NebV1           ESIRGKGLTEMEDTPDMLRAKNATQILNEKEYKRDLELEVKGRGLNAMANETPDFMRARN 
NebV2           ESIRGKGLTEMEDTPDMLRAKNATQILNEKEYKRDLELEVKGRGLNAMANETPDFMRARN 
                ************************************************************ 
 
NebV1           ATDIASQIKYKQSAEMEKANFTSVVDTPEIIHAQQVKNLSSQKKYKEDAEKSMSYYETVL 
NebV2           ATDIASQIKYKQSAEMEKANFTSVVDTPEIIHAQQVKNLSSQKKYKEDAEKSMSYYETVL 
                ************************************************************ 
 
NebV1           DTPEIQRVRENQKNFSLLQYQCDLKNSKGKITVVQDTPEILRVKENQKNFSSVLYKEDVS 
NebV2           DTPEIQRVRENQKNFSLLQYQCDLKNSKGKITVVQDTPEILRVKENQKNFSSVLYKEDVS 
                ************************************************************ 
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NebV1           PGTAIGKTPEMMRVKQTQDHISSVKYKEAIGQGTPIPDLPEVKRVKETQKHISSVMYKEN 
NebV2           PGTAIGKTPEMMRVKQTQDHISSVKYKEAIGQGTPIPDLPEVKRVKETQKHISSVMYKEN 
                ************************************************************ 
 
NebV1           LGTGIPTTVTPEIERVKRNQENFSSVLYKENLGKGIPTPITPEMERVKRNQENFSSILYK 
NebV2           LGTGIPTTVTPEIERVKRNQENFSSVLYKENLGKGIPTPITPEMERVKRNQENFSSILYK 
                ************************************************************ 
 
NebV1           ENLSKGTPLPVTPEMERVKLNQENFSSVLYKENVGKGIPIPITPEMERVKHNQENFSSVL 
NebV2           ENLSKGTPLPVTPEMERVKLNQENFSSVLYKENVGKGIPIPITPEMERVKHNQENFSSVL 
                ************************************************************ 
 
NebV1           YKENLGTGIPIPITPEMQRVKHNQENLSSVLYKENMGKGTPLPVTPEMERVKHNQENISS 
NebV2           YKENLGTGIPIPITPEMQRVKHNQENLSSVLYKENMGKGTPLPVTPEMERVKHNQENISS 
                ************************************************************ 
 
NebV1           VLYKENMGKGTPLPVTPEMERVKHNQENISSVLYKENMGKGTPLAVTPEMERVKHNQENI 
NebV2           VLYKENMGKGTPLPVTPEMERVKHNQENISSVLYKENMGKGTPLAVTPEMERVKHNQENI 
                ************************************************************ 
 
NebV1           SSVLYKENVGKATATPVTPEMQRVKRNQENISSVLYKENLGKATPTPFTPEMERVKRNQE 
NebV2           SSVLYKENVGKATATPVTPEMQRVKRNQENISSVLYKENLGKATPTPFTPEMERVKRNQE 
                ************************************************************ 
 
NebV1           NFSSVLYKENMRKATPTPVTPEMERAKRNQENISSVLYSDSFRKQIQGKAAYVLDTPEMR 
NebV2           NFSSVLYKENMRKATPTPVTPEMERAKRNQENISSVLYSDSFRKQIQGKAAYVLDTPEMR 
                ************************************************************ 
 
NebV1           RVRETQRHISTVKYHEDFEKHKGCFTPVVTDPITERVKKNMQDFSDINYRGIQRKVVEME 
NebV2           RVRETQRHISTVKYHEDFEKHKGCFTPVVTDPITERVKKNMQDFSDINYRGIQRKVVEME 
                ************************************************************ 
 
NebV1           QKRNDQDQETITGLRVWRTNPGSVFDYDPAEDNIQSRSLHMINVQAQRRSREQSRSASAL 
NebV2           QKRNDQDQETITGLRVWRTNPGSVFDYDPAEDNIQSRSLHMINVQAQRRSREQSRSASAL 
                ************************************************************ 
 
NebV1           SISGGEEKSEHSEAPDHHLSTYSDGGVFAVSTAYKHAKTTELPQQRSSSVATQQTTVSSI 
NebV2           SISGGEEKSEHSEAPDHHLSTYSDGGVFAVSTAYKHAKTTELPQQRSSSVATQQTTVSSI 
                ************************************************************ 
 
NebV1           PSHPSTAGKIFRAMYDYMAADADEVSFKDGDAIINVQAIDEGWMYGTVQRTGRTGMLPAN 
NebV2           PSHPSTAGKIFRAMYDYMAADADEVSFKDGDAIINVQAIDEGWMYGTVQRTGRTGMLPAN 
                ************************************************************ 
 
NebV1           YVEAI 
NebV2           YVEAI 
                ***** 
 
Nebulin Fragment Variation 2 (from the Y-2-H) 
D T V S D V K Y K E D L T W L K G I G C Y A Y D T P D F T L A E K N K T L Y 
S K Y K Y K E V F E R T K S D F K Y V A D S P I N R H F K Y A T Q L M N E R 
K Y K S S A K M F L Q H G C N E I L R P 
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   A.6 Analysis of KBTBD13 
A.6.1 Amino Acid Alignment for KBTBD13 and Klhl31  
The amino acid sequences for KBTBD13 (Gene ID: 390594) and Klhl31 (Gene ID: 
401265) were aligned using Clustal2W software.  
 
 
 
CLUSTAL 2.1 multiple sequence alignment 
 
 
kbtbd13         ----------------------------------------------------MARGP--- 
Klhl31          MAPKKKIVKKNKGDINEMTIIVEDSPLNKLNALNGLLEGGNGLSCISSELTDASYGPNLL 
                                                                     : **    
 
kbtbd13         -----------QTLVQVWVGGQLFQADRALLVEHCGFFRGLFRSGMRETRAAEVRLGVLS 
Klhl31          EGLSKMRQENFLCDLVIGTKTKSFDVHKSVMASCSEYFYNILKKDPSIQRVDLNDISPLG 
                              : : .  : *:..::::.. . :* .:::..    *.    :. *. 
 
kbtbd13         AGGFRATLQVLRGDRPALAAEDELLQAVECAAFLQAPALARFLEHNLTSDNCALLCDAAA 
Klhl31          LATVIAYAYTGKLTLSLYTIGSIISAAVYLQIHTLVKMCSDFLIREMSVENCMYVVNIAE 
                 . . *   . :   .  :  . :  **    .  .   : ** :::: :**  : : *  
 
kbtbd13         AFGLRDVFHSAALFICD-------------------GERELAAELALP------------ 
Klhl31          TYSLKNAKAAAQKFIRDNFLEFAESDQFMKLTFEQINELLIDDDLQLPSEIVAFQIAMKW 
                ::.*::.  :*  ** *                   .*  :  :* **             
 
kbtbd13         ----EARAYVAALRPS------------------------------------SYAAVSTH 
Klhl31          LEFDQKRVKYAADLLSNIRFGTISAQDLVNYVQSVPRMMQDADCHRLLVDAMNYHLLPYH 
                    : *.  **   *                                    .*  :. * 
 
kbtbd13         T---------------------PAPGFLEDASRTLCYLDEEEDAWRTLAALPLEASTLLA 
Klhl31          QNTLQSRRTRIRGGCRVLVTVGGRPGLTEKSLSRDILYRDPENGWSKLTEMPAKS--FNQ 
                                        **: *.:        : *:.* .*: :* ::  :   
 
kbtbd13         GVATLGNKLYIVGG-----VRGASKEVVELGFCYDPDGGTWHEFPSPHQPRYDTALAGFD 
Klhl31          CVAVMDGFLYVAGGEDQNDARNQAKHAVSNFCRYDPRFNTWIHLASMNQKRTHFSLSVFN 
                 **.:.. **:.**     .*. :*..*.    ***  .** .:.* :* * . :*: *: 
 
kbtbd13         GRLYAIGGEFQRTPISSVERYDPAAGCWSFVADLPQPAAGVPCAQACGRLFVCLWRPADT 
Klhl31          GLVYAAGGRNAEGSLASLECYVPSTNQWQPKTPLEVARCCHASAVADGRVLVTGGYIANA 
                * :** **.  . .::*:* * *::. *.  : *  . .  ..* * **::*     *:: 
 
kbtbd13         T--AVVEYAVRTDAWLPVAELRRPQSYGHCMVAHRDSLYVVRN---GP-SDDFLHCAIDC 
Klhl31          YSRSVCAYDPASDSWQELPNLSTPR-GWHCAVTLSDRVYVMGGSQLGPRGERVDVLTVEC 
                   :*  *   :*:*  :.:*  *:   ** *:  * :**: .   ** .: .   :::* 
 
kbtbd13         LNLATGQWT-ALPGQFVNSKGALFTAVVRGDTVYTVN------RMFTLLYAIEGGTWRLL 
Klhl31          YSPATGQWSYAAPLQVGVSTAGVSALHGRAYLVGGWNEGEKKYKKCIQCFSPELNEWTED 
                 . *****: * * *.  *...: :   *.  *   *      :     :: * . *    
 
kbtbd13         REKAGFPRPGSLQTFLLR---LPPGAPGPVTSTTAEL 
Klhl31          DELPEATVGVSCCTLSMPNNVTRESRASSVSSVPVSI 
                 * .  .   *  *: :       . ...*:*....: 
 
 
